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Abstract 
 The goal of our research endeavor was to successfully employ modern lead 
discovery and optimization strategies towards the development and identification of 
compounds possessing antimalarial activity. Preliminary data from in vitro screening at 
the Walter Reed Army Institute of Research identified several chemotypes including 
4(1H)-quinolones and 1,2,3,4-tetrahydroacridones to have potent antimalarial activities. 
Multiple synthetic routes were devised and implemented which enabled the rapid 
preparation and isolation of over 400 structurally diverse 4(1H)-quinolones and 1,2,3,4-
tetrahydroacridones.  
 Our research towards discovering and optimizing antimalarials was inspired from 
the severe impact malaria has had on our planet especially on impoverished countries. 
There are over 300 million cases annually and over one million deaths. The staggering 
mortality rates combined with the global emergence of chemical resistance that the 
parasite Plasmodium falciparum has developed towards many of the common 
antimalarials compelled us to extend our research efforts to this growing problem. The 
need for identifying and developing new antimalarial drugs is very important. However, 
our approach focuses on the optimization of historic antimalarials such as endochin, 
floxacrine, or ICI 56,780 which possess liabilities such as lack of poor solubility, poor in 
vivo activity or lingering toxicity issues. Through these optimization efforts using both 
SAR and structure-property relationship (SPR) studies, a more suitable candidate was 
developed that had superior physicochemical properties.  
 xv 
 
 Our drug design approach included not only the identification of liabilities of 
historic compounds but also the synthesis and optimization of numerous analogs guided 
by SAR. All compounds were tested in vitro for antimalarial activity and characterized in 
parallel for physicochemical properties such as solubility, permeability, and logD7.4. 
Insights from both the antimalarial activity as well as the physicochemical properties 
determined which analogs would be advanced in the design process. 
 Based on our early investigations, 6-chloro-7-methoxy-3-phenyl-4(1H)-quinolone 
emerged as a promising hit. Compared to endochin, which possesses EC50s of 8.6 nM and 
46.6 nM against drug resistant strains W2 and TM90C2B, and a solubility of less than 2 
µM, 6-chloro-7-methoxy-3-pheny-4(1H)-quinolone was superior with a 4-fold 
improvement in solubility (6 µM) as well as slightly improved antimalarial activity 
(EC50s of 26.2 nM and 15.3 nM against W2 and TM90C2B, respectively). Unfortunately, 
this compound failed to reduce parasitemia levels in P. berghei infected mice. Hit-to-lead 
optimization lead to the discovery of 6-chloro-7-methoxy-2-methyl-3-o-tolyl-4(1H)-
quinolone which was shown to reduce parasitemia levels by 41% at day 6 post-exposure 
(PE) in P. berghei infected mice at a 50 mg/kg dose. The observed in vivo activity of 6-
chloro-7-methoxy-2-methyl-3-o-tolyl-4(1H)-quinolone was believed to relate to the 3-
fold increase in solubility (19 µM) over the 3-phenyl-susbtituted analogue. Continuation 
of SAR and SPR studies identified additional 4(1H)-quinolones suggesting that the 
microsomal stability of the compounds is as important for in vivo efficacy as the aqueous 
solubility. Several of the analogs that showed minimal degradation in human microsomal 
stability studies demonstrated increased in vivo activity in the ranges of 72-98% 
parasitemia reductions on day 6PE in P. berghei infected mice at 50 mg/kg. These results 
 xvi 
 
helped refine the final SAR and SPR optimization identifying a compound with radical 
curative activity in mice (99% parasitemia reductions on day 6PE in P. berghei infected 
mice at 50 mg/kg with five out of five mice surviving beyond 30 days). 
 Theses studies not only highlight the effectiveness of detailed SAR and SPR 
strategies used in drug discovery programs, but they also showcase the importance of re-
evaluating historic antimalarials and exploiting their shortcomings. These studies have 
opened the doors to several possibilities regarding the 4(1H)-quinolone scaffold 
optimization for future antimalarial development. Several of the compounds described in 
this work are currently being subjected to stringent head-to-head comparative studies to 
determine the analog best suited for pre-clinical trials.  
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Chapter 1: Drug Discovery as a Tool for Developing Antimalarials Targeting Protozoa 
falciparum 
1.1 Overview 
Malaria is one of the most devastating parasitic diseases of man, with over 300 
million cases per year and 1 million deaths annually.
1
 The disease is prevalent in mostly 
tropical and sub-tropical climates, and in these regions P. falciparum and P. vivax are the 
most prevalent strains infecting humans. Forty percent of the global population lives in 
malaria endemic areas. Despite the availability of numerous medications and treatment 
options, the disease continues to be regarded as the most significant public health 
problem in the world
2
 due to the emergence of widespread resistance to common 
antimalarials and a relatively limited number of new chemotypes emerging from the 
pharmaceutical industry. Drug mainstays such as atovaquone, 
sulfadoxine/pyrimethamine, mefloquine, and chloroquine have become increasingly non-
effective for treating malaria.
3-5
 With annual cases of malaria continuing to overwhelm 
tropical societies and current therapeutics steadily declining in efficacy, there has been an 
outcry for modern approaches to the development of new therapeutics, modifications to 
existing treatments, and alternative control measures such as vaccinations and vector 
control.
6
  
 Traditionally, drug discovery involves screening, identification of hit compounds, 
synthesis, characterization, lead selection and lead optimization. Initially, a library is 
screened, from which one or a small set of promising compounds emerge as hits through 
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a variety of assays. Hits are refined through a process known as hit-to-lead optimization.
7
 
The hit is then optimized through structure-activity relationship (SAR) studies to a 
compound that is known as an early lead. Early leads have in vivo activity and are further 
evaluated in lead optimization studies including additional SAR and structure-property 
relationship (SPR) studies. From this emerges a late lead which undergoes several series 
of pharmacology and toxicology studies to refine the compounds properties and 
ultimately enter clinical trials. This process is very time consuming and resource 
intensive. There is a mounting problem of a lack in truly innovative medicines being 
approved by the US Food and Drug Administration (FDA) and other major regulatory 
bodies worldwide. These problems are further complicated due to numerous 
socioeconomic factors which cause pharmaceutical industries to carefully assess which 
diseases they will target.
8
 Unfortunately, pharmaceutical industry focuses on targeting 
diseases that yield higher profit margins such as chronic diseases (HIV, cancer) rather 
than microbial or neglected diseases such as malaria.
9
  
 Malaria research was recently invigorated in November of 2007, when the Bill 
and Melinda Gates Foundation set an agenda with the final goal being the eradication of 
malaria, that is, the extinction of all species of Plasmodium that can cause malaria in 
humans. This goal has been further supported by the World Health Organization (WHO) 
and several other non-profit initiatives.
2
 To achieve this goal, antimalarial drug discovery 
not only has to be aimed at targeting the asexual blood stages of P. falciparum but multi-
drug resistance, exo-erythrocytic stage, dormant liver stage P. vivax, and mosquito vector 
control.
10
 A two-pronged approach is critical to the overall success in the eradication of 
malaria, in which new compounds/chemotypes are discovered as well as the advancement 
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of currently known chemotypes to clinical studies. To overcome these hurdles, the Bill 
and Melinda Gates Foundation reached out to academic and industrial researchers alike to 
innovate the way in which antimalarials are discovered and developed. The challenges 
that present themselves to these researchers are multi-faceted. Firstly, there are five 
species of the malaria parasite that infect humans, P. falciparum, P. vivax, P. ovale P. 
knowlesi, and P. malariae. P. falciparum is responsible for the majority of the infections 
and thus is the most important in terms of mortality. However, P. vivax causes as much as 
25-40% of the malaria cases worldwide.
2
 The differences in the species and their 
morphology within the host create a number of complications in the search for a unified 
global treatment. While there are drugs on the market that can prevent or cure all species 
of human infecting Plasmodium with the emergence of drug resistance, concurrent 
research for each species is becoming cost prohibitive. Therefore, much innovation is 
needed to design a drug that can affect all five human infecting species.  
1.2 Protozoa and Plasmodium falciparum 
1.2.1 Protozoa Pathology and Structure 
Protozoan pathogens are responsible for many important human and animal 
diseases. These pathogens are responsible for diarrhea, malaria, Chagas‟ disease, and 
African sleeping sickness.
11, 12
 These microorganisms are well known parasites, however 
they also may be opportunistic pathogens typically affecting immunocompromised 
individuals.
13
 Protozoa are typically known as animal-like protists because they are single 
cell eukaryotic organisms. Because of the extreme diversity amongst protozoa it is very 
difficult to classify themselves from one another. The only feature common to them all is 
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that they are unicellular eukaryotic microorganisms.
14
 They typically contain one of four 
modes of motility: flagella, cilia, gliding, or pseudopodia.
13
  
Most protozoa exist in aqueous or soil environments and are positioned in several 
different orders of the food chain. They are not dependent on a host for survival, 
however, some exhibit parasitism in which a host is required. The protozoa that are 
capable of living freely are (a) autotrophs that rely on the energy from the sun for 
metabolism or (b) heterotrophs which obtain organic material from other living organism. 
They must ingest either through pinocytosis, phagocytosis, and osmotrophy, which they 
then digest in organelles known as vacuoles.
13
 These vacuoles play an integral role in the 
capability of P. falciparum to sustain the microorganism while breaking down red blood 
cells (RBC) of the invaded host.
15
 The parasite uses a polymerization process to break 
down toxic free heme into a non-toxic form of heme that that can be stored safely in the 
vacuole.
15
 Compounds such as chloroquine prevent the polymerization of free heme 
which subsequently builds up in the vacuole and eventually kills the parasite. 
Furthermore, one mode of resistance to this drug is reduced drug accumulation in the 
vacuole of the target via an efflux transport.
15
  
1.2.2 Protozoa and Plasmodium falciparum Lifecycles 
 Protozoa have three distinct reproductive stages: (a) asexual, (b) sexual, and (c) 
dormant cyst stages. During these different life cycles they will alternate between their 
feeding (trophic) and dormant forms. The ability to become cysts, which are capable of 
withstanding very harsh conditions, is an evolutionary response to exist in environments 
of minimal sustenance and they can stay this way for many years.
16
 When conditions are 
favorable and nutrients are plentiful, protozoa exist in a trophozoite form where the 
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organism has tremendous feeding and growth potential. The transformation from cyst to 
trophozoite is known as encystations or excystation when the reverse transformation 
occurs. During these trophic growth periods, the microorganism will reproduce either 
sexually or asexually in a number of different ways including cellular fission, budding, 
and segmentation.
14
 Protozoa exhibit very complicated sexual reproduction which varies 
from species to species. Meiosis and fusion of gametes to form a zygote is common. 
Figure 1.1 displays the general life cycle of an apicomplexan parasite. 
Figure 1.1. General Life Cycle of an Apicomplexan Parasite 
 
(1) zygote, the initial cell formed when two gametes fuse (2) sporozoite, the cell that infects new hosts (3) 
merozoite, the cell that infects red blood cells and can have several iterations in this form (4) gametocyte, 
the cell formed by meiotic cell division (Courtesy of Franciscosp2 on the world wide web) 
 
 Plasmodium falciparum belong to a group of protists known as apicomplexans. 
Their defining feature is the possession of a unique organelle system called the apical 
complex that is used to penetrate host cells (Figure 1.2).
17
 They have flagella when in the 
gamete stages, while they lack any form of flagella, pseudopodia, or cilia in other life 
stages. The nucleus is haploid. The mitochondria contain cristae. A golgi apparatus is 
present in the basal body, and the organism is devoid of chloroplasts. All members of the 
phylum apicomplexa have an infectious stage known as the sporozoite, which possess the 
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apical complex while in this stage.
13
 The apical complex consists of a set of spirally 
arranged microtubules, a secretory body, and one or more polar rings. The organism has 
three distinct secretory organelles: (a) the rhoptries, (b) micronemes, and (c) dense 
granules.
17
  
 During the invasion process the apicomplexan orients itself so that the apical end 
(end containing apical organelles) is juxtaposed to the host cell. Upon initial contact with 
the host cell the contents of the micronemes are expelled, followed by discharge of the 
rhoptries. Finally, the dense granules are extruded after the parasite has completed its 
entry, which play a role in modifying the host cell. The micronemes contain numerous 
proteins that are homologous to known adhesion protein domains. Proteins such as 
thrombospondin-related anonymous protein (TRAP) are responsible for adhesion in 
cellular and extracellular matrix molecules. The micronemes contains proteins that share 
domains of TRAP. Micronemes also contain epidermal growth factor (EGF)-like 
domains and lectin domains which play a role in motility and adhesion aspects when 
entering the cell. Some of the micronemal proteins are receptor specific while some are 
promiscuous.   
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Figure 1.2. Apicomplexan Structure 
 
(1) polar ring (2) conoid (3) micronemes (4) rhoptries (5) nucleous (6) nucleolus (7) mitochondria (8) 
posterior ring (9) suppedicular microtubules (10) golgi apparatus (11) micropore (Courtesy of Franciscosp2 
on the world wide web) 
 
 Most apicomplexans have complex life-cycles which are typically characterized 
by three separate processes (a) sporogony, (b) merogony, and (c) gametogony. 
Sporogony is the asexual reproduction that generates the infectious sporozoites. These 
sporozoites will invade new cells and develop into forms that undergo another asexual 
reproduction known as merogony. Merogony is a unique set of asexual reproductions that 
generate merozoites, it differs from sporogony in that there can be multiple rounds of 
replication. This is important because merozoites are also invasive and thus, can replicate 
and re-invade new cells. At some point merozoites can develop into gametes through the 
process known as gametogony. These gametes fuse to generate a zygote which will 
undergo sporogony (Figure 1.1). In monoxenous species the entire life cycle will be 
carried out in a single host, while in heteroxenous the cycle will occur in multiple hosts. 
The apicomplexan P. falciparum has a heteroxenous life cycle that includes the 
transmission of the parasite through an anopheline mosquito vector to a human host.
18
 
Sporogony begins with the replication and maturation of sporozoites in the salivary 
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glands of the mosquito.
16
 The infection begins when the mosquito is taking a blood meal 
and sporozoites are injected to the human host.  
Figure 1.3. P. falciparum Life Cycle 
 
Within 30-60 minutes sporozoites reach the liver via the blood vasculature and the lymph 
system. Sporozoites gain access to the hepatocytes by first invading and traversing a 
macrophage within the liver cell known as a Kupffer cell. Host cell entry and exit is 
achieved via the apical organelles described previously. Maturation of these hepatic 
parasites marks the beginning of merogony and includes reproducing asexually by 
multiple rounds of nuclear division without cytoplasmic division followed by budding to 
form a progeny known as merozoites. This process can be anywhere from 48 hours to 
several weeks depending on the Plasmodium species. During this process P. vivax and P. 
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ovale can form hypnozoites which can lay dormant for weeks to many years. Mature 
merozoites are released to the blood stream upon rupturing of the host hepatocyte. The 
merozoites subsequently invade red blood cells by a recognition process of specific 
proteins located on the erythrocyte surface.
19
 Upon entrance the parasite undergoes the 
trophic feeding period followed by an asexual replication. This period of the parasites life 
cycle is known as the ring stage due to the morphology in Geisma-stained blood 
smears.
20
 The trophozoite ingests host cell cytoplasm and hemoglobin breaking them 
down into amino acids. The parasite can digest up to 75% of the RBC‟s content in a 
process whereby the globin is cleaved enzymatically into small peptides, which thereby 
produces free heme known as Fe
2+
- protoporphyrin IX or Fe
2+ 
PPIX. This Fe
2+ 
PPIX is 
toxic to the parasite, however, the PPIX undergoes a one electron oxidation to form 
ferriprotoporphyrin Fe
3+ 
PPIX also known as hemozoin which can be safely precipitated 
inside the digestive food vacuole.
15
 The precipitation occurs through the crystallization of 
the unit cell β-hematin (Figure 1.4). Merogony continues within the RBC, which is also 
known as erythrocytic schizogony. The host erythrocyte erupts and releases mature 
merozoites. These merozoites invade new erythrocytes and repeat the process. This 
process is typically synchronous, and a concomitant release of antigens and waste 
products (e.g. hemozoin) with the rupture of each cell triggers the intermittent fevers 
associated with the onset of the disease.
21
 During this time as an alternative to schizogony 
some of the parasites will begin a sexual cycle and differentiate into either micro- (male) 
or macrogametocytes (female). They do not affect the human host and will perish if not 
taken up by a mosquito. After ingestion by a mosquito the gametocytes will exit the 
erythrocyte and begin gametogenesis inside of the mosquito gut.  
10 
 
Figure 1.4. Fe
2+
- Protoporphyrin IX and β-Hematin 
 
This process includes three nuclei divisions that emerge from the body of the 
microgametocyte as part of the flagella, forming a microgamete. Microgamete‟s fuse 
with macrogamete‟s which will then develop into an ookinete in 12-24 hours. This 
ookinete makes its way to the extracellular space within the epithelial cells where it 
matures into an oocyst. Sporogony begins by the asexual reproduction of oocysts, which 
ends in the formation of thousands of sporozoites. These sporozoites make their way to 
the salivary glands which are then eventually re-injected to a host through a blood meal 
of the mosquito.  
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1.3 Modern Drug Discovery Techniques 
1.3.1 Drug Discovery Overview 
The drug discovery process is the central focus of the pharmaceutical industry‟s 
ability to generate new medicines. This process is directly tied to a particular research 
program indentifying and optimizing leads that target clinically relevant pathways. 
Consequently, the research community is consistently seeking to expand and improve 
lead identification and optimization strategies.
22, 23
 The two major forms of drug 
discovery that comprise most of the design efforts are (a) ligand-based design, and (b) 
structure-based design. A ligand-based design is an approach where knowledge of a 
known molecule that binds to or inhibits a particular biological target of interest is used 
to gain insight to the design process. A structure-based design is an approach which uses 
structural knowledge of the biological target to predict the types of molecules capable of 
possessing the desired interactions.
24, 25
  
Ligand-based approaches rely on exploiting structural knowledge of the ligand to 
gain insight to the biological target. Typically, a library of molecules will be screened 
using an efficacy assay to assess which molecules exhibit biological activity with the 
target. Next, it is important to determine what parts of the active molecules are 
responsible for the biological activity. Techniques such as structure-activity relationships 
(SAR) are heavily utilized to develop such structural understandings. Many structural 
modifications can be taken to achieve the insight such as rigidification, expansion, and 
functional group removal and addition. Once the necessary functional groups and 
individual atoms responsible for the action are established, the identification of the 
pharmacophore must be made. The pharmacophore is the functionality and atoms 
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responsible for the activity and their relative positions in space with respect to each 
other.
26
 Once a pharmacophore is identified, further ligands can be generated to probe the 
target, and increase efficacy,  leading to a general model of the biological target.
27-29
  
In a structure-based approach, knowledge of the biological target is achieved 
through X-ray crystallography or NMR spectroscopy. These analytic techniques help to 
pinpoint the active sites, allosteric sites, and native molecules bound to the targets.
30
 
Many of these targets are enzymes and proteins in which x-ray structures must be solved 
or NMR analysis must be completed to determine the relevant biological information. 
The amount of information that can be gathered from these two experimental techniques 
has dramatically increased in the past decade due to improved technology in both fields, 
making the structure-based design strategy evermore promising. The structure based 
approach can be further divided into two broad categories: (a) ligand search and (b) 
ligand building. The first category, ligand searching consists of mining databases in 
which potential ligand molecules are screened using computer modeling against the 
biological target in order to determine which ones fit into the target.
31
 The advantage of 
this approach is the reduction of synthetic efforts which leads to resource efficiency. 
Ligand building or receptor based design uses computer modeling to generate ligands that 
adhere to a specific set of constraints that are justified based on structural information of 
the biological target. By using these constraints the ligand can be piece-wise adapted to 
fit the target.
32
 
1.3.2 Combinatorial Chemistry 
Combinatorial chemistry has long been viewed by the pharmaceutical, 
agrochemical, and biotech industries as a key discipline in facilitating the advancement of 
13 
 
novel therapeutics.
33
 Combinatorial chemistry was originally designed for the production 
of multiple compounds via solid-phase synthesis which has evolved over many years 
since its discovery by Merrifield in 1988. Combinatorial chemistry has become as widely 
accepted as any of the various technologies for the rapid synthesis of large collections of 
compounds to facilitate the identification of new active compounds for drug targets by 
high-throughput screening (HTS) techniques.
34, 35
 HTS is a process of screening large 
numbers of molecules (thousands to millions) using a combination of robotics, liquid 
handling devices, and sensitive detectors.  However, since its inception several decades 
ago, only one known de novo analog, sorafenib has been advanced for clinical use by the 
FDA utilizing a combinatorial chemistry synthesis (Figure 1.5).
36
 The project team that 
initially discovered sorafenib in 1994 used a scintillation proximity assay (SPA), a 
process that uses fluoromicrospheres coated with streptavidin to detect phosphorylation 
of substrates by kinases, to screen approximately 200,000 compounds.  
14 
 
Figure 1.5. Design of Sorafenib
35
 
Two commercially available 3-theinyl-urea compounds were identified as early leads.
37
 
Using traditional medicinal chemistry approaches they had no success in generating a 
more potent compound so they turned to rapid parallel synthesis, a method of making 
combinatorial libraries using robotic liquid handling and orbital shaker heating blocks.
37
 
A small library (~1000 compounds) was prepared and underwent a second HTS which 
identified a compound with nanomolar activity.
38
 This molecule was optimized using 
basic SAR to generate sorafenib. 
15 
 
Combinatorial chemistry has become the major source in developing numerous 
novel chemical entities (NCEs) to the pharmaceutical industry.
39
 The exact reason why 
this method is so efficient for discovering NCEs yet so ineffective in progressing 
compounds though the clinic is unclear, however, it is believed to be in part due to the 
type of structures generated using combinatorial approaches which often lack chirality 
and structural rigidity.
39
  
1.3.3 Chemical Library Design and Application 
1.3.3.1 Fragment-Based Design and Diversity Oriented Synthesis (DOS) 
 There is an urgent need to improve the libraries of compounds being used in drug 
discovery to find better leads in medicinal chemistry programs.
26
 Since the discovery of 
combinatorial chemistry, myriad processes to develop and optimize chemical library 
preparation have been developed. The challenges of designing a chemical library is a 
balancing act with cost, size, and structural diversity variables. Two approaches have 
emerged in library generation, fragment-based drug design (FBDD) and diversity-
oriented synthesis (DOS). These approaches are depicted in Figure 1.6 which was 
inspired by Galloway et al.(Figure 1.6).
26
 FBDD involves screening ligands that are small 
molecules which are not intrinsically drug-like, but might become fragments of drug-like 
compounds.
40
 While DOS generates structurally diverse, drug-like compounds for 
screening that involve minimal synthetic preparation.
41
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Figure 1.6. Fragment-Based Drug Design (FBDD) / Diversity-Oriented Synthesis 
(DOS)
26 
 
 
The two approaches have different advantages. FBDD uses a relatively small number of 
fragment-like compounds, usually less than ten thousand, capable of achieving greater 
chemical diversity and exploring more chemical space. Additionally, the synthetic 
resources used to generate such libraries are considered to be more cost effective than the 
more target specific approaches in DOS. Furthermore, several compounds from this 
approach are currently in clinical trials.
42
 The DOS approach efficiently utilizes more 
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drug-like compounds to screen against specific biological targets. Moreover, DOS 
provides access to molecules that have escaped the attention of humans and perhaps even 
nature by using common chemical intermediates.
26
 Ultimately, a diverse library of 
chemicals is desired to efficiently screen against the biological target. 
1.3.3.2 Library Screening: HTS versus Fragment-Based Screening 
The techniques of library generation have become quite specialized, however, 
without adequate ways to screen these libraries there would be little need to generate such 
massive or specific libraries. Thus, in the wake of library design technologies, screening 
technologies have also risen to the forefront of research programs.
43
 For almost two 
decades high throughput screening (HTS) of large molecule libraries in enzymatic and 
cellular assays have been the mainstay in terms of discovering early leads.
44
 However, for 
some time the school of thought suggested that a suitable lead would present itself 
provided the library of compounds was large enough. This thinking has not proven 
fruitful in terms of successful advancement of many new compounds to the clinic.
44
 For 
small molecule drug discovery, the natural limit in molecular weight is 300-500 Da to 
ensure reasonable bioavailability.
45
 Based on this molecular weight, Guida et al. 
estimates the size of chemical space comprises 10
60
 molecules, which would not be 
feasible to prepare or screen.
46
 Subsequently, as an alternative approach commercial and 
academic groups have turned to fragment-based screening in the past decade with 
renewed success in generating leads.
22, 47
 Two major aspects of fragment-based screening 
have set it apart from traditional HTS.
22
 Firstly, chemical space can be more efficiently 
probed screening pools of small fragments rather than large libraries because the number 
of potential fragments with 12 heavy atoms has been estimated at 10
7
 while the number 
18 
 
of drug-like molecules with up to 30 heavy atoms is approximately 10
60
.
47
 Secondly, 
since fragments are defined to be small in size, typically less than 250 Da, they should 
bind with a lower affinity (milli- and micromolar) to the biological target as compared to 
a more drug-like molecule (micro- and nanomolar) containing more interactions and 
larger chemical space, but will bind more efficiently on a per atom basis.
47
 This concept 
is also known as ligand efficiency.
48
 Finally, with a collection of fragments in hand, there 
are several methods to screen the library including nuclear magnetic resonance (NMR), 
mass spectrometry, and X-ray crystallography. SAR-by-NMR is considered by many to 
be the original and marquis technique in terms of fragments based screening 
approaches.
49, 50
 SAR-by-NMR has medium throughput, a low rate of false positives, and 
nets a tremendous amount of structural knowledge of the target.
43
 The disadvantage of 
this technique is the large of amount of protein required, typically >2 mg. SAR-by-MS is 
amongst the more powerful mass spectrometry based approaches for fragment based 
screening. These techniques are also considered to have medium throughput with a low 
rate of false positives. Additionally, the sizes of the proteins that can be screened against 
are much higher, typically up to 100 kDa, as compared to NMR screens which are 
typically 40 kDa or less, and can be screened with a smaller amount of protein.
43
 Finally, 
X-ray crystallography fragment based screens yield arguably the most complete picture 
of fragments binding to their target.
51
 However, one major disadvantage of this method is 
the relatively low throughput. Nevertheless, advances in this field are allowing for a 
steady increase in the throughput rates.
52
 
 
 
19 
 
1.3.4 Target-guided Synthesis (TGS) 
 Target-guided synthesis (TGS) has become an alternative to lead identification 
and optimization studies.
53
 When considering the aforementioned strategies, TGS 
combines a unique blend of chemical library synthesis and chemical library screening in 
one step that uses the protein as a template to generate inhibitors.
54
 There are three major 
classes of TGS: (a) Dynamic Combinatorial Chemistry (DCC), (b) catalyst/reagent-
accelerated TGS, and (c) kinetic TGS (Figure 1.7).
54-57
  
Figure 1.7. Convention Lead Discovery, DCC, and Kinetic TGS 
 
In DCC, two libraries of fragments with complementary functional groups will react 
reversibly to form all possible combinations. The equilibrium of the library is shifted in a 
dynamic fashion upon addition of the desired protein towards the assembled fragments 
with the highest affinity for the protein. Several potent inhibitors have been discovered 
using this technique.
55
 The catalyst/reagent-accelerated TGS approach acts similarly, 
however a reactant or catalyst is required to promote the reaction between the 
appropriately decorated fragments. Without a catalyst, there will be no covalent bond 
formation.
57
 Kinetic TGS makes use of a library consisting of fragments that will react in 
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an irreversible fashion to form a larger molecule. Hit identification consists of 
determining whether a given combination of reactive fragments in the presence of the 
target protein will generate an inhibitory molecule that can be readily detected. The key 
to the success of this technique is the use of a covalent reaction with a relatively slow 
rate, a water compatible transition state, and a minimal amount of side-product 
production. While studying 1,3-dipolar cycloadditions, Sharpless and co-workers 
discovered the reactivity profile of this heterocyclic formation to be well suited for 
kinetic TGS. This methodology, also known as in situ click chemistry, was used to 
develop potent enzyme inhibitors.
58, 59
  
1.3.4.1 Click Chemistry  
Click chemistry is a new approach that complements drug discovery processes 
well by making use of a near-perfect chemical reaction for the synthesis and assembly of 
building blocks into inhibitors.
59
 A click reaction must meet the following criteria: (a) 
wide scope, (b) high yield, (c) synthetic ease, (d) oxygen and water compatibility, (e) 
facile work-up and (f) simple product isolation.
59
 The reactions that fit these 
characteristics are typically carbon-heteroatom bond-forming with highly energetic 
„spring-loaded‟ starting materials. Examples of such click reactions are (a) cycloaddition 
reactions such as 1,3-dipolar and hetero-Diels-Alder, (b) nucleophilic ring-opening 
reactions such as epoxide and aziridine openings, (c) non-aldol carbonyl based reactions 
such as oxime ether and hydrazone formation, and (d) olefin additions such as 
epoxidation (Figure 1.8).
59
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Figure 1.8. Various Click Chemistry Reactions 
 
The premier click reaction is the Huisgen 1,3-dipolar cycloaddition of azides and 
alkynes that generates 1,2,3-triazoles as syn and anti regioisomers. Interestingly, azides 
and alkynes are amongst the least reactive functional groups used in organic synthesis 
despite being one of the most energetically rich click reactions.
58
 There are just a few 
well known protocols for the production of regioselective disubstituted 1,2,3-triazoles. To 
generate 1,4-disubstituted triazoles also known as anti triazoles, copper-(I) catalysts are 
employed, whereas 1,5-disubstituted isomers known as syn triazoles are generated using 
magnesium acetylides or ruthenium catalysis. The Huisgen 1,3-dipolar cycloaddition 
reaction is very appealing to drug discovery because of the reliability in reactivity as well 
as the favorable physicochemical properties of triazoles.
60-63
 Furthermore, they cannot be 
cleaved hydrolytically and they are very difficult to oxidize or reduce.
59
 Since the 
discovery of click chemistry the Huisgen cycloaddition has seen an unprecedented re-
emergence in synthetic chemistry, ranging from biophysics to materials science.
64-66
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1.3.4.2 In Situ Click Chemistry 
 In situ click chemistry is modular approach to library generation and screening 
that relies on fundamental organic transformations.
58
 Mock and co-workers discovered 
that there was a dramatic rate acceleration of the Huisgen 1,3-dipolar cycloaddition when 
the reagents were sequestered inside a host structure due to decreased entropic factors.
67
 
The reaction between azide and alkyne was increased by a factor 10
5
 when cucurbituril 
was used as the host molecule.
68
 This discovery prompted Sharpless to apply the Huisgen 
1,3-dipolar cycloaddition to kinetic TGS. Central to a successful kinetic TGS endeavor 
are clean reactivity, water tolerable intermediates, and relatively slow reaction rates at 
room temperature. The Huisgen reaction is highly dependent on spatial arrangements of 
the azide and alkyne, giving rise to large negative values of ΔS±. Moreover, these 
functionalities are inert at physiological pH and react extremely slow at room 
temperature. Sharpless and co-workers were successful in using the triazole forming 
cycloaddition to develop a method known as in situ click chemistry using the protein 
acetylcholine esterase (AChE) as the biological target/host.
69
  
 AChE was used as the protein template in the original proof of concept studies.
69-
71
 AChE plays a key role of neurotransmitter hydrolysis in the central and peripheral 
nervous system.
72
 The enzyme has an active center that is located at the base of a narrow 
gorge, ~20 Å in depth. This active center is comprised of the acylation and choline-
binding sites.
69
 There is a second binding site at the rim of this gorge near the surface of 
the enzyme, known as the peripheral binding site (Figure 1.9).
73
 Inhibitors that span the 
active site and peripheral site have been shown to exhibit tighter binding than the 
individual components. 
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Figure 1.9. Structure of AChE Active Site and Peripheral Binding Site 
 
 Forty nine combinations of azide and alkyne building blocks (PZ6-8, PA2-6, 
TA1-3, and TZ2-6) which were known inhibitory compounds of AChE were incubated 
in the presence of eel AChE at room temperature for 6 days (Figure 1.10). With the 
enzyme serving as a template for the Huisgen 1,3-dipolar cycloaddition, the formation of 
a single product, syn-TZ2PA6, was generated in regioselective fashion out of the 98 
possible combinations (49 building blocks with syn and anti triazoles). The rate of 
reaction without protein is negligible, and therefore detectable amounts of triazole should 
form only when one azide and one alkyne are brought together by the enzyme. TZ2PA6 
when generated thermally produced an approximate 1:1 mixture of syn and anti products. 
The syn-TZ2PA6 was shown to have a 99 fM dissociation constant, more potent than any 
known non-covalent inhibitor of AChE by two orders of magnitude (Figure 1.11). The 
dissociation constant of anti-TZ2PA6 was determined to be 14,000 fM, binding 140 
narrow gorge
~ 20 Å depth
active site
peripheral 
binding site
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times less tightly than syn-TZ2PA6. Thus, the more potent syn-TZ2PA6 was preferably 
synthesized by the enzyme. 
Figure 1.10. Initial In Situ Click Chemistry Experiments Using eel AChE 
 
Initially, desorption/ionization on silicon mass spectrometry (DIOS-MS) which is a 
matrix free MALDI technique that is devoid of background matrix peaks, was used for 
detection in the screening process. However, the sensitivity was poor due to background 
signals of the protein which limited the detection of the corresponding triazole.  
Figure 1.11. Known Inhibitors of AChE 
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 Follow up X-ray crystallographic studies on mouse AChE (mAChE) with syn-
TZ2PA6 and anti-TZ2PA6 confirmed the bivalent nature of these inhibitors occupying 
both binding sites.
74
 As envisioned, the TZ2 moiety engages the active site while the PA6 
unit was seen bound to the periphery site. Interestingly these studies also revealed that the 
triazole portion of the compound engaged in hydrogen bonding and non-polar stacking 
interaction with several of the amino acids lying in the gorge of the enzyme. This 
observation highlighted that not only were triazoles good linkers, but that they could also 
serve as active pharmacophores which could contribute to target binding.
71
 Furthermore, 
the rate acceleration witnessed by the protein templated reaction as compared to the 
thermal triazole formation is not only due to entropic effect, but also due to an enthalpic 
stabilization of a triazole-like transition state during the in situ reaction.  
 Sharpless and co-workers further aimed to optimize this approach by investigating 
several aspects including (a) increasing the sensitivity and throughput of the analysis 
method and (b) using in situ click chemistry to find new inhibitors based on building 
blocks with unknown peripheral binding potentials of AChE.
71
 The analysis method was 
changed several ways including sampling the buffer/enzyme reaction mixture directly as 
well as adopting HPLC that utilized electrospray ionization in the positive selected ion 
mode (LC/MS-SIM). This method provides fewer “false-negatives”, and allows for 
shorter reaction times. The products of the enzyme templated reaction are identified 
based on molecular weight and retention time. The protocol was validated by using the 
TZ2 and PA6 fragments which combine to generate the previously observed in situ hit 
syn-TZ2PA6 (Figure 1.10). After an incubation period of only 6 hours, a distinct product 
signal corresponding to TZ2PA6 was observed. The high sensitivity of this protocol 
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allowed for the shorter incubation time, cutting it from 6 days to 6 hours. Control 
experiments using bovine serum albumin (BSA) instead of AChE failed to provide any 
detectable amount of TZ2PA6. Based on these results, the previous library of 49 possible 
combinations was screened again with an additional member, PZ5, which increased the 
number of possible combinations to 52 (104 potential products). Using the new LC/MS-
SIM protocol, 4 hits emerged as opposed to the one hit previously reported using DIOS-
MS (Figure 1.12). TZ2PA6, TA2PZ6, TZ2PA5, and TA2PZ5 were identified by 
looking for a significant difference between the chromatograms of the enzyme reactions 
and the control reactions (BSA instead of AChE). The hits were further confirmed by 
making them synthetically and comparing the retention times of the synthetic compounds 
versus the retention times of the in situ hits.
71
 Interestingly, only TZ/PA and TA/PZ 
combinations, not TZ/TA provided in situ hits. Furthermore, all of the hits contained 
triazole moieties two methylene units from the tacrine core. Other analogs containing the 
same overall linkage but with the triazole in a different location did not form (ex: 
TZ3PA5) suggesting that there is a critical interaction for the triazole formation in that 
corresponding location of the enzyme. This was further supported by the previous X-ray 
structures showing π-interactions of phenyl residues and the triazole moiety.74 
 The initial X-ray studies were completed with mAChE therefore to determine the 
species dependence of product formation the same library was incubated and screened 
against eel AChE. The two species share a 58% sequence identity and 70% residue 
homology.
75
 Incubation of the library and screening revealed the same four hit 
compounds that hit against mAChE also hit eel AChE.  
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 The LC/MS-SIM method was further tested to determine if combinatorial sets of 
fragments could be screened simultaneously. Thus, the azide TZ2 and a mixture of 4 
phenylphenanthridinium building blocks, PA2-PA5, were incubated with eel AChE at 
37ºC overnight. LC/MS-SIM detected TZ2PA5 as the sole product. This experiment 
proved that the multicomponent screening was possible with a slight decrease in 
sensitivity.  
Figure 1.12. In Situ Click Chemistry Hits Using LC/MS-SIM 
 
 Analysis of the X-ray crystal structure revealed that the less tightly bound anti-
TZ2PA6 had a minor effect in dictating enzyme conformation. However, the tightly 
bound syn-TZ2PA6 isomer, which had a shorter total distance between the tacrine and 
phenylphenanthridinium portions of the molecule, forces the enzyme into an 
unprecedented conformation.
71
 The difference in length between the tacrine and 
phenylphenanthridinium portions of the molecule is due to the spatial arrangement 
generated by the syn- as compared to the anti-triazole. The distance between the tacrine 
and phenylphenanthridinium moieties is 1.52 Å shorter in the syn-isomer, which is 
approximately one C-C bond in length. This raised the question whether AChE could 
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accommodate the shorter anti-TZ2PA5 based on a longer anti-triazole with a deleted 
methylene group. Subsequently, TZ2PA5, TA2PZ6, and TA2PZ5 were synthesized as 
mixtures of both regioisomers as well as the pure anti-isomer. The mixtures were 
generated by thermal cycloaddition, while the anti-isomers were prepared using a CuSO4 
catalyzed protocol (Figure 1.13). 
Figure 1.13. Synthesis of Triazoles 
 
 The regioisomer determination for the triazoles generated by the protein was 
accomplished by comparing HPLC traces of the in situ reactions with authentic samples 
from the thermal and the Cu(I) catalyzed reactions. The LC/MS-SIM method was able to 
aid further in the regioisomer determination by limiting the amount of protein necessary 
to one-third the amount originally used in the screen. It was determined that the TZ2PA6, 
TZ2PA5, TA2PZ6, and TA2PZ5 were all the syn-isomer. This was not surprising for 
TZ2PA6 and TA2PZ6 based on the previously described results. However, this was 
surprising for the analogs bearing only a total of seven methylene units, in which “anti-
mode” conformation would elongate the overall distance. These results suggested that the 
stereoelectronics controlling the cycloaddition inside the enzyme are very demanding and 
would not allow for this anti-conformation for these analogs. 
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 Finally, the binding measurements were performed on the four triazole hits 
(Figure 1.14). Both anti- and syn-isomers were examined. For both mouse and eel syn-
TZ2PA6 remained the most potent out of the four inhibitors (three new hits plus syn-
TZ2PA6) at 99 fM. 
Figure 1.14. Dissociation Constants for anti and syn-Triazole Hits  
 
 Ultimately, these results were encouraging enough to begin using in situ click 
chemistry to search for novel inhibitory compounds via building blocks decorated with 
azides and alkynes that were not known to bind to AChE. 
70
 To alleviate the number of 
variables in the search the building block TZ2 served as an “anchor” molecule. This 
building block would engage and link irreversibly to novel peripheral alkyne building 
blocks to form new AChE triazole inhibitors. The two methylene TZ2 building block was 
optimal in terms of distance from the active site. A library of heteroaryl alkynes with five 
syn-TZ2PA5 syn-TA2PZ6 syn-TA2PZ5syn-TZ2PA6
99 fM
410 fM
100 fM
2300 fM
540 fM
3000 fM
830 fM
610 fM
eel
mouse
Kd
anti-TZ2PA5 anti-TA2PZ6 anti-TA2PZ5anti-TZ2PA6
14000 fM
8900 fM
42000 fM
33000 fM
140000 fM
44000 fM
100000 fM
42000 fM
eel
mouse
Kd
30 
 
and six methylene units separating the aryl moiety from the alkyne was prepared (Figure 
1.15).  
Figure 1.15. Library of Unknown Inhibitors and Anchor Molecule 
 
Multicomponent screening would be employed to increase the throughput by using ten 
alkyne containing building blocks simultaneously with the anchor molecule in the 
presence of the enzyme. This would also probe the systems capabilities of whether an 
enzyme complex with a single reaction partner bound can selectively choose the best 
triazole-forming partner in situ amongst other alkyne containing partners.
70
 
 The screen was initially performed by incubating TZ2 and single alkyne building 
blocks with eel or mouse AChE at pH 7.4 for 6h and analyzing each reaction mixture by 
LC/MS-SIM. From the entire alkyne library two phenyltetrahydroisoquinoline analogs 
emerged as hits with the TZ2 building block to generate TZ2PIQ-A5 and TZ2PIQ-A6. 
These compounds were prepared and both regioisomers were isolated as previously 
described.
71
 These hits were encouraging because the phenyltetrahydroisoquinoline 
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displayed better physicochemical properties lacking any formal positive charge and two 
free amino groups. The hits were validated by running the same screen in the presence of 
bovine serum albumin (BSA) which resulted in no triazole formation. 
 Next, the multicomponent mixtures were examined by using TZ2 and 10 
structurally related alkynes including PIQ-A5 and PIQ-A6 (Figure 1.16). The total 
number of possible combinations was 32 due to the 2 enantiomeric forms of the racemic 
compounds as well as the anti and syn-triazole possibilities.  
Figure 1.16. Multicomponent Screening of Mouse AChE 
 
The only formed products in this screen were TZ2PIQ-A5 and TZ2PIQ-A6. Thus, the 
TZ2/enzyme complex was able to selectively recognize alkyne structures to generate 
triazoles inhibitors. This experiment proved that these screens were indeed practical and 
could prove useful for multicomponent medium-throughput screening. 
 The regioisomers that were generated in situ were determined as previously 
described.
71
 However, the individual building blocks PIQ-A5 and PIQ-A6 were racemic 
and had to be individually isolated using recrystallization techniques. Then, the 
enantiopure alkynes were combined with TZ2 to generate enantiopure TZ2PIQ-A5 and 
TZ2PIQ-A6. The four compounds were then tested for their corresponding dissociation 
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constants. An even more potent compound emerged, syn-(R)-TZ2PIQA6 with a KD of 
33 fM (Figure 1.17). 
Figure 1.17. Novel mAChE and eel AChE Inhibitors via In Situ Click Chemistry 
 
 In situ click chemistry has been extended to several other protein systems 
recently. Carbonic anhydrase (CA), HIV protease, and bacterial chitinases.
76-78
 In 2009 
Heath and co-workers explored the possibility of using in situ click chemistry to develop 
antibody-like protein-capture agents.
79
 This was achieved using resin-bound peptides 
containing azides and alkynes in the presence of bCA II.  
 In summary, the initial in situ click chemistry proof of concept experiments 
revealed that the approach has great potential for lead discovery and optimization.
69-71
 
Potent inhibitors could be produced within the enzyme‟s binding site provided one of the 
two building blocks had sufficient affinity for the active site to serve as an “anchor” 
molecule. These triazole containing inhibitors are the most potent known inhibitors of 
AChE to date with low-femtomolar dissociation constants. A direct comparison of anti- 
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and syn-isomers was achieved as well using this technique which highlighted the 
difference in binding potential of the individual regioisomers. This method has promising 
potential in medicinal applications as well as FBDD approaches.  
1.3.4.3 Alternative Kinetic TGS 
 A reaction that is suitable for kinetic TGS has to meet several criteria. The 
Huisgen 1,3-dipolar cycloaddition is by far the most qualified reaction for this approach, 
however, many alternative reactions that fit this profile have been discovered. These 
modern approaches rely on the following reactions: (a) carbon-sulfur bond formation, (b) 
carbon-nitrogen bond formation, (c) carbon-carbon bond formation, (d) amide formation 
arising from thio acids and sulfonyl azides, and (e) Ugi reactions (Figure 1.18 A-E).
80-85
  
Figure 1.18 A-E. Alternative Kinetic TGS Reactions 
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1.3.5 Drug Design and Drug Optimization 
1.3.5.1 Structure-Activity Relationship (SAR) 
 Ligand based drug design uses insight from structural information in a molecule 
to gather new information of a desired biological target.
24
 Once a target has been 
identified and the preliminary screening process has been achieved using the techniques 
previously described, a pharmacophore will emerge. The pharmacophore is the core 
structural motif from which the lead optimization strategy will be based upon. This motif 
consists of the key atoms in the molecule central to the biological activity as well as their 
relative position in space to one another. The pharmacophore can be a natural product, a 
natural product analog, a fragment-like molecule discovered in a screen, or a very 
specific drug-like molecule discovered in a DOS screen.
9, 22, 26
 During the initial 
screening process, an activity assay or an efficacy assay of some sort is used to discover 
the lead. Generally, this process will be in place and present for the research program to 
move forward with the optimization process. Nonetheless, in more advanced stages of 
development more intricate assays or experiments may be necessary. The eventual drug 
should have a good selectivity and activity for the biological target with little to no side 
effects. It should also be relatively easy to synthesize and chemically stable. Finally, the 
pharmacokinetic, pharmacodynamic, and toxicity properties must be optimized. 
Pharmacokinetics refer to the drugs ability to reach its target and to have an acceptable 
lifetime, while, pharmacodynamics refer to the ability of the drug to interact with its 
target or interact adversely with other targets along the way leading to potential toxicity. 
SAR is directly related to pharmacodynamics while many of the SPR techniques are 
related to the pharmacokinetics of the drug. 
35 
 
 Developing the structure-activity relationship (SAR) involves the synthesis of 
numerous analogs. Next, the synthesized analogs are tested for biological activity 
utilizing the respective assay that was used to discover the pharmacophore. Then, 
decisions are made based on the activities of the new analogs as to what direction to take 
in the design process. Functional groups of the pharmacophore are the first place to start, 
and can typically be manipulated in a number of synthetic transformations.
86
 By 
removing the key functionality that is present, a loss of activity should be apparent. 
However, there may be more functional groups present in the molecule that are not 
required for biological activity.
86
 These groups can be replaced, tethered at various 
distances, removed all together, protected, etc. The three key interactions that are targeted 
in the design are: (a) ionizable groups, (b) potential van der Waals binding groups, and 
(c) hydrogen bonding groups. The interaction of the functional groups with different 
targets can vary significantly. The placement or position of functional groups within the 
molecule can be very important for activity. Extensions of the core structure, ring 
expansion/contraction, ring variations, ring fusions, rigidification of the core structure, 
and conformational constraints are all possible design opportunities that are capable of 
increasing affinity towards the target. There are other more rare structural elements that 
may present themselves such as the possibility of tautomers. Tautomers exist when a 
functional group or heterocycle has the capability of two different structures in 
equilibrium with one another. SAR studies can be performed on a trapped tautomeric 
form or in some cases one tautomer is thermodynamically more stable than the other.
86
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1.3.5.2 Structure-Property Relationship (SPR) 
 Structure-property relationship (SPR) studies are a more modern aspect of the 
drug design process.
87
 Pharmacokinetics is the ability of a drug to reach its target with an 
acceptable lifetime, and the optimization is done through SPR. Advancement in assay 
techniques as well as detection equipment have allowed for implementation of such 
strategies in many research programs.
88
 Some of the key properties that are analyzed 
when optimizing the pharmacokinetics are lipophilicity, pKa, solubility, permeability, and 
metabolic stability. By examining these properties during the earlier stages of the lead 
optimization it is believed that the attrition rates of drugs going into clinical studies will 
be reduced.
89
 
 Lipophilicity is the tendency of a compound to partition into a nonpolar lipid 
matrix versus an aqueous matrix. Lipophilicity of simple systems is readily calculated by 
modern modeling software. Traditionally, the lipophilicity is assessed by octanol and 
water mixtures. Log D is the log of the distribution coefficient of the compound between 
an organic phase (octanol) and an aqueous phase (water or buffer) at a specified pH. Log 
D assays at a pH of 7.4 can be useful for estimating drug-like properties.
7
 Log D7.4 <1 
have good solubility and poor permeability due to a polar nature. Log D7.4 between 1 and 
3 is ideal since the compound has a good balance of solubility and permeability leading 
to a favorable absorption. Log D7.4 >5 typically have poor bioavailability due to a very 
poor solubility.
7
 
 Solubility is one of the most important properties in drug design.
90
 Solubility is 
the maximal dissolved concentration under given solution conditions. This property is 
determinant of intestinal absorption and bioavailability. 
90
 Several factors affect solubility 
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including the physical state that the compound is introduced into a solution, the 
composition and physical condition of the solvent, as well as the method and 
measurement used to determine the solubility. The two major types of measureable 
solubility are kinetic solubility and thermodynamic solubility.
7
 Kinetic solubility has two 
major characteristics: (a) the compound is initially fully dissolved in an organic solvent, 
and (b) equilibrium is not reached between dissolved compound and solid compound. 
Therefore, the compound should not precipitate out from solution during the assay. 
Kinetic solubility measurements are useful for determining bioassay liabilities, 
developing structure-solubility relationships, and developing different formulation for in 
vivo experiments. Thermodynamic solubility also has two fundamental characteristics: 
(a) aqueous solvent is added directly to solid crystalline material, and (b) an equilibrium 
is established between the dissolved and solid material. Long mixing times are used as 
well as an excess of solid. This method is not useful in early drug development stages but 
is more relevant in late stage development to determine the properties of the crystal form. 
 In order for a compound to absorb in the intestine, it must first dissolve, and 
diffuse to the surface of the intestinal epithelium. As the compound concentration 
increases when it dissolves, more drug molecules are present at the surface of the 
epithelial cells. Thus, a greater amount of drug molecules per unit time per surface area 
are absorbed. This is known as flux. Ironically, compound solubility and permeability are 
typically inverse to one another and so a balance of both properties must be met to 
achieve the maximum absorption. Just as with SAR studies, many of the same 
transformations that are taken in increasing the affinity of the lead to the biological target 
are relevant in optimizing the solubility of the compound. Several HPLC techniques are 
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known to determine the solubilities, which can be studied to determine which 
modifications increase the solubility while maintaining a reasonable activity.
90
 
 Permeability is defined as the velocity of a molecule through a membrane barrier. 
During the absorption process it is necessary for the molecule to pass through the 
intestine, blood-organ barrier, liver and kidneys, as well as the cell of the target.
91
 
Prediction of drug permeability can aid in the drug discovery process immensely by 
helping to optimize cell-based assays and assist in pharmacokinetic data interpretation.
7
 
When a drug molecule approaches a membrane/barrier, there are several different 
possible permeability mechanisms in which the molecule can make its way pass the 
membrane. The different types are passive diffusion, active transport, endocytosis, efflux, 
and paracellular diffusion (Figure 1.19).  
Figure 1.19. Major Permeability Mechanisms
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They are caused by different qualities of lipid matrices. For example, membrane 
transporter expression causes some molecules to bind to known receptors where they 
trigger a biochemical response and are brought inside the cell and through to the other 
side. In other cases tightness or junctions between cells may cause paracellular diffusion.
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 The most heavily assayed form of permeability is passive diffusion, because of a 
molecules natural tendency to move through the body into different cellular 
compartments and tissues through cellular lipid bilayer membranes. Generally, a 
molecule must move through several membranes and cellular matrix during this process. 
This process is driven by a concentration gradient, drug molecules move from an area of 
high concentration to an area of low concentration. The more lipophilic a compound is 
the greater its permeability will be, however, the less soluble it will be as well. Since a 
concentration gradient is central to this process, pH and pKa are important to overall 
outcome. Permeability data is typically gathered through a parallel artificial membrane 
assay known as PAMPA, where the same pH is held on both sides of the membrane. 
Using UV absorption analysis, one can determine how much of a compound is in the 
membrane and how much diffused.
91
 The passive diffusion of acids is greater at low pH 
and the diffusion of bases is greater at high pH. Several pHs can be screened and a 
correlation can be made as to the nature of the molecules overall permeability. This assay 
not only gives a sense of the overall permeability, it allows the prediction of permeability 
in different organelles of the biological target which will vary in pH. Again, structural 
modifications can be made and screened to increase or decrease permeability. As data 
emerges the direction of where to take the molecule in terms of advancement begin to 
become apparent, however, some results may contradict one another or become blurry as 
to which design decision is correct. Nonetheless, if an adequate library is screened 
properly, and the most insightful decisions are made these processes can lead to a 
preclinical candidate.
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1.4 Malaria Prevention and Drug Discovery 
1.4.1 Endemic Regions, Immunity, and Vaccine Development 
 Malaria has the greatest impact upon humans of all the protozoan diseases. 
Although it has been eradicated in many temperate zones such as the United States and 
northern Europe, it is still endemic in over 40% of the world‟s population. This endemic 
region is mostly located in Africa, Asia, and South and Central America which have a 
tropic or sub-tropic environment.
92
 Malaria was quite common in the United States up 
until about 1940‟s, with the peak of incidence around 1875.93 Massive population shifts 
from rural to urban zones marked the decline of malaria due to drainage of swamps, 
better living conditions, greater medical care, and the widespread availability of 
quinine.
93
 In the 1940‟s more preventative measures became common such as larviciding 
and house spraying.  
 Immunity to the disease is observed in people living in endemic areas. When a 
person is exposed to the disease, they will have symptoms and in further exposures these 
symptoms are reduced. However, the immunity develops slowly and requires multiple 
exposures. Unfortunately, in the endemic areas small children are the most at risk for 
transmission of severe malaria, thus, more mature children and adults are less susceptible 
to death during exposures.  Immunity is not a sterilizing affect and the susceptibility of 
patients can resurge. For example, when an adult has been in an endemic area for a long 
period of time and leaves for some time, when that adult returns they will be capable of 
contracting severe malaria again.
94
 This immune response is associated with pre-
erythrocytic or erythrocytic stages of the parasite. It is believed that the blood stage is the 
most important in terms of clearing the parasite and eventually diminishing the disease. 
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Antibodies block merozoite invasion and destroy infected cells which help reduce 
parasitemia. The Plasmodium genus has complex genetic machinery and therefore, the 
different types of antibodies that a host must develop cause a slow generation of 
immunity to the disease. Nonetheless, individuals displaying natural immunities to the 
disease have triggered interest in the search for developing a vaccine. 
 There is not a current vaccine on the market, however, much research is being 
dedicated to the development of one. There is interest in developing a vaccine to malaria 
because of the overwhelming difficulty in clinically treating chemical resistance and a 
rising socioeconomic barrier. A major hurdle is the stage specific targeting point that a 
vaccine must have.
95
 Sporozoite and exo-erythrocytic stage vaccines would prevent the 
disease. The major setback with this approach is the survival of even one sporozoite can 
cause a subsequent infection. Vaccines aimed at the merozoite or infected erythrocytes 
would stop the pathogenesis of the disease by eliminating infected red blood cells. A 
vaccine targeting the toxic antigens produced by the parasite itself is a possibility. This 
route would not lower parasitemia but would reduce the amount of pathogenesis the 
patient experiences. Finally, a vaccine targeting the sexual stages of the gametocytes 
could be envisioned in which antibodies targeting gamete antigens would prevent 
infection of the mosquito and stop the transmission of the disease.
96
 
1.4.2 Malaria Stage Specific Therapeutics and Eradication 
 In 2007 the Bill and Melinda Gates Foundation set an agenda with the final goal 
being the eradication of malaria. Although this may sound like a lofty goal, when 
analyzing the fronts on which antimalarial research is attacking the disease it becomes 
apparent that this could be achieved. Currently, there are efforts ongoing to develop drugs 
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against all life cycle stages including: blood/erythrocytic stages, exo-erythrocytic/liver 
stages, and sexual/gamete stages. Furthermore, vaccines, insecticides, larvicides, and 
sleeping nets are further supporting the war on malaria. If all of these agendas were to be 
met with a successful candidate emerging it is hard to believe that the eradication of the 
disease would be far off.
2
 
1.4.2.1 Blood Stage Antimalarials 
 The majority of historical and modern antimalarial medicines target the blood 
stages of P. falciparum, which is responsible for the majority of the global infections. 
There are five known species to infect humans: P. falciparum, P. vivax, P. ovale, P. 
knowlesi, and P. malariae, and drugs such as the artemisinin combination therapies 
(ACTs) that are known to be active against P. falciparum are assumed to be active 
against all of the species. The fifth known species recently seen to infect humans known 
as P. knowlesi, is still under detailed investigation. There are three key differences 
amongst the species from a treatment perspective: (a) following infection by a mosquito 
P. falciparum and P. malariae rapidly progress through the hepatocytes undergoing 
asexual divisions while P. vivax and P. ovale can become dormant within the hepatocytes 
forming hypnozoites, (b) replication times within the host, and (c) time of appearance in 
gametocytes in the bloodstream.
2
  
 Quinine was the first widely used antimalarial drug, and was critical in the 
removal of widespread infection in the United States and Northern Europe 
2, 93
 Synthetic 
analogs of quinine such as chloroquine and the 8-aminoquinolines (8AQs) have been 
mainstays in endemic areas (Figure 1.20). Therapeutics of this class target hemoglobin  
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Figure 1.20. Classical and Modern Antimalarials
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degradation in the food vacuole of the parasite. Leading to accumulation of toxic free 
heme that results in cell lysis and parasite cell autodigestion.
15
 Many other drugs and 
drug targets have been identified in the past 3 to 4 decades, however emerging chemical 
resistance to most therapeutics is quite concerning. Atovaquone, 
sulfadoxine/pyrimethamine, mefloquine, and chloroquine have become increasingly non-
effective for treatment, with resistance to enzyme targeting drugs occurring more rapidly 
than drugs targeting hemoglobin degradation. Furthermore, some resistance is more rapid 
in one species than another, such as P. falciparum which developed resistance to 
chloroquine in the 1960‟s whereas P. vivax developed resistance to chloroquine in the 
1990‟s.  
 The World Health Organization (WHO) recently promoted the widespread use of 
artemisinin combination therapies (ACTs) in Africa.
97
 Artemisinin was discovered in 
1972 by Chinese scientists.
98
 This endoperoxide-containing natural product isolated from 
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the leaves of Artemisia annua has been the focus of much research in terms of analog 
design. Many potent derivatives such as dihydroartemisinin (DHA), artemether, 
artemotil, and artesunate can be combined in different proportions to generate the 
artemisinin combinations seen in ACTs (Figure 1.20).
2
 Drug combination therapies make 
use of two or more drugs at once during a treatment to reduce the chances of drug 
resistance developing. Unfortunately, recent reports of emerging resistance with ACTs in 
Asian countries has further strengthened the efforts of alternatives to common medicines 
and new chemotypes.
99, 100
 Artemisinin works to rapidly clear blood stage parasites as 
well as destroy sexual gametocyte stage parasites. However, they are not effective against 
exo-erythrocytic stages.
101
 Severe malaria, often seen in young children, is typically 
manifested in unconscious patients and must rapidly be administered intravenously. 
Quinine was used traditionally, however, rapid parasite clearance times (PCT) of 
artemisinin analogs make them the superior candidate in terms of severe clinical 
treatments. Currently, the efforts to continue the battle against blood stage malaria faces 
challenges such as drug resistance, limited supply of ACTs, and a lack of suitable drug 
candidates in the pipeline. 
1.4.2.2 Exo-erythrocytic Stage Antimalarials and Prophylaxis 
 Liver stage parasites of all species must undergo a proliferation period before they 
invade red blood cells. This stage can be targeted by several drugs but, primaquine is the 
only drug used against this stage clinically.
16
 Hypnozoites are responsible for the 
persistent reoccurrence of the disease which are found in P. vivax, P. ovale and 
primaquine is known to kill these forms. Currently, primaquine is the only drug approved 
for clinical use that kills dormant liver stages of parasite development, thus preventing 
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relapse, while simultaneously reducing infectivity of mature gametocytes, ultimately 
contributing to reduced transmission (Figure 1.20). Unfortunately, primaquine is toxic for 
patients with glucose-6-phosphate dehydrogenase deficiency and has poor 
pharmacokinetics, requiring 14 daily doses to achieve radical cures.
102, 103
 Due to the 
success of ACTs, there has not been an avid search for liver stage therapeutics. However, 
with the emerging resistance and the challenge set forth from the Bill and Melinda Gates 
Foundation, renewed interest in developing these agents has arisen. Since the short 
hepatic phase precludes the invasion of erythrocytes, only full inhibition of liver stage 
parasites will lead to true overall prophylaxis. Transmission would also become 
interrupted because the gametocytes mature in the RBCs. The major hurdles to the 
development of true liver stage medications include: (a) the difficulty in 
studying/assaying the liver stage of P. falciparum, (b) cost and ethical considerations of 
obtaining a significant amount of the infected hepatocytes, and (c) highly variable 
replication times in the hepatocytes. The time from sporozoite infection to invasion of 
RBCs by merozoites varies from 48 hours in P. falciparum to 15 days in P. malariae.  
 Until recently, researchers could only screen large numbers of compounds in vivo 
which were costly and time consuming. Several new advances with in vitro assays have 
driven the search to include some limited HTS.
104, 105
 Possession of infective sporozoites 
is the most important resource when beginning liver stage assays. This requires access to 
mosquitoes in which development can be achieved with a supply of blood that contains 
infectious gametocytes. Large laboratories and expensive equipment with highly trained 
staff are required.
16
 In the 1950‟s most screening was conducted on avian models. This 
slowed the early efforts of liver stage antimalarial development because avian species of 
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Plasmodium develop in endothelial cells not in hepatocytes. A key discovery for malaria 
research was made when it was found that a species of Plasmodium (P. berghei and P. 
yoelii) that infected African thicket rats could subsequently infect laboratory rodents and 
be transmitted by laboratory-bred anophelines. This eventually affected liver stage 
research as it was now possible to investigate hepatocytes without having to use infected 
primates and humans.
106
 The hepatic stages of P. berghei mature in 48-68 hours and have 
an erythrocytic cycle of 21 hours, which makes for improved data analysis. 
Unfortunately, none of the Plasmodium that infect laboratory rodents undergo hypnozoite 
formation, making it increasingly difficult to study this aspect of liver stage 
development.
16
 Humans are by far the best test subject for identifying and treating disease 
clinically, however, there are numerous ethical considerations. Therefore, primates have 
become the model of choice. P. cynomologi is the parasite known to infect primates. 
Furthermore, this species is known to develop hypnozoites and has been the subject of 
much liver stage research.
107, 108
 Currently, of the compounds that display anti-liver stage 
efficacy, only a very few are suited for drug development. Substantial hurdles must be 
overcome to advance the drug design of liver stage antimalarials. Hopefully, by 
employing new in vitro models and P. cynomologi in vivo studies a drug candidate can 
emerge. 
1.4.3 Endochin and Quinolone Based Antimalarials  
 Recent understanding of the mechanism of action and resistance to current drugs 
in the antimalarial field suggest that previously discovered leads remain viable candidates 
provided renewed efforts are taken to overcome chemotype specific hurdles. One 
example of this challenge is the 4(1H)-quinolone, endochin (Figure 1.21), which, in the 
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1940s, was identified to be a causal prophylactic (kill growing liver stage parasites) and 
potent erythrocytic stage agent in avian malaria models. However, the lead languished 
due to inadequate preclinical models and a poor understanding of parasite 
biochemistry.
109
 Approximately 25 years later, Casey tested a focused series of 3-alkenyl- 
and 3-alkyl-2-methyl-4(1H)quinolones (Figure 1.21), but no antimalarial activity was 
observed in the utilized preclinical screen (Rane single dose rodent malaria model).
110, 111
 
A simultaneous evaluation of coccidiostat quinolone ester analogs identified compound 
ICI56,780 (Figure 1.17), which displayed causal prophylactic (single dose of 30 mg/kg 
subcutaneous) and blood schizonticidal activity (ED50 = 0.05 mg/kg) in rodent malaria 
models.
112
 This compound and another structurally related 4(1H)-quinolone ester were 
later shown to have antirelapse activity in P. cynomolgi infected rhesus monkeys (10-30 
mg/kg subcutaneous).
108
 Unfortunately a high degree of resistance to these agents was 
obtained after one passage in P. berghei infected mice plus a lack of oral bioavailability 
led to their abandonment.
112
 
 A similarly related heterocyclic motif to the 4(1H)-quinolones are the 1,2,3,4-
tetrahydroacridin-9(10H)-ones (THAs). In 1975, Durckheimer and co-workers 
discovered the dihydroacridinedione floxacrine (Figure 1.21).
113
 Though floxacrine had 
promising characteristics including causal prophylactic activity,
114-116
 it suffered from 
poor solubility
117
, parasite drug-resistance, and dose-dependent chronic periarteritis.
118
 
Shortly after, a new synthetic analog, WR243251, with superior properties devoid of the 
aforementioned disadvantages of floxacrine, emerged (Figure 1.21).
117
 However, during 
late preclinical development, compound 2 was abandoned due to suboptimal stability, 
cross-resistance with atovaquone, and lingering concerns over toxicity.
119
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Figure 1.21. Quinolone Based Antimalarials 
 
 Since the aforementioned studies were conducted over 20 years ago without 
adequate evaluation in current preclinical efficacy models and without assessment for 
proper drug-like properties, the endochin series has recently gained attention by several 
research teams. More than 40 endochin and quinolone ester analogs obtained from the 
Walter Reed Army Institute of Research (WRAIR) chemical inventory were re-evaluated 
in a current erythrocytic in vitro study.
86
 Surprisingly, several 4(1H)-quinolones were 
found to have remarkable in vitro potency in the low nM-range against erythrocytic 
stages of multidrug resistant isolates and clones of P. falciparum (D6 and TM90-C2B), 
while the cross resistance with atovaquone was not found to be complete across the 
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chemical series. Additionally, Riscoe and Winter reported similar results with endochin 
and analogs thereof.
120
 Most compounds displayed in vitro antiplasmodial activities with 
EC50 values in the low nM-range against a panel of P. falciparum isolates (D6, Dd2 and 
TM90-C2B) as well as negligible cross resistance and cytotoxicity. Also, preliminary 
mechanism of action studies based on oxygen consumption by P. yoelii infected 
erythrocytes indicate that the 4(1H)-quinolones target the cytochrome bc1 complex, 
which is responsible for the parasite‟s respiration. These data suggest that endochin and 
analogs thereof have great potential as novel antimalarials. 
1.5 Research Aims 
 With the tremendous impact of malaria on impoverished countries, including 
hundreds of millions of cases and over one million deaths annually combined with the 
emergence of chemical resistance to many common antimalarials, the need for 
identifying and developing new compounds is very important. Historically, compounds 
such as endochin, floxacrine, and chloroquine have either failed completely in vivo, 
possessed poor physicochemical properties that led to the abandonment in clinical phases, 
or have induced considerable levels of chemical resistance. Initial investigations of 
malaria were based on screenings at the WRAIR that included 4(1H)-quinolones, 1,2,3,4-
tetrahydroacridones (THAs), and 7-(2-phenoxyethoxy)-4(1H)-quinolones (PEQs) 
scaffolds. The results of the preliminary findings made apparent three main objectives: 
(a) re-evaluate the efficacy of older compounds using SPR, (b) improve the potency of 
each through SAR while improving on any liabilities such as poor solubility and 
permeability discovered in the SPR studies and (c) optimize improved compounds to 
become in vivo active with an emphasis of producing a bio-orally available candidate. 
51 
 
 Furthermore, efforts to generate species specific inhibitors of AChE using in situ 
click chemistry have been conducted. The generation of species specific inhibitors is 
medicinally relevant especially in the fields of antimicrobial and pesticide development. 
THA derived inhibitors of AChE were designed and synthesized based off previous proof 
of concept studies by Sharpless and co-workers. Knowledge of the mouse AChE, eel 
AChE and drosophila AChE was obtained through detailed X-ray studies of these 
enzymes. By exploiting significant structural differences, a small library of compounds 
capable of selectively inhibiting these enzymes was designed and synthesized. The 
library was to be screened using in situ click chemistry as a proof of concept to show that 
this approach could be used to not only generate highly potent inhibitors but species 
selective inhibitors as well. 
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Chapter 2: Endochin Optimization: Structure-Activity and Structure-Property 
Relationship Studies of 3-Substituted 2-Methyl-4(1H)-quinolones with Antimalarial 
Activity 
2.1 Overview 
 Since the 1940’s endochin (2.1) and analogs thereof were known to be causal 
prophylactic and potent erythrocytic stage agents in avian models (Figure 2.1). 
Preliminary screening in a current in vitro assay identified several 4(1H)-quinolones with 
nM EC50s against erythrocytic stages of multidrug resistant W2 and TM90-C2B isolates 
of P. falciparum. Follow-up structure-activity relationship (SAR) studies on endochin 
analogs identified several key features for biological activity. Nevertheless, structure-
property relationship (SPR) studies conducted in parallel revealed that endochin and its 
analogues are limited by poor solubilities and rapid microsomal degradations. To 
improve the overall efficacy, multiple 4(1H)-quinolone series with varying substituents 
on the benzenoid quinolone ring and/or the 3-position were synthesized and tested for in 
vitro antimalarial activity.  Several structurally diverse 6-chloro-7-methoxy-2-methyl-
4(1H)-quinolones with EC50s in the low nM range against the clinically relevant isolates 
W2 and TM90-C2B were identified with improved physicochemical properties to 
endochin while maintaining little to no cross-resistance with atovaquone. 
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Figure 2.1: Structures of Several Antimalarials Including Endochin 
 
  
2.2 Synthetic Chemistry 
 Previously, a series of diverse 4(1H)-quinolones from WRAIR was tested for 
antimalarial activity suggesting that the 3-position as well as the benzenoid ring of the 
4(1H)-quinolone are important for biological activity. Several series of compounds with 
varying substitutions at these positions have been synthesized following the Topliss 
operational schemes which are based upon physicochemical parameters related to 
hydrophobicity, electronics and sterics.
1, 2
 Additionally, a series of N-alkyl-4-quinolones 
and O-alkyl-4-quinolinols were synthesized locking the quinolone scaffold into either one 
of the two possible tautomeric forms to test the significance of the hydrogen bond donor 
capabilities of the 4(1H)-quinolones. Using various synthetic strategies, a total of 79 
compounds were synthesized and tested. Initially, 1 and its analogues 2.2-2.4 were 
prepared to determine the necessity of the heptyl- and methoxy-substituents (Scheme 
2.1).  According to a known procedure, 2-heptyl-substituted ethyl acetoacetate was 
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prepared from ethyl acetoacetate and heptyl bromide (Scheme 2.1.A).
3
 Subsequent 
Conrad-Limpach cyclization of ethyl acetoacetate and its 2-heptyl-analogue with aniline 
and 3-methoxyaniline furnished 4(1H)-quinolones 2.1-2.4 in good yields. Furthermore, 
via the same synthetic protocol, a series of 4(1H)-quinolones, which differ in the 
substitution at the 3-position, was prepared. 3-Alkyl and 3-aryl-4(1H)-quinolones 2.5-2.8 
were synthesized in good yields from aniline. 3-Alkenyl-4(1H)-quinolones 2.11-2.17 
were prepared by an alternative route utilizing a Heck cross coupling protocol as the key 
step (Scheme 2.1.B). Bromination of quinolone 2.4 followed by O-benzylation gave 
intermediate 2.10. Heck cross coupling of bromide 2.10 with 1-nonene yielded a mixture 
of 3-alkenyl-4(1H)-quinolone isomers (2.11-2.13), which were separated by reversed-
phase preparative HPLC. Similarly, 4(1H)-quinolones 2.11-2.17, were prepared starting 
from bromide 2.10 using the same Heck cross coupling protocol as above. Coupling of 
the free N-H quinolone (2.9) provided minimal to no product.  The amine was protected 
as the O-benzyl precursor and subjected to Heck cross-coupling conditions. Interestingly, 
the cross-coupling adduct with tandem deprotection of the benzyl moiety was obtained. 
To the best of our knowledge this tandem reaction sequence has not been reported in 
Heck cross-couplings and is currently being studied by our group.  
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Scheme 2.1. Synthesis of 3-Substituted-4(1H)-quinolones 2.1-2.17 via Conrad-Limpach 
Cyclization or Heck Cross-coupling
 
 
 
a
Reaction conditions: a) Na, R
2
X, EtOH (anhy.), reflux, overnight; b) R
1
-aniline, AcOH, benzene, Dean-
Stark trap, reflux, overnight then Ph2O, reflux, 15min; c) KBr (20% aq.), Br2, 2M NaOH, r.t. 2-12h; d) 
BnCl, Bu3BnNCl, NaOH, DCM/H2O (1:1), r.t. ; e) Pd2(dba)3, XPHOS, TEA, toluene, alkene; f) Pd2(dba)3, 
XPHOS, TEA, toluene, 1-nonene, 130
o
C. 
i
compound 24 is commercially available. 
ii
see supporting 
information. 
  
 Next, a series of 3-bromo-4(1H)-quinolones was synthesized to investigate 
whether varying the substituents of the benzenoid ring affects the antimalarial activity. 
Conrad-Limpach cyclization of various para-substituted anilines with ethyl acetoacetate 
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followed by bromination at the 3-position yielded the corresponding 3-bromo-4(1H)-
quinolones 2.18-2.22 each possessing a unique substituent at the 6-position (Scheme 
2.2.A). Additionally, a small series of 3-alkynyl-4(1H)-quinolones was prepared to test 
whether a carbon-carbon triple bond at the 3-position would improve biological activity. 
Following a known procedure,
4
 bromides 2.9, 2.18, and 2.21-2.22 were first O-
benzylated using phase transfer catalysis conditions to furnish O-benzyl intermediates 
2.23-2.26a and then subjected to Sonogashira cross coupling
5
 conditions with 1-hexyne. 
Analogous to the previous Heck cross coupling reactions, the Sonogashira cross coupling 
step was accompanied by tandem debenzylation furnishing 6-substituted-3-hexynyl-
4(1H)-quinolones 2.23-2.26b.  
 A series of compounds was prepared in which the benzenoid ring was substituted 
with a methoxy- or a chloro- substituent at the 5-, 6-, 7-, or 8-position, elaborating upon 
the previous set of 4(1H)-quinolones (Scheme 2.2.B). Conrad-Limpach cyclization of p-
methoxy- or p-chloroanilines with commercially available ethyl 2-benzyl- or 2-phenyl-
acetoacetate afforded 6-methoxy- or 6-chloro-4(1H)-quinolones 2.27, 2.28, 2.29, and 
2.30 while cyclization of ortho-substituted anilines gave 8-methoxy- or 8-chloro-4(1H)-
quinolones 2.31, 2.32, 2.33, and 2.34. Dichloro-3-phenyl-4(1H)-quinolones 2.35-2.37 
were directly obtained from corresponding di-choroanilines. The cyclization with m-
methoxy- or m-chloroanilines furnished mixtures of 5- and 7-substituted-4(1H)-
quinolones which has traditionally been a problematic outcome (Scheme 2.2.C). Much to 
our delight, recrystallization of these mixtures from DMF produced the major isomers  
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Scheme 2.2. Synthesis of 5-, 6-, 7-, or 8-Substituted-4(1H)-quinolones 2.18-2.42
a
 
 
 
 
a
Reaction conditions: a) ethyl acetoacetate, AcOH, benzene, Dean-Stark trap, reflux, overnight then Ph2O, 
reflux, 15min; b) KBr (20% aq.), Br2, 2M NaOH, r.t. 2-12h; c) BnCl, Bu3BnNCl, NaOH, DCM/H2O (1:1); 
d) Pd(Cl)2(PPh3)2, CuI, TEA, DMF, 1-hexyne, 130
o
C. e) ethyl 2-benzyl- or 2-phenyl-acetoacetate, AcOH, 
benzene, Dean-Stark trap, reflux, overnight then Ph2O, reflux, 15min. 
i 
Recrystallized from DMF, 
ii
Preparative HPLC separation of isomer b. 
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2.38-2.42a while the resulting mother liquor could be purified via preparative HPLC to 
isolate the minor isomers 2.38-2.42b. 
A selected number of N-methyl-4-quinolones or O-methyl-4-quinolinols were 
prepared by alkylation of the corresponding 3-benzyl-4(1H)-quinolones 2.27, 2.28, and 
2.39a (Scheme 2.3). The alkylation conditions generated mixtures of N- and O-
methylated compounds in an approximately 2:1 ratio respectively which, by column 
chromatography, were separated into the N-methylated-4(1H)-quinolones 2.43-2.45a, and 
the O-methylated-quinolinols 2.43-2.45b. Using routine 1D-nOe experiments, 
compounds 2.43-2.45a were shown to display a correlation between the N-methyl and the 
2-methyl group, while correlations between the O-methyl group and the proton at the 5-
position were observed for compounds 2.43-2.45b. This nOe data reinforces the 
difference in the chemical shift of the carbonyl carbon versus the phenolic carbon. 
Scheme 2.3. Synthesis of N-Methyl-4(1H)-quinolones 2.43-2.45a, and O-Methylated-4-
quinolinols 2.43-2.45b
a
 
 
a
Reaction conditions: a) Cs2CO3, DMF, MeI, 0
o
C to r.t. 5-10h. 
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 Finally, a series of 6-halo-7-methoxy-4(1H)-quinolones was prepared based on 
results from compounds 2.1-2.45, combining the 6,7-disubstitution pattern while 
simultaneously incorporating the most active substituents at the 3-position (Scheme 2.4), 
and screened for activity. 4-Chloro-3-methoxyaniline (2.46) was prepared starting from 
2,5-dichloroanisole using sodium amide conditions
6
 while 4-bromo and 4-
fluoromethoxyanilines were commercially available. Starting with 4-halo-3-
methoxyanilines, 3-phenyl- and 3-ethyl-quinolones 2.47-2.53 were prepared.  
 Focusing on 3-substituted 6-chloro-7-methoxy-4(1H)-quinolones, 2.54-2.60 were 
prepared from 2-substituted β-ketoesters via Conrad-Limpach cyclization, while using 
intermediates 2.60-2.62, 4(1H)-quinolones 2.64-2.66 were synthesized via cross coupling 
reactions. Analogous to the 3-alkenyl-4(1H)-quinolones 2.8-2.10, compounds 2.64 and 
2.65 were synthesized as a mixture and subsequently separated into their constituent 
isomers by reversed-phase preparative HPLC. 
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Scheme 2.4. Synthesis of 3-Substituted-6-halo-7-methoxy-4(1H)-quinolones 2.47-2.66
a
 
 
a
Reaction conditions: a) Na, NH3(l); b) ethyl 2-substituted-acetoacetate, AcOH, benzene, Dean-Stark trap, 
reflux, overnight then Ph2O, reflux, 15min; c) KBr (20% aq.), Br2, 2M NaOH, r.t. 12h; d) BnCl, Bu3BnNCl, 
NaOH, DCM/H2O (1:1); e) Pd(Cl)2(PPh3)2, CuI, TEA, DMF, 1-hexyne, 130
o
C; f) Pd2(dba)3, XPHOS, TEA, 
toluene, acrylate or alkene, 130
o
C 
i
see experimental section for preparation. 
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2.3 Antimalarial Activity 
 All synthesized compounds were routinely tested against the clinically relevant 
multi-drug resistant malarial strains W2 (chloroquine and pyrimethamine resistant) and 
TM90-C2B (chloroquine, mefloquine, pyrimethamine and atovaquone resistant). See 
experimental section for details on parasite culturing, assay preparation, SYBR Green I 
processing, and data analysis. The human malaria parasite P. falciparum has been grown 
in vitro in dilute human erythrocytes in RPMI 1640 media containing 10% heat 
inactivated plasma.
7
 Concentration response data has been analyzed by a nonlinear 
regression logistic dose response model and the 50% inhibition for each compound 
against the individual strains has been calculated as the effective concentrations (EC50s). 
The emergence of resistance and cross resistance with atovaquone is a major concern for 
any new antimalarial chemotype series, especially for compounds that target the 
cytochrome bc1 complex.  The resistance index (RI) of each 4(1H)-quinolone has been 
calculated as the ratio of the effective concentrations of W2 and TM90-C2B (RI = 
EC50(TM90-C2B)/EC50(W2)). Compounds with an RI = 0.3 - 3.0 are desirable, whereas 
compounds with an RI > 10 or < 0.1 are likely to have clinically relevant levels of cross 
resistance with atovaquone and are not candidates for additional preclinical studies. For 
both chloroquine and atovaquone a >3 fold increase in the in vitro EC50 is associated with 
clinically relevant resistance.
8, 9
 
Heat inactivated plasma has been shown to play an integral role for the correct 
determination of the EC50 constants and ultimately the calculation of the resistance index. 
Although Albumax-supplemented media has been reported to deliver the most consistent 
results for in vitro screening,
10
 the testing of the 4(1H)-quinolones from the WRAIR 
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inventory in assay conditions containing heat inactivated plasma rendered reproducible 
data with significantly increased cross resistance to atovaquone in comparison to the 
testing in media containing Albumax; therefore heat inactivated plasma was used for all 
in vitro assessment of endochin analogs. 
2.3.1 Structure-Activity Relationship Studies 
 Quinolone 2.1 displayed EC50s in the low nM-range against TM90-C2B and 
single digit nM activity for W2 in the current in vitro assay, nevertheless in previous 
studies, endochin 2.1 failed to display in vivo efficacy in rodent malaria models. This 
inconsistency in antimalarial activity was believed to be directly related to endochin’s 
structure. The highly lipophilic n-heptyl substituent rich in different conformations has 
been considered to be prone to metabolism while the methoxy group in 7-position is 
likely to undergo demethylation. Thus, a series of 4(1H)-quinolones 2.2-2.4, and 2.9 were 
designed initially to identify the key structural features of 2.1 that render its unique 
antimalarial activity. For the endochin analogue 2.2, in which the lipophilic chain at the 
3-position has been replaced by a hydrogen, at least a 300- to 1000-fold reduction in 
potency was observed. In contrast, the removal of endochin’s methoxy group furnished 3-
heptyl-2-methyl-4(1H)-quinolone 2.3 with only a 10-fold decrease of potency. Finally, 
the 2-methyl-4(1H)-quinolone 2.4 became completely devoid of antimalarial activity, 
while introduction of a bromo- substituent at the 3-position restored modest antimalarial 
activity for quinolone 2.9. These results suggest that the substituent at the 3-position is of 
primary importance, while the substituents on the benzenoid ring affect the antimalarial 
activity to a lesser extent. The dramatic potency increase for 4(1H)-quinolones 
substituted at the 3-position with a heptyl or a bromo substituent also strongly suggests 
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the presence of a hydrophobic pocket with a reasonable volume in proximity to the 
4(1H)-quinolone binding pocket. 
 Consequently, a series of 3-substituted-4(1H)-quinolones was designed to further 
correlate the antimalarial activity with the nature of the residue at the 3-position (Table 
2.1). In comparison to quinolone 2.3, elongation of the lipophilic chain by two methylene 
units increased the potency of quinolone 2.5 by about 3-fold. This result is in agreement 
with the previous observation that shortening the lipophilic chain results in a decrease of 
antimalarial activity. Furthermore, the potency of the 3-alkyl-substituted-4(1H)-
quinolones changed when the hydrophobic chain contained a carbon-carbon double bond. 
In comparison to 4(1H)-quinolone 2.5, introduction of a Z-configured olefin as the side 
chain of quinolone 2.13 decreased the antimalarial activity while quinolones 2.11, 
possessing an E-configured olefin and 2.12 possessing a 1,1-disubstituted olefin, are 
more potent by a factor of approximately 7 and 3 respectively. Strikingly, the potencies 
of the alkenyl-substituted 4(1H)-quinolones 2.11-2.13 depend on the geometry of the 
carbon-carbon double bond. In contrast to the Z-alkene side chain of 2.13, the 
conformational rigidity of the E-configured 3-substituent seem to match the conformation 
of the saturated heptyl group of 2.5.  
 Next, an E-configured α,β-unsaturated ester 2.14 and E-configured stilbene-like 
quinolones 2.15-2.17 have been shown to have poor EC50s in the µM range. These 
observations could possibly be explained by the assumption that a significant extension 
of the conjugated π-system to the side chain may not favor binding to the biological 
target. Next, quinolones 2.6-2.8 were designed with the intent of replacing the flexible  
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Table 2.1. SAR Study Focusing on Substituents at the 3-Position 
 
Compound R
1
 R
2
 
EC50
a 
W2 (nM) 
EC50
a 
TM90-C2B 
(nM) 
RI 
EC50 
J774 
(μM) 
CI 
2.1 -OCH3 
 
8.59 46.6 5.42 >34.8 >747 
2.2 -OCH3 -H >13212 12512 >0.95 >52.8 >4.2 
2.3 -H  
93.2 105 1.13 5.1 48.3 
2.4 -H -H >44696 >62820 >1.41 >62.8 >1.0 
2.5 -H  
24.1 39.8 1.65 2.8 69.9 
2.6 -H 
 
590.7 2231 3.77 >41.4 >18.6 
2.7 -H 
 
711 537.6 0.76 >42.5 >79.1 
2.8 -H 
 
>5014 6203 >1.23 >40.1 >6.5 
2.9 -H -Br 453 77.6 0.92 >42.0 >542 
2.11 -H  
12.9 15.0 1.17 28.0 187 
2.12 -H 
 
39.6 33.7 0.85 89.1 265 
2.13 
-H 
 
101.9 187 1.83 48.5 26.0 
2.14 -H 
 
>8351 >8351 >1.00 >40.0 >4.8 
2.15 -H 
 
>9079 >9080 >1.00 >36.3 >4.0 
2.16 -H 
 
4599 1489 0.32 >32.6 >21.9 
2.17 -H 
 
>9014 >9015 >1.00 >36.1 >4.0 
a
Dihydroartemisinin
 
(DHA) and chloroquine (CQ) are internal controls for each in vitro assay. 
DHA (1.8 nM W2 and 0.9 nM TM90C2B) and CQ (131 nM W2 and 162 nM TM90-C2B) 
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side chain to rigidify the 4(1H)-quinolone through installation of cyclic residues at the 3-
position. Substitution of the n-heptyl- side chain of 2.3 by a cyclohexyl-, benzyl-, or 
phenyl-substituent yielded moderately active 4(1H)-quinolones 2.6-2.8 with EC50s in the 
higher nM range. 
Subsequently, compounds varying their 6-substituents on the benzenoid ring have 
been prepared and tested (Table 2.2). Synthetic considerations combined with modest 
antimalarial activities obtained for quinolones 2.7, 2.8, and 2.9, led to the design of a 
variety of 2-methyl-4(1H)-quinolones substituted with bromo-, phenyl-, and benzyl-
substituents at the 3-position. First, 3-bromo-2-methyl-4(1H)-quinolones substituted with 
a methoxy-, bromo-, chloro-, and fluoro-substituents at the 6-position were screened.  
Table 2.2. SAR Study Focusing on Substituents at the Benzenoid Ring 
 
Compound R
1
 R
2
 
EC50 W2
a
 
(nM) 
EC50 T90-C2B
a
 
(nM) 
RI 
EC50 J774 
(μM) 
CI 
2.18 -Br -OCH3 3000 1165 0.39 >37.3 >32 
2.19 -Br -CH3 288 261 0.90 19.6 74.9 
2.20 -Br -Br 1404 339 0.24 >31.5 >93 
2.21 -Br -Cl 845 126 0.14 21.7 172 
2.22 -Br -F 929 125 0.13 >39.1 >313 
2.23b 
 
-OCH3 >9213 >9213 >1.00 >36.8 >4.0 
2.24b 
 
-H 8288 >10359 >1.25 8.90 >0.9 
2.25b 
 
-Cl >9065 43066 >4.75 >36.3 >0.8 
2.26b 
 
-F >9642 >9641 >1.00 >38.6 >4.0 
a
Dihydroartemisinin
 
(DHA) and chloroquine (CQ) are internal controls for each in vitro assay. 
DHA (1.8 nM W2 and 0.9 nM TM90C2B) and CQ (131 nM W2 and 162 nM TM90-C2B) 
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Of these compounds, the methoxy analog 2.18 appeared the least active while the chloro 
and fluoro analogs 2.21 and 2.22 exhibited the best activity. Moreover, to complement 
the previous study with the 3-alkenyl-4(1H)-quinolones 2.11-2.13, a 6-substituted 
quinolone series possessing linear geometry at the 3-position was designed and 
synthesized. Nevertheless, the 3-alkynyl-substituted 4(1H)-quinolones 2.23-2.26b 
displayed poor activities with EC50s of 8 µM or higher. 
 Furthermore, an approach following the Topliss operational scheme for aromatic 
substitutions has been conducted to systematically probe the 5-, 6-, 7-, and 8-positions 
(Table 2.3). This was achieved utilizing methoxy-, chloro-, and dichloro- substitutions 
with 3-phenyl- and 3-benzyl-2-methyl-4(1H)-quinolone as the main scaffold. All 
dichloro-4(1H)-quinolones 2.35-2.38, displayed EC50s in the µM range and thus seemed 
inferior to the mono-substituted compounds. Testing against the W2 strain revealed 
activity trends, in which the potency decreased according to 7- >> 8- > 6- ≈ 5-position for 
the methoxy-substituted compounds, and 7- ≈ 6- >> 5- > 8-position for the chloro-
substituted compounds. For the TM90-C2B strain, the same substitution dependence was 
identified for the methoxy-4(1H)-quinolones, however the chloro-substituted compounds 
followed the inhibitory trend of 6- > 7- >> 5- > 8-position. These results demonstrate that 
substituents at the 5- and 8-positions are not tolerated while substituents at the 6- and 7-
positions influence the antimalarial activity as well as the resistance index. In comparison 
to 4(1H)-quinolone 2.7 for example, the 6-chloro substituent in 2.30 increases the 
antimalarial potency by a factor of three for W2, however it does not change the activity 
against TM90-C2B. This strain-specific potency enhancement consequently reverses the 
resistance index from 0.76 to 3.18. On the contrary, the methoxy group in 7-position of 
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compounds such as 2.1, 2.39a, or 2.41a improves the activity for both strains whereby 
the enhancement is more prominent for W2 in comparison to TM90-C2B. A possible 
explanation for the observed substituent effects is that the chloro and methoxy 
substituents are influencing the electronic nature of the 4(1H)-quinolone core. The 6-
chloro substituent increases the acidity of the quinolone N-H and possibly strengthens the 
binding between the 4(1H)-quinolone and the target. In contrast, the electron donating 
nature of the methoxy group at the 7-position improves the carbonyl’s capacity to accept 
hydrogen bonds in the binding pocket. 
Table 2.3. SAR Study Focusing on Positions 5-8 on the Quinolone Ring 
 
Cmpd R
1
 R
2
 R
3
 R
4
 R
5
 
EC50 W2
a 
(nM) 
EC50 C2B
a 
(nM) 
RI 
EC50 J774 
(μM) 
2.39b -Bn -OCH3 -H -H -H 6442 2113 0.33 11.2 
2.27 -Bn -H -OCH3 -H -H >8950 23744 >2.65 >23.7 
2.39a -Bn -H -H -OCH3 -H 733 1384 1.89 >35.8 
2.31 -Bn -H -H -H -OCH3 >2238 >5454 >2.44 >35.8 
2.41b -Ph -OCH3 -H -H -H 8154 5075 0.62 >37.7 
2.29 -Ph -H -OCH3 -H -H >9423 >9423 >1.00 >37.7 
2.41a -Ph -H -H -OCH3 -H 287 269 0.93 >37.7 
2.33 -Ph -H -H -H -OCH3 2063 1665 0.81 >37.7 
2.40b -Bn -Cl -H -H -H 630 5261 8.35 >35.2 
2.28 -Bn -H -Cl -H -H 2471 3276 1.33 >35.2 
2.40a -Bn -H -H -Cl -H 2168 15679 7.23 >35.2 
2.32 -Bn -H -H -H -Cl >8811 >8811 >1.00 >35.2 
2.42b -Ph -Cl -H -H -H 5064 4740 0.93 >37.1 
2.30 -Ph -H -Cl -H -H 244 777 3.18 >37.1 
2.42a -Ph -H -H -Cl -H 216 1858 8.59 >37.1 
2.34 -Ph -H -H -H -Cl >9269 >9269 >1.00 >37.1 
2.38b -Ph -Cl -Cl -H -H 659 3211 4.87 >32.9 
2.38a -Ph -H -Cl -Cl -H 569 350.0 0.61 >32.9 
2.35 -Ph -H -H -Cl -Cl >8219 >8219 >1.00 >32.9 
2.36 -Ph -H -Cl -H -Cl >8219 >8219 >1.00 >32.9 
2.37 -Ph -Cl -H -Cl -H 2147 3437 1.60 >32.9 
 
a
Dihydroartemisinin
 
(DHA) and chloroquine (CQ) are internal controls for each in vitro assay. 
DHA (1.8 nM W2 and 0.9 nM TM90C2B) and CQ (131 nM W2 and 162 nM TM90-C2B) 
 In general, a 4(1H)-quinolone is in equilibrium with the tautomeric 4-quinolinol 
form and it has been reported that the equilibrium lies in favor of the 4(1H)-quinolone in 
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both the solid and solution state.
11
 Thus, a study was designed to lock a particular 4-
quinolone in one of its two tautomeric forms (keto and enol-ether) via methylation. These 
compounds were then screened to determine the difference in activities (Table 4). A 
small set of N-methylated-3-benzyl-substituted-4-quinolones 2.43-2.46a, and their O-
methylated versions 2.43-2.46b, have been shown to have reduced antimalarial activity in 
comparison to their 4(1H)-quinolone congeners 2.27, 2.28, 2.30, and 2.39a. Differences 
in activities amongst analogs are negligible for compounds such as 2.27, 2.43a, and 
2.43b, which are all approximately 9µM. However, the 6-chloro-3-phenyl-4-quinolones 
2.30, 2.45a, and 2.45b display up to 40-fold differences in activity between the 
methylated and non-methylated compounds. It should be noted that compounds ≥8 µM 
are approaching or at the limit of experimentally observed inhibition, compounds such as 
these are said to be inactive within our assay, and thus, compounds 2.30, 2.45a, and 
2.45b provides the most insight suggesting the necessity of the free 4(1H)-quinolone core 
for enhanced activity. 
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Table 2.4. Activity of N-Methyl-4-quinolones and O-Methyl-4-quinolinols Against W2 
and TM90-C2B 
Tautomeric 
Structure 
Compound R
1 
R
2
 R
3
 
EC50 W2
a
 
μM 
EC50 C2B
a 
μM 
 
27 -Bn -OCH3 -H >8.95 >8.95 
28 -Bn -Cl -H 2.47 3.27 
30 -Ph -Cl -H 0.24 0.78 
39a -Bn -H -OCH3 0.73 1.38 
 
43a -Bn -OCH3 -H >8.52 8.06 
44a -Bn -Cl -H >8.40 >8.40 
45a -Ph -Cl -H >8.80 >8.80 
46a -Bn -H - OCH3 >8.52 7.84 
 
43b -Bn -OCH3 -H >8.52 >8.52 
44b -Bn -Cl -H >8.40 >8.40 
45b -Ph -Cl -H >8.80 >8.80 
46b -Bn -H -OCH3 >8.52 >8.52 
a
Dihydroartemisinin
 
(DHA) and chloroquine (CQ) are internal controls for each in vitro assay. 
DHA (1.8 nM W2 and 0.9 nM TM90C2B) and CQ (131 nM W2 and 162 nM TM90-C2B) 
 Finally, a series of compounds with the most promising substituents at the 3-, 6- 
and 7-positions incorporated into the same molecule were tested (Table 2.5) with the 
rational that the substituents may enhance the antimalarial activity in an additive or 
synergistic fashion. Chloro- and fluoro- substituents at the 6-position have previously 
been identified to modestly improve the antimalarial activity. For example, the methoxy 
group in 2.1, contributes approximately a ten-fold increase in potency against W2 than 
2.3. Thus, compounds containing the 6-halo-7-methoxy substituency 2.48-2.53 have been 
screened to identify the substituent combination yielding the greatest synergy. Of these 
compounds, the best antimalarial activity was obtained with the chloro-methoxy-
disubstituted compounds 2.49 and 2.52 with EC50 values in the lower nM range while the 
bromo- and fluoro-methoxy-disubstituted 4(1H)-quinolones 2.48, 2.50, 2.51, and 2.53  
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Table 2.5. SAR Study of 6-Halo-7-methoxy-4(1H)-quinolones 
 
Compound R
1
 R
2
 
EC50 W2
a 
(nM) 
EC50 C2B
a 
(nM) 
RI 
EC50 J774 
(μM) 
CI 
2.48 -F 
 
167 83.0 0.50 >35.3 >425 
2.49 -Cl 
 
26.2 15.3 0.58 >33.4 >2,173 
2.50 -Br 
 
79.4 25.0 0.31 >29.1 >1,164 
2.51 -F 
 
368 161 0.44 9.4 58.3 
2.52 -Cl 
 
48.2 27.6 0.57 19.0 689 
2.53 -Br 
 
179 36.3 0.20 >33.9 >933 
2.54 -Cl 
 
12.3 2.95 0.22 >37.1 >10,520 
2.55 -Cl 
 
6.03 1.59 0.26 >28.7 >18,038 
2.56 -Cl 
 
237 397 1.68 >32.7 >82.3 
2.57 -Cl 
 
93.7 68.6 0.73 >31.9 >465 
2.58 -Cl -CH3 56.6 27.3 0.48 12.2 449 
2.59 -Cl -
i
Pr 112 194 1.72 21.7 112 
2.60 -Cl -
i
Bu 86.4 63.3 0.73 >35.7 >564 
2.61 -Cl -H 3,175 1,856 0.58 >44.7 >24.1 
2.64 -Cl 
 
2,156 4,212 1.95 15.0 3.6 
2.65 -Cl 
 
39.4 14.8 0.38 18.9 1,278 
2.66 -Cl 
 
31.5 10.6 0.34 >31.2 >2,947 
2.67 -Cl 
 
61.7 53.6 0.87 >28.6 >533 
atovaquone     
0.54 6,232 11,540 n.d n.d. 
  chloroquine    
162             131         0.29 n.d n.d. 
a
Dihydroartemisinin
 
(DHA) and chloroquine (CQ) are internal controls for each in vitro assay. 
DHA (1.8 nM W2 and 0.9 nM TM90C2B) and CQ (131 nM W2 and 162 nM TM90-C2B). 
lost potency by a factor of five or more. Ultimately, 6-chloro-7-methoxy-4(1H)-
quinolones 2.54-2.67 possessing various substituents at the 3-position were screened and, 
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in general, a slight increase in potency was observed for the TM90-C2B strain. Although 
the 6-chloro-7-methoxy-4(1H)-quinolone 2.61, lacking a group at the 3-position, is a poor 
inhibitor of W2 and TM90-C2B with EC50 values in the single digit µM range, it 
demonstrates a 30-fold potency increase in comparison to 2-methyl-4(1H)-quinolone 2.4. 
For compound 2.58, an EC50 of 27 nM was determined, which corresponds to a two-fold 
gain in activity in comparison to 2.1. The most active compounds are endochin analogs 
2.54 and 2.55 with activities lower than 3 nM for TM90-C2B and lower than 13 nM for 
W2. 3-Alkenyl-substituted analogs 2.65 and 2.66 exhibit slightly decreased activities than 
2.54-2.55. Heck adduct 2.67 had slightly decreased activity than 2.1 of 61.7 nM for W2 
and 53.6 nM for TM90-C2B, however, exhibited a RI of approximately 1. Importantly, 
the proficiency of the 6-chloro-7-methoxy backbone is clearly manifested in the 
identification of multiple 4(1H)-quinolones that surpass the biological activity of the 
original compound, 2.1. 
2.3.2 Strain Selectivity and Resistance Index (RI) 
 In vitro testing demonstrates that the majority of the 4(1H)-quinolone compounds 
exhibit moderate strain dependence (RI) with up to threefold differences in their EC50s 
against W2 and TM90-C2B. The most potent 4(1H)-quinolones tend to be marginally 
more potent against TM90-C2B than against W2 (Table 2.5 and Figure 2.2). Noticeable 
exceptions to this trend are the 7-chloro-substituted-4(1H)-quinolones 2.40a and 2.42a 
which inhibit W2 10-fold greater than TM90-C2B. In contrast, the very potent 
compounds 2.49, 2.54, 2.55, and 2.65 tend to be modestly more potent against TM90-
C2B than against W2. To further analyze strain selectivity and tendency to induce 
resistance, the entire 4-(1H)-quinolone compound series was divided into various classes 
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based on substitution of the benzenoid ring (Figure 2.2.A) and substitution at the 3-
position (Figure 2.2.B). The pEC50s for W2 were plotted against the pEC50s for TM90-
C2B. All 4(1H)-quinolones exhibiting single digit EC50 constants for TM90-C2B are 
exclusively substituted with a chloro- substituent at the 6-position and with methoxy- 
substituent at the 7-position. Furthermore, it also generally appears that 6-halo-7-
methoxy-4(1H)-quinolones have the tendency to inhibit TM90-C2B more potently than 
W2. In contrast, for the substituents at the 3-position, no obvious correlation or strain 
preference is observed.  
Figure 2.2: Plot of the pEC50s for W2 versus the pEC50s for TM90-C2B 
 
2.4 Cytotoxicity 
 An important quality of the 4(1H)-quinolones is their selectivity to inhibit parasite 
growth selectively over mammalian cells. In a 96-well plate format, the cytotoxicity of 
the test compounds to J774 mammalian cells has been assessed in vitro (Table 2.5).
12
 The 
cytotoxicity index (CI) of each compound has been calculated as the ratio of the EC50 
value for J774 and the value of TM90-C2B (CI = EC50(J774)/EC50(TM90-C2B)). Of all 
the compounds tested, none displayed signs of cytotoxicity at concentrations lower than 2 
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µM. Thus, it is not surprising that most 4(1H)-quinolones displaying potent antimalarial 
activity, also posses CI values of several thousand indicating that they are selective, 
nontoxic chemotypes. 
2.5 Structure-Property Relationship Studies 
 To assess potential compound liabilities, physicochemical properties including 
aqueous solubility, Log D7.4, permeability, and hepatic microsomal stability were 
determined (Table 2.6). Since the in vitro efficacy assay was performed in presence of 
10% of heat inactivated plasma, protein binding was regarded to be of secondary 
importance and therefore the compounds were not tested for protein binding. Solubility 
and Log D7.4 for each compound were determined utilizing HPLC-based methods. 
Passive transcellular permeability was determined using the standard parallel artificial 
membrane permeability assay (PAMPA). Microsomal stability was assessed for a subset 
of 4(1H)-quinolones along with 2.1 in the presence of human and murine liver 
microsomes.
13
 
 The distribution coefficients and the permeabilities of almost all 4(1H)-
quinolones are within the acceptable ranges (1 < Log D7.4 < 4; Permeability (Pe) > 50 x 
10
-6
 cm
-1
). A plot of in vitro activity against Log D7.4 values revealed a trend, in which 
the Log D7.4 lipophilicity slightly increases with an increase in potency against W2 and 
TM90-C2B. Evidently, the log D7.4 of the entire 4(1H)-quinolone compound series is 
considered to be well balanced, since the majority of the compounds possess an optimal 
log D7.4 between 1 and 3. Nevertheless, with the exception of 3-phenyl-substituted 6-
chloro-7-methoxy-4(1H)-quinolone 2.49, a distribution coefficient of 3.8 or higher has 
89 
 
been determined for endochin 2.1 and the 4(1H)-quinolones 2.54, and 2.55 with EC50s in 
the single digit nM range. 
Figure 2.3. Plot of In Vitro Efficacy versus Distribution Coefficient Log D7.4 
 
 For 4(1H)-quinolone 2.1, an aqueous solubility with less than 2 µM has been 
identified as a major liability. In comparison, 6-chloro-7-methoxy-4(1H)-quinolones 2.54 
and 2.66 with alkyl- and alkenyl- substituents, respectively, at the 3-position and 
compound 2.56, the cyclohexyl analog, displayed similar or diminished aqueous 
solubilities. Improvements have been observed for 2.67 possessing an α,β-unsaturated 
ester substituent. Furthermore, compound 2.49 with a shortened 3-alkyl substituent and 
2.52 with a phenyl substituent possess slightly better solubility than (1). Finally, as 
exemplified with 2.51-2.53, the 6-fluoro- and 6-bromo-7-methoxy-4(1H)-quinolones are 
less soluble than their 6-chloro congener 2.52. 
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Table 2.6. Physicochemical Properties of Selected 4(1H)-quinolones 
Compound 
MW 
(g/mol) 
Log D
a 
pH=7.4 
mp 
o
C 
Solubility
b 
(μM) 
Permeability
c,#
 
Microsomal 
Stability
$
 
Pe 
(10
-6
 
cm/s) 
pH=7.4 
Pe 
(10
-6
 
cm/s) 
pH=4.0 
Mouse 
T½ 
(min) 
Human 
T½ 
(min) 
1 287.40 3.69 216-218 ** 679 1020 7.9 10.2 
47 283.30 1.72 361-363 *** 124 192 nd nd 
48 299.75 1.65 329-330 *** 48.3 105 21.3 128.3 
49 344.20 2.20 328-329 * 330 306 nd nd 
50 235.25 1.20 306-307 * 91.1 172 nd nd 
51 251.71 2.43 326-328 **** 57.3 96.4 28.4 33.8 
52 296.16 1.70 325-327 ** 75.1 81.9 nd nd 
53 321.84 3.83 238-239 * <0.01 <0.01 nd nd 
55 305.80 3.04 313-314 *** 630 1236 nd nd 
56 313.78 1.99 254-255 ** 566 575 nd nd 
60 223.66 1.95 nd ** 25.2 11.9 62.4 161.2 
64 319.83 3.58 nd ** 755 768 nd nd 
66 349.81 1.81 nd *** 261 249 43.9 60.3 
A
Standards for the LogD7.4 assay include cinnarizine (LogD7.4 5.68), hydrocortisone-21-acetate (LogD7.4 
2.19), ketoconazole (LogD7.4 3.83), metronidazole (LogD7.4 -0.02), nadolol (LogD7.4 0.68), pyrene (LogD7.4 
4.88), theophyline (LogD7.4 -0.05), and tolnaftate (LogD7.4 5.40). 
b
Standards for the solubility assay include carbamazepine and albendazole. Solubility for carbamazepine at 
pH 7.4, 4.0, and 2.0 is 95 and 100  respectively. Solubility for albendazole at pH 7.4, 4.0, 
and 2.0 is 6.1 , 12, and 100respectively 
c
Standards for the permeability assay include verapamil HCl (Pe = 1405 x10-6 cm/s at pH=7.4 and 39 x10-
6 cm/s at pH=4.0), carbamazepine (Pe = 112 x10-6 cm/s at pH=7.4 and 108 x10-6 cm/s at pH=4.0), and 
ranitidine HCl (Pe = 0.5 x10-6 cm/s at pH=7.4 and 0 x10-6 cm/s at pH=4.0). 
 
#
 Passive transcellular permeability (effective permeability Pe)  
$
 In vitro metabolic stability using liver microsomes; T½ corresponds to degradation half-
time; nd – not determined  
*  solubility < 2 μM:   * 
2 μM < solubility < 5 μM: ** 
            5 μM < solubility < 10 μM: *** 
            10 μM < solubility < 20 μM: **** 
            solubility > 20 μM:   ***** 
 
Given that the Log D7.4 values of the entire compound series are moderate and in the 
acceptable range, the solubility appears worse than predicted by the distribution 
coefficients. Strong lattice energy and intermolecular hydrogen bonding are possible 
reasons for the unusual solubility and this hypothesis is strongly supported by the fact 
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that structural features perturbing the crystal packing and/or the intermolecular hydrogen 
bonds of the 4(1H)-quinolones increase the solubility. For instance, blocking of the 5- or 
8-positions with a methoxy or a chloro substituent, as seen in compounds 2.31, 2.39b, 
2.41b and 2.42b, dramatically increases the aqueous solubility in comparison to the 
4(1H)-quinolones, which are methoxy- or a chloro-substituted in 6- or 7-position.
13
 
Furthermore, N-methyl-4(1H)-quinolones 2.43a-2.46a or O-methyl-4(1H)-quinolinols 
2.43b-2.46b also seem to possess better aqueous solubilities in comparison to the 
corresponding N(1H)-quinolones 2.27, 2.28, 2.30 or 2.39a. Nevertheless, the structural 
modifications leading to compounds with better solubility are combined with significant 
losses in antimalarial activity.  
 Finally, microsomal stability of a selected set of compounds has been determined. 
Compound 2.1 has poor microsomal stabilities with half-lives of 10 minutes or shorter in 
murine and human systems. Comparison of the half-lives of compounds 2.1, 2.52 and 
2.61 suggests that the long and flexible alkyl chain at the 3-position is prone to metabolic 
degradation in hepatic microsomes. Replacing the 3-heptyl-substituent with a phenyl 
residue as in compound 2.49, an electron-deficient carbon-carbon double bond in 2.67, or 
a short ethyl group as in 2.52, yields 4(1H)-quinolones with prolonged half-lives of 25 
minutes or longer. 
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2.6 Conclusions 
 An initial study with 2.1 and its analogs 2.2-2.5 suggested that the 4(1H)-
quinolone scaffold, the 7-methoxy-group, and the alkyl chain at the 3-position are 
important for inhibitory activity towards P. falciparum. Parallel testing of the same 
4(1H)-quinolones for key physicochemical properties identified poor aqueous solubility 
and rapid degradation in microsomes as the compound’s major liabilities. Subsequently, a 
total of 79 2-methyl-4(1H)-quinolones with varying substituents at the 1-, 3-, 4-, 5-, 6-, 7, 
and/or 8-positions have been synthesized and tested against the clinically relevant isolates 
TM90-C2B and W2 with the objective to obtain detailed SAR data. The best antimalarial 
activities were observed if a) the 4(1H)-quinolone nitrogen and oxygen were 
unsubstituted, b) the benzenoid ring was disubstituted with 6-chloro- and 7-methoxy- 
groups, c) the 5- and 8-position of the benzenoid ring were unsubstituted, and d) the 
4(1H)-quinolone’s 3-position was substituted with an alkyl-, alkenyl- or aryl-group. 
Among the most active 4(1H)-quinolones against the multi-drug resistant isolate of P. 
falciparum TM90-C2B were compounds 2.49, 2.52, 2.54, 2.55, 2.56, and 2.65, with 
EC50s in the low nM range surpassing the potency of 2.1. Importantly, no cytotoxicity 
was observed at 4(1H)-quinolone concentrations lower than 2 µM providing cytotoxicity 
indices of 1000 or more for the best compounds. Furthermore, this SAR study also 
demonstrated that, in comparison to atovaquone or chloroquine, the majority of the 
4(1H)-quinolones lack any cross resistance. Though the exact mechanism of action is not 
known at this point, due to structural similarities between the 3-substituted 4(1H)-
quinolones and atovaquone or GSK’s pyrridones14 in conjunction with the oxygen 
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consumption testing
15
, cytochrome bc1 is probably the potential parasite target inhibited 
by the 3-substituted 4(1H)-quinolones. 
 In parallel to the SAR testing, a SPR study focusing on solubility, distribution 
coefficient, permeability and microsomal stability identified significant differences 
between the best inhibitors 2.49, 2.56, and 2.65 particularly in the microsomal stability 
and aqueous solubility. 3-Aryl-substituted 4(1H)-quinolone 2.49 displayed better 
solubility and stability in comparison to 2.1, 3-alkenyl- and 3-alkyl-4(1H)-quinolones 
2.55 and 2.65. These results suggest that 2-methyl-3-phenyl-4(1H)-quinolone 2.49 is 
better suited as a platform for further development, despite it being slightly less potent in 
comparison to 3-alkyl- or 3-alkenyl-substituted compounds 2.55 and 2.65. Testing of 
frontrunner compounds for exo-erythrocytic stage activity as well as in vivo efficacy in 
rodent malaria models is currently under investigation. 
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2.7 Experimental Section 
2.7.1 General Information 
 All reagents and anhydrous solvents were obtained from Aldrich Chemical Co. 
and used without further purification unless otherwise noted. Ethyl 2-phenylacetoacetate 
and 2,5-dichloroanisole were bought from Alfa Aesar. 4-Fluoro-3-methoxyaniline was 
bought from Oakwood Products, Inc. while 4-bromo-3-methoxyaniline was bought from 
TCI America. The identity of all title compounds were verified via 
1
H NMR, 
13
C NMR, 
and HPLC/HRMS. The chemical purity of the titled compounds was determined using 
the following conditions: an Agilent 1100 series LC/MSD with a Eclipse XDB-C18 
(4.6mm x 100 mm, 5 μm) reversed phase column; method: 10% (v/v) of acetonitrile 
(+0.05% TFA) in 90% (v/v) of H2O (+0.05% TFA), ramped to 100% acetonitrile 
(+0.05% TFA) over 9 min, and holding at 100% acetonitrile for 4 min with a flow rate of 
0.7 mL/min, UV detector, 254 nm. The purity of each compound was ≥95% in this 
analysis. NMR spectra were recorded at ambient temperature on a 400 or 500 MHz 
Varian NMR spectrometer in the solvent indicated. All 
1
H NMR experiments are 
reported in ≥ units, parts per million (ppm) downfield of TMS and were measured 
relative to the signals for chloroform (7.26 ppm) and dimethylsulfoxide (2.50 ppm). All 
13
C NMR spectra were reported in ppm relative to the signals for chloroform (77 ppm) 
and dimethylsulfoxide (39.5 ppm) with 
1
H decoupled observation. Data for 
1
H NMR are 
reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet), integration and coupling constant (Hz), whereas 
13
C-
NMR analyses were obtained at 101 MHz and reported in terms of chemical shift. NMR 
data was analyzed by using MestReNova Software ver. 5.3.2-4936. High resolution mass 
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spectra (HRMS) were performed on an Agilent LC/MSD TOF system G3250AA. 
Isomers were separated by reverse phase HPLC system (Waters Prep LC 4000 system 
with Waters 996 Photodiode Array Detector, Agilent column Eclipse XDB-C18, 5 μM, 
9.4x250 mm). Compounds were eluted using a gradient elution of 70/30 to 50/50 A/B 
over 30 minutes at a flow rate of 5.0 mL/min, where solvent A was water and solvent B 
was acetonitrile. Analytical thin layer chromatography (TLC) was performed on silica gel 
60 F254 pre-coated plates (0.25 mm) from EMD Chemical Inc. and components were 
visualized by ultraviolet light (254 nm). Silicycle silica gel 230-400 (particle size 40-63 
μm) mesh was used for all flash column chromatography.  
Permeability Pe has been determined by a standard parallel artificial membrane 
permeability assay (PAMPA by pION). PAMPA was conducted on a Biomek FX lab 
automation workstation (Beckman Coulter, Inc., Fullerton, CA) with PAMPA evolution 
96 command software (pION Inc., Woburn, MA) as follows: 3 μL of 10μM test 
compound stock was mixed with 600 μL of system solution buffer, pH 7.4 or 4 (pION 
Inc., Woburn, MA) to make diluted test compound. Then 150 μL of diluted test 
compound was transferred to a UV plate (pION Inc., Woburn, MA), and the UV 
spectrum was read as the reference plate. The membrane on a preloaded PAMPA 
sandwich (pION Inc., Woburn, MA) was painted with 4 μL of GIT lipid (pION Inc., 
Woburn, MA). The acceptor chamber was then filled with 200 μL of acceptor solution 
buffer (pION Inc., Woburn, MA), and the donor chamber was filled with 180 μL of 
diluted test compound. The PAMPA sandwich was assembled, placed on the Gut-Box 
controlled environment chamber and stirred for 30 min. The aqueous boundary layer was 
set to 40 μm for stirring. The UV spectrum (250–500 nm) of the donor and the acceptor 
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were read. The permeability coefficient was calculated using PAMPA Evolution 96 
Command software (pION Inc., Woburn, MA) based on the AUC of the reference plate, 
the donor plate, and the acceptor plate. All compounds were tested in triplicate. Standards 
for this assay include Verapamil HCl (Pe = 1405 x10
-6
 cm/s at pH=7.4 and 39 x10
-6
 cm/s 
at pH=4.0), Carbamazepine (Pe = 112 x10
-6
 cm/s at pH=7.4 and 108 x10
-6
 cm/s at 
pH=4.0), and Ranitidine HCl (Pe = 0.5 x10
-6
 cm/s at pH=7.4 and 0 x10
-6
 cm/s at pH=4.0). 
Solubility has been determined via an in-house HPLC assay. A calibration curve 
was made by plotting the area under the curve at 254 nm (uv by HPLC) against the 
concentration of each compound injected after performing a serial dilution (25  to 
0.781 ) using a solvent in which the compound is soluble (DMSO).  A 100  
solution was then made for each compound in a buffer at pH 7.4, 4.0, and 2.0 by 
performing a 1:100 serial dilution using a 10mM DMSO stock solution of each 
compound. This solution was incubated at 21
o
C for 18 hours, filtered using a filter plate, 
and injected into the HPLC to compare the area found at wavelength 254 nm with the 
previously made calibration curve. Standards for this assay include carbamazepine and 
albendazole. Solubility for carbamazepine at pH 7.4, 4.0, and 2.0 is 95 and 
100  respectively. Solubility for albendazole at pH 7.4, 4.0, and 2.0 is 6.1 , 12, 
and 100respectively 
*  solubility < 2 μM:   * 
2 μM < solubility < 5 μM:   ** 
5 μM < solubility < 10 μM: *** 
10 μM < solubility < 20 μM **** 
solubility > 20 μM:   ***** 
 
Log D was also determined in-house via an HPLC method adapted from the 
strategy reported by Donovan and Pescatore.
1
 Two buffers were made at a concentration 
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of 50 each: ammonium acetate at pH 7.4 and ammonium formate at pH 3.0. A set of 
compounds with known log D values between -0.36 and 5.68 were used to make a 
calibration curve at each pH by using a liner gradient between 0 and 100% acetonitrile, 
with buffer at the specific concentration used as the second solvent. The curve was made 
by plotting the log D value against the retention time. Compounds were then injected into 
the HPLC and the retention time compared to the calibration curve previously 
determined. Standards for this assay include Cinnarizine (LogD7.4 5.68), Hydrocortisone-
21-acetate (LogD7.4 2.19), Ketoconazole (LogD7.4 3.83), Metronidazole (LogD7.4 -0.02), 
Nadolol (LogD7.4 0.68), Pyrene (LogD7.4 4.88), Theophyline (LogD7.4 -0.05), and 
Tolnaftate (LogD7.4 5.40). 
The microsomal stability of 4(1H)-quinolones was determined by Susan Charman 
at the Monash University in Australia. The compounds are incubated at a concentration 
of 1 µM with human microsomes at 37ºC and 0.4 mg/mL of microsomal protein. The 
metabolic reaction was initiated with the addition of an NADPH-regenerating system (i.e. 
NADPH is the cofactor required for CYP450-mediated metabolism) and quenched at 
various time points over the incubation period by the addition of acetonitrile. Controls 
were incubated without the NADPH to assess the amount of degradation without 
metabolic initiation. The relative loss of compound was monitored by LC-MS using a 
Waters/Micromass ZQ mass spectrometer.  
 The test compounds concentration versus time data was fitted to an 
exponential decay function to determine the first order rate constant for substrate 
degradation. Each rate constant was then used to calculate microsomal half-life (Table 
6.2). Entries of C.N.C. (could not calculate) are compounds that displayed little to no 
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observable degradation throughout the assay duration (typically 250 minutes), whereas 
N.D. entries were molecules that were not assayed. Endochin was used as a control for 
comparing half-lives of 4(1H)-quinolones. Endochin possesses half-lives of 7.9 minutes 
in Mouse and 10.2 in human microsomes. 
2.7.2 General Procedures 
General Procedure A: Preparation of 3-substituted 2-methylquinolin-4(1H)-ones 
(2.3, 2.5, 2.6, 2.7, 2.8, 2.28, 2.29, 2.31-2.37, 2.38a&b-2.42a&b, 2.47, 2.49-2.55). 
Quinolin-4-ones were prepared by using one of the standard procedures for Conrad-
Limpach reaction.
16
 An oven-dry 100 ml rbf attached to a Dean-Stark trap equipped with 
a reflux condenser was charged with an aniline (0.025 mol), corresponded ethyl 
acetoacetate (0.25-0.05 mol)
3, 17, 18
, benzene (25 ml) and glacial acidic acid (1 ml). The 
mixture was heated at 100
o
C until no more water was separated (3-24 hours). The 
benzene was distilled under the reduced pressure and resulting enamine was then used in 
the next step without further purification.  Biphenyl ether (30 ml) was stirred and heated 
at reflux while enamine was added rapidly through the dropping funnel. Stirring and 
refluxing continued for 10-15 minutes until no more ethanol separates within the Dean-
Stark trap. The mixture was then allowed to cool down to room temperature while 
precipitation arises. The solid was filtered off and washed with hexane and acetone. Ice 
cold methanol washing may be necessary in some cases. No further purification was 
needed. Compounds 2.1, 2.2, 2.27, 2.30, 2.35, 2.48, 2.56, 2.57, 2.58, 2.60 were prepared 
by slightly different procedures with using CaSO4 instead of Dean-Stark trap and ethanol 
as a solvent in order to obtain enamine.
19
 The cyclization reaction was performed as 
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described above. The yield is reported over the two steps. Compound 4 was bought from 
Sigma-Aldrich. 
General Procedure B: Halogenation of substituted 2-methylquinolin-4(1H)-one (2.9, 
2.18, 2.19, 2.20, 2.21, 2.22, 2.62). The halogenation was done following a procedure 
reported by Renault et al.
20
 Thus 1.2 equivalent of a 16% solution of bromine in 30% 
aqueous potassium bromide was added dropwise to a stirred solution or slurry of 
2‐methylquinolin‐4(1H)‐one in 2M solution of sodium hydroxide at r.t. Stirring was 
continued until LCMS indicates absence of starting material (3‐24 hours). In some cases 
more than 1.2 eq of halogen was needed. The mixture was then acidified with acetic acid; 
precipitation was collected by filtration, washed with water, and recrystallized from 
DMF. 
General Procedure C: Benzylation of 3-bromo-2-methylquinolin-4(1H)-one (2.10, 
2.23a, 2.25a, 2.26a, 2.63).  The benzylation was done following a procedure reported by 
McKillop et al.
4
 Thus, a mixture of dichloromethane (50 ml), water (50 ml), 3-bromo-2-
methylquinolin-4(1H)-one (10 mmol), sodium hydroxide (15 mmol), benzyl chloride (30 
mmol) and benzyltributylammonium chloride (1 mmol) was stirred at r.t. between 8 – 
24h. The organic layer is separated then washed with H2O x2 (100 ml), Brine x1 (100 
ml), and finally 1M NH4OH then dried over Na2SO4. The crude material is purified 
further via flash chromatography on silica gel.  
General Procedure D: Heck coupling of 4-(benzyloxy)-3-bromo-2-methylquinoline 
(2.11-2.17, 2.65-2.67).  An oven-dried schlenk tube was flame-dried and backfilled with 
argon(x3). The tube is then charged with quinoline (100 mg, 1.5 mmol), Pd2(dba)3 (36 
mg, 0.039 mmol), XPHOS (37 mg, 0.078 mmol), alkene (0.277ml, 1.8 mmol), and 
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anhydrous triethylamine (1.31 ml, 0.01 mmol). The schlenk tube was fitted with a rubber 
septum and then evacuated and backfilled with argon (this process was repeated three 
times). Dry toluene (8 ml) was added through the septum via syringe and the resulting 
solution was stirred for 1 min while purging with argon before replacing the rubber 
septum with the Teflon screwcap. The reaction was set to the oil bath at 135
o
C until 
completion was observed via HPLC analysis. The crude product is brought to a boil in 
chloroform / methanol and filtered over celite then concentrated in vacuo. The residual 
material is diluted in hexane and filtered off. More soluble products were purified via 
flash chromatography. 
General Procedure E: Sonogashira coupling of 4-(benzyloxy)-3-bromo-2-
methylquinoline (2.23b-2.26b, 2.64). An oven-dried schlenk tube was flame-dried and 
backfilled with argon(x3). The tube is then charged with quinoline (0.2 g, 0.5 mmol), 
Pd(PPh3)2(Cl)2 (18 mg, 0.025 mmol), CuI (6 mg, 0.025 mmol), alkyne (0.277ml, 1.8 
mmol), and anhydrous triethylamine (0.5 ml, 3.5 mmol). The schlenk tube was fitted with 
a rubber septum and then evacuated and backfilled with argon (this process was repeated 
three times). Dry DMF (3 ml) was added through the septum via syringe and the resulting 
solution was stirred for 1 min while purging with argon before replacing the rubber 
septum with the Teflon screwcap. The reaction was set to the oil bath at 135
o
C until 
completion was observed via HPLC analysis. The crude product is filtered over celite 
then concentrated in vacuo. The residual material is purified via flash chromatography.  
General Procedure F: Methylation of 3-benzyl-2-methylquinolin-4(1H)-one 
(2.43a&b-2.46a&b). To a flame dried-backfilled round bottom flask is added quinolone 
(0.72 g, 2.8 mmol) and Cs2CO3 (1.37 g, 4.2 mmol). DMF (14.5 ml) is added and this 
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slurry is allowed to stir at r.t. for 1h. Next, iodomethane (0.88 ml, 14 mmol) is added 
dropwise and the reaction is left until completion is observed via HPLC analysis. The 
reaction is the poured onto water (20 ml) and then diluted with chloroform (20 ml). The 
organic layer is then washed with water (20 ml) twice followed by brine (20 ml). The 
organic layer is then dried over sodium sulfate and concentrated in vacuo. The crude 
compound is columned via flash chromatography (Hex / EtOAc gradient). 
2.7.3 Compound Characterization 
3-heptyl-7-methoxy-2-methylquinolin-4(1H)-one (2.1). Compound 2.1 was prepared 
following modified general procedure A using CaSO4. The precipitate was collected, 
washed with hexane and recrystallized from ethanol to give 27% yield as a white solid. 
1H NMR (400 MHz, DMSO) δ 11.16 (s, 1H), 7.92 (d, J = 6.4 Hz, 1H), 6.85 – 6.79 (m, 
2H), 3.83 (s, 3H), 2.45 – 2.41 (m, 2H), 2.33 (s, 3H), 1.37 – 1.24 (m, 10H), 0.86 (t, J = 6.6 
Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 175.16, 161.23, 145.01, 140.79, 126.89, 118.66, 
117.82, 112.26, 98.19, 55.25, 31.30, 29.24, 28.67, 24.68, 22.08, 17.40, 13.93.  HRMS 
(ESI) calcd. for C18H25NO2 [M+H]
+
: 288.19581, found: 288.19495.   
7-methoxy-2-methylquinolin-4(1H)-one (2.2). Compound 2.2 was prepared following 
modified general procedure A using CaSO4. The precipitate was collected, washed with 
hexane to give 43% yield over the two isomers (3:1, 7 and 5-substituted isomers 
respectively). Recrystallization from methanol gave desired isomer exclusively as a white 
solid, mp = 249 - 250°C. 
1H NMR (400 MHz, DMSO) δ 11.38 (s, 1H), 7.92 (d, J = 9.6 
Hz, 1H), 6.86 (d, J = 6.7 Hz, 2H), 5.81 (s, 1H), 3.83 (s, 3H), 2.29 (s, 3H). 
13
C NMR (101 
MHz, DMSO) δ 176.34, 161.64, 149.11, 141.81, 126.58, 118.80, 112.46, 108.10, 98.82, 
55.33, 19.36.  HRMS (ESI) calcd. for C11H11NO2 [M+H]
+
: 190.08626, found: 190.08559. 
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3-heptyl-2-methylquinolin-4(1H)-one (2.3). Compound 2.3 was prepared following 
general procedure A. Yield: 69%, mp = 229 - 230°C. 
1H NMR (400 MHz, DMSO) δ 
11.33 (s, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.55 (t, J = 7.6 Hz, 1H), 7.45 (d, J = 8.3 Hz, 1H), 
7.22 (t, J = 7.5 Hz, 1H), 2.46 (d, J = 7.9 Hz, 2H), 2.37 (s, 3H), 1.40 – 1.23 (m, 10H), 0.85 
(t, J = 6.5 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 175.45, 145.60, 139.11, 130.80, 
125.04, 123.33, 122.13, 119.15, 117.36, 31.31, 29.27, 28.69, 28.60, 24.79, 22.10, 17.46, 
13.94. HRMS (ESI) calcd. for  C17H23NO [M+H]
+
: 258.18524, found: 258.18576.  
2-methyl-3-nonylquinolin-4(1H)-one (2.5). Compound 2.5 was prepared following 
general procedure A. Yield: 30%, mp = 215 - 216°C. 
1H NMR (400 MHz, DMSO) δ 
11.35 (s, 1H), 8.05 (d, J = 7.8 Hz, 1H), 7.55 (t, J = 7.2 Hz, 1H), 7.46 (d, J = 8.0 Hz, 1H), 
7.23 (t, J = 7.2 Hz, 1H), 2.47 (d, J = 6.5 Hz, 2H), 2.38 (s, 3H), 1.26 (d, J = 16.9 Hz, 14H), 
0.85 (t, J = 6.5 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 176.19, 146.28, 139.81, 131.47, 
125.73, 124.03, 122.80, 119.84, 118.05, 31.95, 29.97, 29.71, 29.39, 29.26, 25.47, 22.74, 
18.12, 14.58. HRMS (ESI) calcd. for C19H27NO [M+H]
+
: 286.21654, found: 286.21538.  
3-cyclohexyl-2-methylquinolin-4(1H)-one (2.6). Compound 2.6 was prepared following 
general procedure A. Yield: 36%, mp = 286 - 287°C. 
1
H NMR (400 MHz, DMSO) δ 
11.21 (s, 1H), 8.02 (d, J = 7.5 Hz, 1H), 7.53 (t, J = 7.6 Hz, 1H), 7.43 (d, J = 8.2 Hz, 1H), 
7.20 (t, J = 7.3 Hz, 1H), 2.40 (s, 3H), 2.34 – 2.20 (m, 2H), 1.79 – 1.62 (m, 3H), 1.46 – 
1.12 (m, 6H).
 13C NMR (101 MHz, DMSO) δ 175.77, 145.39, 138.92, 130.73, 125.05, 
124.40, 122.41, 122.08, 117.16, 28.91, 26.90, 25.76, 18.25. HRMS (ESI) calcd. for 
C16H19NO [M+H]
+
: 242.15394, found: 242.15342. 
2-methyl-3-phenylquinolin-4(1H)-one (2.7).  Compound 2.7 was prepared following 
general procedure A. Yield:  52%. 
1H NMR (400 MHz, DMSO) δ 11.63 (s, 1H), 8.09 (d, 
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J = 8.0, 1H), 7.63 (t, J = 7.6, 1H), 7.53 (d, J = 8.2, 1H), 7.39 (t, J = 7.4, 2H), 7.31 – 7.23 
(m, 4H), 2.22 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 175.52, 147.16, 140.02, 136.89, 
132.10, 131.67, 128.42, 127.12, 126.01, 125.06, 123.36, 121.56, 118.24, 19.54. HRMS 
(ESI) calcd. for C16H13N [M+H]
+ 
236.10699, found 236.10795. 
3-benzyl-2-methylquinolin-4(1H)-one (2.8). Compound 2.8 was prepared following 
general procedure A. Yield: 81%, mp = 283 - 284°C. 
1H NMR (400 MHz, DMSO) δ 
11.51 (s, 1H), 8.11 (d, J = 7.7 Hz, 1H), 7.59 (t, J = 7.1 Hz, 1H), 7.50 (d, J = 8.0 Hz, 1H), 
7.32 – 7.06 (m, 7H), 3.90 (s, 2H), 2.34 (s, 3H). 13C NMR (101 MHz, DMSO) δ 175.62, 
147.03, 141.32, 139.21, 131.08, 128.07, 127.99, 125.42, 125.22, 123.57, 122.49, 118.14, 
117.56, 29.93, 17.83. HRMS (ESI) calcd. for C17H15NO [M+H]
+
: 250.12264, found: 
250.12182. 
3-bromo-2-methylquinolin-4(1H)-one (2.9).  Compound 2.9 was prepared using general 
procedure B. Yield: 96%. 
1H NMR (250 MHz, DMSO) δ 8.09 (d, J = 8.1, 1H), 7.65 (t, J 
= 7.6, 1H), 7.53 (d, J = 8.2, 1H), 7.34 (t, J = 7.5, 1H), 2.54 (s, 3H). 
13
C NMR (63 MHz, 
DMSO) δ 171.05, 148.63, 138.61, 131.82, 125.24, 123.61, 122.73, 117.84, 105.90, 21.38. 
HRMS (ESI) calcd. for C10H8BrNO [M+H]
+
: 237.98620, found: 237.98711. 
4-(benzyloxy)-3-bromo-2-methylquinoline (2.10).  Compound 2.10 was prepared 
following general procedure C. Yield: 70%. 
1
H NMR (400 MHz, CD2Cl2) δ 8.00 (d, J = 
8.4, 1H), 7.96 (d, J = 8.4, 1H), 7.68 (ddd, J = 8.4, 7.0, 1.3, 1H), 7.58 (d, J = 6.6, 2H), 7.44 
(m, 4H), 5.19 (s, 2H), 2.85 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 159.60, 159.46, 
148.09, 136.32, 130.22, 128.92, 128.89, 128.84, 128.54, 126.53, 123.84, 122.11, 112.42, 
76.20, 26.72. HRMS (ESI) calcd. for C17H14BrNO [M+H]
+
: 328.03315, found: 
328.03337. 
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(E)-2-methyl-3-(non-1-enyl)quinolin-4(1H)-one (2.11). Compound 2.11 was prepared 
similarly to general procedure D. An oven-dried schlenk tube was flame-dried and 
backfilled with argon(x3). The tube is then charged with 4-(benzyloxy)-3-bromo-2-
methylquinoline (1.15g, 3.5 mmol), Pd2(dba)3 (180 mg, 0.175 mmol), XPHOS (190 mg, 
0.35 mmol), alkene (1.08 ml, 6.3 mmol), and anhydrous triethylamine (2.9 ml, 21.0 
mmol). The schlenk tube was fitted with a rubber septum and then evacuated and 
backfilled with argon (this process was repeated three times). Dry Toluene (20 ml) was 
added through the septum via syringe and the resulting solution was stirred for 1 min 
while purging with argon before replacing the rubber septum with the Teflon screwcap. 
The reaction was added to an oil bath at 130
o
C for 3d. The crude mixture was pre-
purified using flash chromatography to obtain the mixture of 2.11, 2.12, and 2.13. Yield: 
64%. Then the oil was dissolved in minimal MeOH and purified further using preparative 
HPLC to obtain the three titled compounds 2.11, 2.12, and 2.13. Other isomers were 
generated however, were unable to be adequately purified by preparative HPLC. 
1
H 
NMR (400 MHz, CDCl3) δ 8.37 (d, J = 8.2, 1H), 7.70 (d, J = 8.3, 1H), 7.48 (t, J = 7.5, 
1H), 7.28 – 7.23 (m, 1H), 6.47 – 6.38 (m, 2H), 2.56 (d, J = 14.8, 3H), 2.06 (dd, J = 12.0, 
6.9, 2H), 1.30 – 1.14 (m, 10H), 0.82 (t, J = 6.9, 3H). 13C NMR (101 MHz, CDCl3) δ 
177.14, 148.11, 139.29, 135.69, 131.33, 125.74, 124.85, 123.50, 122.90, 118.52, 117.69, 
34.34, 32.01, 31.78, 29.72, 29.44, 29.37, 22.84, 19.66. HRMS (ESI) calcd. for C19H25NO 
[M+H]
+
: 284.20089, found: 284.20112. 
2-methyl-3-(non-1-en-2-yl)quinolin-4(1H)-one (2.12). Compound 2.12 was prepared 
using modified procedure D as it is mentioned above for 11. The crude mixture was pre-
purified using flash chromatography to obtain the mixture of 11, 12, and 13. Then the oil 
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was dissolved in minimal MeOH and purified further using preparative HPLC. 
1
H NMR 
(400 MHz, CDCl3) δ 8.35 (d, J = 8.1, 1H), 7.69 (d, J = 8.3, 1H), 7.49 (t, J = 7.6, 1H), 
7.29 – 7.24 (m, 1H), 5.22 (s, 1H), 4.89 (s, 1H), 2.47 (s, 3H), 2.44 – 2.36 (m, 2H), 1.36 (br 
t, 2H), 1.23 – 1.14 (m, 8H), 0.81 (t, J = 6.8, 3H). 13C NMR (101 MHz, CDCl3) δ 176.64, 
147.97, 146.25, 140.03, 131.38, 125.58, 124.76, 123.45, 123.39, 118.76, 115.64, 36.90, 
32.05, 29.87, 29.47, 28.16, 22.81, 19.33,14.26. HRMS (ESI) calcd. for C19H25NO 
[M+H]
+
: 284.20089, found: 284.20112. 
(Z)-2-methyl-3-(non-2-enyl)quinolin-4(1H)-one (2.13). Compound 2.13 was prepared 
using modified procedure D as it is mentioned above for 11. The crude mixture was pre-
purified using flash chromatography to obtain the mixture of 11, 12, and 13. Then the oil 
was dissolved in minimal MeOH and purified further using preparative HPLC. 
1
H NMR 
(400 MHz, CDCl3) δ 11.26 (s, 1H), 8.37 (d, J = 8.0, 1H), 7.57 (d, J = 8.3, 1H), 7.50 (dd, J 
= 11.1, 4.1, 1H), 7.28 (d, J = 7.5, 1H), 5.55 – 5.33 (m, 2H), 3.42 (d, J = 5.2, 2H), 2.49 (s, 
3H), 1.87 (d, J = 6.3, 2H), 1.22 (br m, J = 24.5, 10H), 0.83 (t, J = 6.8, 3H). 
13
C NMR 
(101 MHz, CDCl3) δ 177.20, 147.86, 139.65, 131.30, 130.81, 127.25, 125.94, 124.37, 
123.30, 118.62, 118.09, 32.62, 31.89, 29.62, 29.07, 28.56, 22.78, 18.63, 14.25. HRMS 
(ESI) calcd. for C19H25NO [M+H]
+
: 284.20089, found: 284.20112. 
(E)-tert-butyl 3-(2-methyl-4-oxo-1,4-dihydroquinolin-3-yl)acrylate 2.14. Compound 
2.14 was prepared following general procedure D. Yield: 83%. 
1
H NMR (400 MHz, 
DMSO) δ 12.05 (s, 1H), 8.13 (d, J = 8.0, 1H), 7.66 (t, J = 7.6, 1H), 7.57 (d, J = 16, 1H), 
7.54 (d, J = 8, 1H) 7.39 – 7.33 (m, 2H), 2.59 (s, 3H), 1.47 (s, 9H). 13C NMR (101 MHz, 
DMSO) δ 176.19, 168.12, 153.11, 138.75, 137.74, 132.55, 126.08, 125.50, 124.61, 
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119.16, 118.63, 112.63, 79.58, 28.63, 18.98. HRMS (ESI) calcd. for C17H19NO3 [M+H]
+
: 
286.14377, found: 286.14439. 
(E)-2-methyl-3-styrylquinolin-4(1H)-one (2.15). Compound 2.15 was prepared 
following general procedure D. Yield: 71%. 
1H NMR (400 MHz, DMSO) δ 8.15 (d, J = 
8.0, 1H), 8.08 (d, J = 16.0, 1H), 7.62 (t, J = 7.5, 1H), 7.53 (d, J = 7.9, 3H), 7.37 – 7.30 
(m, 3H), 7.20 (d, J = 7.6, 1H), 7.14 (d, J = 16.0, 1H), 2.62 (s, 3H). 
13
C NMR (101 MHz, 
DMSO) δ 175.87, 149.33, 139.70, 138.80, 131.88, 129.82, 129.28, 127.34, 126.51, 
125.99, 125.23, 123.77, 123.30, 118.34, 115.09, 19.19. HRMS (ESI) calcd. for C18H15NO 
[M+H]
+
: 262.12264, found: 262.12280. 
(E)-2-methyl-3-(3-nitrostyryl)quinolin-4(1H)-one (2.16). Compound 2.16 was prepared 
following general procedure D. Yield:  96%. 
1H NMR (400 MHz, DMSO) δ 12.62 (s, 
1H), 8.30 (s, 1H), 8.24 (d, J = 15.9, 1H), 8.15 (d, J = 7.9, 1H), 8.02 (dd, J = 13.2, 4.9, 
2H), 7.74 (d, J = 8.2, 1H), 7.65 – 7.59 (m, 2H), 7.35 – 7.29 (m, 2H), 2.71 (s, 3H). 13C 
NMR (101 MHz, DMSO) δ 175.88, 150.75, 149.10, 141.86, 138.95, 132.77, 131.85, 
130.69, 126.96, 126.48, 125.89, 125.32, 123.94, 121.56, 120.46, 118.63, 114.31, 18.99. 
HRMS (ESI) calcd. for C18H14N2O3 [M+H]
+
: 307.10772, found: 307.10830. 
(E)-3-(4-hydroxystyryl)-2-methylquinolin-4(1H)-one (2.17). Compound 2.17 was 
prepared starting from 3-bromo-1,2-dimethylquinolin-4(1H)-one (0.4g, 1.6 mmol) and 1-
methoxy-4-vinylbenzene (0.19 ml, 1.4 mmol)  following general procedure D. The 
resulting heck adduct (1.2 mmol) was de-methylated by refluxing sodium ethanethiolate 
(2.0 g, 24 mmol) in DMF for 12h. Both methyl groups were removed thus yielding the 
title compound in 14% yield. 
1
H NMR (500 MHz, CD3OD) δ 8.28 (d, J = 8.2, 1H), 7.63 
(s, 1H), 7.57 (d, J = 16.3, 1H), 7.52 (d, J = 8.3, 1H), 7.39 (dd, J = 7.8, 6.3, 3H), 7.01 (dd, 
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J = 16.3, 2.0, 1H), 6.81 – 6.77 (m, 2H), 2.65 (s, 3H). 13C NMR (126 MHz, CD3OD) δ 
177.22, 156.97, 148.73, 138.68, 132.28, 131.54, 130.47, 127.33, 125.29, 124.45, 123.62, 
118.60, 117.54, 117.11, 115.27, 18.16. HRMS (ESI) calcd. for C18H15NO2 [M+H]
+
: 
278.11756, found: 278.11756. 
3-bromo-6-methoxy-2-methylquinolin-4(1H)-one (2.18). Compound 2.18 was prepared 
following general procedure B. Yield 77%, mp = 262 - 264°C.  
1
H NMR (400 MHz, 
DMSO) δ 12.11 (s, 1H), 7.49 (dd, J = 13.3, 5.9 Hz, 2H), 7.31 (dd, J = 9.0, 2.9 Hz, 1H), 
3.83 (s, 3H), 2.54 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 170.32, 155.74, 147.37, 
133.23, 123.78, 122.26, 119.62, 105.11, 104.46, 55.36, 21.27. HRMS (ESI) calcd. for 
C11H10BrNO2 [M+H]
+
: 267.99677, found: 267.99789. 
3-bromo-2,6-dimethylquinolin-4(1H)-one (2.19). Compound 2.19was prepared 
following general procedure B. Yield 60%, mp = 266 - 268°C. 
1
H NMR (400 MHz, 
DMSO) δ 12.07 (s, 1H), 7.88 (s, 1H), 7.51 – 7.41 (m, 2H), 2.54 (s, 3H), 2.40 (s, 3H).13C 
NMR (101 MHz, DMSO) δ 170.74, 148.07, 136.68, 133.19, 132.93, 124.36, 122.69, 
117.73, 105.66, 21.32, 20.70. HRMS (ESI) calc. for C11H10BrNO [M+H]
+
: 252.00185, 
found: 252.00114. HRMS (ESI) calcd. for C19H25NO [M+H]
+
: 284.20089, found: 
284.20112. 
3,6-dibromo-2-methylquinolin-4(1H)-one (2.20). Compound 2.20 was prepared 
following general procedure B. Yield 70%, mp = 295 - 296°C.   
1
H NMR (400 MHz, 
DMSO) δ 12.30 (s, 1H), 8.16 (d, J = 2.2 Hz, 1H), 7.81 (dd, J = 8.8, 2.2 Hz, 1H), 7.52 (d, 
J = 8.8 Hz, 1H), 2.55 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 169.73, 149.16, 137.42, 
134.52, 127.23, 123.98, 120.46, 116.07, 106.16, 21.43. HRMS (ESI) calcd. for 
C10H7Br2NO [M+H]
+
: 315.89672, found: 315.89722. 
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3-bromo-6-chloro-2-methylquinolin-4(1H)-one (2.21). Compound 2.21 was prepared 
following general procedure B. Yield 66%, mp = 288 - 290°C.  
1
H NMR (400 MHz, 
DMSO) δ 12.31 (s, 1H), 8.01 (d, J = 2.0 Hz, 1H), 7.70 (dd, J = 8.8, 2.2 Hz, 1H), 7.58 (d, 
J = 8.8 Hz, 1H), 2.56 (s, 3H). 
13
C NMR (101 MHz, DMSO) δ 169.84, 149.10, 137.15, 
131.91, 128.11, 124.05, 123.57, 120.30, 106.12, 21.40. HRMS (ESI) calcd. for 
C10H7BrClNO [M+H]
+
: 271.94723, found: 271.94788. 
3-bromo-6-fluoro-2-methylquinolin-4(1H)-one (2.22). Compound 2.22 was prepared 
following general procedure B. Yield 67%, mp = 282 - 285°C.  
1
H NMR (400 MHz, 
DMSO) δ 12.29 (s, 1H), 7.73 (dd, J = 9.3, 2.4 Hz, 1H), 7.60 (qd, J = 9.1, 3.8 Hz, 2H), 
2.56 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 170.18, 159.57, 157.16, 148.72, 135.29, 
123.69, 120.50, 109.28, 105.40, 21.35. HRMS (ESI) calcd. for C10H7BrFNO [M+H]
+
: 
255.97678, found: 255.97763. 
4-(benzyloxy)-3-bromo-6-methoxy-2-methylquinoline (2.23a). Compound 2.23a was 
prepared using general procedure C. Yield: 73%. 
1
H NMR (400 MHz, CDCl3) δ 7.88 (d, 
J = 9.2, 1H), 7.55 (d, J = 6.3, 2H), 7.41 (t, J = 7.5, 3H), 7.30 (dd, J = 9.2, 2.8, 1H), 7.13 
(d, J = 2.8, 1H), 5.19 (s, 2H), 3.76 (s, 3H), 2.85 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 
158.72, 157.92, 156.47, 144.20, 136.60, 130.37, 128.93, 128.85, 128.68, 124.80, 122.82, 
112.96, 99.96, 55.62, 26.37. HRMS (ESI) calcd. for C18H16BrNO2 [M+H]
+
: 358.04372, 
found: 358.04507. 
4-(benzyloxy)-3-bromo-6-chloro-2-methylquinoline (2.25a). Compound 2.25a was 
prepared using general method C. Yield: 74%. 
1H NMR (400 MHz, CDCl3) δ 7.92 (d, J 
= 9.3, 2H), 7.60 (dd, J = 8.9, 2.3, 1H), 7.56 (d, J = 6.8, 2H), 7.46 – 7.39 (m, 3H), 5.20 (s, 
2H), 2.88 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 159.87, 158.74, 146.40, 135.96, 
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132.54, 131.11, 130.58, 129.02, 128.93, 128.62, 124.63, 121.16, 113.43, 26.72. HRMS 
(ESI) calcd. for C17H13BrClNO [M+H]
+
: 361.99418, found: 361.99414. 
4-(benzyloxy)-3-bromo-6-fluoro-2-methylquinoline (2.26a). Compound 2.26a was 
prepared using general procedure C. Yield: 43%. 
1
H NMR (400 MHz, CDCl3) δ 8.00 (dd, 
J = 9.2, 5.2, 1H), 7.57 (d, J = 6.5, 3H), 7.47 – 7.40 (m, 4H), 5.20 (s, 2H), 2.88 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 160.71 (d, J = 247 Hz), 159.04, 158.77, 145.18, 136.03, 
131.52 (d, J = 9 Hz), 128.99, 128.94, 128.61, 124.76, 120.34 (d, J = 25.25), 113.44, 
105.86 (d, J = 23.23 Hz), 26.58. HRMS (ESI) calcd. for C17H13NBrFO [M+H]
+
: 
346.02373, found: 346.02479. 
3-(hex-1-ynyl)-6-methoxy-2-methylquinolin-4(1H) one (2.23b). Compound 2.23b was 
prepared using general method E. Yield: 32%. 
1
H NMR (500 MHz, CDCl3) δ 7.99 (d, J = 
9.2, 1H), 7.45 (d, J = 2.8, 1H), 7.25 (dd, J = 9.2, 2.8, 1H), 6.53 (s, 1H), 3.98 (s, 3H), 2.89 
(t, J = 7.5, 2H), 2.80 (s, 4H), 1.82 – 1.77 (m, 2H), 1.48 (m, 2H), 0.99 (t, J = 7.4, 3H). 13C 
NMR (126 MHz, CDCl3) δ 159.79, 157.65, 154.44, 150.98, 141.11, 130.64, 121.57, 
119.84, 116.93, 101.40, 101.39, 98.41, 55.89, 30.22, 28.42, 22.77, 22.56, 14.07. HRMS 
(ESI) calcd. for C17H19NO2 [M+H]
+
: 270.14886, found: 270.14972. 
3-(hex-1-ynyl)-2-methylquinolin-4(1H)-one (2.24b).  Compound 2.24b was prepared 
using general method E. Yield: 15%. 
1
H NMR (400 MHz, CDCl3) δ 8.15 (d, J = 8.0, 1H), 
8.07 (d, J = 8.1, 1H), 7.57 (t, J = 7.3, 1H), 7.49 (t, J = 7.4, 1H), 6.48 (s, 1H), 2.85 – 2.78 
(m, 5H), 1.79 – 1.72 (m, 2H), 1.43 (dd, J = 14.7, 7.3, 2H), 0.95 (t, J = 7.3, 3H).  13C 
NMR (101 MHz, CDCl3) δ 159.87, 154.72, 153.74, 145.16, 128.84, 127.82, 125.90, 
121.36, 119.84, 116.41, 101.23, 30.11, 28.28, 22.88, 22.47, 13.98. HRMS (ESI) calcd. 
for C16H17NO [M+H]
+
: 240.13829, found: 240.13928. 
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6-chloro-3-(hex-1-ynyl)-2-methylquinolin-4(1H)-one (2.25b). Compound 2.25b was 
prepared using general method E. Yield: 25%. 
1
H NMR (400 MHz, CDCl3) δ 8.12 (d, J = 
2.3, 1H), 7.98 (d, J = 9.0, 1H), 7.51 (dd, J = 9.0, 2.3, 1H), 6.52 (s, 1H), 2.87 (d, J = 7.5, 
2H), 2.79 (s, 3H), 1.80 – 1.75 (m, 2H), 1.48 – 1.43 (m, 2H), 0.98 (d, J = 7.3, 3H). 13C 
NMR (101 MHz, CDCl3) δ 160.51, 154.10, 153.70, 143.52, 131.65, 130.66, 128.50, 
122.02, 119.00, 116.99, 101.36, 30.10, 28.32, 22.98, 22.47, 13.98. HRMS (ESI) calcd. 
for C16H16ClNO [M+H]
+
: 274.09932, found: 274.10055. 
6-fluoro-3-(hex-1-ynyl)-2-methylquinolin-4(1H)-one (2.26b). Compound 2.26b was 
prepared using general method E. Yield: 31%. 
1
H NMR (400 MHz, CDCl3) δ 8.08 (dd, J 
= 9.2, 5.2, 1H), 7.78 (dd, J = 8.8, 2.8, 1H), 7.40 – 7.33 (m, 1H), 6.56 (s, 1H), 2.89 (t, J = 
7.6, 2H), 2.82 (s, 3H), 1.84 – 1.77 (m, 2H), 1.50 – 1.45 (m, 2H), 0.99 (t, J = 7.4, 3H). 13C 
NMR (101 MHz, CDCl3) δ 160.44, 160.38 (d, J = 247.5), 152.98, 142.12, 131.38 (d, J = 
9.09), 121.83, 117.41 (d, J = 41), 116.86, 116.67, 104.88 (d, J = 24.24), 101.34, 30.09, 
28.30, 22.77, 22.47, 13.97. HRMS (ESI) calcd. for C16H16FNO [M+H]
+
: 258.12887, 
found: 258.12903. 
3-benzyl-6-methoxy-2-methylquinolin-4(1H)-one (2.27). Compound 2.27 was prepared 
following modified general procedure A using CaSO4. Yield: 65%, mp = 294 - 295°C. 
1
H 
NMR (400 MHz, DMSO) δ 11.50 (s, 1H), 7.52 (d, J = 2.4 Hz, 1H), 7.46 (d, 1H), 7.27 – 
7.06 (m, 6H), 3.91 (s, 2H), 3.82 (s, 3H), 2.32 (s, 3H).
 13C NMR (101 MHz, DMSO) δ 
174.94, 155.10, 146.08, 141.46, 133.89, 128.06, 128.03, 125.40, 124.50, 121.63, 119.34, 
117.23, 104.45, 55.23, 30.04, 17.75. HRMS (ESI) calcd. for C18H17NO2 [M+H]
+
: 
280.13321, found: 280.13237.  
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3-benzyl-6-chloro-2-methylquinolin-4(1H)-one (2.28). Compound 2.28 was prepared 
following general procedure A. Yield: 77%, mp = 328 - 329°C. 
1
H NMR (400 MHz, 
DMSO) δ 11.69 (s, 1H), 8.03 (d, J = 2.3 Hz, 1H), 7.62 (dd, J = 8.8, 2.4 Hz, 1H), 7.53 (d, 
J = 8.8 Hz, 1H), 7.24 – 7.08 (m, 5H), 3.89 (s, 2H), 2.34 (s, 3H). 13C NMR (101 MHz, 
DMSO) δ 174.45, 147.61, 140.99, 137.75, 131.22, 128.11, 127.98, 127.12, 125.51, 
124.50, 124.12, 120.07, 118.58, 29.91, 17.89.  HRMS (ESI) calcd. for C17H14ClNO 
[M+H]
+
: 284.08367, found: 284.08330. 
6-methoxy-2-methyl-3-phenylquinolin-4(1H)-one (2.29). Compound 2.29 was prepared 
following general procedure A. Yield: 95%, mp = 362 - 362°C. 
1
H NMR (400 MHz, 
DMSO) δ 11.62 (s, 1H), 7.50 (d, J = 8.9 Hz, 2H), 7.38 (t, J = 7.4 Hz, 2H), 7.32 – 7.21 (m, 
4H), 3.82 (s, 3H), 2.20 (s, 3H). 
13
C NMR (101 MHz, DMSO) δ 174.11, 155.20, 145.54, 
136.50, 134.01, 131.02, 127.71, 126.33, 125.35, 121.77, 119.91, 119.35, 104.69, 55.28, 
18.82. HRMS (ESI) calcd. for C17H15NO2 [M+H]
+
: 266.11756, found: 266.11718. 
6-chloro-2-methyl-3-phenylquinolin-4(1H)-one (2.30). Compound 2.30 was prepared 
following modified general procedure A using CaSO4. Yield: 12%, mp = 347 - 348°C. 
1
H 
NMR (400 MHz, DMSO) δ 11.86 (s, 1H), 8.01 (s, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.59 (d, 
J = 8.7 Hz, 1H), 7.42 – 7.22 (m, J = 29.9, 18.5, 7.1 Hz, 5H), 2.22 (s, 3H). 13C NMR (101 
MHz, DMSO) δ 173.64, 147.13, 137.97, 135.77, 131.51, 130.87, 127.79, 127.27, 126.59, 
125.36, 124.19, 121.14, 120.13, 18.90.  HRMS (ESI) calcd. for C16H12ClNO [M+H]
+
: 
269.06074, found: 269.05982. 
3-benzyl-8-methoxy-2-methylquinolin-4(1H)-one (2.31). Compound 2.31 was prepared 
following general procedure A. Yield: 59%, mp = 188 - 189°C. 
1
H NMR (400 MHz, 
DMSO) δ 10.84 (s, 1H), 7.68 (dd, J = 6.9, 2.2 Hz, 1H), 7.23 – 7.10 (m, 7H), 3.98 (s, 3H), 
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3.90 (s, 2H), 2.40 (s, 3H).
 13C NMR (101 MHz, DMSO) δ 175.33, 148.08, 147.07, 
141.21, 130.04, 128.07, 127.97, 125.42, 124.49, 122.27, 118.74, 116.55, 110.52, 56.10, 
29.98, 17.50. HRMS (ESI) calcd. for C18H17NO2 [M+H]
+
: 280.13321, found: 280.13205.  
3-benzyl-8-chloro-2-methylquinolin-4(1H)-one (2.32). Compound 2.32 was prepared 
following general procedure A. Yield: 54%, mp = 230 - 231°C. 
1
H NMR (400 MHz, 
DMSO) δ 10.57 (s, 1H), 8.10 (d, J = 8.0 Hz, 1H), 7.78 (d, J = 6.7 Hz, 1H), 7.29 (t, J = 7.9 
Hz, 1H), 7.23 – 7.09 (m, 5H), 3.91 (s, 2H), 2.46 (s, 3H). 13C NMR (101 MHz, DMSO) δ 
175.16, 148.43, 140.78, 135.79, 131.45, 128.15, 127.96, 125.55, 125.12, 124.67, 122.97, 
120.79, 119.24, 29.96, 17.79. HRMS (ESI) calcd. for C17H14ClNO [M+H]
+
: 284.08367, 
found: 284.08295. 
8-methoxy-2-methyl-3-phenylquinolin-4(1H)-one (2.33). Compound 2.33 was prepared 
following general procedure A. Yield: 46%, mp = 233 - 234°C. 
1
H NMR (400 MHz, 
DMSO) δ 10.97 (s, 1H), 7.65 (d, J = 6.4 Hz, 1H), 7.38 (t, J = 7.0 Hz, 2H), 7.25 (dd, J = 
24.1, 6.7 Hz, 5H), 4.01 (s, 3H), 2.26 (s, 3H).
 13C NMR (101 MHz, DMSO) δ 174.59, 
148.14, 146.52, 136.36, 130.96, 130.15, 127.75, 126.44, 125.35, 122.45, 121.51, 116.63, 
110.90, 56.18, 18.70. HRMS (ESI) calcd. for C17H15NO2 [M+H]
+
: 266.11756, found: 
266.11705. 
8-chloro-2-methyl-3-phenylquinolin-4(1H)-one (2.34). Compound 2.34 was prepared 
following general procedure A. Yield: 27%, mp = 298-299°C. 
1
H NMR (400 MHz, 
DMSO) δ 10.71 (s, 1H), 8.08 (dd, J = 8.0, 1.1 Hz, 1H), 7.81 (dd, J = 7.6, 1.2 Hz, 1H), 
7.40 (t, J = 7.4 Hz, 2H), 7.35 – 7.27 (m, 2H), 7.24 (d, J = 7.0 Hz, 2H), 2.31 (s, 3H). 13C 
NMR (101 MHz, DMSO) δ 174.42, 147.89, 135.95, 135.74, 131.73, 130.82, 127.85, 
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126.72, 125.99, 124.75, 123.12, 121.89, 120.83, 18.97. HRMS (ESI) calcd. for 
C16H12ClNO [M+H]
+
: 270.06802, found: 270.06871. 
7,8-dichloro-2-methyl-3-phenylquinolin-4(1H)-one (2.35). Compound 2.35 was 
prepared following modified general procedure A using CaSO4. Yield: 17%, mp = 336 - 
337°C. 
1H NMR (400 MHz, DMSO) δ 10.81 (s, 1H), 8.06 (d, J = 8.7 Hz, 1H), 7.53 (d, J 
= 8.7 Hz, 1H), 7.41 (t, J = 7.4 Hz, 2H), 7.33 (t, J = 7.3 Hz, 1H), 7.24 (d, J = 7.1 Hz, 2H), 
2.32 (s, 3H).
 13C NMR (101 MHz, DMSO) δ 173.96, 148.68, 137.43, 135.48, 134.80, 
130.75, 127.89, 126.82, 125.62, 124.28, 123.78, 122.24, 19.18. HRMS (ESI) calcd. for 
C16H11Cl2NO [M+H]
+
: 304.02905, found: 304.02952. 
6,8-dichloro-2-methyl-3-phenylquinolin-4(1H)-one (2.36). Compound 2.36 was 
prepared following general procedure A. Yield: 14%, mp = 318 - 319°C. 
1
H NMR (400 
MHz, DMSO) δ 10.91 (s, 1H), 8.00 (d, J = 4.6 Hz, 1H), 7.41 (t, J = 7.3 Hz, 2H), 7.33 (t, J 
= 7.3 Hz, 2H), 7.23 (d, J = 7.0 Hz, 2H), 2.31 (s, 3H).
 13C NMR (101 MHz, DMSO) δ 
173.26, 148.51, 135.36, 134.97, 131.33, 130.75, 127.94, 127.08, 126.91, 126.42, 123.81, 
122.51, 122.16, 19.02.  HRMS (ESI) calcd. for C16H11Cl2NO [M+H]
+
: 304.02905, found: 
304.02786. 
5,7-dichloro-2-methyl-3-phenylquinolin-4(1H)-one (2.37). Compound 2.37 was 
prepared following general procedure A. Yield: 13%, mp = 305 - 306°C. 
1
H NMR (400 
MHz, DMSO) δ 11.68 (s, 1H), 7.51 (d, J = 1.9 Hz, 1H), 7.39 (t, J = 7.4 Hz, 2H), 7.31 
(dd, J = 11.8, 4.6 Hz, 2H), 7.21 (d, J = 7.0 Hz, 2H), 2.15 (s, 3H).
 13
C NMR (101 MHz, 
DMSO) δ 173.75, 145.78, 142.25, 135.49, 134.88, 134.07, 130.83, 127.79, 126.71, 
124.74, 123.11, 119.03, 116.26, 18.58.  HRMS (ESI) calcd. for C16H11Cl2NO [M+H]
+
: 
304.02905, found: 304.02755. 
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6,7-dichloro-2-methyl-3-phenylquinolin-4(1H)-one (2.38a). Compound 2.38a was 
prepared following general procedure A. Yield: 54% over the two isomers (1:1, 5,6 and 
6,7-disubstituted isomers respectively). Desired isomer was separated by recrystallization 
from DMF. 
1H NMR (400 MHz, DMSO) δ 11.83 (s, 1H), 8.15 (s, 1H), 7.75 (s, 1H), 7.39 
(d, J = 6.6 Hz, 2H), 7.32 (d, J = 6.3 Hz, 1H), 7.24 (d, J = 6.6 Hz, 2H), 2.22 (s, 3H).
 13
C 
NMR (101 MHz, DMSO) δ 173.27, 147.65, 138.40, 135.36, 133.99, 131.37, 130.79, 
127.85, 126.77, 125.49, 124.06, 121.57, 119.41, 19.00.  HRMS (ESI) calcd. for  
C16H11Cl2NO [M+H]
+
: 304.02905, found: 304.02778. 
5,6-dichloro-2-methyl-3-phenylquinolin-4(1H)-one (2.38b). Compound 2.38b was 
prepared following general procedure A. Yield: 54% over the two isomers (1:1, 5,6 and 
6,7-disubstituted isomers respectively). Desired isomer was separated by preparative 
HPLC. 
1H NMR (400 MHz, DMSO) δ 11.77 (s, 1H), 7.79 (d, J = 8.5 Hz, 1H), 7.51 (d, J 
= 8.5 Hz, 1H), 7.38 (d, J = 6.3 Hz, 2H), 7.32 (d, J = 6.2 Hz, 1H), 7.22 (d, J = 6.3 Hz, 2H), 
2.16 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 173.71, 145.79, 140.54, 135.80, 132.26, 
130.98, 129.98, 127.95, 127.39, 126.83, 123.10, 121.61, 118.45, 18.59.  HRMS (ESI) 
calcd. for C16H11Cl2NO [M+H]
+
: 304.02905, found: 304.02773. 
3-benzyl-7-methoxy-2-methylquinolin-4(1H)-one (2.39a). Compound 2.39a was 
prepared following general procedure A. Yield: 71% over the two isomers (4:1, 7 and 5-
substituted isomers respectively). Desired isomer was separated by recrystallization from 
methanol as a white solid, mp = 272 - 273°C. 
1H NMR (400 MHz, DMSO) δ 11.33 (s, 
1H), 8.00 (d, J = 9.6 Hz, 1H), 7.20 (d, J = 4.3 Hz, 4H), 7.10 (dt, J = 8.7, 4.2 Hz, 1H), 
6.91 – 6.85 (m, 2H), 3.86 (s, 2H), 3.83 (s, 3H), 2.30 (s, 3H). 13C NMR (101 MHz, 
DMSO) δ 175.27, 161.45, 146.43, 141.42, 140.89, 128.05, 127.99, 127.06, 125.38, 
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118.00, 117.69, 112.60, 98.39, 55.30, 29.82, 17.77.  HRMS (ESI) calcd. for C18H17NO2 
[M+H]
+
: 280.13321, found: 280.13280. 
3-benzyl-5-methoxy-2-methylquinolin-4(1H)-one (2.39b). Compound 2.39b was 
prepared following general procedure A. Yield: 71% over the two isomers (4:1, 7 and 5-
substituted isomers respectively). Desired isomer was separated by preparative HPLC as 
a white solid, mp = 258 - 259°C. 
1H NMR (400 MHz, DMSO) δ 11.14 (s, 1H), 7.43 (t, J 
= 8.1 Hz, 1H), 7.25 – 7.06 (m, 5H), 6.99 (d, J = 8.3 Hz, 1H), 6.67 (d, J = 8.0 Hz, 1H), 
3.80 (s, 2H), 3.77 (s, 3H), 2.27 (s, 3H).
 13C NMR (101 MHz, DMSO) δ 175.48, 159.46, 
144.53, 141.97, 141.53, 131.39, 128.00, 125.32, 119.77, 114.19, 109.50, 103.47, 55.49, 
29.90, 17.39.  HRMS (ESI) calcd. for C18H17NO2 [M+H]
+
: 280.13321, found: 280.13190.  
3-benzyl-7-chloro-2-methylquinolin-4(1H)-one (2.40a). Compound 2.40a was prepared 
following general procedure A. Yield: 45% over the two isomers (1.5:1, 7 and 5-
substituted isomers respectively). Desired isomer was separated by double 
recrystallization from methanol as a white solid, mp = 318 - 319°C. 
1
H NMR (400 MHz, 
DMSO) δ 11.57 (s, 1H), 8.08 (d, J = 8.4 Hz, 1H), 7.51 (s, 1H), 7.30 – 7.07 (m, 6H), 3.88 
(s, 2H), 2.34 (s, 3H).
 13C NMR (101 MHz, DMSO) δ 175.09, 147.57, 141.01, 139.91, 
135.67, 128.11, 127.98, 127.60, 125.50, 122.89, 122.14, 118.83, 116.65, 29.83, 17.93.  
HRMS (ESI) calcd. for C17H14ClNO [M+H]
+
: 284.08367, found: 284.08328. 
3-benzyl-5-chloro-2-methylquinolin-4(1H)-one (2.40b). Compound 2.40b was 
prepared following general procedure A. Yield: 45% over the two isomers (1.5:1, 7 and 
5-substituted isomers respectively). Desired isomer was separated by preparative HPLC. 
1H NMR (400 MHz, DMSO) δ 11.54 (s, 1H), 7.47 (q, J = 7.9 Hz, 2H), 7.17 (dd, J = 32.9, 
6.4 Hz, 6H), 3.84 (s, 2H), 2.32 (s, 3H).
 13C NMR (101 MHz, DMSO) δ 174.82, 146.02, 
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141.82, 141.11, 132.03, 130.84, 128.09, 127.98, 125.46, 125.10, 119.83, 119.53, 117.25, 
30.00, 17.62.  HRMS (ESI) calcd. for C17H14ClNO [M+H]
+
: 284.08367, found: 
284.08282. 
7-methoxy-2-methyl-3-phenylquinolin-4(1H)-one (2.41a). Compound 2.41a was 
prepared following general procedure A. Yield: 63% over the two isomers (4:1, 7 and 5-
substituted isomers respectively). Desired isomer was separated by recrystallization from 
DMF as a white solid, mp = 346 - 349°C. 
1H NMR (400 MHz, DMSO) δ 11.45 (s, 1H), 
7.97 (d, J = 8.9 Hz, 1H), 7.38 (t, J = 6.9 Hz, 2H), 7.28 (t, J = 7.3 Hz, 1H), 7.23 (d, J = 7.3 
Hz, 2H), 6.93 – 6.85 (m, 2H), 3.86 (s, 3H), 2.18 (s, 3H). 13C NMR (101 MHz, DMSO) δ 
174.46, 161.65, 146.01, 141.13, 136.31, 131.02, 127.67, 127.20, 126.32, 120.51, 118.74, 
112.60, 98.59, 55.36, 18.85.  HRMS (ESI) calcd. for C17H15NO2 [M+H]
+
: 266.11756, 
found: 266.11788. 
5-methoxy-2-methyl-3-phenylquinolin-4(1H)-one (2.41b). Compound 2.41b was 
prepared following general procedure A. Yield: 63% over the two isomers (4:1, 7 and 5-
substituted isomers respectively). Desired isomer was separated by preparative HPLC. 
1
H 
NMR (400 MHz, DMSO) δ 11.40 (s, 1H), 7.49 (t, J = 8.2 Hz, 1H), 7.37 (t, J = 7.4 Hz, 
2H), 7.28 (t, J = 7.2 Hz, 1H), 7.19 (d, J = 7.3 Hz, 2H), 7.06 (d, J = 8.3 Hz, 1H), 6.72 (d, J 
= 8.1 Hz, 1H), 3.77 (s, 3H), 2.14 (s, 3H).
 13C NMR (101 MHz, DMSO) δ 174.44, 159.54, 
144.70, 142.08, 136.33, 131.88, 131.01, 127.65, 126.35, 122.48, 114.68, 109.70, 103.98, 
55.65, 18.43.  HRMS (ESI) calcd. for C17H15NO2 [M+H]
+
: 266.11756, found: 266.11717. 
7-chloro-2-methyl-3-phenylquinolin-4(1H)-one (2.42a). Compound 2.42a was 
prepared following general procedure A. Yield: 92% over the two isomers (1:1, 7 and 5-
substituted isomers respectively). Desired isomer was separated by recrystallization from 
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DMF as a white solid, mp = 357 - 359°C. 
1H NMR (400 MHz, DMSO) δ 11.70 (s, 1H), 
8.07 (d, J = 8.6 Hz, 1H), 7.55 (d, J = 1.7 Hz, 1H), 7.39 (t, J = 7.4 Hz, 2H), 7.34 – 7.27 
(m, 2H), 7.24 (d, J = 7.1 Hz, 2H), 2.21 (s, 3H).
 13C NMR (101 MHz, DMSO) δ 174.33, 
147.06, 140.05, 135.97, 135.71, 130.87, 127.79, 127.74, 126.62, 123.06, 122.98, 121.47, 
116.67, 18.92. HRMS (ESI) calcd. for C16H12ClNO [M+H]
+
: 270.06802, found: 
270.06867. 
5-chloro-2-methyl-3-phenylquinolin-4(1H)-one (2.42b). Compound 2.42b was 
prepared following general procedure A. Yield: 92% over the two isomers (1:1, 7 and 5-
substituted isomers respectively). Desired isomer was separated by preparative HPLC. 
1
H 
NMR (400 MHz, DMSO) δ 11.62 (s, 1H), 7.54 – 7.18 (m, 8H), 2.16 (s, 3H). HRMS 
(ESI) calcd. for C16H12ClNO [M+H]
+
: 270.06802, found: 270.06723. 
3-benzyl-6-methoxy-1,2-dimethylquinolin-4(1H)-one (2.43a). Compound 2.43a was 
prepared following general procedure F. Yield: 90% as a mixture of OMe and NMe 
tautomers. (1:1 respectively), mp = 215 - 216°C. 
1H NMR (400 MHz, DMSO) δ 7.75 (d, 
J = 9.4, 1H), 7.67 (d, J = 2.8, 1H), 7.31 (dd, J = 9.3, 3.0, 1H), 7.23 – 7.18 (m, 4H), 7.13 – 
7.09 (m, 1H), 4.02 (s, 2H), 3.85 (s, 3H), 3.74 (s, 3H), 2.42 (s, 3H). 
13
C NMR (101 MHz, 
DMSO) δ 174.21, 155.03, 149.10, 141.47, 135.71, 128.08, 127.92, 125.69, 125.40, 
121.39, 118.76, 118.38, 105.39, 55.28, 35.22, 31.00, 17.87. HRMS (ESI) calcd. for 
C19H19NO2 [M+H]
+
: 294.14886, found: 294.14903.  
3-benzyl-4,6-dimethoxy-2-methylquinoline (2.43b). Compound 2.43b was prepared 
following general procedure F. Yield:  90% as a mixture of OMe and NMe tautomers. 
(1:1 respectively), mp = 115 - 116°C. 
1
H NMR (400 MHz, CDCl3) δ 7.92 (d, J = 9.0, 
1H), 7.31 (dt, J = 5.9, 2.7, 2H), 7.24 (t, J = 5.7, 2H), 7.17 (t, J = 7.3, 1H), 7.11 (d, J = 7.3, 
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2H), 4.24 (s, 2H), 3.94 (s, 3H), 3.88 (s, 3H), 2.54 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 
160.69, 158.27, 157.51, 144.67, 139.63, 130.55, 128.65, 128.21, 126.27, 124.07, 123.20, 
121.59, 100.09, 62.03, 55.70, 32.08, 23.73. HRMS (ESI) calcd. for C19H19NO2 [M+H]
+
: 
294.14886, found: 294.14903. 
3-benzyl-6-chloro-1,2-dimethylquinolin-4(1H)-one (2.44a). Compound 2.44a was 
prepared following general procedure F. Yield:  75% as a mixture of OMe and NMe 
tautomers. (1:2 respectively), mp = 192 - 193°C. 
1
H NMR (400 MHz, CDCl3) δ 8.46 (d, J 
= 2.0, 1H), 7.52 (dd, J = 9.1, 2.1, 1H), 7.39 (d, J = 9.1, 1H), 7.23 – 7.13 (m, 5H), 4.11 (s, 
2H), 3.71 (s, 3H), 2.43 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 175.56, 149.44, 141.04, 
139.70, 131.99, 129.28, 128.49, 128.32, 126.56, 126.47, 125.90, 121.87, 117.07, 35.32, 
31.84, 18.59. HRMS (ESI) calcd. for C18H16ClNO [M+H]
+
: 298.09932, found: 
298.09920. 
3-benzyl-6-chloro-4-methoxy-2-methylquinolin-4(1H)-one (2.44b). Compound 2.44b 
was prepared following general procedure F. Yield: 61% as a mixture of OMe and NMe 
tautomers. (1:2.7 respectively), mp = 82 – 84°C. 1H NMR (400 MHz, CDCl3) δ 7.99 (s, 
1H), 7.94 (d, J = 8.9, 1H), 7.58 (d, J = 8.9, 1H), 7.25 – 7.08 (m, 5H), 4.23 (s, 2H), 3.88 
(s, 3H), 2.55 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 161.53, 160.77, 146.90, 139.16, 
131.65, 130.67, 130.10, 128.72, 128.15, 126.41, 124.81, 123.29, 121.13, 62.72, 32.01, 
24.03. HRMS (ESI) calcd. for C18H16ClNO [M+H]
+
: 298.09932, found: 298.09920. 
6-chloro-1,2-dimethyl-3-phenylquinolin-4(1H)-one (2.45a). Compound 2.45a was 
prepared following general procedure F. Yield:  83% as a mixture of OMe and NMe 
tautomers. (1:2.4 respectively) as a pink solid, m.p. = 208 – 209oC. 1H NMR (400 MHz, 
CDCl3) δ 8.40 (d, J = 2.6, 1H), 7.54 (dd, J = 9.1, 2.6, 1H), 7.41 (dd, J = 17.0, 8.4, 3H), 
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7.33 – 7.28 (m, 1H), 7.23 – 7.18 (m, 2H), 3.77 (s, 3H), 2.33 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 174.92, 148.73, 139.90, 136.82, 132.19, 130.91, 129.41, 128.57, 127.29, 
126.60, 124.85, 117.09, 35.41, 20.10. HRMS (ESI) calcd for C17H14ClNO [M+H]
+ 
284.08367, found 284.08482. 
6-chloro-4-methoxy-2-methyl-3-phenylquinoline-4(1H)-one (2.45b). Compound 2.45a 
was prepared following general procedure F. Yield:  83% as a mixture of OMe and NMe 
tautomers. (1:2.4 respectively) as a white crystalline solid, m.p. = 92-94
o
C. 
1
H NMR (400 
MHz, CDCl3) δ 7.96 (s, 1H), 7.92 (d, J = 8.8 Hz, 1H), 7.60 (d, J = 8.8 Hz, 1H), 7.29 – 
7.12 (m, 5H), 3.91 (s, 3H), 2.58 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 161.02, 159.87, 
145.84, 138.86, 131.17, 130.34, 129.82, 128.13, 127.15, 125.91, 123.98, 122.29, 121.67, 
31.34, 23.83 HRMS (ESI) calcd for C17H14ClNO [M+H]
+ 
284.08367, found 284.08482. 
3-benzyl-7-methoxy-1,2-dimethylquinolin-4(1H)-one (2.46a). Compound 2.46a was 
prepared following general procedure F. Yield:  75% as a mixture of OMe and NMe 
tautomers. (1:2 respectively), mp = 220 - 222°C. 
1
H NMR (400 MHz, CDCl3) δ 8.45 (d, J 
= 8.9, 1H), 7.22 (m, J = 7.9, 4H), 7.12 (t, J = 6.8, 1H), 6.99 – 6.94 (m, 1H), 6.80 (d, J = 
1.3, 1H), 4.13 (s, 2H), 3.92 (s, 3H), 3.66 (s, 3H), 2.41 (s, 3H). 
13
C NMR (101 MHz, 
CDCl3) δ 176.35, 162.68, 148.75, 142.99, 141.52, 129.39, 128.41, 128.37, 125.71, 
121.07, 120.01, 111.43, 98.41, 55.69, 35.13, 31.71, 18.66. HRMS (ESI) calcd. for 
C19H19NO2 [M+H]
+
: 294.14886, found: 294.14903. 
3-benzyl-4,7-dimethoxy-2-methylquinoline (2.46b). Compound 2.46b was prepared 
following general procedure F. Yield:  75% as a mixture of OMe and NMe tautomers. 
(1:2 respectively), mp = 126 - 128°C. 
1
H NMR (400 MHz, CDCl3) δ 7.92 (d, J = 9.1, 
1H), 7.38 (d, J = 2.2, 1H), 7.24 (d, J = 7.5, 2H), 7.19 – 7.14 (m, 2H), 7.11 (d, J = 7.4, 
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2H), 4.22 (s, 2H), 3.94 (s, 3H), 3.88 (s, 3H), 2.56 (s, 3H). HRMS (ESI) calcd. for 
C19H19NO2 [M+H]
+
: 294.14886, found: 294.14903. 
4-chloro-3-methoxyaniline (2.47). 900 ml of ammonia is condensed at -78
o
C. 1g of 
thinly shaven strips of sodium was added followed by 1.0g of iron (III) nitrate 
nonahydrate. Upon disappearance of the deep blue color 25g of thinly shaven strips of 
sodium was added. After 30 minutes of stirring at -78
o
C 50g of 2,5-dichloroanisole is 
added as a solution in hexane (70 ml) dropwise and the reaction is warmed to -45
o
C for 
2h. Upon completion the ammonia is allowed to evaporate. The crude pot is then diluted 
in chloroform and 100g of NH4Cl is added slowly. The combines are taken up in a 
separatory funnel and washed with H2O (X3) followed by brine (X1). The organic layer 
is dried over Na2SO4 and concentrated in vacuo. The resulting solid can be used without 
further purification. Yield: 99%. 
1H NMR (400 MHz, DMSO) δ 6.98 (d, J = 8.4, 1H), 
6.34 (d, J = 1.8, 1H), 6.16 (dd, J = 8.4, 1.9, 1H), 5.23 (s, 2H), 3.74 (s, 3H). 
13
C NMR 
(101 MHz, DMSO) δ 154.90, 149.16, 129.68, 107.02, 106.74, 98.66, 55.38. HRMS (ESI) 
calcd. for C7H8ClNO [M+H]
+
: 157.03672, found: 157.03612. 
6-fluoro-7-methoxy-2-methyl-3-phenylquinolin-4(1H)-one (2.48). Compound 2.48 
was prepared following general procedure A. Yield: 79%, mp = 361 - 362°C. 
1
H NMR 
(400 MHz, DMSO) δ 11.62 (s, 1H), 7.69 (d, J = 11.8 Hz, 1H), 7.38 (t, J = 7.6 Hz, 2H), 
7.29 (t, J = 7.3 Hz, 1H), 7.23 (d, J = 7.8 Hz, 2H), 7.10 (d, J = 7.3 Hz, 1H), 3.95 (s, 3H), 
2.19 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 174.39, 151.04 (d, J = 64.64), 149.52 (d, J = 
245.43), 146.84, 137.83, 136.77, 131.65, 128.40, 127.11, 120.80, 118.58, 110.79 (d, J = 
9.1), 101.20, 56.81, 19.57. HRMS (ESI) calcd. for C17H14FNO2 [M+H]
+
: 284.10813, 
found: 284.10820. 
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6-chloro-7-methoxy-2-methyl-3-phenylquinolin-4(1H)-one (2.49). Compound 2.49 
was prepared following modified general procedure A using CaSO4. Yield: 55%, mp = 
329 – 330°C. 1H NMR (400 MHz, DMSO) δ 11.63 (s, 1H), 7.99 (s, 1H), 7.38 (t, J = 7.4 
Hz, 2H), 7.29 (t, J = 7.4 Hz, 1H), 7.23 (d, J = 6.9 Hz, 2H), 7.06 (s, 1H), 3.96 (s, 3H), 2.19 
(s, 3H).
 13C NMR (101 MHz, DMSO) δ 173.48, 156.66, 146.42, 139.59, 135.85, 130.94, 
127.75, 126.53, 126.17, 120.78, 118.78, 117.94, 99.40, 56.37, 18.85.  HRMS calcd. for 
C17H14ClNO2 [M+H]
+
: 300.07858, found: 300.07901.  
6-bromo-7-methoxy-2-methyl-3-phenylquinolin-4(1H)-one (2.50). Compound 2.50 
was prepared following general procedure A. Yield: 61%, mp = 328 - 329°C. 
1
H NMR 
(400 MHz, DMSO) δ 11.67 (s, 1H), 8.16 (s, 1H), 7.38 (t, J = 7.4 Hz, 2H), 7.29 (t, J = 7.3 
Hz, 1H), 7.23 (d, J = 7.0 Hz, 2H), 7.04 (s, 1H), 3.95 (s, 3H), 2.19 (s, 3H).
 13
C NMR (101 
MHz, DMSO) δ 173.34, 157.28, 146.52, 140.18, 135.88, 130.91, 129.54, 127.73, 126.49, 
120.82, 119.46, 107.01, 99.26, 56.47, 18.88. . HRMS calcd. for C17H14BrNO2 [M+H]
+
: 
344.02807, found: 344.02752.  
3-ethyl-6-fluoro-7-methoxy-2-methylquinolin-4(1H)-one (2.51). Compound 2.51 was 
prepared following general procedure A. Yield: 62%, mp = 306 - 307°C. 
1
H NMR (400 
MHz, DMSO) δ 11.34 (s, 1H), 7.66 (d, J = 11.9 Hz, 1H), 7.02 (d, J = 7.3 Hz, 1H), 3.92 
(s, 3H), 2.45 (q, J = 7.1 Hz, 2H), 2.36 (s, 3H), 0.98 (t, J = 7.3 Hz, 3H). 
13
C NMR (101 
MHz, DMSO) δ 174.96, 151.07 (d, J = 14.14), 149.27 (d, J = 244.42), 145.73, 137.47, 
120.33, 117.68, 110.45 (d, J = 19.19), 100.89, 56.71, 18.58, 17.92, 14.11. HRMS calcd. 
for C13H14FNO2 [M+H]
+
: 236.10813, found: 236.10713. 
3-ethyl-6-chloro-7-methoxy-2-methylquinolin-4(1H)-one (2.52). Compound 2.52 was 
prepared following general procedure A. Yield: 70%, mp = 326 - 328°C. 
1
H NMR (400 
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MHz, DMSO) δ 11.36 (s, 1H), 7.96 (s, 1H), 6.99 (s, 1H), 3.92 (s, 3H), 2.49 – 2.42 (q, 
2H), 2.35 (s, 3H), 0.98 (t, J = 7.4 Hz, 3H).
 13C NMR (101 MHz, DMSO) δ 173.97, 
156.25, 145.39, 139.33, 125.91, 120.35, 117.93, 117.49, 99.19, 56.27, 17.90, 17.26, 
13.47. HRMS calcd. for C13H14ClNO2 [M+H]
+
: 252.07858, found: 252.07828.   
3-ethyl-6-bromo-7-methoxy-2-methylquinolin-4(1H)-one (2.53). Compound 2.53 was 
prepared following general procedure A. Yield: 32%, mp = 325 - 327°C. 
1
H NMR (400 
MHz, DMSO) δ 11.36 (s, 1H), 8.13 (s, 1H), 6.95 (s, 1H), 3.91 (s, 3H), 2.48 – 2.43 (q, 
2H), 2.35 (s, 3H), 0.98 (t, J = 7.2 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 173.88, 
156.89, 145.40, 139.85, 129.32, 120.42, 118.61, 106.58, 98.97, 56.36, 17.90, 17.26, 
13.41.  HRMS calcd. for C13H14BrNO2 [M+H]
+
: 296.02807, found: 296.02821.  
6-chloro-3-heptyl-7-methoxy-2-methylquinolin-4(1H)-one (2.54). Compound 2.54 was 
prepared following general procedure A. Yield: 30%, mp = 238 - 239°C. 
1
H NMR (400 
MHz, DMSO) δ 11.34 (s, 1H), 7.95 (s, 1H), 6.98 (s, 1H), 3.92 (s, 3H), 2.46 – 2.40 (m, 
2H), 2.34 (s, 3H), 1.25 (d, J = 10.4 Hz, 10H), 0.84 (d, J = 7.0 Hz, 3H).
 13
C NMR (101 
MHz, DMSO) δ 174.16, 156.23, 145.52, 139.31, 125.92, 119.08, 117.86, 117.47, 99.16, 
56.25, 31.31, 29.23, 28.68, 28.56, 24.70, 22.10, 17.45, 13.94.  HRMS calcd. for 
C18H24ClNO2 [M+H]
+
: 322.15683, found: 322.15720. 
6-chloro-7-methoxy-2-methyl-3-nonylquinolin-4(1H)-one (2.55). Compound 2.55 was 
prepared following general procedure A. Yield: 27%, 219 - 220
o
C. 
1
H NMR (400 MHz, 
DMSO) δ 11.33 (s, 1H), 7.95 (s, 1H), 6.97 (s, 1H), 3.91 (s, 3H), 2.45 – 2.39 (m, 2H), 2.33 
(s, 3H), 1.35 – 1.20 (m, 14H), 0.84 (t, J = 6.3 Hz, 3H). 13C NMR (101 MHz, DMSO) δ 
174.16, 156.22, 145.48, 139.31, 125.92, 119.07, 117.86, 117.46, 99.14, 56.23, 31.28, 
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29.25, 29.01, 28.71, 28.53, 24.69, 22.07, 17.43, 13.91.  HRMS calcd. for C20H28ClNO2 
[M+H]
+
: 350.18813, found: 350.18766. 
6-chloro-3-cyclohexyl-7-methoxy-2-methylquinolin-4(1H)-one (2.56). Compound 2.56 
was prepared following general procedure A. Yield: 21%, mp = 313 - 314
o
C. 
1
H NMR 
(400 MHz, DMSO) δ 11.23 (s, 1H), 7.94 (s, 1H), 6.96 (s, 1H), 3.91 (s, 3H), 2.37 (s, 3H), 
2.23 (d, J = 11.1 Hz, 2H), 1.70 (m, 3H), 1.44 – 1.17 (m, 6H). 13C NMR (101 MHz, 
DMSO) δ 174.38, 156.18, 145.33, 139.11, 125.98, 122.36, 118.92, 117.38, 98.97, 56.25, 
28.92, 26.85, 25.72, 18.25. HRMS calcd. for C17H20ClNO2 [M+H]
+
: 306.12553, found: 
306.12493.  
3-benzyl-6-chloro-7-methoxy-2-methylquinolin-4(1H)-one (2.57). Compound 2.57 
was prepared following modified general procedure A using CaSO4. Yield: 40%, mp = 
254 - 255
o
C. 
1H NMR (500 MHz, DMSO) δ 11.49 (s, 1H), 8.02 (s, 1H), 7.20 (dd, J = 8.9, 
5.3 Hz, 4H), 7.10 (ddd, J = 8.6, 6.3, 2.5 Hz, 1H), 6.99 (s, 1H), 3.92 (s, 3H), 3.86 (s, 2H), 
2.30 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 174.26, 156.40, 146.89, 141.15, 139.41, 
128.09, 127.99, 126.05, 125.46, 118.04, 117.82, 99.31, 56.27, 29.84, 17.83. HRMS calcd. 
for C18H16ClNO2 [M+H]
+
: 314.09423, found: 314.09330.  
6-chloro-7-methoxy-2,3-dimethylquinolin-4(1H)-one (2.58). Compound 2.58 was 
prepared following modified general procedure A using CaSO4. Yield: 40%, mp = 337 - 
338
o
C. 
1H NMR (400 MHz, DMSO) δ 11.40 (s, 1H), 7.96 (s, 1H), 6.97 (s, 1H), 3.92 (s, 
3H), 2.32 (s, 3H), 1.92 (s, 3H).
 13
C NMR (101 MHz, CDCl3) δ 174.37, 156.18, 145.72, 
139.21, 125.86, 117.50, 113.99, 99.17, 56.24, 17.96, 10.3. HRMS calc. for C12H12ClNO2 
[M+H]
+
: 238.06293, found: 238.06311.  
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6-chloro-3-isopropyl-7-methoxy-2-methylquinolin-4(1H)-one (2.59). Compound 2.59 
was prepared following modified general procedure A using CaSO4. Yield: 52%, mp = 
289 – 291oC. 1H NMR (400 MHz, DMSO) δ 11.23 (s, 1H), 7.94 (s, 1H), 6.95 (s, 1H), 
3.91 (s, 3H), 3.11 – 2.96 (m, 1H), 2.35 (s, 3H), 1.27 (d, J = 7.0 Hz, 6H). 13C NMR (101 
MHz, DMSO) δ 174.32, 156.19, 144.99, 139.15, 125.92, 122.80, 118.85, 117.41, 98.95, 
56.24, 26.76, 20.13, 18.06. HRMS calc. for C14H16ClNO2 [M+H]
+
: 266.09423, found: 
266.09493.  
6-chloro-3-isobutyl-7-methoxy-2-methylquinolin-4(1H)-one (2.60). Compound 2.60 
was prepared from 61 (0.1 g, 0.3 mmol), Pd(PPh3)4 (16mgs, 0.014 mmol), K3PO4 (0.242 
g, 0.6 mmol), isobutylboronic acid (87 mg, 0.45 mmol), toluene (0.9 ml) and H2O (0.1 
ml) in an oven-dried flame dried schlenk tube backfilled with argon (3X) for 14h at 
100
o
C. Yield: 17%. Product was isolated using preparative HPLC. 
1
H NMR (400 MHz, 
DMSO) δ 11.82 (s, 1H), 8.03 (s, 1H), 7.08 (s, 1H), 3.94 (s, 3H), 2.39 (s, 5H), 1.85 (dt, J = 
13.5, 6.8, 1H), 0.85 (d, J = 6.6, 6H).
 13C NMR (101 MHz, DMSO) δ 174.12, 159.07, 
158.70, 157.12, 147.93, 139.97, 126.46, 118.78, 99.98, 56.90, 34.23, 28.36, 23.14, 18.81. 
6-chloro-7-methoxy-2-methylquinolin-4(1H)-one (2.61). Compound 2.61 was prepared 
following modified general procedure A using CaSO4. Yield: 63%. 
1
H NMR (400 MHz, 
DMSO) δ 11.53 (s, 1H), 7.94 (s, 1H), 6.99 (s, 1H), 5.85 (s, 1H), 3.92 (s, 3H), 2.30 (s, 
3H). 
13C NMR (101 MHz, DMSO) δ 175.91, 157.26, 150.24, 141.01, 126.28, 119.54, 
118.51, 108.93, 100.29, 56.97, 20.07.  HRMS calc. for C11H10ClNO2 [M+H]
+
: 224.04728, 
found: 224.04634.  
3-bromo-6-chloro-7-methoxy-2-methylquinolin-4(1H)-one (2.62). Compound 2.62 
was prepared using general procedure B. Yield: 90%. 
1H NMR (400 MHz, DMSO) δ 
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12.06 (s, 1H), 7.95 (s, 1H), 6.98 (s, 1H), 3.93 (s, 3H), 2.57 (s, 3H). 
13
C NMR (101 MHz, 
DMSO) δ 171.38, 156.81, 151.15, 139.12, 126.16, 118.77, 114.82, 99.29, 85.78, 56.40, 
26.08. HRMS (ESI) calcd. for C11H9BrClNO2 [M+H]
+
: 301.95780, found: 301.95764. 
4-(benzyloxy)-3-bromo-6-chloro-7-methoxy-2-methylquinoline (2.63). Compound 
2.63 was prepared using general method C. Yield: 70%. 
1
H NMR (400 MHz, CDCl3) δ 
7.91 (s, 1H), 7.54 (d, J = 6.5, 2H), 7.45 – 7.40 (m, 3H), 7.37 (s, 1H), 5.19 (s, 2H), 4.01 (s, 
3H), 2.84 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 160.20, 158.71, 156.61, 148.23, 
136.03, 128.99, 128.91, 128.64, 124.69, 122.92, 118.92, 110.79, 108.32, 56.63, 26.72. 
HRMS calc. for C11H9ClBrNO2 [M+H]
+
: 301.95834, found: 301.95851. 
6-chloro-3-(hex-1-ynyl)-7-methoxy-2-methylquinolin-4(1H)-one (2.64). Compound 
2.64 was prepared using general method E. Yield: 26%. 
1
H NMR (400 MHz, CDCl3) δ 
8.17 (s, 1H), 7.53 (s, 1H), 6.50 (s, 1H), 4.02 (s, 3H), 2.85 (t, J = 7.5, 2H), 2.79 (s, 3H), 
1.76 (d, J = 7.5, 2H), 1.45 (d, J = 7.5, 2H), 0.96 (d, J = 7.4, 3H). 
13
C NMR (101 MHz, 
CDCl3) δ 159.69, 154.95, 154.50, 147.25, 145.31, 123.53, 120.75, 120.53, 111.11, 
109.26, 101.19, 56.51, 30.13, 28.27, 23.09, 22.47, 14.31. HRMS calc. for C17H18ClNO2 
[M+H]
+
: 304.10988, found: 304.11005. 
6-chloro-3-(hept-1-en-2-yl)-7-methoxy-2-methylquinolin-4(1H)-one (2.65). 
Compound 2.65 was prepared using general procedure D. The crude mixture was pre-
purified using flash chromatography to obtain the mixture of isomers. Then the resulting 
crude oil was dissolved in minimal MeOH and purified further using preparative HPLC.  
1
H NMR (500 MHz, CDCl3) δ 8.44 (s, 1H), 7.38 (s, 1H), 5.35 (s, 1H), 4.94 (s, 1H), 3.92 
(s, 3H), 2.55 (s, 3H), 2.35 – 2.28 (m, 2H), 1.36 – 1.23 (br m, 6H), 0.81 (t, J = 6.9, 3H). 
HRMS calc. for C18H22ClNO2 [M+H]
+
: 320.14118, found: 320.14174. 
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(E)-6-chloro-3-(hept-1-enyl)-7-methoxy-2-methylquinolin-4(1H)-one (2.66). 
Compound 2.66 was prepared using general procedure D. The crude mixture was pre-
purified using flash chromatography to obtain the mixture of isomers. Then the resulting 
crude oil was dissolved in minimal MeOH and purified further using preparative HPLC.  
1
H NMR (500 MHz, CDCl3) δ 8.53 (s, 1H), 7.29 (s, 1H), 5.40 (dd, J = 12.2, 5.3, 2H), 
3.96 (s, 3H), 3.39 (br d, 2H), 2.56 (s, 3H), 1.90 (br d, 2H), 1.20 (s, 4H), 0.81 (s, 3H). 
HRMS calc. for C18H22ClNO2 [M+H]
+
: 320.14118, found: 320.14174. 
(E)-tert-butyl-3-(6-chloro-7-methoxy-2-methyl-4-oxo-1,4-dihydroquinolin-3-
yl)acrylate (2.67). Compound 2.67 was prepared following general procedure D. Yield:  
96%. 
1H NMR (400 MHz, DMSO) δ 12.06 (s, 1H), 8.04 (s, 1H), 7.53 (d, J = 15.4, 1H), 
7.32 (d, J = 15.4, 1H), 7.06 (s, 1H), 3.96 (s, 3H), 2.55 (s, 3H), 1.48 (s, 9H). 
13
C NMR 
(101 MHz, DMSO) δ 174.69, 168.00, 157.57, 153.00, 139.03, 137.48, 126.88, 119.80, 
119.67, 119.47, 112.60, 100.56, 79.65, 57.14, 28.62, 19.01. HRMS calc. for 
C18H20ClNO4 [M+H]
+
: 350.11536, found: 350.11575. 
In vitro Parasite Culturing: P. falciparum clone W2/Indochina and 
TM90C2B/Thailand were grown in continuous culture using RPMI 1640 media 
containing 10% heat-inactivated type A+ human plasma, sodium bicarbonate (2.4g/L), 
HEPES (5.94g/L) and 4% washed human type A+ erythrocytes. Cultures were gassed 
with a 90% N
2
, 5% O
2
 and 5%CO
2
 mixture followed by incubation at 37°C.  
Assay Preparation: Test compounds at 5 mg/mL in DMSO were diluted at least 1:400 
and then serially diluted in duplicate over 11 concentrations. P. falciparum cultures with 
>70% ring stage parasites were diluted to 0.5-0.7% parasitemia and 1.5% hematocrit in 
RPMI 1640 media. In 96-well plates a volume of 90µl/well of parasitized erythrocytes 
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was added on top of 10µL/well of the test compound. A separate plate containing 
chloroquine, dihydroartemisinin and atovaquone was added to each set of assay plates as 
control drugs. A Beckman Coulter Biomek 3000 was used to dispense test compounds, 
control drugs and parasitized erythrocytes into the microtiter plates.  Positive and 
negative controls were included in each plate. Positive controls consisted of drug-free 
parasitized erythrocytes and negative controls consisted of parasitized erythrocytes dosed 
with a high concentration of chloroquine or dihydroartemisinin that ensured 100% 
parasite death. Assay plates were placed into a plastic gassing chamber and equilibrated 
with 90% N2, 5% O2 and 5%CO2 mixture then incubated at 37°C for 72 hours. After 72 
hours of incubation the assay plates were frozen at -80°C until later processed for parasite 
growth determinations. 
SYBR Green I Processing: Assay plates were removed from -80°C and allowed to thaw 
at room temperature. Using the Beckman Biomek 3000 100µL was transferred from the 
assay plates into 96-well black assay plates. Next, 100µl of SYBR green I (Invitrogen) in 
2X lysis buffer (0.2µl SYBR green I/mL of 2X lysis buffer [0.008% saponin, 0.08% 
Triton X-100, 20mM Tris and 5mM EDTA]) was dispensed into each well of the 96-well 
black assay plate using the Beckman Coulter Biomek 3000. Upon addition of SYBR 
green I the microtiter plates were incubated for one hour in the dark. Relative 
Fluorescence units (RFU) were read using a Molecular Devices Spectramax microplate 
reader. 
Data Analysis: Data analysis was performed using a custom database manager 
(Dataspects, Inc). Non-linear regression analysis was used to calculate EC50. 
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Chapter 3: The Suzuki-Miyaura Cross-coupling and Other Related Processes Utilized in 
the Development of Antimalarials 
3.1 Suzuki-Miyaura Cross-coupling in Drug Discovery 
 The formation of carbon-carbon bonds are key steps in the formation of building 
complex, bio-active molecules. They are also important in the generation of novel 
materials such as electronics, optics, and nanodevices.
1
 The Suzuki coupling has arguably 
become the most important reaction for carbon-carbon bond formation.
1
 This cross-
coupling reaction employs various organoboranes with organic electrophiles, such as 
organohalides and organotriflates, and palladium metals.
2
 Typically, the reactants are 
readily available, non-toxic, and water-stable. Generally, the borane by-product is easily 
removed after reaction completion.
2
 Many of the palladium complexes used to catalyze 
Suzuki couplings are also non-toxic, cost-effective, and water stable. The reaction 
proceeds with excellent region- and stereoselectivity, and is minimally affected by steric 
hindrance. The methodology was originally discovered between alkenyl (sp
2
) starting 
materials but has been extended to include alkynyl (sp), aryl (sp
2
), and alkyl (sp
3
) 
reactants.
1
 
 The importance of the Suzuki-Miyaura cross-coupling has manifested itself in the 
construction of complex natural products such Epothilone A and P in the past decade 
(Figure 3.1).
3-6
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Figure 3.1. Suzuki-Miyaura Cross-coupling in Natural Product Synthesis
 
Similarly, the pharmaceutical industry has relied heavily on this process for the 
generation of libraries, kg scale up in process development and the synthesis of small 
molecules that would be difficult to construct otherwise (Figure 3.2).
7
 
Figure 3.2. Suzuki-Miyaura Cross-coupling in the Pharmaceutical Industry 
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The reliability of these reactions accompanied with facile scale-up has been a boon for 
academic and industrial settings alike. However, the reaction does have some 
shortcomings in industrial settings, including cost of the precious metal in terms of long-
term application, product contamination, and inorganic salt waste (namely bromide 
salts).
7
 Nonetheless, several solutions are presenting themselves such as catalyst 
recycling, and employment of aryl chlorides as substrates for the generation of less toxic 
salts.
8
 
3.2 Synthesis of Structurally Diverse 4(1H)-Quinolones via Suzuki-Miyaura Cross-
couplings  
3.2.1 Medicinal application of 4(1H)-Quinolones 
 Substituted 4-quinolones are relevant for various medicinal applications including 
inhibition of tubulin formation, antimicrobial and antiviral therapies, antiallergy 
treatments, as well as cancer chemotherapies, and they are common scaffolds found in 
various natural products.
9-20
 In the past decade, 4-quinolones have re-surfaced as 
antimalarial agents.
21
 Using in vitro activity assays against erythrocytic stages of 
multidrug resistant isolates and clones of P. falciparum, Kyle, Manetsch and Riscoe 
recently demonstrated that 3-substituted 4(1H)-quinolone derivatives display antimalarial 
activity at low to single-digit nM concentrations.
22
 Most routes to access 4-quinolones 
rely on traditional reactions such as the Gould-Jacobs, Conrad-Limpach, Niementowski, 
or Camps cyclizations.
23-26
 However, these transformations are limited by elevated 
reaction temperatures, unsatisfactory yields and poor regioselectivities. Furthermore, 
several mild synthetic approaches focusing primarily on 2-substituted 4-quinolones have 
been developed utilizing transition metal catalysis as well as base-promoted Camps 
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cyclization of N-(ketoaryl)amides.
27-31
 Among the entire repertoire of 4-quinolone 
syntheses, the Conrad-Limpach cyclization is the most prevalent reaction for the 
preparation of 3-substituted 4-quinolones involving 2-substituted-β-ketoesters and 
anilines as starting materials. Nevertheless, the cyclization step using sterically hindered 
and/or acid sensitive 2-substituted β-ketoesters commonly generates 3-substituted-4-
quinolones in poor yields and requires difficult purification protocols. 
3.2.2 Divergent Route to Access Structurally Diverse 4(1H)-Quinolones 
 The need to access structurally diverse 3-aryl-4-quinolones, in conjunction with 
the lack of a contemporary synthetic approach to such compounds, motivated us to devise 
a reliable and divergent synthetic route (Scheme 3.1).  
Scheme 3.1. Divergent Route to Access Diverse 4(1H)-Quinolones 
 
The key step of our method involves substitution of the quinolone core at the 3-position 
using a Suzuki-Miyaura cross-coupling. Strikingly, our approach further demonstrates the 
utility of sequential cross-couplings with di-halogenated quinolones culminating in the 
synthesis of structurally diverse analogs. The quinolone intermediate is obtained by a 
combination of easily synthesized or commercially available anilines and ethyl 
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acetoacetate cyclized through a high-yielding Conrad-Limpach reaction (Table 3.1, 
entries 1 - 16). Subsequent regioselective 3-halogenation of the quinolone core provides 
the Suzuki-Miyaura coupling precursor (Table 3.1).
32
 These halides and their N-methyl 
analogs could be directly subjected to cross coupling conditions. 
Table 3.1. Synthesis of Quinolone Suzuki-Miyaura Cross-coupling Precursor 
 
4(1-Alkyl)-quinolones have also found utility in medicinal applications and their 
preparations have been explored.
33
 Standard alkylation conditions were screened using 
the group 1 and silver carbonates at various temperatures. Heating of the reaction 
mixtures resulted in both lower selectivities and yields due to reduction of the halide 
substituent to the 3-H-4-quinolone. Likewise, the use of cold reaction conditions resulted 
in poor yields due to the decreased solubility of the quinolones at lower temperatures. 
Ultimately, the use of Cs2CO3 in DMF at room temperature provided excellent yields 
albeit modest chemoselectivities (Table 3.2 entries 1 – 7). 33 
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Table 3.2. Methylation of Halo-quinolones 
 
 Screening of appropriate Suzuki-Miyaura conditions applicable to our substituted 
quinolones commenced with a study of different catalyst systems and solvents.   
Table 3.3. Optimization of Cross-coupling Conditions 
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The choice to use SPHOS as the ligand and K3PO4 as the base was suggested by previous 
and extensive work of Buchwald et al.
34
 Couplings using quinolones 3.1a and the 
standard catalyst Pd(PPh3)4 furnished quinolone 3.2a in good yields (Table 3.3 entry 1). 
However, reactions were completed in less time using a Pd/SPHOS system and resulted 
in higher yields of the 3-substituted quinolones (Table 3.3 entries 2-4). When applying 
the same conditions to a quinolone with an iodo- substituent rather than a bromo- 
substituent, an improvement in yield was obtained (Table 3.3 entry 5). The use of toluene 
as solvent for the N-methylated quinolone substrates was found to be superior, while the 
couplings with 4(1H)-quinolones required DMF for complete conversion, although 
resulting in modest yields (Table 3.3 entry 6 and 7). Similarly, 6-Chloro-N-methyl-
quinolones required the use of DMF as a solvent, while 2-butanol was found to be 
suboptimal (Table 3.3 entry 8 and 9). 
 Next, the substrate scope of the coupling reaction was studied in detail. Couplings 
with various phenylboronic acids with both N-methylated 3-bromo- and 3-iodo-
quinolones (Table 3.4 entry 1 and 2) resulted in 92 and 95% yields of quinolones, 
respectively. DMF was required for the less soluble 4(1H)-quinolone (Table 3.4 entry 3) 
providing a 72% yield. Halides were efficiently coupled with electron rich boronic acids 
(Table 3.4 entry 4-6) in a short amount of time. 4-Methoxyphenyl boronic acid was also 
reacted with N-methyl- and N-H-3-bromo-6-fluoro-quinolones (Table 3.4 entry 7 and 8),  
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Table 3.4. Scope of 3-Halo-4-quinolone Cross-couplings 
 
furnishing the corresponding products in 95% and 73% yields, respectively. Sterically 
hindered boronic acids were coupled smoothly with electron deficient and electron 
neutral quinolones (Table 3.4 entry 9 and 10). Meta-substituted arylboronic acids (Table 
3.4 entries 11-14) including 3-(dimethylcarbamoyl)phenylboronic acid (Table 3.4 entries 
13 and 14) provided yields of 95% and 65% for both the N-alkyl- and the N-H-quinolone. 
A fluorinated quinolone was cross-coupled with 4-fluorophenyl boronic acid (Table 3.4 
entries 15 and 16) in 81% and 73% yields. 
 While furan-2-boronic acids have been reported to be problematic with the 
Pd/SPHOS catalyst/ligand system, Molander and coworkers realized these problematic 
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couplings by the use of 2-furanyl organotrifluoroborates.
35
 Strikingly, the substitution of 
N-methyl- and N-H-4-quinolones with furan-2-boronic acids provided the desired 
products in 97% and 75% yields, respectively (Table 3.4 entry 19 and 20). Finally, E-
phenylethenylboronic acid (Table 3.4 entry 25) was installed at the 3-position in excellent 
yields with a trans:cis ratio of 12:1. Conveniently, this set of conditions was effective for 
coupling our quinolones with all of the major sub-classes of substrates including 
heteroaryl, both electron-rich and deficient, alkenyl, fluorinated, pyridyl, as well as 
sterically hindered substrates (Table 3). 
 6-Chloro-3-aryl-4-quinolones (Table 3.4, entries 9 and 17-24) were studied to 
highlight the divergent nature of this synthetic route further by taking advantage of the 
reactivity differences between the iodo and chloro substituents. The 3-position could be 
subjected to Suzuki-Miyaura coupling followed by a subsequent coupling with a different 
boronic acid at the 6-position, providing the capability of building complex 4-quinolones 
(Table 3.5). 3-Phenyl-6-chloroquinolones were coupled with 4-fluorophenylboronic acid 
smoothly in 94% yields for the N-methylated and in 72% yields with N-H-quinolone 
(Table 3.5 entry 1 and 2). 3-Phenyl-6-chloroquinolone was next coupled with 4-
(hydroxymethyl)phenylboronic acid (Table 3.5 entries 3 and 4) in  good yields for both 
amino forms. 3-Furanyl-6-chloro quinolones reacted well in the N-methyl form with a 
92% yield for phenylboronic acid (Table 3.5 entry 5) and 91% for the sterically 
encumbered 2,5-dimethylphenylboronic acid (Table 3.5 entry 7). The free N-H 
containing 3-furanyl-6-chloro quinolones only produced modest yields when coupled 
with phenyl and dimethylphenylboronic acids (Table 3.5 entry 6 and 8) of 41 and 47%, 
respectively. 3-Pyrimidine-6-chloro-4-quinolone (Table 3.5 entry 9) was coupled with 3- 
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Table 3.5. Scope of 6-Chloro-4-quinolone Cross-couplings 
 
pyridylboronic acid in 88% yield to generate a 3-pyrimidine-6-pyridyl-4-quinolone 
heterocycle. 
To build in additional avenues for diversity, we explored the possibilities of 
installing cyano groups at both the 3- and 6-positions (Table 3.6 entries 1-2). 6-Chloro-3-
cyano-quinolones could provide an intermediate to diversify the benzenoid ring of the 
quinolone while enabling a potential transformation to a 3-carboxylate group similar to 
Ciprofloxacin. An extension of the method developed by Eli Lilly using a Pd/dppf 
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catalyst with Zn
0
 as the in situ reductant efficiently transformed the 6-chloro-4-quinolone 
to 3-furanyl-6-cyano quinolone (Table 3.6 entry 1) in high yields.
36
  
Table 3.6. Cyanation of 4-Quinolone 
 
The same conditions failed to catalyze the cyanation of 3-iodo-quinolone. Previous work 
shows that many palladium-catalyzed methods proceed with only low to moderate yields 
of the product.
37
 Ultimately, switching to a copper iodide/DMEDA system with sodium 
cyanide resulted in cyanation of the 3-position with excellent yields (Table 3.6 entry 2).
38
 
 In summary, using the Pd/SPHOS catalyst/ligand system, a divergent synthetic 
route was designed and optimized to access structurally diverse 3-aryl-4-quinolones 
resulting in medicinally important heterocyclic scaffolds. A 6-chloro-3-iodo quinolone 
was used as a core intermediate to diversify the quinolone scaffold via mono or 
sequential Suzuki-Miyaura cross-couplings including fluoro, pyridyl, sterically hindered, 
heteroaryl, electron rich and electron poor substrates. In addition, iodo-4-quinolones were 
subjected to cyanations via Pd-catalysis while chloro-4-quinolones were transformed by 
copper catalysis. Ongoing efforts at preparing 3-aryl-4-quinolones via this route led to the 
identification of several analogues displaying antimalarial activity in the nanomolar 
range. 
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3.3 Experimental Section 
3.3.1 General Information 
 All reactions were carried out under an argon atmosphere. Granular K3PO4 was 
ground with a mortar and pestle then dried on high-vacuum for 24 before being placed in 
a bench-top desiccator and subsequently used. 
 All new compounds were characterized by 
1
H NMR, 
13
C NMR, Melting point 
analysis, and HRMS. Known compounds were characterized by 
1
H NMR, 
13
C NMR. 
1
H 
NMR, 
13
C NMR was obtained on a 400 MHz NMR spectrometer. All 
1
H NMR 
experiments are reported in ≥ units, parts per million (ppm) downfield of TMS and were 
measured relative to the signals for chloroform (7.26 ppm) and dimethylsulfoxide (2.50 
ppm). All 
13
C NMR spectra were reported in ppm relative to the signals for chloroform 
(77 ppm) and dimethylsulfoxide (39.5 ppm) with 
1
H decoupled observation. 
 The yields reported in Tables 3.1 – 3.6 are isolated yields with purity ≥ 95% 
determined via 
1
H NMR. All reactions were monitored by TLC or LC-MS for 
completion. 
3.3.1.1 Experimental for Conrad-Limpach cyclizations (Table 3.1, Entries 1-8). 
 Quinolin‐4‐ones were prepared by using one of the standard procedures for 
Conrad‐Limpach reaction.25 An oven‐dry 100 ml rbf attached to a Dean‐Stark trap 
equipped with a reflux condenser was charged with an aniline (0.025 mol), ethyl 
3‐oxobutanoate (0.05 mol), benzene (25 ml) and glacial acidic acid (1ml). The flask was 
heated at 100
o
C until no more water separates (3‐24 hours). The benzene was distilled 
under the reduced pressure and the resulting enamine was then used in the next step 
without further purification. Biphenyl ether (30 ml) was stirred and heated at reflux while 
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enamine was added rapidly through the dropping funnel. Stirring and refluxing continued 
for 10‐15 until no more ethanol is separated by using the Dean‐Stark trap. The mixture 
was allowed to cool down to r.t. while precipitation arises. The solid was filtered off and 
washed with hexane and acetone. No further purification was needed. 6-fluoro-2-
methylquinolin-4(1H)-one was commercially available. 
2‐methylquinolin‐4(1H)‐one (Table 3.1, entry 1). A mixture of aniline and ethyl 
3‐oxobutanoate in benzene was heated while water was removed azeotropically for 18 
hours. Filtration and washing yielded title compound in 55% yield over the two steps (2.2 
g) as a tan powder, m.p. = 230 – 231oC. 1H NMR (400 MHz, DMSO) δ 11.54 (s, 1H), 
8.03 (d, J = 8.0 Hz, 1H), 7.60 (t, J = 8.2 Hz, 1H), 7.48 (d, J = 8.2 Hz, 1H), 7.26 (t, J = 7.4 
Hz, 1H), 5.90 (s, 1H), 2.33 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 176.7, 149.5, 140.1, 
131.4, 124.8, 124.5, 122.6, 117.7, 108.4, 19.4. HRMS (ESI) calcd. for C10H9NO [M+H]
+
: 
160.0757, found: 160.0763. 
6‐chloro‐2‐methylquinolin‐4(1H)‐one (Table 3.1, entry 4). A mixture of 
4‐chloroaniline and ethyl 3‐oxobutanoate in benzene was heated while water was 
removed azeotropically for 18hours. Filtration and washing yielded title compound in 
63% yield over the two steps (3.06 g) as a yellow solid, m.p. = 316 – 318oC. 1H NMR 
(400 MHz, DMSO) δ 11.72 (s, 1H), 7.95 (d, J = 2.2 Hz, 1H), 7.63 (dd, J = 8.8, 2.3 Hz, 
1H), 7.52 (d, J = 8.8 Hz, 1H), 5.94 (s, 1H), 2.33 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 
175.4, 150.1, 138.6, 131.5, 127.3, 125.5, 123.7, 120.1, 108.6, 19.4. HRMS (ESI) calcd. 
for C10H8ClNO [M+H]
+
: 194.0367, found: 194.0376. 
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6‐methoxy‐2‐methylquinolin‐4(1H)‐one (Table 3.1, entry 6). A mixture of 4‐methyl 
aniline and ethyl 3‐oxobutanoate in benzene was heated while water was removed 
azeotropically for 16 hours. Filtration and washing yielded title compound in 57% yield 
over the two steps (3.11 g) as a light-yellow solid, m.p. = 294 – 298oC. 1H NMR (400 
MHz, DMSO) δ 11.57 (s, 1H), 7.57 – 7.37 (m, 2H), 7.24 (d, J = 9.0 Hz, 1H), 5.88 (s, 
1H), 3.81 (s, 3H), 2.32 (s, 3H). 
13C NMR (101MHz, DMSO) δ 176.0, 155.2, 148.5, 
134.7, 125.4, 121.6, 119.4, 107.4, 104.3, 55.2, 19.3. HRMS (ESI) calcd. for C11H11NO2 
[M+H]
+
: 190.0863, found: 190.0872. 
2,6‐dimethylquinolin‐4(1H)‐one (Table 3.1, entry 7).  A mixture of 4‐methyl aniline 
and ethyl 3‐oxobutanoate in benzene was heated while water was removed azeotropically 
for 19 hours. Filtration and washing yielded title compound in 72% yield over the two 
steps (3.11 g) as a yellow solid, m.p. = 276 – 277oC. 1H NMR (400 MHz, DMSO) δ 
11.49 (s, 1H), 7.83 (s, 1H), 7.41 (q, J = 8.4 Hz, 2H), 5.86 (s, 1H), 2.37 (s, 3H), 2.31 (s, 
3H). 
13C NMR (101 MHz, DMSO) δ 177.3, 149.9, 138.9, 133.4, 132.5, 125.1, 124.7, 
118.3, 108.8, 21.4, 20.1. HRMS (ESI) calcd. for C11H11NO [M+H]
+
: 174.0913, found: 
174.0921. 
5,7‐dichloro‐2‐methylquinolin‐4(1H)‐one (Table 3.1, entry 8). A mixture of 3,5‐ 
dichloroaniline and ethyl 3‐oxobutanoate in benzene was heated while water was 
removed azeotropically for 18 hours. Filtration and washing yielded title compound in 
73% yield over the two steps (4.1 g) as an off-white solid, m.p. = 348 – 349oC. 1H NMR 
(400 MHz, DMSO) δ 11.59 (s, 1H), 7.44 (s, 1H), 7.29 (s, 1H), 5.89 (s, 1H), 2.28 (s, 4H). 
13C NMR (101 MHz, DMSO) δ 175.4, 148.8, 143.1, 134.9, 133.6, 124.7, 119.2, 116.4, 
111.0, 18.9. HRMS (ESI) calcd. for C10H7Cl2NO [M+H]
+
: 227.9978, found: 227.9982. 
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3.3.1.2 Experimental Details for Alkali Halogenations (Table 3.1, Entries 9-16). 
 The halogenation was done followed by procedure reported by Renault et al.
32
 
Thus 1.2 equivalent of a 16% solution of bromine in 30% aqueous potassium bromide, or 
a 15% solution of iodine in 20% aqueous potassium iodide was added dropwise to a 
stirred solution or slurry of 2‐methylquinolin‐4(1H)‐one in 2M solution of sodium 
hydroxide at r.t. Stirring was continued until LCMS indicates absence of starting material 
(3‐24 hours). In some cases more than 1.2 eq of halogen was needed. The mixture was 
then acidified with acetic acid, precipitation was collected by filtration, washed heavily 
with water, dried in air overnight and recrystallized from DMF. 
3-iodo-2-methylquinolin-4(1H)-one (Table 3.1, entry 9).  2.5g of iodine in 26 ml of 
20% solution of potassium iodide was added dropwise to 5 g of quinolone in a 2M 
solution of sodium hydroxide. Filtration, washing and recrystallization yielded the title 
compound in 8.6g (96%) as a white solid, m.p. = 217 - 219
o
C. 
1
H NMR (400 MHz, 
DMSO) δ 8.07 (d, J = 7.9 Hz, 1H), 7.66 (t, J = 7.3 Hz, 1H), 7.55 (d, J = 8.3 Hz, 1H), 7.34 
(t, J = 7.5 Hz, 1H), 2.63 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 173.5, 152.0, 139.6, 
132.5, 126.1, 124.4, 121.2, 118.3, 86.7, 26.8. HRMS (ESI) calcd. for C10H8INO [M+H]
+
: 
285.9723, found: 285.9729. 
3-bromo-2-methylquinolin-4(1H)-one (Table 3.1, entry 10). 15.5 ml of bromine in 97 
ml of 30% solution of potassium bromide was added dropwise to 40 g of quinolone in a 
2M solution of sodium hydroxide. Filtration, washing and recrystallization yielded the 
title compound in 57.41 g (96%) as a tan solid, m.p. = 264 - 268
o
C. 
1
H NMR (250 MHz, 
DMSO) δ 8.09 (d, J = 8.1 Hz, 1H), 7.65 (t, J = 7.6 Hz, 1H), 7.53 (d, J = 8.2 Hz, 1H), 7.34 
(t, J = 7.5 Hz, 1H), 2.54 (s, 3H). 
13C NMR (63 MHz, DMSO) δ 171.1, 148.6, 138.6, 
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131.8, 125.2, 123.6, 122.7, 117.8, 105.9, 21.4. HRMS (ESI) calcd. for C10H8BrNO 
[M+H]
+
: 237.9862, found: 237.9871. 
3‐bromo‐6‐fluoro‐2‐methylquinolin‐4(1H)‐one (Table 3.1, entry 11). 1.08 g of 
bromine in 6.5 ml of 30% solution of potassium bromide was added dropwise to 1 g of 
quinolone in 2M solution of sodium hydroxide. Additional 0.62 g of bromine was added 
to complete the reaction in 19 hours. Filtration, washing and recrystallization yielded title 
compound in 1.1 g (67%) as a off-white powder, m.p. = 282 - 285
o
C. 
19
F NMR (376 
MHz, DMSO) δ -117.8. 1H NMR (400 MHz, DMSO) δ 12.29 (s, 1H), 7.73 (dd, J = 9.3, 
2.4 Hz, 1H), 7.60 (qd, J = 9.1, 3.8 Hz, 2H), 2.56 (s, 3H). 
13
C NMR (101 MHz, DMSO) δ 
170.9, 160.3, 157.9, 149.4, 136.0, 124.4, 121.4 (d, J = 8.08 Hz), 121.3 (d, J = 8.08 Hz), 
109.9 (d, J = 23.23 Hz), 106.1, 22.0. HRMS (ESI) calcd. for C10H7BrFNO [M+H]
+
: 
255.9768, found: 255.9776.  
3‐bromo‐6‐chloro‐2‐methylquinolin‐4(1H)‐one (Table 3.1, entry 12). 1 g of bromine 
in 6.25 ml of 30% solution of potassium bromide was added dropwise to 1 g of quinolone 
in 2M solution of sodium hydroxide. Additional 0.62 g of bromine was added to 
complete the reaction in 19 hours. Filtration, washing and recrystallization yielded title 
compound in 1 g (66%) as a sandy brown solid, m.p. = 288 - 290
o
C. 
1
H NMR (400 MHz, 
DMSO) δ 12.31 (s, 1H), 8.01 (d, J = 2.0 Hz, 1H), 7.70 (dd, J = 8.8, 2.2 Hz, 1H), 7.58 (d, 
J = 8.8 Hz, 1H), 2.56 (s, 3H). 
13
C NMR (101 MHz, DMSO) δ 169.9, 149.0, 137.1, 131.9, 
128.2, 123.9, 123.4, 120.3, 94.1, 21.4.
 
HRMS (ESI) calcd. for C10H7BrClNO [M+H]
+
: 
271.9472, found: 271.9479.
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6‐chloro‐3‐iodo‐2‐methylquinolin‐4(1H)‐one (Table 3.1, entry 13). 4.7 g of iodine in 
32 ml of 30% solution of potassium iodide was added dropwise to 3 g of quinolone in 2M 
solution of sodium hydroxide. Stirring was continued for 16 hours. Additional 2 g of 
iodine was needed to complete the reaction. Filtration and washing yielded title 
compound in 4.8 g (97%) as a pale yellow solid, m.p. = 237 - 238
o
C. 
1
H NMR (400 
MHz, DMSO) δ 12.29 (s, 1H), 7.99 (d, J = 2.2 Hz, 1H), 7.69 (dd, J = 8.8, 2.3 Hz, 1H), 
7.57 (d, J = 8.8 Hz, 1H), 2.63 (s, 4H). 
13C NMR (101 MHz, DMSO) δ 171.8, 151.8, 
137.5, 132.0, 128.1, 124.3, 121.3, 120.1, 86.1, 26.1. HRMS (ESI) calcd. for C10H7ClINO 
[M+H]
+
: 319.9334, found: 319.9347. 
3‐bromo‐6‐methoxy‐2‐methylquinolin‐4(1H)‐one (Table 3.1, entry 14). 1.01 g of 
bromine in 5 ml of 30% solution of potassium bromide was added dropwise to 1 g of 
quinolone in 2M solution of sodium hydroxide. Additional 0.6 g of bromine was added to 
complete the reaction in 20 hours. Filtration, washing and recrystallization yielded title 
compound in 1.096 g (77%) as a purple solid, m.p. = 262 - 264
o
C. 
1
H NMR (400 MHz, 
DMSO) δ 12.11 (s, 1H), 7.49 (dd, J = 13.3, 5.9 Hz, 2H), 7.31 (dd, J = 9.0, 2.9 Hz, 1H), 
3.83 (s, 3H), 2.54 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 170.3, 155.7, 147.4, 133.2, 
123.8, 122.3, 119.6, 105.1, 104.5, 55.4, 21.3. HRMS (ESI) calcd. for C11H10BrNO2 
[M+H]
+
: 267.9968, found: 267.9975. 
3‐iodo‐2,6‐dimethylquinolin‐4(1H)‐one (Table 3.1, entry 15). 5.26 g of iodine in 35 ml 
of 30% solution of potassium iodide was added dropwise to 3 g of quinolone in 2M 
solution of sodium hydroxide. Stirring was continued for 18 hours. Filtration and washing 
yielded titled compound in 4.7 g (91%) as a yellow crystalline solid, m.p. = 214 - 215
o
C. 
1H NMR (400 MHz, DMSO) δ 12.06 (s, 1H), 7.86 (s, 1H), 7.47 (dd, J = 16.2, 8.4 Hz, 
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2H), 2.62 (s, 3H), 2.41 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 172.6, 150.7, 137.0, 
133.2, 133.1, 124.6, 120.5, 117.5, 85.7, 26.1, 20.7. HRMS (ESI) calcd. for C11H10INO 
[M+H]
+
: 299.9880, found: 299.9874. 
5,7‐dichloro‐3‐iodo‐2‐methylquinolin‐4(1H)‐one (Table 3.1, entry 16). 5.47 g of 
iodine in 36 ml of 30% solution of potassium iodide was added dropwise to 4.1 g of 
quinolone in 2M solution of sodium hydroxide. Stirring was continued for 20 hours. 
Additional 5 g of iodine was needed to complete the reaction. Filtration, washing and 
recrystallization from DMF yielded titled compound in 5.32 g (83%) as a white 
crystalline solid, m.p. = 231 - 232
o
C. 
1H NMR (400 MHz, DMSO) δ 12.08 (s, 1H), 7.44 
(s, 1H), 7.33 (s, 1H), 2.55 (s, 4H). 
13C NMR (101 MHz, DMSO) δ 171.0, 150.9, 141.7, 
135.1, 133.7, 125.5, 116.3, 115.3, 89.5, 26.0. HRMS (ESI) calcd. for C10H6Cl2INO 
[M+H]
+
: 353.8944, found: 353.8959. 
3.3.1.3 Experimental for N-Alkylation of 3-Halo-2-methyl-4(1H)-quinolinones (Table 
3.2). 
 To a flame dried-backfilled round bottom flask is added quinolone (0.72 g, 2.8 
mmol) and Cs2CO3 (1.37 g, 4.2 mmol). DMF (14.5 ml) is added and this slurry is allowed 
to stir at r.t. for 1h. Next, Iodomethane (0.88 ml, 14 mmol) is added dropwise and the 
reaction is left until completion is observed via HPLC analysis. The reaction is the 
poured onto water (20 ml) and then diluted with chloroform (20 ml). The organic layer is 
then washed with water (20 ml) twice followed by brine (20 ml). The organic layer is 
then dried over sodium sulfate and concentrated in vacuo. The crude compound is 
columned via flash chromatography (Hex / EtOAc gradient).  
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3-bromo-1,2-dimethylquinolin-4(1H)-one (Table 3.2, entry 1). To a flame dried-
backfilled round bottom flask is added 3-bromo-2-methylquinolin-4(1H)-one (0.99 g, 4.2 
mmol) and Cs2CO3 (2.06 g, 6.3 mmol). DMF (21 ml) is added and this slurry is allowed 
to stir at r.t. for 1h. Next, Iodomethane (1.31 ml, 21 mmol) is added dropwise and the 
reaction is left until completion is observed via HPLC analysis. The reaction is the 
poured onto water (25 ml) and then diluted with chloroform (25 ml). The organic layer is 
then washed with water (25 ml) twice followed by brine (25 ml). The organic layer is 
then dried over sodium sulfate and concentrated in vacuo. The crude compound is 
columned via flash chromatography (Hex / EtOAc gradient) to provide a mixture of N-
methyl and O-methyl (1.67 : 1)  quinolones in 99% yield (1.04 g) with the title compound 
isolated as a tan crystalline solid m.p. = 206 - 208
o
C. 
1
H NMR (400 MHz, CDCl3) δ 8.36 
(dd, J = 8.0, 1.4 Hz, 1H), 7.58 (t, J = 8.6 Hz, 1H), 7.40 (d, J = 8.7 Hz, 1H), 7.29 (t, J = 
7.5 Hz, 1H), 3.76 (s, 3H), 2.71 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 172.1, 149.7, 
140.6, 132.5, 127.4, 124.1, 115.5, 110.0, 36.6, 22.7. HRMS (ESI) calcd. for C11H10BrNO 
[M+H]
+
 252.0019, found 252.0007. 
3-iodo-2-methylquinolin-4(1H)-one (Table 3.2, entry 2). To a flame dried-backfilled 
round bottom flask was added 3-iodo-2-methylquinolin-4(1H)-one (1.0 g, 3.5 mmol) and 
Cs2CO3 (1.72 g, 5.3 mmol). DMF (20 ml) is added and this slurry is allowed to stir at r.t. 
for 1h. Next, Iodomethane (1.09 ml, 17.5 mmol) is added dropwise and the reaction is left 
until completion is observed via HPLC analysis. The reaction is the poured onto water 
(25 ml) and then diluted with chloroform (25 ml). The organic layer is then washed with 
water (25 ml) twice followed by brine (25 ml). The organic layer is then dried over 
sodium sulfate and concentrated in vacuo. The crude compound is columned via flash 
150 
 
chromatography (Hex / EtOAc gradient) to provide a mixture of N-methyl and O-methyl 
(2.37 : 1)  quinolones in 95% yield (99 mg) with the title compound isolated as a white 
crystalline solid m.p. = 203 - 205
o
C. 
1
H NMR (400 MHz, CDCl3) δ 8.39 (d, J = 7.9 Hz, 
1H), 7.62 (t, J = 7.0 Hz, 1H), 7.44 (d, J = 6.9 Hz, 1H), 7.33 (d, J = 6.8 Hz, 1H), 3.83 (s, 
3H), 2.88 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 173.8, 151.8, 140.9, 132.5, 127.9, 
124.2, 122.5, 115.29, 90.8, 37.2, 28.4. HRMS (ESI) calcd. for C11H10INO [M+H]
+
 
299.9880, found 299.9884. 
3-bromo-6-fluoro-1,2-dimethylquinolin-4(1H)-one (Table 3.2, entry 3). To a flame 
dried-backfilled round bottom flask was added 3-bromo-6-fluoro-2-methylquinolin-
4(1H)-one (0.72 g, 2.8 mmol) and Cs2CO3 (1.37 g, 4.2 mmol). DMF (14.5 ml) is added 
and this slurry is allowed to stir at r.t. for 1h. Next, Iodomethane (0.88 ml, 14 mmol) is 
added dropwise and the reaction is left until completion is observed via HPLC analysis. 
The reaction is then poured onto water (25 ml) and then diluted with chloroform (25 ml). 
The organic layer is washed with water (25 ml) twice followed by brine (25 ml). The 
organic layer is then dried over sodium sulfate and concentrated in vacuo. The crude 
compound is columned via flash chromatography (Hex / EtOAc gradient) to provide a 
mixture of N-methyl and O-methyl (1.7 : 1) quinolones in 94% yield (0.716 g) with the 
title compound isolated as a white amorphous solid m.p. = 237 - 240
o
C. 
19
F NMR (376 
MHz, DMSO) δ -118.5. 1H NMR (400 MHz, DMSO) δ 7.92 (dd, J = 9.3, 4.1 Hz, 1H), 
7.80 (dd, J = 8.8, 2.4 Hz, 1H), 7.64 (t, J = 8.4 Hz, 1H), 3.86 (s, 3H), 2.79 (s, 3H). 
13
C 
NMR (101 MHz, DMSO) δ 170.2, 159.1 (d, J = 244.42 Hz), 151.8, 137.9, 125.6, 121.3 
(d, J = 25.25 Hz), 120.8 (d, J = 8.08 Hz), 110.5 (d, J = 22.22 Hz), 108.5, 37.8, 22.9. 
HRMS (ESI) calcd. for C11H9BrFNO [M+H]
+
 269.9924, found 269.9916. 
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6-chloro-3-iodo-1,2-dimethylquinolin-4(1H)-one (Table 3.2, entry 4). To a flame 
dried-backfilled round bottom flask was added 6-chloro-3-iodo-2-methylquinolin-4(1H)-
one (5 g, 15.6 mmol) and Cs2CO3 (7.6 g, 23.4 mmol). DMF (100 ml) is added and this 
slurry is allowed to stir at r.t. for 1h. Next, Iodomethane (4.8 ml, 74.4 mmol) is added 
dropwise and the reaction is left until completion is observed via HPLC analysis. The 
reaction is the poured onto water (25 ml) and then diluted with chloroform (25 ml). The 
organic layer is then washed with water (25 ml) twice followed by brine (25 ml). The 
organic layer is then dried over sodium sulfate and concentrated in vacuo. The crude 
compound is columned via flash chromatography (Hex / EtOAc gradient) to provide a 
mixture of N-methyl and O-methyl (3.5 : 1) quinolones in 97% yield (5.14 g) with the 
title compound isolated as a bright yellow crystalline solid m.p. = 209 -212
o
C. 
1
H NMR 
(400 MHz, DMSO) δ 8.06 (d, J = 2.3 Hz, 1H), 7.87 (d, J = 9.2 Hz, 1H), 7.74 (dd, J = 9.2, 
2.4 Hz, 1H), 3.88 (s, 3H), 2.92 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 171.9, 154.3, 
140.0, 132.8, 129.2, 125.6, 123.3, 120.1, 90.4, 38.2, 28.5. HRMS (ESI) calcd. for 
C11H9ClINO [M+H]
+
 333.9490, found 333.9485. 
3-bromo-6-methoxy-1,2-dimethylquinolin-4(1H)-one (Table 3.2, entry 5). To a flame 
dried-backfilled round bottom flask was added 3-bromo-6-methoxy-2-methylquinolin-
4(1H)-one (0.43 g, 1.6 mmol) and Cs2CO3 (0.78 g, 2.4 mmol). DMF (8.6 ml) is added 
and this slurry is allowed to stir at r.t. for 1h. Next, Iodomethane (0.498 ml, 8 mmol) is 
added dropwise and the reaction is left until completion is observed via HPLC analysis. 
The reaction is the poured onto water (25 ml) and then diluted with chloroform (25 ml). 
The organic layer is then washed with water (25 ml) twice followed by brine (25 ml). The 
organic layer is then dried over sodium sulfate and concentrated in vacuo. The crude 
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compound is columned via flash chromatography (Hex / EtOAc gradient) to provide a 
mixture of N-methyl and O-methyl (1.6 : 1) quinolones in 97% yield (0.44 g) with the 
title compound isolated as an off-white solid m.p. = 217 - 218
o
C. 
1
H NMR (400 MHz, 
CDCl3) δ 7.81 (d, J = 2.7 Hz, 1H), 7.42 (d, J = 9.3 Hz, 1H), 7.26 (d, J = 3.6 Hz, 1H), 3.91 
(s, 3H), 3.82 (s, 3H), 2.78 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 171.5, 156.4, 148.5, 
135.4, 125.7, 123.0, 117.1, 109.1, 106.5, 56.0, 36.7, 22.5. HRMS (ESI) calcd. for 
C12H12BrNO2 [M+H]
+
 282.0124, found 282.0120. 
3-iodo-1,2,6-trimethylquinolin-4(1H)-one (Table 3.2, entry 6). To a flame dried-
backfilled round bottom flask was added 3-iodo-2,6-dimethylquinolin-4(1H)-one  (2.98 
g, 10 mmol) and Cs2CO3 (4.89 g, 14.9 mmol). DMF (60 ml) is added and this slurry is 
allowed to stir at r.t. for 1h. Next, Iodomethane (3.11 ml, 0.5 mmol) is added dropwise 
and the reaction is left until completion is observed via HPLC analysis. The reaction is 
the poured onto water (125 ml) and then diluted with chloroform (125 ml). The organic 
layer is then washed with water (125 ml) twice followed by brine (125 ml). The organic 
layer is then dried over sodium sulfate and concentrated in vacuo. The crude compound is 
columned via flash chromatography (Hex / EtOAc gradient) to provide a mixture of N-
methyl and O-methyl (2.51 : 1) quinolones in 99% yield (3.08 g) with the title compound 
isolated as a rust brown solid m.p. = 196 - 199
o
C. 
1
H NMR (400 MHz, CDCl3) δ 8.16 (s, 
1H), 7.42 (dd, J = 8.7, 1.4 Hz, 1H), 7.34 (d, J = 8.8 Hz, 1H), 3.81 (s, 3H), 2.87 (s, 3H), 
2.43 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 173.6, 151.4, 139.0, 134.1, 133.8, 127.1, 
122.4, 115.3, 90.33, 37.1, 28.3, 20.9. HRMS (ESI) calcd. for C12H12INO [M+H]
+
 
314.0036, found 314.0029. 
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5,7-dichloro-3-iodo-1,2-dimethylquinolin-4(1H)-one (Table 3.2, entry 7). To a flame 
dried-backfilled round bottom flask was added 5,7-dichloro-3-iodo-2-methylquinolin-
4(1H)-one (3 g, 8.5 mmol) and Cs2CO3 (4.14 g, 12.8 mmol). DMF (60 ml) is added and 
this slurry is allowed to stir at r.t. for 1h. Next, iodomethane (3.65 ml, 58.5 mmol) is 
added dropwise and the reaction is left until completion is observed via HPLC analysis. 
The reaction is the poured onto water (125 ml) and then diluted with chloroform (125 
ml). The organic layer is then washed with water (125 ml) twice followed by brine (125 
ml). The organic layer is then dried over sodium sulfate and concentrated in vacuo. The 
crude compound is columned via flash chromatography (Hex / EtOAc gradient) to 
provide a mixture of N-methyl and O-methyl (12 : 1) quinolones in 80% yield (2.49 g) 
with the title compound isolated as a beige solid m.p. = 217 - 219
o
C. 
1
H NMR (400 MHz, 
DMSO) δ 7.89 (d, J = 1.6 Hz, 1H), 7.52 (d, J = 1.6 Hz, 1H), 3.83 (s, 3H), 2.90 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 170.7, 152.9, 143.6, 136.0, 134.1, 125.9, 116.9, 116.0, 
93.1, 38.5, 28.0. HRMS (ESI) calcd. for C11H8Cl2INO [M+H]
+
 367.9100, found 
367.9111. 
3.3.1.4 Experimental Details for Suzuki-Miyaura Couplings of 3-Halo-quinolones 
(Tables 3.3 and 3.4) 
 General Procedure A for 1(Methyl)-3-halo-quinolones (Tables 3.3 and 3.4) begins 
with flame-drying and backfilling with argon(x3) an oven-dried schlenk tube. The tube is 
then charged with quinolone (100 mg, 0.4 mmol), Pd2(dba)3 (14.5 mg, 0.016 mmol), 
SPHOS (13 mg, 0.032 mmol), boronic acid (97mg, 0.6 mmol), and anhydrous powdered 
K3PO4 (168 mg, 0.79 mmol). The schlenk tube was fitted with a rubber septum and then 
evacuated and backfilled with argon (this process was repeated three times). Dry solvent 
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(Toluene, DMF, or 2-butanol, 3mL) was added through the septum via syringe and the 
resulting solution was stirred for 1 min while purging with argon before replacing the 
rubber septum with the Teflon screwcap. The reaction was set to the oil bath until 
completion was observed via HPLC analysis. The reaction is cooled to room temperature 
and then diluted with 20 ml chloroform and 20 ml of methanol. This mixture was brought 
to a boil with a heat gun and then filtered over a pad of celite. The eluent was 
concentrated under reduced pressure and the residual oil was purified further via flash 
chromatography. 
 General Procedure B for 1(H)-3-halo-quinolones (Tables 3.3 and 3.4). Is the same 
as general procedure A with the following changes: After the reaction is complete and the 
initial eluent has been passed through the filter pad 10 ml of boiling DMF are then passed 
through the celite pad. This eluent is then concentrated under reduced pressure purified as 
general procedure A. Some 4(1H)-quinolones required two columns. The columned 
solids were then collected and placed in a 2-ml frit and washed with ice cold methanol, 
followed by diethyl ether then dried in vacuo to obtain the NMR pure samples. 
1,2-dimethyl-3-phenylquinolin-4(1H)-one (Table 3.4, entry 2). Following general 
procedure A, a mixture of 3-iodo-1,2-dimethylquinolin-4(1H)-one (100 mg, 0.4 mmol), 
phenylboronic acid (97 mg, 0.59 mmol), K3PO4 (168 mg, 0.79 mmol), Pd2(dba)3 (14.5 
mg, 0.016 mmol), and SPHOS (13 mg, 0.032 mmol) was heated to 80
o
C in Toluene (1 
mL) for 45 min. The crude product was purified via flash chromatography on silica gel 
(Hexanes/EtOAc gradient) to provide the title compound in 95% yield (94 mg) as an off-
white solid, m.p. = 208 – 210oC. 1H NMR (400 MHz, CDCl3) δ 8.46 (dd, J = 8.0, 1.5 Hz, 
1H), 7.61 (dd, J = 9.4, 7.8 Hz, 1H), 7.48 (d, J = 8.6 Hz, 1H), 7.40 – 7.27 (m, 4H), 7.24 – 
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7.17 (m, 2H), 3.75 (s, 3H), 2.31 (s, 3H).
13
C NMR (101 MHz, CDCl3) δ 176.1, 148.5, 
141.6, 137.3, 132.1, 131.1, 128.5, 127.5, 127.2, 126.4, 125.3, 124.6, 123.3, 115.3, 35.3, 
20.2. HRMS (ESI) calcd for C17H15NO [M+H]
+
 250.1226, found 250.1237. 
2-methyl-3-phenylquinolin-4(1H)-one (Table 3.4, entry3). Following general 
procedure B, a mixture of 3-iodo-2-methylquinolin-4(1H)-one (100 mg, 0.35 mmol), 
phenylboronic acid (64 mg, 0.053 mmol), K3PO4 (148 mg, 0.70 mmol), Pd2(dba)3 (13 
mg, 0.014 mmol), and SPHOS (12 mg, 0.028 mmol) was heated to 110
o
C in DMF (1 mL) 
for 1h. The crude product was purified via flash chromatography on silica gel (DCM / 
MeOH 1%) to provide the title compound in 72% (59 mg) as a yellow-white solid, m.p. = 
283 – 285oC. 1H NMR (400 MHz, DMSO) δ 11.63 (s, 1H), 8.09 (d, J = 8.0 Hz, 1H), 7.63 
(t, J = 7.6 Hz, 1H), 7.53 (d, J = 8.2 Hz, 1H), 7.39 (t, J = 7.4 Hz, 2H), 7.31 – 7.23 (m, 4H), 
2.22 (s, 3H).
 13C NMR (101 MHz, DMSO) δ 175.5, 147.2, 140.0, 136.9, 132.1, 131.7, 
128.4, 127.1, 126.0, 125.1, 123.4, 121.6, 118.2, 19.5. HRMS (ESI) calcd for C16H13NO 
[M+H]
+ 
236.1070, found 236.1079. 
3-(4-methoxyphenyl)-1,2-dimethylquinolin-4(1H)-one (Table 3.4, entry 4). Following 
general procedure A, a mixture of 3-bromo-1,2-dimethylquinolin-4(1H)-one (100 mg, 
0.39 mmol), 4-methoxyphenyl boronic acid (91 mg, 0.6 mmol), K3PO4 (165 mg, 0.78 
mmol), Pd2(dba)3 (14.5 mg, 0.015 mmol), and SPHOS (13 mg, 0.031 mmol) was heated 
to 80
o
C in Toluene (3 mL) for 2h. The crude product was purified by flash 
chromatography on silica gel (Hexanes/EtOAc gradient) to provide the title compound in 
89% yield (98 mg) as a light brown solid, m.p. = 219 to 221
o
C. 
1
H NMR (400 MHz, 
CDCl3) δ 8.48 (dd, J = 8.0, 1.2 Hz, 1H), 7.64 (ddd, J = 8.6, 7.1, 1.6 Hz, 1H), 7.50 (d, J = 
8.6 Hz, 1H), 7.34 (t, J = 7.5 Hz, 1H), 7.16 (d, J = 8.6 Hz, 2H), 6.95 (d, J = 8.6 Hz, 2H), 
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3.82 (s, 3H), 3.78 (s, 3H), 2.36 (s, 3H).
13
C NMR (101 MHz, CDCl3) δ 176.4, 158.7, 
148.6, 141.5, 132.2, 132.1, 129.5, 127.5, 126.3, 124.1, 123.3, 115.2, 114.1, 55.5, 35.3, 
20.2. HRMS (ESI) calcd for C18H17NO2 [M+H]
+ 
280.1332, found 280.1346. 
3-(4-methoxyphenyl)-1,2,6-trimethylquinolin-4(1H)-one (Table 3.4, entry 5). 
Following general procedure A, a mixture of 3-iodo-1,2,6-trimethylquinolin-4(1H)-one 
(100 mg, 0.32 mmol), 4-methoxyphenyl boronic acid (97 mg, 0.64 mmol), K3PO4 (202 
mg, 0.96 mmol), Pd2(dba)3 (12 mg, 0.012 mmol), and SPHOS (11 mg, 0.024 mmol) was 
heated to 80
o
C in Toluene (3 mL) for 30 min. The crude product was purified by flash 
chromatography on silica gel (Hexanes/EtOAc gradient) to provide the title compound in 
99% yield (93 mg) as a brown solid, m.p. = 227 – 229oC. 1H NMR (400 MHz, CDCl3) δ 
8.25 (s, 1H), 7.42 (dd, J = 20.0, 8.7 Hz, 2H), 7.14 (d, J = 8.4 Hz, 2H), 6.93 (d, J = 8.4 Hz, 
2H), 3.81 (s, 3H), 3.76 (s, 3H), 2.44 (s, 3H), 2.33 (s, 3H).
13
C NMR (101 MHz, CDCl3) δ 
176.2, 158.6, 148.1, 139.6, 133.4, 133.0, 132.1, 129.6, 126.9, 126.2, 123.8, 115.1, 114.0, 
55.4, 35.2, 20.9, 20.0. HRMS (ESI) calcd for C19H19NO2 [M+H]
+ 
294.1489, found 
294.1488. 
3-(4-methoxyphenyl)-2,6-dimethylquinolin-4(1H)-one (Table 3.4, entry 6). Following 
general procedure B, a mixture of 3-iodo-2,6-dimethylquinolin-4(1H)-one (100 mg, 0.33 
mmol), 4-methoxyphenyl boronic acid (76 mg, 0.5 mmol), K3PO4 (142 mg, 0.67 mmol), 
Pd2(dba)3 (12.2 mg, 0.013 mmol), and SPHOS (11 mg, 0.026 mmol) was heated to 110
o
C 
in 2-butanol (2 mL) for 1h. The crude product was purified by flash chromatography on 
silica gel (Hexanes/EtOAc/MeOH gradient) to provide the title compound in 62% yield 
(58 mg) as an off-white solid, m.p. = 322 -324
o
C. 
1H NMR (400 MHz, DMSO) δ 11.52 
(s, 1H), 7.86 (s, 1H), 7.44 (s, 2H), 7.14 (d, J = 4.9 Hz, 2H), 6.95 (s, 2H), 3.78 (s, 3H), 
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2.39 (s, 3H), 2.20 (s, 3H).
13C NMR (101 MHz, DMSO) δ 174.9, 157.8, 146.1, 137.4, 
132.7, 132.0, 131.7, 128.4, 124.6, 124.3, 120.2, 117.5, 113.2, 55.0, 20.8, 18.9. HRMS 
(ESI) calcd for C18H17NO2 [M+H]
+ 
294.1487, found 294.1488. 
6-fluoro-3-(4-methoxyphenyl)-1,2-dimethylquinolin-4(1H)-one (Table 3.4, entry 7). 
Following general procedure A, a mixture of 6-fluoro-3-iodo-1,2-dimethylquinolin-
4(1H)-one (100 mg, 0.37 mmol), 4-methoxyphenyl boronic acid (113 mg, 0.74 mmol), 
K3PO4 (240 mg, 1.1 mmol), Pd2(dba)3 (14 mg, 0.015 mmol), and SPHOS (11 mg, 0.03 
mmol) was heated to 80
o
C in toluene (3 mL) for 1h. The crude product was purified by 
flash chromatography on silica gel (Hexanes/EtOAc 25%) to provide the title compound 
in 95% yield (104 mg) as a tan solid, m.p. = 235 – 237oC. 19F NMR (376 MHz, DMSO) δ 
-119.9. 
1
H NMR (400 MHz, CDCl3) δ 8.12 (dd, J = 8.9, 2.9 Hz, 1H), 7.51 (dd, J = 9.3, 
4.0 Hz, 1H), 7.42 – 7.34 (m, 1H), 7.15 (d, J = 8.3 Hz, 2H), 6.96 (d, J = 8.3 Hz, 2H), 3.84 
(s, 3H), 3.81 (s, 3H), 2.37 (s, 3H).
 13
C NMR (101 MHz, CDCl3) δ 175.5, 159.1 (d, J = 
246.44 Hz), 158.8, 148.7, 138.0, 132.0, 129.1, 127.8, 123.6, 120.4 (d, J = 25.25 Hz), 
117.4 (d, J = 7.07 Hz), 114.1, 112.9 (d, J = 22.22 Hz), 55.4, 35.6, 20.1. HRMS (ESI) 
calcd for C18H16FNO2 [M+H]
+ 
298.1238, found 298.1237. 
6-fluoro-3-(4-methoxyphenyl)-2-methylquinolin-4(1H)-one (Table 3.4, entry 8). 
Following general procedure B, a mixture of 6-fluoro-3-bromo-2-methylquinolin-4(1H)-
one (100 mg, 0.37 mmol), 4-methoxyphenyl boronic acid (191 mg, 1.4 mmol), K3PO4 
(240 mg, 1.1 mmol), Pd2(dba)3 (14 mg, 0.015 mmol), and SPHOS (11 mg, 0.03 mmol) 
was heated 110
o
C in DMF (1 mL) for 18h. The crude product was purified by flash 
chromatography on silica gel (DCM / MeOH 3%) to provide the title compound in 73% 
yield (81 mg) as a white amorphous solid, m.p. = 329 – 330oC. 19F NMR (376 MHz, 
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DMSO) δ -119.3. 1H NMR (400 MHz, DMSO) δ 11.76 (s, 1H), 7.70 (dd, J = 9.4, 2.8 Hz, 
1H), 7.60 (dd, J = 9.0, 4.7 Hz, 1H), 7.53 (dt, J = 8.6, 2.9 Hz, 1H), 7.16 (d, J = 8.6 Hz, 
2H), 6.95 (d, J = 8.6 Hz, 2H), 3.79 (s, 3H), 2.23 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 
174.9, 158.7 (d, J = 241.39 Hz), 158.6, 147.5, 136.7, 132.7, 128.6, 126.0, 121.0, 121.0, 
120.6 (d, J = 17.17 Hz), 114.0, 109.9 (d, J = 22 Hz), 55.7, 19.6. HRMS (ESI) calcd for 
C17H14FNO2 [M+H]
+ 
284.1081, found 284.1091. 
6-chloro-3-(2,4-dimethoxypyrimidin-5-yl)-1,2-dimethylquinolin-4(1H)-one (Table 
3.4, entry 9). Following general procedure A, a mixture of 6-chloro-3-iodo-1,2-
dimethylquinolin-4(1H)-one (100 mg, 0.29 mmol), 2,4-dimethoxypyrimidin-5-ylboronic 
acid (110 mg, 0.59 mmol), K3PO4 (190 mg, 0.87 mmol), Pd2(dba)3 (11 mg, 0.011 mmol), 
and SPHOS (10 mg, 0.022 mmol) was heated to 85
o
C in DMF (3 mL) for 1h. The crude 
product was purified by flash chromatography on silica gel (Hexanes/EtOAc gradient) to 
provide the title compound in 91% yield (93 mg) as a yellow solid, m.p. = 206 – 208oC. 
1
H NMR (400 MHz, CDCl3) δ 8.41 (d, J = 2.4 Hz, 1H), 8.12 (s, 1H), 7.59 (dd, J = 9.1, 
2.4 Hz, 1H), 7.47 (d, J = 9.1 Hz, 1H), 4.03 (s, 3H), 3.93 (s, 3H), 3.82 (s, 3H), 2.34 (s, 
3H).
13
C NMR (101 MHz, CDCl3) δ 174.7, 169.1, 165.2, 160.4, 150.3, 140.0, 132.5, 
129.9, 127.0, 126.7, 117.2, 115.7, 110.9, 55.0, 54.2, 35.6, 19.9. HRMS (ESI) calcd for 
C17H16ClN3O3 [M+H]
+ 
346.0953, found 346.0958. 
1,2-dimethyl-3-o-tolylquinolin-4(1H)-one (Table 3.4, entry 10). Following general 
procedure A, a mixture of 3-bromo-1,2-dimethylquinolin-4(1H)-one (100 mg, 0.39 
mmol), o-tolylboronic acid (110 mg, 0.8 mmol), K3PO4 ( 255 mg, 1.2 mmol), Pd2(dba)3 
(11 mg, 0.011 mmol), and SPHOS (10 mg, 0.022 mmol) was heated to 80
o
C in toluene (3 
mL) for 1h. The crude product was purified by flash chromatography on silica gel 
159 
 
(Hexanes/EtOAc gradient) to provide the title compound in 83% yield (87 mg) as a light 
brown solid, m.p. = 214 – 216oC. 1H NMR (400 MHz, CDCl3) δ 8.50 (dd, J = 8.0, 1.4 
Hz, 1H), 7.67 (ddd, J = 8.6, 7.1, 1.6 Hz, 1H), 7.54 (d, J = 8.6 Hz, 1H), 7.37 (t, J = 7.5 Hz, 
1H), 7.33 – 7.16 (m, 4H), 7.14 – 7.03 (m, 1H), 3.82 (s, 3H), 2.26 (s, 3H), 2.13 (s, 3H).13C 
NMR (101 MHz, CDCl3) δ 175.8, 148.5, 141.7, 137.7, 137.0, 132.1, 131.0, 130.2, 127.7, 
127.6, 126.3, 126.2, 123.9, 123.3, 115.2, 35.2, 20.0, 19.5. HRMS (ESI) calcd for 
C18H17NO [M+H]
+ 
264.1383, found 264.1394. 
3-(3,5-dimethylphenyl)-6-methoxy-1,2-dimethylquinolin-4(1H)-one (Table 3.4, entry 
11). Following general procedure A, a mixture of 3-bromo-6-methoxy-1,2-
dimethylquinolin-4(1H)-one (100 mg, 0.35 mmol), 3,5-dimethylphenylboronic acid acid 
(107 mg, 0.71 mmol), K3PO4 ( 225 mg, 1.1 mmol), Pd2(dba)3 (13 mg, 0.014 mmol), and 
SPHOS (12 mg, 0.028 mmol) was heated to 80
o
C in toluene (3 mL) for 4.5h. The crude 
product was purified by flash chromatography on silica gel (Hexanes/EtOAc gradient) to 
provide the title compound in 73% yield (80 mg) as an off white solid, m.p. = 209 – 
212
o
C. 
1
H NMR (400 MHz, CDCl3) δ 7.89 (d, J = 3.0 Hz, 1H), 7.44 (d, J = 9.3 Hz, 1H), 
7.24 (dd, J = 9.3, 3.1 Hz, 1H), 6.93 (s, 1H), 6.83 (s, 2H), 3.88 (s, 3H), 3.76 (s, 3H), 2.32 
(s, 3H), 2.31 (s, 6H). 
13
C NMR (101 MHz, CDCl3) δ 175.5, 155.9, 147.5, 137.8, 137.2, 
136.1, 128.7, 128.7, 127.4, 123.9, 122.5, 116.9, 106.5, 55.8, 35.3, 21.5, 19.9. HRMS 
(ESI) calcd for C20H21NO2 [M+H]
+ 
308.1645, found 308.1645. 
3-(3,5-dimethylphenyl)-6-methoxy-2-methylquinolin-4(1H)-one (Table 3.4, entry 12). 
Following general procedure B, a mixture of 3-bromo-6-methoxy-2-methylquinolin-
4(1H)-one (100 mg, 0.32 mmol), 3,5-dimethylphenylboronic acid acid (165 mg, 1.12 
mmol), K3PO4 ( 134 mg, 0.63 mmol), Pd2(dba)3 (12 mg, 0.013 mmol), and SPHOS (11 
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mg, 0.026 mmol) was heated to 110
o
C in DMF (1 mL) for 3h. The crude product was 
purified by flash chromatography on silica gel (DCM/MeOH gradient) to provide the title 
compound in 51% yield (47 mg) as a white solid, m.p. = 362 – 364oC . 1H NMR (400 
MHz, DMSO) δ 11.57 (s, 1H), 7.49 (d, J = 8.9 Hz, 2H), 7.27 (dd, J = 8.9, 2.9 Hz, 1H), 
6.92 (s, 1H), 6.82 (s, 2H), 3.81 (s, 3H), 2.28 (s, 6H), 2.19 (s, 3H).
13
C NMR (101 MHz, 
DMSO) δ 174.2, 155.1, 145.4, 136.5, 136.4, 134.0, 128.7, 127.8, 125.3, 121.7, 120.1, 
119.3, 104.7, 55.3, 20.9, 18.8. HRMS (ESI) calcd for C19H19NO2 [M+H]
+ 
294.1489, 
found 294.1502. 
N,N-dimethyl-3-(1,2,6-trimethyl-4-oxo-1,4-dihydroquinolin-3-yl)benzamide (Table 
3.4, entry 13).  Following general procedure A, a mixture of 3-iodo-1,2,6-
trimethylquinolin-4(1H)-one (100 mg, 0.33 mmol), 3-(dimethylcarbamoyl)phenylboronic 
acid (216 mg, 1.1 mmol), K3PO4 (305 mg, 1.4 mmol), Pd2(dba)3 (12 mg, 0.013 mmol), 
and SPHOS (11 mg, 0.026 mmol) was heated to 110
o
C in DMF (1 mL) for 36h. The 
crude product was purified by flash chromatography on silica gel 
(Hexanes/EtOAc/MeOH gradient) to provide the title compound in 95% yield (102 mg) 
as white solid, m.p. = 174 - 175
o
C. 
1H NMR (400 MHz, DMSO) δ 8.00 (s, 1H), 7.74 (d, J 
= 8.7 Hz, 1H), 7.57 (d, J = 8.5 Hz, 1H), 7.46 (t, J = 7.5 Hz, 1H), 7.34 (d, J = 7.4 Hz, 1H), 
7.25 (d, J = 7.3 Hz, 1H), 7.20 (s, 1H), 3.80 (s, 3H), 2.98 (s, 6H), 2.42 (s, 3H), 2.34 (s, 
3H).
13
C NMR (101 MHz, CDCl3) δ 175.9, 171.9, 148.3, 139.6, 137.3, 136.4, 133.7, 
133.4, 132.3, 130.0, 128.6, 126.7, 126.2, 125.8, 123.4, 115.3, 40.0, 35.3, 20.9, 20.2. 
HRMS (ESI) calcd for C21H22N2O2 [M+H]
+ 
335.1754, found 335.1769. 
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3-(2,6-dimethyl-4-oxo-1,4-dihydroquinolin-3-yl)-N,N-dimethylbenzamide (Table 3.4, 
entry 14). Following general procedure B, a mixture of 3-iodo-2,6-dimethylquinolin-
4(1H)-one (100 mg, 0.33 mmol), 3-(dimethylcarbamoyl)phenylboronic acid (129 mg, 
0.67 mmol), K3PO4 (280mg, 1.3 mmol), Pd2(dba)3 (15 mg, 0.017 mmol), and SPHOS (11 
mg, 0.051 mmol) was heated to 110
o
C in 2-butanol (2 mL) for 37h. The crude product 
was purified by flash chromatography on silica gel (DCM/MeOH gradient) to provide the 
title compound in 65% yield (69 mg) as a white solid, m.p. = 278 – 281oC. 1H NMR (400 
MHz, DMSO) δ 11.63 (s, 1H), 7.88 (s, 1H), 7.44 (d, J = 11.2 Hz, 3H), 7.32 (d, J = 7.5 
Hz, 2H), 7.27 (s, 1H), 2.98 (s, 6H), 2.40 (s, 3H), 2.24 (s, 3H).
13
C NMR (101 MHz, 
DMSO) δ 174.6, 170.2, 146.3, 137.4, 136.1, 135.8, 132.9, 132.0, 132.0, 129.6, 127.7, 
125.2, 124.5, 124.3, 119.8, 117.6, 34.7, 20.8, 18.9. HRMS (ESI) calcd for C20H20N2O2 
[M+H]
+
 321.1598, found 321.1605. 
6-fluoro-3-(4-fluorophenyl)-1,2-dimethylquinolin-4(1H)-one (Table 3.4, entry 15). 
Following general procedure A, a mixture of 3-bromo-6-fluoro-1,2-dimethylquinolin-
4(1H)-one (100 mg, 0.37 mmol), 4-fluorophenylboronic acid (172 mg, 1.29 mmol), 
K3PO4 (148 mg, 0.74 mmol), Pd2(dba)3 (13 mg, 0.015 mmol), and SPHOS (18 mg, 0.044 
mmol) was heated to 110
o
C in DMF (1 mL) for 36h. The crude product was purified by 
flash chromatography on silica gel (Hexanes/EtOAc gradient) to provide the title 
compound in 81% yield (84 mg) as white solid, m.p. = 233 – 236oC. 19F NMR (376 
MHz, DMSO) δ -116.4, -119.7. 1H NMR (400 MHz, CDCl3) δ 8.10 (dd, J = 8.7, 2.7 Hz, 
1H), 7.53 (dd, J = 9.2, 3.8 Hz, 1H), 7.41 – 7.34 (m, 1H), 7.19 (t, J = 6.8 Hz, 2H), 7.10 (t, 
J = 8.6 Hz, 2H), 3.82 (s, 3H), 2.35 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 175.2, 161.6 
(d, J = 247.45 Hz), 159.1 (d, J = 246.44 Hz), 148.7, 138.0, 132.8, 132.6 (d, J = 8.08 Hz), 
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127.7 (d, J = 6.06 Hz), 122.9, 120.6 (d, J = 25.25 Hz), 117.6 (d, J = 8.08 Hz), 115.5 (d, J 
= 22.22 Hz), 111.8 (d, J = 22.22 Hz), 35.6, 20.0. HRMS (ESI) calcd for C17H13F2NO 
[M+H]
+ 
286.1038, found 286.1048.  
6-fluoro-3-(4-fluorophenyl)-2-methylquinolin-4(1H)-one (Table 3.4, entry 16). 
Following general procedure B, a mixture of 3-bromo-6-fluoro-2-methylquinolin-4(1H)-
one (100 mg, 0.33 mmol), 4-fluorophenylboronic acid (223 mg, 1.65 mmol), K3PO4 (140 
mg, 0.66 mmol), Pd2(dba)3 (12 mg, 0.013 mmol), and SPHOS (16 mg, 0.039 mmol) was 
heated to 110
o
C in DMF (1 mL) for 23h. The crude product was purified by flash 
chromatography on silica gel (DCM/MeOH gradient) to provide the title compound in 
73% yield (79 mg) as a white solid, m.p. = 347 – 348oC. 19F NMR (376 MHz, DMSO) δ -
116.5, -119.1. 
1H NMR (400 MHz, DMSO) δ 11.83 (s, 1H), 7.71 (d, J = 9.2 Hz, 1H), 
7.59 (dd, J = 18.7, 5.9 Hz, 2H), 7.28 (d, J = 5.3 Hz, 2H), 7.21 (t, J = 8.1 Hz, 2H), 2.23 (s, 
3H). 
13C NMR (101 MHz, DMSO) δ 174.1, 161.1 (d, J = 244.42 Hz), 158.2 (d, J = 
241.39 Hz), 147.1, 136.1, 132.9 (d, J = 7.07 Hz), 132.1, 125.4, 120.4 (d, J = 9.09 Hz), 
120.24, 119.2, 114.7 (d, J = 21.21 Hz), 109.3 (d, J = 22.22 Hz), 18.9. HRMS (ESI) calcd 
for C16H11F2NO [M+H]
+ 
272.0882, found 272.0881. 
6-chloro-1,2-dimethyl-3-phenylquinolin-4(1H)-one (Table 3.4, entry 17). Following 
general procedure A, a mixture of 6-chloro-3-iodo-1,2-dimethylquinolin-4(1H)-one (1g, 
3 mmol), phenylboronic acid (550 mg, 4.5 mmol), K3PO4 (1.27 g, 6 mmol), Pd2(dba)3 
(110 mg, 0.12 mmol), and SPHOS (100 mg, 0.24 mmol) was heated to 110
o
C in DMF (1 
mL) for 70h. At 24h and 48h intervals the starting material was not consumed and 70 mg 
of phenylboronic acid and 10 mg of Pd2(dba)3 /  SPHOS was added each interval. The 
crude product was purified by flash chromatography on silica gel (Hexanes/EtOAc 
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gradient) to provide the title compound in 85% yield (724 mg) as a pink solid, m.p. = 208 
– 209oC . 1H NMR (400 MHz, CDCl3) δ 8.40 (d, J = 2.6 Hz, 1H), 7.54 (dd, J = 9.1, 2.6 
Hz, 1H), 7.41 (dd, J = 17.0, 8.4 Hz, 3H), 7.33 – 7.28 (m, 1H), 7.23 – 7.18 (m, 2H), 3.77 
(s, 3H), 2.33 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 174.9, 148.7, 139.9, 136.8, 132.2, 
130.9, 129.4, 128.6, 127.3, 126.6, 124.9, 117.1, 35.4, 20.1. HRMS (ESI) calcd for 
C17H14ClNO [M+H]
+ 
284.0837, found 284.0848. 
6-chloro-2-methyl-3-phenylquinolin-4(1H)-one (Table 3.4, entry 18). Following 
general procedure B, a mixture of 6-chloro-3-iodo-2-methylquinolin-4(1H)-one (2g, 6.3 
mmol), phenylboronic acid (1.15 g, 9.5 mmol), K3PO4 (2.65 g, 12.6 mmol), Pd2(dba)3 
(230 mg, 0.25 mmol), and SPHOS (205 mg, 0.5 mmol) was heated to 110
o
C in DMF (1 
mL) for 16h. The crude product was concentrated in vacuo then diluted and sonicated 
with diethyl ether. Next this solid was collected in a Fine frit and washed heavily with 
acetone, and a small amount of cold methanol to provide 450 mg clean. The entire set of 
combines was then purified by flash chromatography on silica gel (DCM/MeOH 
gradient) to provide the title compound in an overall yield of 68% (1.14 g) as a brown 
solid, m.p. = 355 – 357oC. 1H NMR (400 MHz, DMSO) δ 11.86 (s, 1H), 8.00 (s, 1H), 
7.69 – 7.65 (m, 1H), 7.59 (d, J = 8.7 Hz, 1H), 7.40 – 7.25 (m, 5H), 2.22 (s, 3H). 13C 
NMR (101 MHz, DMSO) δ 173.6, 147.1, 138.0, 135.8, 131.5, 130.9, 127.8, 127.3, 126.6, 
125.4, 124.2, 121.1, 120.1, 18.9. HRMS (ESI) calcd for C16H12ClNO [M+H]
+ 
270.0680, 
found 270.0693. 
6-chloro-3-(furan-2-yl)-1,2-dimethylquinolin-4(1H)-one (Table 3.4, entry 19). 
Following general procedure A, a mixture of 6-chloro-3-iodo-1,2-dimethylquinolin-
4(1H)-one (100 mg, 0.29 mmol), 2-furanylboronic acid (65 mg, 0.58 mmol), K3PO4 (190 
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mg, 0.9 mmol), Pd2(dba)3 (11 mg, 0.012 mmol), and SPHOS (10 mg, 0.024 mmol) was 
heated to 85
o
C in DMF (3 mL) for 30 min. The crude product was purified by flash 
chromatography on silica gel (Hexanes/EtOAc gradient) to provide the title compound in 
97% yield (80 mg) as a purple-red solid, m.p. = 153 – 155oC. 1H NMR (400 MHz, 
CDCl3) δ 8.31 (d, J = 2.5 Hz, 1H), 7.54 – 7.44 (m, 2H), 7.35 (d, J = 9.1 Hz, 1H), 6.59 (d, 
J = 3.0 Hz, 1H), 6.50 (dd, J = 3.1, 1.9 Hz, 1H), 3.71 (s, 3H), 2.42 (s, 3H). 
13
C NMR (101 
MHz, CDCl3) δ 174.2, 151.5, 148.7, 141.7, 139.5, 132.3, 129.8, 127.0, 126.3, 117.3, 
114.5, 111.6, 111.1, 35.5, 20.1. HRMS (ESI) calcd for C15H12ClNO2 [M+H]
+
274.0629, 
found 274.0633. 
6-chloro-3-(furan-2-yl)-2-methylquinolin-4(1H)-one (Table 3.4, entry 20). Following 
general procedure B, a mixture of 6-chloro-3-iodo-2-methylquinolin-4(1H)-one (100 mg, 
0.33 mmol), 2-furanylboronic acid (53 mg, 0.47 mmol), K3PO4 (133 mg, 0.66 mmol), 
Pd2(dba)3 (11.5 mg, 0.013 mmol), and SPHOS (15 mg, 0.026 mmol) was heated to 110
o
C 
in DMF (1 mL) for 18h. The crude product was purified by flash chromatography on 
silica gel (DCM/MeOH gradient) twice to provide the title compound in 75% yield (81 
mg) as a purple-red solid, m.p. = 290 – 292oC. 1H NMR (400 MHz, DMSO) δ 12.00 (s, 
1H), 8.03 (s, 1H), 7.67 (d, J = 10.9 Hz, 2H), 7.58 (d, J = 8.4 Hz, 1H), 6.81 (s, 1H), 6.55 
(s, 1H), 2.48 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 172.8, 148.9, 148.6, 141.4, 137.4, 
131.8, 127.9, 125.2, 124.3, 120.3, 111.0, 110.9, 110.6, 19.6. HRMS (ESI) calcd for 
C14H10ClNO2 [M+H]
+
260.0473, found 260.0476. 
6-chloro-1,2-dimethyl-3-(pyridin-3-yl)quinolin-4(1H)-one (Table 3.4, entry 21).  
Following general procedure A, a mixture of 6-chloro-3-iodo-1,2-dimethylquinolin-
4(1H)-one (100 mg, 0.29 mmol), 3-pyridylboronic acid (55 mg, 0.45 mmol), K3PO4 (127 
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mg, 0.6 mmol), Pd2(dba)3 (11 mg, 0.012 mmol), and SPHOS (10 mg, 0.024 mmol) was 
heated to 100
o
C in DMF (1 mL) for 36h. The crude product was purified by flash 
chromatography on silica gel (Hexanes/EtOAc/MeOH gradient) to provide the title 
compound in 65% yield (55 mg) as a brown solid, m.p. = 216 – 220oC. 1H NMR (400 
MHz, CDCl3) δ 8.59 (dd, J = 4.8, 1.6 Hz, 1H), 8.45 (dd, J = 15.7, 2.0 Hz, 2H), 7.67 – 
7.61 (m, 2H), 7.51 (d, J = 9.1 Hz, 1H), 7.38 (dd, J = 7.7, 4.9 Hz, 1H), 3.84 (s, 3H), 2.40 
(s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 174.9, 151.7, 149.1, 148.57, 140.0, 138.9, 132.7, 
130.0, 127.3, 126.7, 123.5, 121.2, 117.2, 35.6, 20.2. HRMS (ESI) calcd for C16H13ClN2O 
[M+H]
+
285.0789, found 285.0794. 
6-chloro-2-methyl-3-(pyridin-3-yl)quinolin-4(1H)-one (Table 3.4, entry 22). 
Following general procedure B, a mixture of 6-chloro-3-iodo-2-methylquinolin-4(1H)-
one (100 mg, 0.33 mmol), 3-pyridylboronic acid (56 mg, 0.47 mmol), K3PO4 (133 mg, 
0.66 mmol), Pd2(dba)3 (14 mg, 0.016 mmol), and SPHOS (20 mg, 0.048 mmol) was 
heated to 110
o
C in 2-butanol (2 mL) for 44h. The crude product was purified by flash 
chromatography on silica gel (Hex/EtOAc/MeOH gradient) to provide the title compound 
in 51% yield (43 mg) as a brown solid. 
1H NMR (400 MHz, DMSO) δ 11.97 (s, 1H), 
8.51 (d, J = 4.6 Hz, 1H), 8.46 (s, 1H), 8.01 (s, 1H), 7.70 (d, J = 8.5 Hz, 2H), 7.61 (d, J = 
8.8 Hz, 1H), 7.46 – 7.40 (m, 1H), 2.27 (s, 3H). 13C NMR (101 MHz, DMSO) δ 173.6, 
151.3, 147.9, 147.6, 138.4, 138.0, 131.8, 131.5, 127.6, 125.2, 124.2, 123.0, 120.2, 117.6, 
18.9. HRMS (ESI) calcd for C15H11ClN2O [M+H]
+ 
271.0633, found 271.0638. 
6-chloro-3-(2,4-difluorophenyl)-1,2-dimethylquinolin-4(1H)-one (Table 3.4, entry 
23).  Following general procedure A, a mixture of 6-chloro-3-iodo-1,2-dimethylquinolin-
4(1H)-one (100 mg, 0.29 mmol), 2,4-difluorophenylboronic acid (166 mg, 1.02 mmol), 
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K3PO4 (127 mg, 0.6 mmol), Pd2(dba)3 (16 mg, 0.015 mmol), and SPHOS (22 mg, 0.045 
mmol) was heated to 110
o
C in DMF (1 mL) for 36h. The crude product was purified by 
flash chromatography on silica gel (Hexanes/EtOAc/MeOH gradient) to provide the title 
compound in 90% yield (86 mg) as a light yellow solid, m.p. = 270 – 273oC . 19F NMR 
(376 MHz, DMSO) δ -109.6, -111.9. 1H NMR (400 MHz, DMSO) δ 8.10 (d, J = 2.2 Hz, 
1H), 7.92 (d, J = 9.2 Hz, 1H), 7.79 (dd, J = 9.1, 2.2 Hz, 1H), 7.29 (dd, J = 13.9, 7.4 Hz, 
2H), 7.15 (t, J = 8.3 Hz, 1H), 3.83 (s, 3H), 2.32 (s, 4H). 
13C NMR (101 MHz, DMSO) δ 
172.6, 161.7, (dd, J = 246.44, 11.11 Hz), 160.0 (dd, J = 246.44, 12.12 Hz), 151.2, 139.9, 
134.3 (d, J = 4.04 Hz), 132.0, 128.2, 126.2, 124.5, 120.8 (d, J = 17.17 Hz), 119.6, 115.9, 
111.3 (d, J = 21.21 Hz), 103.8 (t, J = 26.26 Hz), 35.7, 19.4. HRMS (ESI) calcd for 
C17H12ClF2NO [M+H]
+ 
320.0648, found 320.0663. 
6-chloro-3-(2,4-difluorophenyl)-2-methylquinolin-4(1H)-one (Table 3.4, entry 24). 
Following general procedure B, a mixture of 6-chloro-3-iodo-2-methylquinolin-4(1H)-
one (100 mg, 0.33 mmol), 2,4-difluorophenylboronic acid (173 mg, 1.16 mmol), K3PO4 
(133 mg, 0.66 mmol), Pd2(dba)3 (11.5 mg, 0.012 mmol), and SPHOS (10 mg, 0.024 
mmol) was heated to 110
o
C in DMF (1.3 mL) for 17h. The crude product was purified by 
flash chromatography on silica gel (DCM/MeOH gradient) to provide the title compound 
in 51% yield (49 mg) as a brown solid, m.p. = 353 – 355oC . 19F NMR (376 MHz, 
DMSO) δ -109.6, -111.9. 1H NMR (400 MHz, DMSO) δ 11.98 (s, 1H), 7.99 (s, J = 2.3 
Hz, 1H), 7.70 (dd, J = 8.8, 2.4 Hz, 1H), 7.60 (d, J = 8.8 Hz, 1H), 7.32 – 7.27 (m, 3H), 
7.13 (td, J = 8.5, 2.3 Hz, 1H), 2.20 (s, 4H). 
13C NMR (101 MHz, DMSO) δ 173.3, 161.7 
(dd, J = 241.39, 13.13 Hz), 160.1 (dd, J = 247.45, 12.12 Hz) 148.3, 138.1, 134.2, 131.8, 
127.7, 125.0, 124.1, 120.3, 119.6 (d, J = 18.18 Hz), 114.2, 111.2, (d, J = 21.21 Hz), 103.8 
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(t, J = 26.26 Hz), 18.5. HRMS (ESI) calcd for C16H10ClF2NO [M+H]
+ 
306.0492, found 
306.0478. 
(E)-6-chloro-1,2-dimethyl-3-styrylquinolin-4(1H)-one (Table 3.4, entry 25). 
Following general procedure A, a mixture of 6-chloro-3-iodo-1,2-dimethylquinolin-
4(1H)-one (100 mg, 0.29 mmol), (E)-phenylethenylboronic acid (67 mg, 0.45 mmol), 
K3PO4 (127 mg, 0.6 mmol), Pd2(dba)3 (11 mg, 0.012 mmol), and SPHOS (10 mg, 0.024 
mmol) was heated to 45
o
C in toluene (2.4 mL) for 19h. The crude product was purified 
by flash chromatography on silica gel (Hexanes/EtOAc/MeOH gradient) to provide the 
title compound in 96% yield (89 mg) as a 12:1 (E:Z) mixture as a light yellow solid, m.p. 
= 215 – 216oC. 1H NMR (250 MHz, CDCl3) δ 8.38 (d, J = 2.5 Hz, 1H), 7.52 – 7.42 (m, 
4H), 7.38 – 7.29 (m, 3H), 7.23 (s, 1H), 7.03 (d, J = 16.2 Hz, 1H), 3.75 (s, 3H), 2.59 (s, 
3H). 
13C NMR (63 MHz, CDCl3) δ 174.7, 149.2, 138.9, 138.3, 133.6, 131.8, 129.3, 
128.6, 127.3, 126.6, 126.4, 126.1, 122.6, 119.2, 117.2, 35.6, 18.9.
 
HRMS (ESI) calcd for 
C19H16ClNO [M+H]
+ 
310.0993, found 310.1003. 
3.3.1.5 Experimental details for Suzuki-Miyaura couplings of 6-chloro-quinolones (Table 
3.5) 
 General Procedure C for 1(Methyl)-6-chloro-quinolones (Table 3.5) begins with 
flame-drying and backfilling an oven-dried schlenk tube with argon(x3). The tube is then 
charged with quinolone (100 mg, 0.36 mmol), Pd2(dba)3 (17 mg, 0.018 mmol), SPHOS 
(23 mg, 0.054 mmol), boronic acid (158 mg, 1.26 mmol), and anhydrous powdered 
K3PO4 (153 mg, 0.72 mmol). The schlenk tube was fitted with a rubber septum and then 
evacuated and backfilled with argon (this process was repeated three times). Dry solvent 
(Toluene or DMF, 1mL) was added through the septum via syringe and the resulting 
168 
 
solution was stirred for 1 min while purging with argon before replacing the rubber 
septum with the Teflon screwcap. The reaction was set to the oil bath until completion 
was observed via HPLC analysis. The reaction is cooled to room temperature and then 
diluted with 20 ml chloroform and 20 ml of methanol. This mixture was brought to a boil 
with a heat gun and then filtered over a pad of celite. The eluent was concentrated under 
reduced pressure and the residual oil was purified further via flash chromatography. 
 General Procedure D for 1(H)-6-chloro-quinolones (Table 4) is the same as 
general procedure C with the following changes: After the reaction is complete and the 
initial eluent has been passed through the filter pad 10 ml of boiling DMF are then passed 
through the celite pad. This eluent is then concentrated under reduced pressure purified as 
general procedure A. Some 1(H)-quinolones required two columns. The columned solids 
were then collected and placed in a 2-ml frit and washed with ice cold methanol, 
followed by diethyl ether then dried in vacuo to obtain NMR pure samples. 
6-(4-fluorophenyl)-1,2-dimethyl-3-phenylquinolin-4(1H)-one (Table 3.5, entry 1). 
Following general procedure C, a mixture of 6-chloro-1,2-dimethyl-3-phenylquinolin-
4(1H)-one (100 mg, 0.35 mmol), 4-fluorophenylboronic acid (171 mg, 1.2 mmol), K3PO4 
(150 mg, 0.7 mmol), Pd2(dba)3 (16 mg, 0.018 mmol), and SPHOS (22 mg, 0.053 mmol) 
was heated to 115
o
C in DMF (1 mL) for 18h. The crude product was purified by flash 
chromatography on silica gel (Hexanes/EtOAc gradient) to provide the title compound in 
94% yield (113 mg) as a white solid, m.p. = 217 – 218oC. 19F NMR (376 MHz, DMSO) δ 
-115.8. 
1H NMR (400 MHz, DMSO) δ 8.41 (s, J = 2.2 Hz, 1H), 8.05 (dd, J = 9.0, 2.3 Hz, 
1H), 7.92 (d, J = 9.0 Hz, 1H), 7.79 (dd, J = 8.6, 5.4 Hz, 2H), 7.47 – 7.12 (m, 8H), 3.85 (s, 
3H), 2.33 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 174.1, 161.9 (d, J = 245.43), 149.4, 
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140.5, 137.4, 135.6, 135.5, 133.5, 131.0, 130.3, 128.6 (d, J = 8.08 Hz), 128.0, 126.6, 
125.7, 123.0, 117.5, 115.9 (d, J = 21.21 Hz), 35.4, 19.6. HRMS (ESI) calcd for 
C23H18FNO [M+H]
+ 
344.1445, found 344.1438. 
6-(4-fluorophenyl)-2-methyl-3-phenylquinolin-4(1H)-one (Table 3.5, entry 2). 
Following general procedure D, a mixture of 6-chloro-2-methyl-3-phenylquinolin-4(1H)-
one (100 mg, 0.37 mmol), 4-fluorophenylboronic acid (182 mg, 1.3 mmol), K3PO4 (158 
mg, 0.74 mmol), Pd2(dba)3 (17 mg, 0.019 mmol), and SPHOS (23 mg, 0.056 mmol) was 
heated to 110
o
C in DMF (1 mL) for 18h. The crude product is taken up in CHCl3:MeOH 
(1:1) and sonicated , the solid is pipette into a 2-ml frit and then washed with cold 
methanol, cold acetone, and finally cold diethyl ether (45 ml). The eluent is collected and 
concentrated and this process is repeated. The title compound is recovered in 72% yield 
(88 mg) as a grey amorphous solid, m.p. = 366 - 367
o
C. 
19
F NMR (376 MHz, DMSO) δ -
116.1. 
1H NMR (400 MHz, DMSO) δ 11.90 (s, 1H), 8.28 (s, J = 1.9 Hz, 1H), 7.95 (dd, J 
= 8.6, 2.1 Hz, 1H), 7.79 – 7.72 (m, 2H), 7.67 (d, J = 8.6 Hz, 1H), 7.40 (t, J = 7.4 Hz, 2H), 
7.29 (dt, J = 14.9, 7.9 Hz, 5H), 2.24 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 174.7, 161.8 
(d, J = 245.43 Hz), 146.9, 139.1, 136.4, 136.1, 133.4, 131.0, 130.9, 128.5 (d, J = 8.08 
Hz), 127.8, 126.4, 124.6, 122.6, 121.0, 118.8, 115.8 (d, J = 21.21 Hz), 19.1. HRMS (ESI) 
calcd for C22H16FNO [M+H]
+ 
330.1289, found 330.1273. 
6-(4-(hydroxymethyl)phenyl)-1,2-dimethyl-3-phenylquinolin-4(1H)-one (Table 3.5, 
entry 3). Following general procedure C, a mixture of 6-chloro-1,2-dimethyl-3-
phenylquinolin-4(1H)-one (100 mg, 0.35 mmol), 4-(hydroxymethyl)phenylboronic acid 
(81 mg, 0.53 mmol), K3PO4 (150 mg, 0.7 mmol), Pd2(dba)3 (16 mg, 0.018 mmol), and 
SPHOS (22 mg, 0.053 mmol) was heated to 115
o
C in DMF (1 mL) for 17h. The crude 
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product was purified by flash chromatography on silica gel (Hexanes/EtOAc/MeOH 
gradient) to provide the title compound in 70% yield (88 mg) as a pink solid, m.p. = 270 - 
271
o
C. 
1H NMR (400 MHz, DMSO) δ 8.45 (s, 1H), 7.99 (dd, J = 58.0, 8.5 Hz, 3H), 7.72 
(d, J = 6.8 Hz, 2H), 7.50 – 7.37 (m, J = 12.8, 7.1 Hz, 7H), 7.34 (d, J = 6.7 Hz, 1H), 7.21 
(d, J = 6.8 Hz, 3H), 5.24 (s, 1H), 4.56 (s, J = 3.6 Hz, 2H), 3.85 (s, 3H), 2.34 (s, 4H). 
13
C 
NMR (101 MHz, DMSO) δ 174.2, 149.3, 141.9, 140.4, 137.5, 137.4, 134.4, 131.0, 130.2, 
127.9, 127.2, 126.6, 126.2, 125.8, 123.0, 122.8, 117.4, 62.6, 35.3, 19.6. HRMS (ESI) 
calcd for C24H21NO2 [M+H]
+ 
356.1645, found 356.1628. 
6-(4-(hydroxymethyl)phenyl)-2-methyl-3-phenylquinolin-4(1H)-one (Table 3.5, 
entry 4). Following general procedure D, a mixture of 6-chloro-2-methyl-3-
phenylquinolin-4(1H)-one (100 mg, 0.37 mmol), 4-(hydroxymethyl)phenylboronic acid 
(197 mg, 1.29 mmol), K3PO4 (158 mg, 0.74 mmol), Pd2(dba)3 (17 mg, 0.019 mmol), and 
SPHOS (23 mg, 0.056 mmol) was heated to 110
o
C in DMF (1 mL) for 21h. The crude 
product was purified by flash chromatography on silica gel (DCM/MeOH gradient) to 
provide the title compound in 73% yield (92 mg) as a light yellow solid, m.p. = 341 - 
344
o
C. 
1H NMR (400 MHz, DMSO) δ 11.73 (s, 1H), 8.32 (s, 1H), 7.97 (d, J = 8.5 Hz, 
1H), 7.66 (dd, J = 20.1, 8.2 Hz, 3H), 7.41 (dd, J = 14.9, 7.6 Hz, 4H), 7.29 (dd, J = 19.8, 
7.2 Hz, 3H), 5.23 (s, 1H), 4.55 (s, 2H), 2.24 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 
174.9, 146.5, 141.7, 138.6, 137.9, 136.2, 134.5, 131.0, 130.1, 127.8, 127.2, 126.5, 126.2, 
124.6, 122.5, 121.0, 118.4, 62.6, 18.9. HRMS (ESI) calcd for C23H19NO2 [M+H]
+ 
342.1489, found 342.1498. 
3-(furan-2-yl)-1,2-dimethyl-6-phenylquinolin-4(1H)-one (Table 3.5, entry 5). 
Following general procedure C, a mixture of 6-chloro-3-(furan-2-yl)-1,2-
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dimethylquinolin-4(1H)-one (100 mg, 0.35 mmol), phenylboronic acid (90 mg, 0.7 
mmol), K3PO4 (310 mg, 1.4 mmol), Pd2(dba)3 (16 mg, 0.018 mmol), and SPHOS (22 mg, 
0.053 mmol) was heated to 110
o
C in toluene (2 mL) for 17h. The crude product was 
purified by flash chromatography on silica gel (Hexanes/EtOAc gradient) to provide the 
title compound in 92% yield (107 mg) as a brown solid, m.p. = 205 - 207
o
C. 
1
H NMR 
(400 MHz, CDCl3) δ 8.72 (d, J = 2.2 Hz, 1H), 7.87 (dd, J = 8.9, 2.3 Hz, 1H), 7.70 (d, J = 
7.3 Hz, 2H), 7.54 (s, 1H), 7.52 – 7.51 (m, 1H), 7.46 (t, J = 7.6 Hz, 2H), 7.36 (t, J = 7.3 
Hz, 1H), 6.65 (d, J = 3.1 Hz, 1H), 6.53 (dd, J = 3.0, 1.9 Hz, 1H), 3.79 (s, 3H), 2.46 (s, 
3H). 
13
C NMR (101 MHz, CDCl3) δ 175.5, 151.0, 149.1, 141.6, 140.5, 139.6, 136.3, 
131.0, 129.1, 127.7, 127.1, 126.5, 125.1, 116.0, 114.4, 111.6, 111.1, 35.4, 20.1. HRMS 
(ESI) calcd for C21H17NO2 [M+H]
+ 
316.1332, found 316.1324. 
3-(furan-2-yl)-2-methyl-6-phenylquinolin-4(1H)-one (Table 3.5, entry 6). Following 
general procedure D, a mixture of 6-chloro-3-(furan-2-yl)-2-methylquinolin-4(1H)-one 
(100 mg, 0.39 mmol), phenylboronic acid (108 mg, 0.88 mmol), K3PO4 (165 mg, 0.8 
mmol), Pd2(dba)3 (14 mg, 0.015 mmol), and SPHOS (20 mg, 0.045 mmol) was heated to 
100
o
C in DMF (1 mL) for 26h. The crude product was purified by flash chromatography 
on silica gel (DCM/MeOH gradient) to provide the title compound in 44% yield (51 mg) 
as a brown solid, m.p. = 297 - 301
o
C. 
1H NMR (400 MHz, DMSO) δ 11.89 (s, 1H), 8.36 
(s, J = 1.8 Hz, 1H), 7.99 (dd, J = 8.6, 2.0 Hz, 1H), 7.77 – 7.69 (m, 3H), 7.65 (d, J = 8.6 
Hz, 1H), 7.50 (t, J = 7.6 Hz, 2H), 7.39 (t, J = 7.3 Hz, 1H), 6.83 (d, J = 3.1 Hz, 1H), 6.57 
(dd, J = 3.1, 1.8 Hz, 1H), 2.51 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 173.9, 149.0, 
148.2, 141.2, 139.4, 138.1, 135.1, 130.3, 129.1, 127.4, 126.6, 124.4, 122.7, 118.6, 110.8, 
110.4, 19.5. HRMS (ESI) calcd for C20H15NO2 [M+H]
+ 
302.1176, found 302.1168. 
172 
 
6-(2,6-dimethylphenyl)-3-(furan-2-yl)-1,2-dimethylquinolin-4(1H)-one (Table 3.5, 
entry 7). Following general procedure C, a mixture of 6-chloro-3-(furan-2-yl)-1,2-
dimethylquinolin-4(1H)-one (100 mg, 0.35 mmol), 2,6-dimethylphenylboronic acid (110 
mg, 0.72 mmol), K3PO4 (310 mg, 1.44 mmol), Pd2(dba)3 (17 mg, 0.0183 mmol), and 
SPHOS (23 mg, 0.055 mmol) was heated to 110
o
C in toluene (2 mL) for 1.5h. The crude 
product was purified by flash chromatography on silica gel (Hexanes/EtOAc gradient) to 
provide the title compound in 91% yield (114 mg) as a brown solid, m.p. = 214 - 217
o
C. 
1
H NMR (400 MHz, CDCl3) δ 8.32 (d, J = 2.0 Hz, 1H), 7.60 (d, J = 8.8 Hz, 1H), 7.50 (d, 
J = 1.1 Hz, 1H), 7.47 (dd, J = 8.7, 2.1 Hz, 1H), 7.18 (dd, J = 8.5, 6.4 Hz, 1H), 7.12 (d, J = 
7.4 Hz, 2H), 6.62 (d, J = 2.9 Hz, 1H), 6.52 (dd, J = 3.1, 1.9 Hz, 1H), 3.87 (s, 3H), 2.51 (s, 
3H), 2.02 (s, 6H). 
13
C NMR (101 MHz, CDCl3) δ 175.6, 151.1, 149.2, 141.7, 140.6, 
140.2, 136.7, 136.3, 133.6, 127.7, 127.5, 127.5, 126.5, 115.6, 114.5, 111.5, 111.1, 35.3, 
21.0, 20.2. HRMS (ESI) calcd for C23H21NO2 [M+H]
+ 
344.1645, found 344.1660.   
6-(2,6-dimethylphenyl)-3-(furan-2-yl)-2-methylquinolin-4(1H)-one (Table 3.5. Entry 
8). Following general procedure D, a mixture of 6-chloro-3-(furan-2-yl)-2-
methylquinolin-4(1H)-one (100 mg, 0.39 mmol), 2,6-dimethylphenylboronic acid (115 
mg, 0.78 mmol), K3PO4 (163 mg, 0.8 mmol), Pd2(dba)3 (17.6 mg, 0.019 mmol), and 
SPHOS (23.6 mg, 0.058 mmol) was heated to 110
o
C in DMF (1 mL) for 17h. The crude 
product was purified by flash chromatography on silica gel (DCM/MeOH gradient) to 
provide the title compound in 47% yield (60 mg) as a brown solid, m.p. = 262 - 267
o
C. 
1H NMR (500 MHz, cdcl3) δ 11.95 (s, 1H), 8.19 (s, 1H), 7.53 (d, J = 4.6 Hz, 1H), 7.30 
(s, 1H), 7.10 (d, J = 23.9 Hz, 4H), 6.59 (s, 1H), 6.31 (s, 1H), 2.37 (s, 3H), 1.99 (s, 6H). 
13C NMR (101 MHz, DMSO) δ 173.9, 149.0, 148.4, 141.2, 140.6, 137.6, 135.4, 135.3, 
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132.7, 127.4, 127.2, 125.0, 124.2, 118.2, 110.7, 110.3, 20.5, 19.4. HRMS (ESI) calcd for 
C22H19NO2 [M+H]
+
330.1489, found 330.1476. 
3-(2,4-dimethoxypyrimidin-5-yl)-1,2-dimethyl-6-(pyridin-3-yl)quinolin-4(1H)-one 
(Table 3.5, entry 9). Following general procedure C, a mixture of 6-chloro-3-(2,4-
dimethoxypyrimidin-5-yl)-1,2-dimethylquinolin-4(1H)-one (100 mg, 0.29 mmol), 3-
pyridineboronic acid (72 mg, 0.6 mmol), K3PO4 (250 mg, 1.2 mmol), Pd2(dba)3 (13 mg, 
0.014 mmol), and SPHOS (23 mg, 0.042 mmol) was heated to 105
o
C in toluene (1 mL) 
for 22h. The crude product was purified by flash chromatography on silica gel (DCM / 
MeOH gradient) to provide the title compound in 88% yield (98 mg) as a white solid, 
m.p. = 232 - 233
o
C. 
1H NMR (400 MHz, DMSO) δ 8.98 (s, J = 1.7 Hz, 1H), 8.60 (d, J = 
4.5 Hz, 1H), 8.45 (s, J = 2.0 Hz, 1H), 8.17 (dd, J = 13.7, 4.9 Hz, 2H), 8.10 (s, 1H), 7.99 
(d, J = 9.0 Hz, 1H), 7.52 (dd, J = 7.9, 4.8 Hz, 1H), 3.96 (s, 3H), 3.87 (d, J = 12.4 Hz, 6H), 
2.33 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 173.9, 168.6, 164.3, 160.1, 151.1, 148.6, 
147.5, 140.9, 134.5, 134.0, 131.8, 130.6, 125.3, 124.0, 123.4, 117.9, 114.3, 111.3, 54.5, 
53.7, 35.5, 19.4. HRMS (ESI) calcd for C22H20N4O3 [M+H]
+ 
389.1608, found 389.1595. 
3.3.1.6 Experimental details for Cyanations of 4-quinolones (Table 3.6).  
3-(furan-2-yl)-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-6-carbonitrile (Table 3.6, 
entry 1). An oven-dried schlenk tube was flame-dried and backfilled with argon(x3). The 
tube is then charged with 6-chloro-3-(furan-2-yl)-1,2-dimethylquinolin-4(1H)-one (100 
mg, 0.37 mmol), Pd2(dba)3 (17 mg, 0.018 mmol), dppf (31 mg, 0.055 mmol), zinc 
cyanide (26 mg, 0.22 mmol), and zinc dust (7 mg, 0.011 mmol). The schlenk tube was 
fitted with a rubber septum and then evacuated and backfilled with argon (this process 
was repeated three times). Dry DMA (1 mL) was added through the septum via syringe 
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and the resulting solution was stirred for 1 min while purging with argon before replacing 
the rubber septum with the Teflon screwcap. The reaction was set to 150
o
C for 23h. The 
reaction is cooled to room temperature and then diluted with 20 ml chloroform and then 
washed with 2N NH4OH followed by brine. This mixture was brought to a boil with a 
heat gun and then filtered over a pad of celite, and concentrated in vacuo. The crude 
product was purified by flash chromatography on silica gel (100% EtOAc) to provide the 
title compound in 91% yield (88 mg) as a light brown solid, m.p. = 213 - 215
o
C. 
1
H NMR 
(400 MHz, CDCl3) δ 8.74 (d, J = 1.9 Hz, 1H), 7.82 (dd, J = 8.9, 1.9 Hz, 1H), 7.58 (d, J = 
8.9 Hz, 1H), 7.51 (d, J = 1.1 Hz, 1H), 6.66 (d, J = 3.1 Hz, 1H), 6.53 (dd, J = 3.1, 1.9 Hz, 
1H), 3.83 (s, 3H), 2.52 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 174.0, 152.1, 147.8, 
143.3, 142.1, 134.2, 133.0, 126.0, 118.4, 116.7, 116.1, 112.2, 111.28, 107.2, 35.7, 20.4. 
HRMS (ESI) calcd for C16H12N2O2 [M+H]
+ 
265.0972, found 265.0959.  
6-chloro-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-3-carbonitrile (Table 3.6, entry 
2). An oven-dried schlenk tube was flame-dried and backfilled with argon(x3). The tube 
is then charged with 6-chloro-3-iodo-1,2-dimethylquinolin-4(1H)-one (100 mg, 0.3 
mmol), CuI (6 mg, 0.03 mmol), DMEDA (32 µL, 0.3 mmol), and sodium cyanide (18 
mg, 0.36 mmol). The schlenk tube was fitted with a rubber septum and then evacuated 
and backfilled with argon (this process was repeated three times). Dry toluene (1 mL) 
was added through the septum via syringe and the resulting solution was stirred for 1 min 
while purging with argon before replacing the rubber septum with the Teflon screwcap. 
The reaction was set to 90
o
C for 23h. The reaction is cooled to room temperature and 
then diluted with 20 ml chloroform and filtered through a pad of celite and concentrated 
in vacuo. The crude product was purified by flash chromatography on silica gel (EtOAc / 
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MeOH 5%) to provide the title compound in 90% yield (63 mg) as a light brown solid, 
m.p. = 255 - 256
o
C. 
1H NMR (400 MHz, DMSO) δ 8.06 (d, J = 2.4 Hz, 1H), 7.97 (d, J = 
9.2 Hz, 1H), 7.86 (dd, J = 9.2, 2.4 Hz, 1H), 3.82 (s, 3H), 2.74 (s, 3H). 
13
C NMR (101 
MHz, DMSO) δ 172.7, 159.9, 139.4, 133.3, 130.1, 126.0, 124.1, 120.4, 116.8, 96.0, 36.5, 
21.0. HRMS (ESI) calcd for C12H9ClN2O [2M+H]
+ 
465.0880, found 465.0878. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
176 
 
3.4 References Cited 
1. Suzuki, A. Carbon-carbon bonding made easy. Chem. Commun. (Cambridge, U. 
K.) 2005, 4759-4763. 
2. Miyaura, N.; Suzuki, A. Palladium-Catalyzed Cross-Coupling Reactions of 
Organoboron Compounds. Chem. Rev. (Washington, D. C.) 1995, 95, 2457-83. 
3. Lin, S.; Danishefsky, S. J. The total synthesis of proteasome inhibitors TMC-95A 
and TMC-95B: discovery of a new method to generate cis-propenyl amides. Angew. 
Chem., Int. Ed. 2002, 41, 512-515. 
4. Zhu, B.; Panek, J. S. Total synthesis of Epothilone A. Org. Lett. 2000, 2, 2575-
2578. 
5. Mapp, A. K.; Heathcock, C. H. Total synthesis of myxalamide A. J. Org. Chem.  
1999, 64, 23-27. 
6. Molander, G. A.; Dehmel, F. Formal total synthesis of oximidine II via a Suzuki-
type cross-cCoupling macrocyclization employing potassium organotrifluoroborates. J. 
Am. Chem. Soc. 2004, 126, 10313-10318. 
7. Torborg, C.; Beller, M. Recent applications of palladium-catalyzed coupling 
reactions in the pharmaceutical, agrochemical, and fine chemical industries. Adv. Synth. 
Catal. 2009, 351, 3027-3043. 
8. Billingsley, K. L.; Anderson, K. W.; Buchwald, S. L. A highly active catalyst for 
Suzuki-Miyaura cross-coupling reactions of heteroaryl compounds. Angew. Chem., Int. 
Ed. 2006, 45, 3484-3488. 
9. Li, L.; Wang, H.-K.; Kuo, S.-C.; Wu, T.-S.; Lednicer, D.; Lin, C. M.; Hamel, E.; 
Lee, K.-H. Antitumor agents. 150. 2',3',4',5',5,6,7-substituted 2-phenyl-4-quinolones and 
177 
 
related compounds: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. 
J. Med. Chem. 1994, 37, 1126-1135. 
10. Li, L.; Wang, H.-K.; Kuo, S.-C.; Wu, T.-S.; Mauger, A.; Lin, C. M.; Hamel, E.; 
Lee, K.-H. Antitumor Agents 155. Synthesis and Biological Evaluation of 3',6,7-
Substituted 2-Phenyl-4-quinolones as Antimicrotubule Agents. J. Med. Chem. 1994, 37, 
3400-3407. 
11. Kimata, A.; Nakagawa, H.; Ohyama, R.; Fukuuchi, T.; Ohta, S.; Suzuki, T.; 
Miyata, N. New series of antiprion compounds: pyrazolone derivatives have the potent 
activity of inhibiting protease-resistant prion protein accumulation. J. Med. Chem. 2007, 
50, 5053-5056. 
12. Albrecht, R. Development of antibacterial agents of the nalidixic acid type. Prog. 
Drug Res. 1977, 21, 9-104. 
13. Arthur, H. R.; Loh, L. Y. S. The rutaceae of Hong Kong. VIII. Synthesis of the 
alkaloid graveoline. J. Chem. Soc. 1961, 4360-1. 
14. Baker, B. R.; Bramhall, R. R. Irreversible enzyme inhibitors. 189. Inhibition of 
some dehydrogenases by derivatives of 4-hydroxyquinoline-2- and -3-carboxylic acids. J. 
Med. Chem. 1972, 15, 230-3. 
15. De la Cruz, A.; Elguero, J.; Goya, P.; Martinez, A.; Gotor, V.; Moris, F.; De 
Clercq, E. Synthesis and antiviral evaluation of new 4-quinolone acyclic nucleosides. J. 
Chem. Res., Synop. 1992, 216-17. 
16. Erickson, E. H.; Lappi, L. R.; Rice, T. K.; Swingle, K. F.; Van Winkle, M. 
Antiallergic activity of tetracyclic derivatives of quinoline-2-carboxylic acids. 1. J. Med. 
Chem. 1978, 21, 984-8. 
178 
 
17. Fokialakis, N.; Magiatis, P.; Mitaku, S.; Tillequin, F.; Sevenet, T. Two new 3-
methoxy-4-quinolone alkaloids from the bark of Sarcomelicope megistophylla. Chem. 
Pharm. Bull. 2000, 48, 2009-2010. 
18. Mitscher, L. A. Bacterial Topoisomerase Inhibitors: Quinolone and Pyridone 
Antibacterial Agents. Chem. Rev. (Washington, DC, U. S.) 2005, 105, 559-592. 
19. Michael, J. P. Quinoline, quinazoline and acridone alkaloids. Nat. Prod. Rep. 
1997, 14, 605-618. 
20. Nakamura, S.; Kozuka, M.; Bastow, K. F.; Tokuda, H.; Nishino, H.; Suzuki, M.; 
Tatsuzaki, J.; Morris Natschke, S. L.; Kuo, S.-C.; Lee, K.-H. Cancer preventive agents, 
Part 2: Synthesis and evaluation of 2-phenyl-4-quinolone and 9-oxo-9,10-dihydroacridine 
derivatives as novel antitumor promoters. Bioorg. Med. Chem. 2005, 13, 4396-4401. 
21. Winter, R. W.; Kelly, J. X.; Smilkstein, M. J.; Dodean, R.; Hinrichs, D.; Riscoe, 
M. K. Antimalarial quinolones: Synthesis, potency, and mechanistic studies. Exp. 
Parasitol. 2008, 118, 487-497. 
22. Cross, R. M.; Monastyrskyi, A.; Mutka, T. S.; Burrows, J. N.; Kyle, D. E.; 
Manetsch, R. Endochin optimization: structure-activity and structure-property 
relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial 
activity. J. Med. Chem. 2010, 53, 7076-7094. 
23. Camps, R. Synthesis of 2- and 4-hydroxyquinolines. Ber. 1899, 32, 3228-34. 
24. Gould, R. G., Jr.; Jacobs, W. A. Synthesis of certain substituted quinolines and 
5,6-benzoquinolines. J. Am. Chem. Soc. 1939, 61, 2890-5. 
25. Conrad, M.; Limpach, L. Syntheses of quinoline-derivatives by means of ethyl 
acetoacetate. gamma -Hydroxyquinaldine. Ber. 20, 944-59. 
179 
 
26. Niementowski, S.; Orzechowski, B. Synthesis of quinoline derivatives from 
anthranilic acid and aldehydes. Ber. 1895, 28, 2809-22. 
27. Bernini, R.; Cacchi, S.; Fabrizi, G.; Sferrazza, A. 1,2-Disubstituted 4-quinolones 
via copper-catalyzed cyclization of 1-(2-halophenyl)-2-en-3-amin-1-ones. Synthesis 
2009, 1209-1219. 
28. Kalinin, V. N.; Shostakovskii, M. V.; Ponomarev, A. B. A new route to 2-aryl-4-
quinolones via palladium-catalyzed carbonylative coupling of o-iodoanilines with 
terminal arylacetylenes. Tetrahedron Lett. 1992, 33, 373-6. 
29. Huang, J.; Chen, Y.; King Anthony, O.; Dilmeghani, M.; Larsen Robert, D.; Faul 
Margaret, M. A mild, one-pot synthesis of 4-quinolones via sequential Pd-catalyzed 
amidation and base-promoted cyclization. Org Lett 2008, 10, 2609-12. 
30. Zhao, T.-K.; Xu, B. Palladium-catalyzed tandem amination reaction for the 
synthesis of 4-quinolones. Org. Lett. 12, 212-215. 
31. Jones, C. P.; Anderson, K. W.; Buchwald, S. L. Sequential Cu-catalyzed 
amidation-base-mediated Camps cyclization: a two-step synthesis of 2-aryl-4-quinolones 
from o-halophenones. J. Org. Chem. 2007, 72, 7968-7973. 
32. Renault, J.; Mailliet, P.; Renault, S.; Berlot, J. A convenient synthesis of 3-halo-4-
oxo-1,4-dihydroquinolines (3-halo-4-hydroxyquinolines). Synthesis 1977, 865-866. 
33. Capparelli, M. V.; Charris, J. E.; Dominguez, J. N. Structures of two N-
methylated tricyclic quinolones with antimalarial activity. J. Chem. Crystallogr. 2006, 
36, 389-398. 
180 
 
34. Billingsley, K.; Buchwald, S. L. Highly eEfficient monophosphine-based catalyst 
for the palladium-catalyzed Suzuki-Miyaura reaction of heteroaryl halides and heteroaryl 
boronic acids and esters. J. Am. Chem. Soc. 2007, 129, 3358-3366. 
35. Molander, G. A.; Canturk, B.; Kennedy, L. E. Scope of the Suzuki-Miyaura cross-
coupling reactions of potassium heteroaryltrifluoroborates. J. Org. Chem. 2009, 74, 973-
980. 
36. Jin, F.; Confalone, P. N. Palladium-catalyzed cyanation reactions of aryl 
chlorides. Tetrahedron Lett. 2000, 41, 3271-3273. 
37. Anderson, B. A.; Bell, E. C.; Ginah, F. O.; Harn, N. K.; Pagh, L. M.; Wepsiec, J. 
P. Cooperative catalyst effects in palladium mediated cyanation reactions of aryl halides 
and triflates. J. Org. Chem. 1998, 63, 8224-8228. 
38. Zanon, J.; Klapars, A.; Buchwald, S. L. Copper-catalyzed domino halide 
exchange-cyanation of aryl bromides. J. Am. Chem. Soc. 2003, 125, 2890-2891. 
181 
 
 
 
Chapter 4. Optimization of 1,2,3,4-Tetrahydroacridin-9(10H)-ones as Antimalarials 
Utilizing Structure-Activity and Structure-Property Relationships 
4.1 Overview 
 Antimalarial activity of 1,2,3,4-tetrahydroacridin-9(10H)-ones (THAs) has been 
known since the 1940s and has garnered more attention with the development of the 
acridinedione floxacrine (4.1) in the 1970s and analogs thereof such as WR 243251(4.2) 
in the 1990s. These compounds failed just prior to clinical development due to 
suboptimal activity, poor solubility, and rapid induction of parasite resistance. Moreover, 
detailed structure-activity relationship studies (SAR) of the THA core scaffold were 
lacking and SPR studies were non-existent. To improve upon initial findings, several 
series of 1,2,3,4-tetrahydroacridin-9(10H)-ones were synthesized and tested in a 
systematic fashion examining each compound for antimalarial activity, solubility, and 
permeability. Furthermore, a select set of compounds was chosen for microsomal 
stability testing to identify physicochemical liabilities of the THA scaffold. Several 
potent compounds (EC50<100 nM) were identified to be active against the clinically 
relevant isolates W2 and TM90-C2B while possessing good physicochemical properties 
and little to no cross-resistance. 
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Figure 4.1. Structures of Several Antimalarials 4.1-4.4 and the Core 1,2,3,4-
Tetrahydroacridin-9(10H)-one 
 
 
4.2 Synthetic Chemistry 
 Previous optimization studies leading to acridinedione compounds 4.1 and 4.2 
demonstrated that a 7-chloro substituent in the benzenoid ring of the acridinedione core 
was important for antimalarial activity, as well as the imine moiety at the carbonyl carbon 
C1 in N10-H analogs.  Over two hundred compounds were prepared and tested, however 
the main investigation focused on analogs varying the nature of the aryl ring at the 3 
position and analogs possessing various alkylamino imines at the 1-position. Of these 
aforementioned analogs, the majority of them possessed a 7-chloro substituent with very 
limited attention paid to benzenoid ring substitution.
1
 It is possible that access to a single 
synthetic route for generating various benzenoid substituents in the acridinedione core 
was a key factor in the limited scope of compounds tested. For the current optimization 
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study, THAs varying in their substituents at the, 2-, 3-, 5-, 6-, 7-, and/or 8-positions have 
been designed to obtain detailed SAR and SPR data, which complements previous studies 
potentially overcoming the liabilities of compounds 4.1 and 4.2. 
 First, a set of THAs were synthesized to determine the optimal size of the 
saturated ring. Based on 3-aryl-substituted 4(1H)-quinolones previously developed in our 
laboratory, five- to eight-membered ring sizes were examined with THAs containing 
either an electron poor or an electron rich substituent at the 6-position.
2
 It should be noted 
that structures shown in Figure 4.1 with aliphatic ring sizes of 5, 7, and 8 are not 
tetrahydroacridone according to the IUPAC nomenclature. Nevertheless, the inclusive 
acronym THA (tetrahydroacridone) was used for all analogs based on a 6-membered 
aliphatic ring. These compounds were prepared using 4-methoxyanthranillic acid or 4-
trifluoromethylanthranillic acid with POCl3 and the appropriate cycloalkanone to yield 9-
chloro-1,2,3,4-tetrahydroacridines. These intermediates were subsequently hydrolyzed 
using acetic acid in a sealed-tube at 200
o
C to generate compounds 4.5-4.12 (Scheme 4.1). 
The two-step synthetic sequence proved to be superior over the more frequently reported 
direct condensation reactions of anthranillic acids and cyclohexanones via azeotropic 
distillation of water.
3-5
 It was observed that these one-step condensations were often 
incomplete and overall problematic especially those starting from electron rich 
anthranillic acids. Recently, Elguero and co-workers utilized microwave irradiation to 
improve the yields through the one-step condensation.
6
 Another hurdle of the one-step 
condensations is the purification of the THA products as unreacted anthranillic acid and 
resultant polar side products are very difficult to remove. In contrast, the two-step 
reaction sequence cleanly provided THA compounds upon precipitation from water 
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which were further recrystallized from either pyridine or DMF. Generally, the use of 
pyridine provided neutral THA products as opposed to DMF which could yield the 
corresponding salt forms. It was observed that the hydrolysis undergoes a nucleophilic 
displacement at the 9-position providing the 1,2,3,4-tetrahydroacridin-9-yl acetate, which 
is subsequently hydrolyzed. This observation is in accordance with the known 
electrophilicity of these 9-chloro-1,2,3,4-tetrahydroacridines since these intermediates are 
commonly found in literature to prepare 4-aminoquinolines.
7, 8
 
 Next, a set of compounds was designed to probe the benzenoid ring positions 
according to the Topliss’ operational schemes, which are based upon physicochemical 
parameters related to hydrophobicity, electronics and sterics.
9, 10
 Upon determination that 
the THAs containing the 6-membered aliphatic ring were the most potent analogs, 
chloro-, methyl-, or methoxy-substituted anthranillic acids were combined with 
cyclohexanone, 3,3-dimethylcyclohexanone, and 4,4,-dimethylcyclohexanone to yield 
THAs 4.13-4.50. Furthermore, a series of mono-substituted THAs 4.51-4.63 with more 
electronegative or sterically encumbering benzenoid ring substituents were prepared 
either by the two-step sequence starting from anthranillic acids and cyclohexanones 
(Scheme 4.2, Route A) or by a Conrad-Limpach cyclization reactions (Scheme 4.2, Route 
B).
11
 The decision as to which route to use for the preparation of a particular THA was 
based on commercial availability and cost of starting materials, and the ease in 
purification of the final product.
12
 The preparation of THAs via the Conrad-Limpach 
synthetic route starting from meta-substituted anilines yields a mixture of 6- and 8-
substituted regioisomers, which are difficult to separate. In contrast, the two-step reaction 
sequence with 4-substituted anthranillic acids cleanly produces the desired THA 
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regioisomer. Nevertheless, the Conrad-Limpach reaction is more suitable for THAs 
which cannot withstand the acetic acid hydrolysis such as compound 4.63. Overall, the 
commercial availability of various anilines as compared to anthranillic acids is much 
greater making this synthetic route very desirable and valuable. 
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Scheme 4.1. Synthesis of Varying Ring-sized 1,2,3,4-Tetrahydroacridin-9(10H)-ones 4.5-
4.50
a
 
 
a
Reaction Conditions: (a) POCl3, cycloalkanone, reflux, 2-8h; (b) AcOH, sealed-tube, 200
o
C. (i) 
Recrystallized from DMF or pyridine. 
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Scheme 4.2. Synthesis of 1,2,3,4-Tetrahydroacridin-9(10H)-ones 4.51-4.63 via Route A 
and B
a 
 
a
Reaction conditions: (a) POCl3, cyclohexanone, reflux, 1-8h; (b) AcOH, sealed-tube, 200
o
C, 24-48h; (c) 
ethyl 2-oxocyclohexanecarboxylate, AcOH, benzene, Dean-Stark trap, reflux, overnight then Ph2O, reflux, 
15min. 
 
 Investigations then focused on THAs equally disubstituted at the benzenoid ring 
to probe potential synergistic effects derived from these mono substituents. Utilizing the 
same pair of synthetic routes in scheme 4.2, compounds 4.64-4.83 were prepared from 
commercially available anilines (Figure 4.2, Route B). Via route B, some anilines 
generated regioisomeric THAs, whose individual isomers were purified via preparative 
HPLC and recrystallization as noted in Scheme 4.2. Furthermore, THAs substituted with 
two different groups at the 6- and 7-positions were synthesized to test whether a 
particular benzenoid ring substituent combination exhibits a potency enhancement similar 
to that observed for the 6-chloro-7-methoxy-4(1H)-quinolone antimalarial series (Scheme 
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4.3). Simultaneously, THAs containing one heteroatom in the saturated ring were 
prepared with the intent to increase either the solubility, the metabolic stability, or both. 
Figure 4.2. Compounds 4.64-4.83 via Route A and B
 
 
 Starting materials, which are commercially unavailable, have been synthesized 
prior to the THA syntheses. 4-Chloro-3-methoxyaniline (4.84) was prepared using 
sodium amide in liquid ammonia, while 4-chloro-3-isopropoxyaniline (4.85) was 
obtained by acetylating 5-amino-2-chlorophenol followed by an alkylation with iso-
propyl iodide in Cs2CO3.
13
 Interestingly, K2CO3 generated lower yields through a 
deprotective hydrolysis of the acetamido group. The amide was subsequently hydrolyzed 
with KOH in EtOH and water (9:1) to provide aniline 4.85. 4-Methyl-3-methoxyaniline 
(4.86) was generated starting from a solution of 2-methoxy-1-methyl-4-nitrobenzene in 
MeOH and hydrogenated for 3h in the presence of 10% Pd/C.
14
 The cyclic -ketoester 
4.87 was prepared by esterifying 3,3'-thiodipropanoic acid to the ethyl ester. 
Subsequently, this intermediate was cyclized via sodium hydride in refluxing THF. Ethyl 
5,5-difluoro-2-oxocyclohexanecarboxylate (4.88) was prepared from 4,4-
difluorocyclohexanone using NaH and diethyl carbonate. 
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Scheme 4.3. Synthesis of Intermediate Anilines 4.84-4.86 and β-Ketoester 4.87-4.88a 
 
a
Reaction Conditions: (a) Na, NH3(l) (b) Ac2O, AcOH, reflux, 5 min; (c) Cs2CO3, 
i
PrI, DMF, 45
o
C, 18h; (d) 
KOH, EtOH/H2O (9:1), reflux, 8h; (e) Pd/C, H2(g) 1 ATM, 10h; (f) conc. H2SO4, EtOH, reflux, 4h; (g) 
NaH, THF, EtOH (cat.), reflux, 8h. 
 
 Compounds 4.89-4.100 were prepared using the Conrad-Limpach reaction 
conditions used in route B (Scheme 4.4). THA 4.97 was synthesized from a commercially 
available anilinoether to examine whether an aryl ether directly attached to the THA core 
would improve biological activity. Similarly, this compound provides a different class of 
ethers as opposed to THAs 4.62, 4.70, 4.73 and 4.89-4.93 which contain alkyl ether 
substituents. Sulfoxide 4.101 and sulfone 4.102 were oxidized from THA 4.92 using 
aqueous hydrogenperoxide at 40
o
C or m-CPBA in CHCl3 at 5
o
C respectively.
15
 Finally, a 
small set of THAs was prepared in which the 2-position possesses a difluoromethylene 
unit. Compound 4.93 was prepared using route B from the chloromethoxy aniline 4.84 
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and cyclic -ketoester 4.88 while Compounds 4.94 and 4.95 were generated using route 
A with 4,4-difluorocyclohexanone. 
Scheme 4.4. Synthesis of THAs 4.89-4.102
a 
a
Reaction conditions: (a) various ethyl 2-oxo-4-substituted cyclohexanecarboxylate, AcOH, benzene, Dean-
Stark trap, reflux, overnight then Ph2O, reflux, 15min; (b) H2O2 (aq), 40
o
C; (c) m-CPBA in CHCl3, 0
o
C, 4h. 
(i) These analogs were prepared using route A. 
 
 Finally, a small series of Suzuki-Miyaura coupled THAs (4.103-4.118) was 
prepared to probe the similarity between the THAs and the 4(1H)-quinolone chemotype 
(Scheme 4.5).
2
 Notably, THA 4.100 was promising in terms of activity prompting the 
investigation of the position and nature of several aryl moieties at the benzenoid ring. A 
variety of mono- and bi-aryl 6- or 7-substituted THAs were prepared. Moreover, recent 
results from GlaxoSmithKline’s (GSK) pyridone project as well preliminary data 
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generated in our laboratory motivated us to synthesize boronic acids 4.119-4.121 used in 
the preparation of 4.109, 4.110, and 4.118 (Scheme 4.6).
16, 17
 Of all the Suzuki-Miyaura 
compounds, the difluoro and pyridyl substrates 4.103, 4.105, and 4.116 demonstrated the 
most sluggish reactivity requiring long reaction times and providing low yields. 
Scheme 4.5. Synthesis of THAs 4.103-4.118 via Suzuki-Miyaura Cross-coupling
a
 
 
a
Reaction conditions: (a) Pd2(dba)3, SPHOS, Na2CO3 (aq), ArB(OH)2, DMF, 80
o
C, 4-36h. 
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Starting from 1-bromo-4-(chloromethyl)benzene, boronic acid 4.119 was prepared using 
60% NaH in anhydrous DMF at 80
o
C. This benzyl intermediate was lithiated using 
nBuLi at -78
o
C in anhydrous THF and stirred in the presence of B(O
i
Pr)3 for 3h at -78
o
C. 
The boronate ester was hydrolyzed via the addition of 6M HCl and subsequently warmed 
to room temperature and stirred overnight. Boronic acids 4.120 and 4.121 were prepared 
similarly; however, an Ullman cross-coupling was used to generate the halo bi-aryl 
intermediate that was subsequently hydrolyzed to the boronic acid as in 4.119.  
Scheme 4.6. Synthesis of Boronic Acids 4.119-4.121
a
 
 
a
Reaction conditions: (a) NaH, DMF (anhy), 80
o
C; (b) B(O
i
Pr)3, THF (anhy), -78
o
C, then nBuLi (1.6M), 
3h; then 6M HCl, rt, 18h; (c) CuCl, NMP (anhy), Cs2CO3, 2,2,6,6-tetramethylheptane-3,5-dione (22 
mol%), 110
o
C, 4-6h. 
 
4.3 Antimalarial Activity  
4.3.1 Structure-Activity Relationship Studies 
 All compounds underwent in vitro screening against P. falciparum as previously 
described in Chapter 2 (Section 2.3 Antimalarial Activity).
2
 THA 4.1 has been reported to 
display EC50 values of 478 nM for W2 (chloroquine and pyrimethamine resistant) and 
270 nM for D6 (drug susceptible strain), while the EC50 values of compound 2 (racemic 
mixture) for W2 are 25 nM, for D6 11 nM, and for TM91 (chloroquine, quinine, and 
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mefloquine resistant) 51 nM.
18
 Great strides were taken to improve the efficacy of 
compound 4.1 and 4.2 and several libraries of analogs related to 4.1 and 4.2 numbering in 
hundreds of compounds were prepared and tested.
1, 19, 20
 Though these optimization 
attempts resulted in several compounds with single digit nM activities to as low as 730 
pM, these efforts lacked in a systematic SAR and accompanying SPR studies. In the end, 
the development of compound 4.2 and analogs thereof have been abandoned since these 
compounds suffered from drug-resistance,
21
 poor aqueous solubility, and lingering 
toxicity issues.
22
 Similarly, in 1947 Stephen and co-workers examined THAs for 
antimalarial activity using an in vivo assay against P. gallinaceum infections in chickens 
without determining key physicochemical properties.
23
 Six mono-substituted THAs and 
one di-substituted compound, which for confirmatory purposes have also been 
reevaluated by us, were tested and compound 4.14 was identified by them to be the most 
potent compound. Interestingly, at the time that Stephen and co-workers initiated their 
studies on THAs, endochin had just been discovered and its’ in vivo antimalarial activity 
against P. gallinaceum was superior to the majority of the THAs. 
 The majority of the analogs of 4.1 and 4.2 that were previously screened 
contained a 7-chloro substituent. Kesten and co-workers reported that the mono-chloro 
substituent was a necessity to achieve the highest levels of activity, while an 
unsubstituted or a disubstituted benzenoid ring resulted in greatly reduced antimalarial 
activities. In contrast, recent work by our lab demonstrates a substantial increase of 
potency in endochin analogs that are disubstituted at the benzenoid ring with a 6-chloro-
7-methoxy substituent pair.
2
 Just as importantly, this synergistic pair of substituents also 
improved the RI values for W2 and TM90-C2B, and the aqueous solubility. Furthermore, 
194 
 
in the past, the aliphatic THA ring was moderately evaluated. Thus, a systematic 
approach to investigate the benzenoid ring and the saturated ring simultaneously was 
considered to be of highest priority to initiate our studies expanding upon the findings of 
Stephen and Kesten. A small series of THAs containing saturated ring sizes with five to 
eight carbons was prepared utilizing the appropriate commercially available 
cycloalkanones (Table 4.1). 
Table 4.1. SAR Focusing on the Aliphatic Ring Size of the 1,2,3,4-Tetrahydroacridin-
9(10H)-ones 
 
Compound R
1
 n 
EC50 W2
a
 
(nM) 
EC50 TM90-C2B
a 
 (nM) 
RI 
EC50 
J774 
(μM) 
4.5 -OMe 
1 
1134 610 0.54 >41.1 
4.6 -OMe 2 89.9 99.9 1.11 >43.6 
4.7 -OMe 3 171 153 0.9 33.8 
4.8 -OMe 4 146 230 1.58 >38.9 
9 -CF3 1 2322 438 0.19 >39.5 
4.10 -CF3 2 120 19.0 0.16 >37.4 
4.11 -CF3 3 4886 >4344 >0.88 >20.0 
4.12 -CF3 4 4739 4233 0.89 >20.0 
a
Dihydroartemisinin
 
(DHA) and chloroquine (CQ) are internal controls for each in vitro assay. 
DHA (1.8 nM W2 and 0.9 nM TM90C2B) and CQ (131 nM W2 and 162 nM TM90-C2B) 
THAs 4.5-4.8 contained one electron rich methoxy substituent at the benzenoid ring, 
while 4.9-4.12 were substituted with one electron-poor trifluoromethyl group. Regardless 
of the benzenoid ring substituent, THAs 4.6 and 4.10 containing a six-membered 
saturated ring were the most potent compounds against both W2 and TM90-C2B. 
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Compounds 4.5 and 4.9 with the five-membered aliphatic ring as well as THAs 4.7, 4.8, 
4.11, and 4.12 with ring sizes of seven or larger were less potent than 4.6 and 4.10. 
Furthermore, the RI value was not found to significantly depend on the aliphatic ring 
size. With the exception of compounds 4.9 and 4.10, acceptable RI values have been 
calculated for all other THAs 4.5-4.8 and 4.11-4.12. In fact, the significant potency 
differences related to the two different benzenoid ring substitutents was determined to be 
of greater importance than the size of the saturated ring. Thus, the results of the subset of 
the methoxy-substituted THAs 4.5-4.V8 urged us to focus on the further optimization of 
compounds containing six-membered saturated rings exclusively.  
 Next, an investigation was designed to explore the THA’s benzenoid ring with 
various substituents at the 5-, 6-, 7-, and 8-positions. Following the Topliss operational 
scheme for aromatic substituents, the first compound set focused on groups probing 
electronic and steric factors.  
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Table 4.2. SAR Focusing on Mono-substituted THA Benzenoid Ring Containing 
Unsubstituted Aliphatic Ring 
 
Compound R 
EC50 
W2
a 
(nM) 
EC50 
TM90-C2B
a
 
(nM) 
RI 
EC50 
J774 
(μM) 
4.13 -H 719 325.1 0.45 >50.2 
4.14 5-OMe 4770 4566 0.95 >20.0 
4.6 6-OMe 273 274.0 1.00 >43.6 
4.15 7-OMe 2443 2527 1.03 >43.6 
4.16 8-OMe 8966 5942 0.66 >20.0 
4.17 5-Me 2203 888 0.40 >46.9 
4.18 6-Me 150 152 1.01 >46.9 
4.19 7-Me 449 656 1.46 >46.9 
4.20 8-Me 6247 4574 0.73 >20.0 
4.21 5-Cl 1353 >10697 7.9 >20.0 
4.22 6-Cl 137 122 0.89 16.2 
4.23 7-Cl 99.4 63.4 0.63 >42.9 
4.24 8-Cl 368 447 1.22 6.9 
a
Dihydroartemisinin
 
(DHA) and chloroquine (CQ) are internal controls for each in vitro assay. 
DHA (1.8 nM W2 and 0.9 nM TM90C2B) and CQ (131 nM W2 and 162 nM TM90-C2B) 
Mono-substituted THAs 4.13-4.24 containing a methyl, a methoxy, or a chloro 
substituent were tested (Table 4.2). The unsubstituted THA 4.13 was used as a reference 
compound to assess whether a particular substituent of 4.13-4.24 has a favorable or an 
adverse effect on the antimalarial activity. Furthermore, two additional compound series 
were designed, in which the 2- or 3-positions of the saturated ring possesses gem-
dimethyl substitution in combination with a methyl, a methoxy, or a chloro substituent on 
197 
 
the benzenoid ring. These analogs not only probe the 2- and 3-position for sterics, but 
also provide information on the saturated ring since the methyl substituents influence the 
ring conformation. All possible combinations of 2,2-dimethyl substituted THAs 4.25-
4.37 (Table 4.3) and 3,3-dimethyl-substituted compounds 4.38-4.50 (Table 4.4) have 
been tested against W2 and TM90-C2B. Analogs 4.25 and 4.38 have been prepared as 
reference compounds to reliably conclude whether the 2-, the 3-position, or both are 
suitable for structural modifications.  
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Table 4.3. SAR Focusing on Mono-substituted THA Benzenoid Ring Containing 2-Gem-
di-methyl Aliphatic Ring 
 
Compound R 
EC50 
W2
a 
(nM) 
EC50 
TM90-C2B
a
 
(nM) 
RI 
EC50 
J774 
(μM) 
4.25 -H 421.3 295 0.70 >43.9 
4.26 5-OMe 1991 620 0.31 >38.9 
4.27 6-OMe 54.3 175 3.22 >38.9 
4.28 7-OMe 8404 >9715 >1.15 >20.0 
4.29 8-OMe 5235 3498 0.67 >20.0 
4.30 5-Me 791 531 0.67 >41.5 
4.31 6-Me 166 1981 11.93 41.4 
4.32 7-Me 474 2184 4.61 41.4 
4.33 8-Me 3017 4132 1.37 41.4 
4.34 5-Cl 4673 4726 1.01 >20.0 
4.35 6-Cl 240 829 3.45 >38.2 
4.36 7-Cl 256 118 0.46 >38.2 
4.37 8-Cl 373 599 1.61 >38.2 
a
Dihydroartemisinin
 
(DHA) and chloroquine (CQ) are internal controls for each in vitro assay. 
DHA (1.8 nM W2 and 0.9 nM TM90C2B) and CQ (131 nM W2 and 162 nM TM90-C2B) 
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Table 4.4. SAR Focusing on Mono-substituted THA Benzenoid Ring Containing 3-Gem-
di-methyl Aliphatic Ring 
 
Compound R 
EC50 
W2 
(nM) 
EC50 
TM90-C2B 
(nM) 
RI 
EC50 
J774 
(μM) 
4.38 -H 1866 335 0.18 >43.9 
4.39 5-OMe 6538 2490 0.38 >20.0 
4.40 6-OMe 355 112 0.32 >38.8 
4.41 7-OMe >9715 >9715 >1.0 >20.0 
4.42 8-OMe >9715 4103 >0.42 >20.0 
4.43 5-Me 2367 1754 0.74 >41.4 
4.44 6-Me 1461 965 0.66 >41.4 
4.45 7-Me 587 319 0.54 >41.4 
4.46 8-Me >10359 >10359 >1.0 >20.0 
4.47 5-Cl 6702 >9551 >1.42 >38.4 
4.48 6-Cl 1080 645 >0.6 >38.2 
4.49 7-Cl 215 538 2.51 >38.2 
4.50 8-Cl 2994 5326 1.77 >20.0 
a
Dihydroartemisinin
 
(DHA) and chloroquine (CQ) are internal controls for each in vitro assay. 
DHA (1.8 nM W2 and 0.9 nM TM90C2B) and CQ (131 nM W2 and 162 nM TM90-C2B) 
 Of compounds 4.13-4.24, the 7-chloro-THA 4.23 exhibiting EC50s of 99.4 nM for 
W2 and 63.4 nM for TM90-C2B is the most active analog, which is closely followed in 
activity by 6-methoxy- or 6-methyl-subtituted THAs 4.6 and 4.18 respectively. 
Compound 6 with a methoxy group at the 6-position was the most potent compound of 
all the methoxy-substituted THAs 4.6 and 4.14-4.16 with EC50 values of  89.9 nM for W2 
and 99.9 nM for TM90-C2B. Thus, depending on the tested strain, THA 4.6 is 
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approximately 3-7-fold more potent compared to the unsubstituted reference compound 
4.13. In contrast, methoxy substitution at the 5-, 7-, or 8-positions provides THAs 4.14, 
4.15, and 4.16 with diminished antimalarial activities in the M range. Testing of THAs 
4.17-4.24 identified that the 6- and 7-positions, when populated with a methyl- or chloro- 
substituent, improves the antimalarial activity by a factor of 2-7. The 6-methyl-THA 4.18 
was approximately 4-fold more potent than the 7-methyl-substituted analog 4.19, while 
the 7-chloro-substituted THA 4.23 was twice as active as the 6-chloro-THA 4.22.  
The 2,2-dimethyl- or the 3,3-dimethyl-substituted THAs 4.25-4.50 were overall 
less active than the THA series 4.13-4.24 containing an unsubstituted saturated ring. The 
methyl groups appear to be less tolerated at the 3-position than at the 2-position with an 
average of a 4-fold difference in antimalarial activity. Furthermore, the 2,2-dimethyl- and 
3,3-dimethyl-THAs 4.25-4.50 display a more pronounced strain selectivity with less 
favorable RI values in comparison to THAs 4.13-4.24 with an unsubstituted saturated 
ring. Especially THA 4.31, which was shown to be potent against W2 with an EC50 of 
166 nM and fairly inactive against TM90-C2B, and its analogs 4.18 and 4.44 are striking 
examples demonstrating that a small variance in structure can significantly impact the 
strain dependence. Regarding the benzenoid ring substituents of the 2,2-dimethyl- or the 
3,3-dimethyl-substituted THAs 4.25-4.50, potency trends were observed, which are 
similar to the THA analogs 4.13-4.24. The 6-methoxy- or 7-chloro-containing 
compounds 4.27, 4.36, 4.40 and 4.49 were considerably more potent compared to the 
non-substituted reference compounds 4.25 and 4.38, while methyl- or chloro-substituents 
in the 5- or 8-positions resulted in compounds with poor activity with EC50s in the M 
range.  
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 The loss in potency and the adverse effect on the RI value observed with the gem-
dimethyl-THAs 4.25-4.50, motivated us to restrict the compound design of THAs 
possessing an unsubstituted aliphatic ring only. A selection of THAs 4.51-4.63 was 
prepared with the intent of exploring additional benzenoid ring substituents of distinct 
steric or electronic withdrawing nature (Table 4.5). Most compounds of this series 
displayed poor antimalarial activity with EC50s in the high nano- or micromolar range. 
The 6-fluoro and the 6-bromo THAs 4.54 and 4.56 were the best analogs inhibiting the 
drug-susceptible strain W2 and the resistant strain TM90-C2B at 100 nM or lower 
concentrations. Compound 4.63 containing an ethyl ester moiety at the 7-position was 
potent against TM90-C2B with an EC50 of 58.3 nM, which is consistent with previous 
observations that an electron-withdrawing group at the 7-position enhances activity. 
Analogs 4.58 and 4.60 containing substitutions at the 5-position were both devoid of 
activity. 7-Ethoxy-THA 4.62 was approximately five-fold more potent as compared to 
the 7-methoxy analogs 4.15, 4.28 and 4.41 suggesting that THA’s with substituents at the 
7-position may have potential to occupy a hydrophobic pocket of the biological target. 
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Table 4.5. SAR Focusing on THA Benzenoid Ring Substituted with Various 
Electronegative and/or Bulky Substituents 
 
Compound R 
EC50 
W2
a 
(nM) 
EC50 
TM90-C2B
a
 
(nM) 
RI 
EC50 
J774 
(μM) 
4.51 6-NO2 1051 959 0.91 >40.9 
4.52 7-NO2 3162 379 0.11 >40.9 
4.53 5-F 536 2914 5.44 >46.0 
4.54 6-F 67.7 119 1.76 >20.0 
4.55 7-I 378 167 0.44 >35.9 
4.56 6-Br 77.7 115 1.48 12.2 
4.57 7-Br 196.8 64.7 0.32 >35.9 
4.58 5-
t
bu >9788 >9788 >1.0 11.8 
4.59 7-
t
bu 78.7 325 4.12 >20.0 
4.60 5-CF3 >9354 >9354 >1.0 >20.0 
4.61 7-
i
Pr 879 732 0.83 >41.4 
4.62 7-OEt 265 226 0.85 >20.0 
4.63 7-CO2Et 153 58.3 0.38 >20.0 
a
Dihydroartemisinin
 
(DHA) and chloroquine (CQ) are internal controls for each in vitro assay. 
DHA (1.8 nM W2 and 0.9 nM TM90C2B) and CQ (131 nM W2 and 162 nM TM90-C2B) 
 Subsequently, a methodical approach to test the benzenoid ring positions, which 
are substituted with two identical groups, was devised to explore synergistic potential 
4.64-4.83 (Table 4.6). This study was accompanied by a second THA series having two 
different groups at the benzenoid ring or containing one heteroatom in the aliphatic ring 
4.89-4.102 (Table 4.7). The majority of the dimethyl-, dimethoxy-, dichloro-, and 
difluoro-substituted THAs 4.64-4.83 lacked sub-micromolar antimalarial activity. 
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Nevertheless, five compounds with EC50s lower than 300 nM suggested di-substitution 
patterns could be effective. The dimethyl and the dichloro analogs 4.68 and 4.78 
substituted at the 6- and 7-positions were moderately potent with EC50s of 210-340 nM, 
whereas the 6,7-difluoro analog 4.83 exhibited slightly better activities with EC50s in the 
100 nM range for W2 and TM90-C2B. In contrast, the 6,8-dichloro 4.76 with EC50s of 
87.8-96.2 nM and especially the 6,8-difluoro 4.81 with EC50s of 16.5-44.9 nM were 
approximately 5-fold more potent than their congeners 4.78 and 4.83. However, 
compound 4.81 has an RI of 2.72, which just falls into the acceptable range for a 
resistance index figure but is still much more active in the drug susceptible strain. Eight 
disubstituted THA analogs containing an R
4
 substituent possessed activities between 1-
10µM, except compound 4.81 and 4.76 which also maintained a 6-substituent. The 6,7-
disubstituted benzenoid moiety was manifested in terms of potency while maintaining 
excellent RIs of 0.82, 1.06, and 0.91 in compounds 4.68, 4.78, and 4.83 respectively. 
Antimalarial activities of THAs 4.68, 4.81, and 4.83 are further evidence that a particular 
combination of substituents can provide not only a potent compound but one that could 
perhaps be free of multi-drug resistance.  
 Based on the SAR of compounds 4.5-4.83 a series was developed with the 
majority of the analogs containing a 6-methoxy-7-substituted THA core, with various 
substitutions on the aliphatic chain 4.89-4.102 (Table 4.7).  
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Table 4.6. SAR of Di-substituted THAs 
 
Compound R1 R2 R3 R4 
EC50 
W2a 
(nM) 
EC50 
TM90-C2Ba 
(nM) 
RI 
EC50 
J774 (μM) 
4.64 -Me -H -H -Me 3074 2387 0.78 25.9 
4.65 -Me -H -Me -H 1074 768 0.72 >43.9 
4.66 -H -Me -H -Me 3131 4827 1.54 N.D. 
4.67 -Me Me -H -H 3922 2283 0.58 >43.9 
4.68 -H -Me -Me -H 262 216 0.82 >20.0 
4.69 OMe -H -H -OMe >9641 >9641 >1.0 >20.0 
4.70 -OMe -H -OMe -H >9641 7981 >0.83 >20.0 
4.71 -H -OMe -H -OMe >7297 2590 0.35 >38.5 
4.72 -OMe -OMe -H -H 6337 3459 0.55 >20.0 
4.73 -H -OMe -OMe -H 8965 3390 0.38 >20.0 
4.74 -Cl -H -H -Cl >9323 >9323 >1.0 >20.0 
4.75 -Cl -H -Cl -H >9323 >9323 >1.0 >20.0 
4.76 -H -Cl -H -Cl 87.8 96.2 1.1 37.9 
4.77 -Cl -Cl -H -H 6327 >9328 >1.47 >20.0 
4.78 -H -Cl -Cl -H 321 341 1.06 >37.2 
4.79 -F -H -H -F 804 1319 1.64 42.5 
4.80 -F -H -F -H 2691 405 0.15 42.5 
4.81 -H -F -H -F 16.5 45.0 2.72 3.8 
4.82 -F -F -H -H 1050 378 0.36 42.5 
4.83 -H -F -F -H 129 118 0.91 >20.0 
a
Dihydroartemisinin
 
(DHA) and chloroquine (CQ) are internal controls for each in vitro assay. 
DHA (1.8 nM W2 and 0.9 nM TM90C2B) and CQ (131 nM W2 and 162 nM TM90-C2B) 
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Table 4.7. SAR of Various THAs Including Heteroatom Containing Aliphatic Ring 
 
Compound R
1
 R
2 
X 
EC50 
W2
a 
(nM) 
EC50 
TM90-C2B
a
 
(nM) 
RI 
EC50 
J774 
(μM) 
4.89 -OMe -Cl -CH2 35.2 11.5 0.32 >37.9 
4.90 -Cl -OMe -CH2 30.6 24.1 0.78 >37.9 
4.91 -Cl -O
i
Pr -CH2 21.3 104 4.88 >20.0 
4.92 -Cl -OMe -S 26.3 130 4.94 >20.0 
4.93 -Cl -OMe -CF2 76.7 5.62 0.07 >37.9 
4.94 -Cl -H -CF2 148 226 1.52 >37.9 
4.95 -H -OMe -CF2 343 351 1.02 >37.9 
4.96 -Me -OMe -CH2 34.8 16.2 0.46 >20.0 
4.97 -Me -OMe -S 113 96.9 0.86 >20.0 
4.98 -Br -H -S 667 >8440 N.D. >20.0 
4.99 -H -H -N(Me) >11668 >11668 >1.0 >20.0 
4.100 
 
-H -CH2 169.3 47.0 0.28 >32.3 
4.101 -Cl -OMe -S(O) 4701 1359 0.29 >31.3 
4.102 -Cl -OMe -S(O)2 4701 8400 1.76 >33.5 
a
Dihydroartemisinin
 
(DHA) and chloroquine (CQ) are internal controls for each in vitro assay. 
DHA (1.8 nM W2 and 0.9 nM TM90C2B) and CQ (131 nM W2 and 162 nM TM90-C2B) 
Compound 4.91 was the most potent against W2 (21.3 nM) but displayed a RI of 4.88, 
well above the desired range. Compounds 4.90, 4.92, 4.96, and 4.97 were all 113 nM or 
less in activity against W2 with 4.92 having a 26.3 nM activity. These analogs support 
the observation that the 6-methoxy-7-substituted (generally chloro) substitution pattern is 
very important for potency. The RI’s of these compounds are all in the acceptable range 
with exception to compound 4.92 which has a good activity with the drug-susceptible 
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strain. Compound 4.100 is interesting in that it has an RI just out of the acceptable range 
of 0.28 but an affinity for the drug-resistant line 47 nM (TM90-C2B) and 169 (W2). This 
O-aryl ether was one of a possible series that we decided to pursue. These compounds 
can be assembled using a number of synthetic pathways. However their synthesis is 
outside the scope of this thesis. Nonetheless, this analog highlights the potential for aryl-
substituted scaffolds on the THA core. Compound 4.90 and 4.96 were the most potent 
against TM90-C2B with 34.8 nM and 16.2 nM respectively. Compound 4.90 displayed 
an acceptable RI as observed with other analogs possessing this substitution pattern.
2
 
3-Aryl substitution was shown to improve potency in the 4(1H)-quinolone series.
2
 
Analogous to the 4(1H)-quinolones, a small THA series was prepared to examine 
whether substitution at the 6- and 7- positions of the benzenoid  ring  have potential to 
improve antimalarial activity, solubility, or both (Table 4.8).  
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Table 4.8. SAR of Suzuki-Miyaura Cross-coupled THAs 
 
Compound Position Ar
 
X 
EC50 
W2
a 
(nM) 
EC50 
TM90-C2B
a
 
(nM) 
4.103 7 
 
-S 6215 4991 
4.104 7 
 
-S 7624 >8492 
4.105 7 
 
-S 193 78.4 
4.106 7 
 
-S 34.6 23.2 
4.107 7 
 
-S 95.1 58.0 
4.108 
7 
 
-S 40.9 143 
4.109 
7 
 
-S 27.7 326 
4.110 
7 
 
-S 129 2835 
4.111 
7 
 
-S 44.5 706 
4.112 
7 
 
-S 35.9 370 
4.113 
7 
 
-S 101 293 
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4.114 
7 
 
-CH2 58.2 44.9 
4.115 
6 
 
-CH2 34.9 8.65 
4.116 
6 
 
-CH2 72.3 25.3 
4.117 
6 
 
-CH2 99.2 161 
4.118 
6 
 
-CH2 12.2 9.1 
a
Dihydroartemisinin
 
(DHA) and chloroquine (CQ) are internal controls for each in vitro assay. 
DHA (1.8 nM W2 and 0.9 nM TM90C2B) and CQ (131 nM W2 and 162 nM TM90-C2B) 
The electronic nature of the aryl ring has been shown to be important for overall efficacy. 
All of the benzenoid positions in the THA scaffold could be decorated with an 
appropriate halide to be used as a Suzuki coupling precursor; however, the focus would 
be on the 6- and 7-position due to the preliminary SAR emerging from tables 1-7. Choice 
of boronic acid was based on the desire to probe a broad chemical space with electronic 
differences in the rings. 7-Pyridyl analogs 4.103 and 4.104 displayed poor activities in the 
micromolar range. 7-Substituted aromatic analogs 4.105, 4.116, and especially 4.106 , 
which has a 34.6 nM activity against W2 and a 23.2 nM activity against TM90-C2B, 
displayed good potencies. Next, 7-bi-aryl-ether and 7-benzyl-aryl-ether substituted 
analogs were tested. Compounds 4.108-4.112 showed good activities against W2 but a 
pronounced decline against TM90-C2B suggesting the presence of resistance for these 
extended bi-aryls-ethers. Alternatively, compound 4.118 displayed excellent activities 
against both strains of 12.2 nM and 9.1 nM against W2 and TM90-C2B respectively. The 
6-dimethylaminobenzene substituted analog 4.117 displayed activities of 99.2 nM and 
161 nM against W2 and TM90-C2B. As a direct comparison of analogs substituted at the 
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6- and 7- position as well as the necessity of a sulfur containing aliphatic ring, analogs 
4.113 – 4.115 were prepared. These 3 compounds were all active in the lower nanomolar 
range with the 6-trifluoromethylphenyl substituent being the most potent at 34.9 nM and 
8.65 nM against W2 and TM90-C2B respectively. This highlights the slight increase in 
activity of a strictly carbon aliphatic ring versus a heteroatom containing ring, however 
the solubilities and half-lives of these analogs varied (see below). Overall, the aryl 
analogs exhibit increased activities in comparison to the mono and di-substituted THAs. 
These analogs make for a large area of opportunity for diversification and improvements 
of the THA chemotype.  
4.3.2 Resistance Index and Cytotoxicity 
 Through in vitro studies one can determine the strain dependence of individual 
compounds, which in turn can generate a proportion known as the resistance index (RI). 
As previously mentioned, an RI > 3 has been linked to chemical resistance in atovaquone 
and chloroquine
24, 25
, while a THA with an RI between 3 and 0.3 are desired (Figure 4.3).  
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Figure 4.3. Plot of pEC50 (W2) versus pEC50 (TM90-C2B) 
The initial SAR probing aliphatic ring size revealed an interesting trend showing that 
electron withdrawing substituents at the 6-position were more potent against TM90-C2B, 
the chemically resistant strain, while the 6-methoxy substituted with 6-membered rings 
were very close to an RI of 1. Generally the aryl-substituted THA series (Table 4.8) is 
more potent against W2 in comparison to TM90-C2B with a few of the compounds 
displaying RIs close to 1. This stands in contrast to the rest of the THA library (Table 1 – 
Table 4.8) whose analogs are slightly more potent against the TM90-C2B strain than W2. 
Compound 4.90, which is one of the most active THAs with EC50(W2) of 30.6 nM and 
EC50(TM90-C2B) of 24.1 with an RI of 0.78, nevertheless the RI is sensitive to structural 
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changes amongst analogs similar to THA 4.90. For example, THA 4.92 containing a 
sulfur in the aliphatic ring has an RI of almost 5, while replacement of the methoxy 
substituent by an isopropoxy group shifts the RI to almost 5 as well. Alternatively, for 
analogs 4.96 and 4.97, in which the 7-chloro has been replaced with a 7-methyl 
substituent, the RIs revert back to 0.48 and 0.86 respectively. Interestingly, the 6-chloro 
and 7-methoxy analogs 4.94 and 4.95 respectively, which contain a –CF2 group in the 
aliphatic ring, display acceptable RIs while compound 4.93 combining the two benzenoid 
ring substituents with the CF2 unit yields a RI of less than 0.1. Ultimately, the placement 
of benzenoid substituents in conjuction with the other favorable aliphatic ring features is 
critical for developing a molecule with an acceptable RI. All compounds were finally 
tested for cytotoxicity against J774 mammalian cells in a 96-well plate format, which has 
been previously reported. Generally, the THAs do not display signs of cytotoxicity at 
concentrations lower than 20 µM rendering cytotoxicity indices 
(CI=EC50(J774)/EC50(TM90-C2B)) of hundred or more. These results indicate that the 
majority of the THAs are selective and nontoxic agents.
2
 
4.3.3 Structure-Property Studies 
 In parallel to the antimalarial activity testing, standard physicochemical properties 
were determined to identify potential compound liabilities prior to the time consuming 
and costly development and optimization of analogs that will ultimately fail within in 
vivo efficacy experiments. Compounds 4.5-4.118 were routinely assessed in parallel for 
aqueous solubility, partition coefficient (log D), and permeability (Pe) at various pH 
values (Section 4.5.1 for experimental details). Protein and plasma binding assays were 
regarded as redundant since the in vitro antimalarial activity assay is conducted in 10% 
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heat inactivated plasma. Furthermore, a selection of promising THAs has also been tested 
for murine microsomal stability to determine potential metabolic liabilities. 
 The determination of aqueous solubility and log D were conducted using HPLC-
based protocols, which were previously utilized for the 3-substituted 4(1H)-quinolone 
series.
2
 The distribution coefficients of all THAs are in the acceptable ranges 
(1<logD7.4<4), whereby a plot of in vitro activity against logD7.4 values implies that 
potency against both strains weakly correlates with lipophilicity (Figure 4.4). The most 
potent compounds 4.109 and 4.118 also possess the greatest lipophilicity with logD7.4 
values of 3.6 or higher.  
Figure 4.4. Plot of LogD (pH = 4.0 and 7.4) versus Activity (W2) and (TM90-C2B) 
 
 Overall, for the majority of the THAs, the solubilities are in the acceptable range 
of 40 M or higher and no significant pH dependence on the aqueous solubility has been 
observed (Table 4.9). Comparison of the solubility of compounds 4.5-4.118 suggests that 
THAs containing a 5- or 6-membered aliphatic ring exhibit greater solubility than the 
analogs with a 7- or 8-membered saturated ring. The solubility depends also on the nature 
and position of substituents on the benzenoid ring. For example, the 5-chloro-THAs 4.21, 
4.34, 4.47 and the 8-chloro-THAs 4.24, 4.37, 4.50 possess significantly increased 
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solubility in comparison to the 6- or 7-chloro-substituted analogs 4.22, 4.23, 4.35, 4.36, 
4.48, and 4.49.  A more pronounced difference in solubility is observed for the compound 
pair 4.58 and 4.59, which is mono-substituted with one tert-butyl group at the 5- or 7-
position. Though THAs 4.58 and 4.59 are similar in electronics, the divergence in 
solubility is purely derived by the position of the bulky alkyl group. A similar 
observation can be made by analyzing the THAs disubstituted on the benzenoid ring 
4.64-4.83 and especially the di-chloro compounds 4.74-4.78, in which the 5,8-dichloro 
analog 74 is much more soluble than compounds 4.75-4.78. Strikingly, the extent of the 
solubility increase for the 5- or 8-substituted analogs stand in contrast to the distribution 
coefficient logD determined to be in the range of 2.4-3.0 for all mono-chloro or di-chloro 
THAs 4.21-4.24, 4.34-4.37, 4.47-4.50, and 4.74-4.78 (Figure 4.5). 
Table 4.9. SPR Data Including Solubility, Permeability (Pe), and Log D 
Compound 
Solubility 
pH 2.4
a 
(µM) 
Solubility 
pH 4.0
a 
(µM)
 
Solubility 
pH 7.4
a 
(µM) 
Pe 
pH 7.4
b
  
(10
-6
 cm/s) 
Pe 
pH 4.0
b 
(10
-6
 cm/s) 
Log D
c 
pH 7.4 
4.5 120 111 91 10.6 8.5 1.5 
4.6 99 95 82 25 14.9 1.9 
4.7 146 65 30 39 37.9 2.1 
4.8 110 106 98 73 53.8 2.4 
4.9 107 105 98.3 60.3 45.6 2.3 
4.10 148 145 158 72.6 85.4 2.7 
4.11 14 15 17 131.1 120.1 3.0 
4.12 19 14 13 251.5 161.2 3.2 
4.13 37 28 24 9.9 10.1 3.0 
4.14 98 96 99 16.1 18.3 1.7 
4.15 91 83 78 16.4 17.0 1.5 
4.16 76 74 76 16.6 19.6 1.2 
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4.17 63 61 47 25.6 24.0 1.9 
4.18 100 92 89 27.2 14.7 2.0 
4.19 55 51 44 19.1 21.5 1.7 
4.20 104 96 99 87.2 72.7 2.1 
4.21 110 104 107 107.0 128.8 2.2 
4.22 22 15 15 74.5 45.7 2.2 
4.23 12 10 3.8 57.1 49.2 2.0 
4.24 103 97 99 47.0 37.6 1.8 
4.25 42 37 35 43.3 44.4 1.8 
4.26 89 90 91 95.4 93.9 2.4 
4.27 61 63 61 87.5 71.6 2.2 
4.28 62 23 38 73.4 64.7 2.0 
4.29 88 84 83 54.1 34.7 1.9 
4.30 37 26 38 90.0 91.9 2.3 
4.31 71 74 75 82.0 77.7 2.4 
4.32 56 54 52 83.8 99.9 2.4 
4.33 59 47 45 269.2 269.6 2.7 
4.34 51 64 62 427.2 455.5 2.9 
4.35 1.0 0.90 0.90 62.4 163.9 2.8 
4.36 1.0 1.0 0.90 63.0 197.5 2.6 
4.37 39 21 23 117.2 156.6 2.4 
4.38 75 72 64 42.5 48.8 1.9 
4.39 91 95 91 113.9 117.8 2.4 
4.40 90 90 92 63.8 71.3 2.2 
4.41 12 10 9.2 127.6 83.7 2.3 
4.42 71 73 64 42.5 48.8 1.7 
4.43 79 58 60 88.4 81.3 2.3 
4.44 17 17 17 53.3 74.5 2.49 
4.45 5.2 3.4 3.8 77.5 88.5 2.4 
4.46 16 11 8.8 240.3 221.3 2.8 
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4.47 10 15 20 406.8 371.4 3.0 
4.48 3.1 1.9 1.1 0.0 0.0 2.9 
4.49 1.8 1.8 1.8 95.5 150.2 2.7 
4.50 13 6.2 5.9 102.7 118.6 2.5 
4.51 3.3 3.9 2.8 62.7 32.2 1.5 
4.52 2.7 4.4 8.0 6.9 37.6 1.5 
4.53 107 107 109 16.5 18.7 1.5 
4.54 66 38 46 20.7 14.2 1.7 
4.55 8.4 7.2 4.0 N.D. N.D. 2.3 
4.56 18 14 14 70.4 72.8 2.8 
4.57 3.5 3.2 2.3 N.D. N.D. 2.1 
4.58 84 89 90 552.6 577.6 3.3 
4.59 9.1 6.1 4.9 164.8 189.5 2.8 
4.60 134 126 116 246.2 213.4 2.6 
4.61 40 27 30 100.4 84.4 2.2 
4.62 46 5.9 5.2 51.8 33.9 1.9 
4.63 12 7.9 7.6 62.8 63.5 2.1 
4.64 102 125 122 262.7 235.1 2.6 
4.65 105 108 108 57.9 56.7 2.2 
4.66 86 23 17 217.6 176.4 2.4 
4.67 16 11 8.3 42.4 48.4 2.2 
4.68 85 46 41 45.7 43.2 2.1 
4.69 103 100 105 9.0 12.7 1.5 
4.70 134 146 152 50.6 33.1 1.9 
4.71 178 161 188 12.7 9.5 1.4 
4.72 180 181 175 18.9 13.8 1.8 
4.73 88 83 88 0.7 12.8 1.3 
4.74 114 112 108 287.7 326.9 2.6 
4.75 4.4 2.1 1.0 251.7 274.3 3.0 
4.76 10 9.0 7.5 133.8 176.2 2.5 
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4.77 46 45 41 348.0 458.7 2.9 
4.78 1.6 1.3 1.1 N.D. N.D. 2.6 
4.79 160 166 159 12.0 11.4 1.3 
4.80 66 64 66 29.1 37.0 1.7 
4.81 4.4 2.6 2.9 12.6 17.4 1.5 
4.82 95 96 93 37.5 41.4 1.9 
4.83 22 22 18 27.9 30.1 1.9 
4.89 63 45 33 23.7 33.8 1.3 
4.90 31 23 17 85.0 69.5 2.2 
4.91 1.4 0.3 0.3 0.0 0.0 2.9 
4.92 10 7.8 13 101.1 91.9 1.0 
4.93 14 11 10 N.D N.D. 2.1 
4.94 4.4 4.3 4.3 N.D N.D. 2.0 
4.95 20 16 14 N.D N.D. 1.6 
4.96 137 28 23 49.5 40.4 2.0 
4.97 23 15 14 67.6 58.7 0.9 
4.98 12 14 17 N.D. N.D. 0.9 
4.99 61 56 33 21.1 0.0 1.0 
4.100 10 6.3 8.0 0.0 0.0 2.8 
4.101 79 65 45 N.D. N.D. 1.3 
4.102 49 37 24 N.D. N.D. 1.0 
4.103 94 96 45 N.D. N.D. 0.8 
4.104 79 76 37 N.D. N.D. 0.8 
4.105 5.2 6.2 6.8 N.D. N.D. 3.6 
4.106 6.7 4.4 2.4 N.D. N.D. 2.4 
4.107 1.5 1.3 1.2 N.D. N.D. 2.5 
4.108 0.9 0.3 0.2 N.D. N.D. 2.8 
4.109 6.5 6.0 6.5 N.D. N.D. 3.6 
4.110 17 13 12 N.D. N.D. 3.5 
4.111 1.7 1.2 1.0 N.D. N.D. 2.8 
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4.112 1.7 1.0 0.80 N.D. N.D. 2.8 
4.113 12 11 10 N.D. N.D. 2.4 
4.114 2.3 2.3 2.2 N.D. N.D. 3.6 
4.115 5.6 4.3 3.3 N.D. N.D. 2.45 
4.116 0.50 0.40 0.30 N.D. N.D. 3.0 
4.117 13 11 11 N.D. N.D. 1.3 
4.118 0.11 0.10 0.10 N.D. N.D. 3.8 
a
Standards for the solubility assay include carbamazepine and albendazole. Solubility for carbamazepine at 
pH 7.4, 4.0, and 2.0 is 95 and 100  respectively. Solubility for albendazole at pH 7.4, 4.0, 
and 2.0 is 6.1 , 12, and 100respectively 
b
Standards for the permeability assay include verapamil HCl (Pe = 1405 x10-6 cm/s at pH=7.4 and 39 x10-
6 cm/s at pH=4.0), carbamazepine (Pe = 112 x10-6 cm/s at pH=7.4 and 108 x10-6 cm/s at pH=4.0), and 
ranitidine HCl (Pe = 0.5 x10-6 cm/s at pH=7.4 and 0 x10-6 cm/s at pH=4.0). 
c
Standards for the LogD7.4 assay include cinnarizine (LogD7.4 5.68), hydrocortisone-21-acetate (LogD7.4 
2.19), ketoconazole (LogD7.4 3.83), metronidazole (LogD7.4 -0.02), nadolol (LogD7.4 0.68), pyrene (LogD7.4 
4.88), theophyline (LogD7.4 -0.05), and tolnaftate (LogD7.4 5.40). 
 
 
Analogous solubility trends for the dimethyl- or the dimethoxy-substituted THAs 4.64-
4.73 were determined, however these results are less pronounced in comparison to the 
dichloro- compounds 4.74-4.78. This data supports the notion that the THA’s solubility is 
strongly influenced by a tight crystal packing. A chloro group at the 5- or 8-position or 
both positions creates steric hindrance which presumably weakens the strength of the 
intermolecular hydrogen bonding between the carbonyl and the amino groups of the THA 
scaffold. 
1
H NMR N-H chemical shifts trends also seem to support such a weakening of 
hydrogen bonding with respect to DMSO in solution. The unsubstituted THA 4.13 (N-H 
δ 11.3 ppm) is similarly shifted as 5-chloro THA 4.21 (N-H δ 10.4 ppm), 5-fluoro THA 
4.53 (N-H δ 11.2 ppm) and 5-methoxy THA 4.14 (N-H δ 10.7 ppm). However, the 5-
methyl THA 4.17 (N-H δ 10.0 ppm) shows a large upfield shift while the 5-tert-butyl 
THA 4.58 (N-H δ 8.7 ppm) is even further shifted almost 3 ppm as compared to the 
unsubstituted THA 4.13. This trend suggests the THA N-H chemical shift is much more 
218 
 
Figure 4.5. Plot of Activity (pEC50 TM90-C2B) versus Solubility (pH = 7.4) Amongst 6-, 
7-, 6,7-, 5-, 8-, or 5,8-Substituted Analogs 
 
dependent on the local steric environment than electronics / σ-effect, especially when 
considering either electron poor or electron rich analogs have similar chemical shifts as 
the unsubstituted THA 4.13. This conclusion is further supported by the increased 
solubility and dramatic loss of antimalarial activity as seen in THAs 4.14, 4.17, 4.21, 
4.58, 4.63, 4.64, 4.69, and 4.74 possessing a sterically encumbered substituent at the 5- or 
8-positions.  
 The crucial role of the benzenoid ring substituents at the 6- and 7-positions on 
antimalarial activity also motivated us to study their effect on solubility. In comparison to 
the unsubstituted compound 4.13, the presence of a 6- methoxy group as in analog 4.6 
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increases the solubility by a factor of three, while 7-chloro-THA 4.23 is threefold less 
soluble. The combination of both substituents in the same compound (4.90) not only 
improves the antimalarial activity, but it also restores the compound’s solubility to that 
similar to 4.13. Replacement of the 7-chloro group in 4.90 by a 7-methyl group yields 
analog 4.96 and restores the aqueous solubility to a range similar to that of analog 4.6. 
The 7-chloro substituent improves the hydrogen bond donor capacity of the THA’s amine 
while the 6-methoxy group enhances the carbonyl’s ability as a hydrogen bond acceptor, 
which possibly strengthens the intramolecular hydrogen bonding in the crystal packing.  
Compounds substituted at the benzenoid ring with an aromatic residue at the 6- or 7-
position belong to another major compound series which in general displayed poor 
solubility with a few exceptions. Nevertheless, the solubility of biarylether 4.108 is 
improved by the out-of-plane ortho-methyl-aryl group in 4.109, depending on the pH in 
which the aqueous solubility has been determined, by a factor 6 or higher. Furthermore, 
the pyridyl analogs 4.103 and 4.104 were extremely soluble at low pH (>80 µM each) 
and >40 µM each at pH 7.4, unfortunately, they were devoid of activity.  
 Finally, the aliphatic ring has been considered to be a suitable site for improving 
the aqueous solubility by perturbing the crystal packing and/or increasing the compound 
polarity. In comparison to the THAs 4.13-4.24, the 2,2-dimethyl-THAs 4.25-4.37 and the 
3,3-dimethyl-substituted analogs 4.38-4.50 have been designed with the idea to introduce 
subtle steric entities while minimally increasing the distribution coefficients. Overall, the 
2,2-dimethyl-THAs 4.25-4.37 are similar or less soluble than the THAs 4.13-4.24, while 
the 3,3-dimethyl-substituted compounds are less soluble. The strategy to improve the 
solubility by steric differences at the aliphatic ring was abandoned given that the 2,2-
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dimethyl- and 3,3-dimethyl-THAs 4.25-4.50 did not improve the aqueous solubility. 
However, replacement of a methylene unit in the aliphatic ring by a nitrogen or a sulfur 
yielded analogs varying in solubility and potency. The tertiary amine in THA 4.99 
significantly enhances the solubility across all pHs, while the antimalarial activity is 
completely abolished. In contrast, the solubility of thioether compounds varies depending 
on the benzenoid ring substituents. 7-Aryl-substituted thioether 4.113 is approximately 
five-fold more soluble than its methylene congener 4.114, while 6-methoxy-substituted 
thioethers 4.97 and 4.92 are less soluble than the aliphatic THAs 4.96 and 4.90. 
Nevertheless, oxidation of the sulfur atom of 4.92, leading to sulfoxide 4.101 and sulfone 
4.102, restores the aqueous solubility of 20 M or higher. Replacement of the same 
methylene by a CF2 unit was synthesized mainly as a probe for examining microsomal 
stability, however, upon comparing the solubility of these three analogs 4.93, 4.94, and 
4.95 an interesting trend emerged. The 7-chloro is the least soluble while the 6-methoxy 
is the most soluble at all three pHs. The 6-chloro-7-methoxy compound’s solubility is 
comparable to the 6-methoxy compound but with an approximate 38-fold increase in 
potency against TM90-C2B.  
 The permeabilities of the majority of the compounds have been determined and 
are not considered to be a major liability for the THA compound series. A plot of the 
permeability against solubility at pH 4.0 and 7.4 demonstrates an insignificant pH 
dependence (Figure 4.6). Furthermore, it also shows that the majority of the tested THAs 
posses acceptable solubilities (20 M - 100 M) and acceptable permeabilities (10x10-6 
cm/s  – 100x10-6 cm/s). 
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Figure 4.6. Permeability (pH = 4.0 and 7.4) versus Solubility (pH = 4.0 and 7.4) 
 
 Microsomal stability was determined for a select set of compounds to 
systematically determine the structural features of the THA core that are most susceptible 
to microsomal degradation (Table 4.10). Compounds which underwent such a minimal 
degradation that half-lives could not be calculated are listed as C.N.C.  
Table 4.10. In vitro Metabolic Stability Using Murine Liver Microsomes 
Compound T1/2  (min) Compound T1/2  (min) 
4.6 6.8 4.95 15.8 
4.13 18.2 4.101 990 
4.17 6.4 4.102 C.N.C. 
18 20.1 4.106 8.4 
4.27 77 4.109 15.1 
4.40 24.8 4.113 11.2 
4.81 3.6 4.114 C.N.C. 
4.93 8.5 4.115 C.N.C. 
4.94 40.8 4.118 173.3 
 
The unsubstituted THA 4.13 had a half-life of 18 minutes, while substitution at the 5-
position with a methyl as in 4.17 or di-substitution at the 5- and 7- position as in 4.81 
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with a fluorine decreased the half-lives to less than 6 minutes. Comparison of geminally 
disubstituted methoxy analogs 4.27 and 4.40 revealed that the 2,2-dimethyl analog had a 
half-life of 77 minutes, which corresponds to a threefold increase of stability over the 3,3-
dimethyl congener. Sulfoxide containing THA 4.101 had a half-life of 990 minutes while 
the sulfone 4.102 was minimally degraded. Next, the aryl substituted analogs were tested 
showing THAs 4.106, 4.109, and 4.113 with sulfur containing aliphatic rings displayed 
the poorest half-lives of 8.3, 15.1, and 11 minutes, respectively. The THA 4.118 
substituted at the 6-position with a bi-arylether demonstrated an improved half-life of 173 
minutes, while the 6- and 7-trifluoromethylphenyl substituted analogs 4.115 and 4.114 
showed minimal degradation. Finally, three compounds were prepared in which the 
methylene at the 2-position was replaced by a CF2 unit with intentions of gaining a 
contrasting result to the sulfur containing aliphatic ring.  The most stable analog was 
4.94, which is mono-substituted with a chloro at the 7-position. The half-life of the 6-
methoxy analog 4.95 was decreased by a factor of 3 whereas the half-life of the 7-chloro-
6-methoxy-THA was less. The di-fluorinated compound 4.93 which was shown to 
increase potency while slightly decreasing solubility, maintained a similar microsomal 
stability as the reference THA 4.13. The bi-aryl-substituted analogs 4.106, 4.109, 4.113-
4.115, and 4.118 vary in half-lives from 8 minutes to minimally detectable degradation. 
The tri-fluoromethylphenyl showed to be the superior substituent in terms of stability as 
compared to the other aryl analogs, and substitution at the 6-position appeared to be 
slightly more stable as compared to the 7-substituted analog. 
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4.4 Conclusions 
 Upon examining the shortcomings of compounds 4.1 and 4.2, a set of compounds 
was prepared to probe the ring size of the aliphatic ring of the THA core and to examine 
whether heteroatoms in the aliphatic ring are tolerated. In addition, a library of THA 
analogs was prepared to systematically identify the key positions and substitutions of the 
benzenoid ring by loosely following the Topliss operational schemes. Generally, the best 
antimalarial activities with acceptable RI values were obtained if (a) the 5-position was 
unsubstituted, (b) the 6-position was substituted with an electron donating or electron 
withdrawing group, (c) the 7-position was substituted with an electron donating group, 
(d) the 8-position was fluorinated or unsubstituted, and (e) the THA core contained a six-
membered aliphatic ring. Furthermore, it was shown that replacement of the C-2 
methylene unit by one CF2 group or one sulfur was tolerated, while introduction of other 
heteroatoms in the aliphatic ring significantly reduced the THA’s antimalarial activity. 
The best substituents were combined in follow-up optimization studies leading to the 
identification of several THAs with improved antimalarial activity against multi-drug 
resistant strains W2 and the TM90-C2B. THAs 4.89 and 4.90, which are disubstituted in 
6- and 7-positions with one electron withdrawing and one electron donating group, or 
6,8-difluoro-substitued THA 4.81 are among the most potent compounds with EC50 
constants of 30 nM or lower. Furthermore, THAs such as 4.106, 4.114, 4.115 and 4.118, 
substituted with an aryl ring either in 6- or 7-position, demonstrated comparable or 
improved antimalarial activity. Of all THAs tested, biarylether 4.118 with EC50s of 12.2 
nM for W2 and 9.1 nM for TM90-C2B, was the most potent compound whereby also 
possessing an acceptable resistance index (RI) of 0.75. Overall, this SAR study 
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demonstrated that the majority of the THA compounds possess RI values in the 
acceptable range and thus lacks, in contrast to atovaquone or chloroquine, any cross 
resistance. Furthermore, the entire THA series did not show any cytotoxicity to J774 
mammalian cells at 20 µM concentrations yielding cytotoxicity indices (CIs) of hundred 
or more for the most potent antimalarial THAs 4.89, 4.90, 4.106, 4.114, 4.115 and 4.118. 
 All THAs have also been examined for aqueous solubility, logD7.4, and 
permeability. In general, the permeability, the logD7.4, and the aqueous solubility of the 
majority of the THAs have been determined to be in the acceptable ranges. Nevertheless, 
the more potent THAs tend to posses increased logD7.4 values and decreased aqueous 
solubility, which is consistent with the previous report on antimalarial 4(1H)-quinolones.
2
 
Furthermore, a selection of THAs has been tested for murine microsomal stability and the 
majority of the tested THAs suffer from short half-lifes of 3 to 20 minutes. The aliphatic 
ring and several groups of the benzenoid ring have been identified to be the major sites 
for metabolism. Nevertheless, THAs 4.114, 4.115, or 4.118, which are substituted with an 
aryl group in 6- or 7-position, possess half-lifes of 3 hours or longer. The improved 
physicochemical properties in conjunction with the potent antimalarial activity and lack 
of cross resistance make the aryl-substituted THAs attractive for further optimization and 
development. Studies are currently ongoing to assess whether the frontrunner compounds 
demonstrate in vivo efficacy in rodent malaria models as well as exoerythrocytic stage 
activity. 
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4.5 Experimental Section 
4.5.1 General Information 
 All anhydrous solvents were obtained from Aldrich Chemical Co. and used 
without further purification unless otherwise noted. 2,5-Dichloroanisole, 4,4-
dimethylcyclohexanone, and 3,3-dimethylcyclohexanone were bought from Alfa Aesar. 
4-Fluoro-3-methoxyaniline was bought from Oakwood Products, Inc. while 4-bromo-3-
methoxyaniline was bought from TCI America. Anthranillic acids were purchased from 
Oakwood Products, Inc. or Aldrich. POCl3, 2-methoxy-1-methyl-4-nitrobenzene, 3,3'-
thiodipropanoic acid, cycloalkanones, and all other anilines were purchased from 
Aldrich. 1-bromo-4-(chloromethyl)benzene, 1-iodo-4-(trifluoromethoxy)benzene, and all 
phenols were purchased from Matrix Scientific.  All palladium catalysts and ligands were 
purchased from Strem. All boronic acids were purchased from Frontier Scientific. The 
identity of all title compounds were verified via 
1
H NMR, 
13
C NMR, and HPLC/HRMS. 
The chemical purity of the titled compounds was determined using the following 
conditions: an Agilent 1100 series LC/MSD with a Eclipse XDB-C18 (4.6mm x 100 mm, 
5 μm) reversed phase column; method: 10% (v/v) of acetonitrile (+0.05% TFA) in 90% 
(v/v) of H2O (+0.05% TFA), ramped to 100% acetonitrile (+0.05% TFA) over 9 min, and 
holding at 100% acetonitrile for 4 min with a flow rate of 0.7 mL/min, UV detector, 254 
nm. The purity of each compound was ≥95% in this analysis. NMR spectra were 
recorded at ambient temperature on a 400 or 500 MHz Varian NMR spectrometer in the 
solvent indicated. All 
1H NMR experiments are reported in ≥ units, parts per million 
(ppm) downfield of TMS and were measured relative to the signals for chloroform (7.26 
ppm) and dimethylsulfoxide (2.50 ppm). All 
13
C NMR spectra were reported in ppm 
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relative to the signals for chloroform (77 ppm) and dimethylsulfoxide (39.5 ppm) with 
1
H 
decoupled observation. Data for 
1H NMR are reported as follows: chemical shift (δ ppm), 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad), 
integration and coupling constant (Hz), whereas 
13
C-NMR analyses were obtained at 101 
MHz and reported in terms of chemical shift. NMR data was analyzed by using 
MestReNova Software ver. 5.3.2-4936. High resolution mass spectra (HRMS) were 
performed on an Agilent LC/MSD TOF system G3250AA. Isomers were separated by 
reverse phase HPLC system (Waters Prep LC 4000 system with Waters 996 Photodiode 
Array Detector, Agilent column Eclipse XDB-C18, 5 μM, 9.4x250 mm). Compounds 
were eluted using a gradient elution of 70/30 to 50/50 A/B over 30 minutes at a flow rate 
of 5.0 mL/min, where solvent A was water and solvent B was acetonitrile. Analytical thin 
layer chromatography (TLC) was performed on silica gel 60 F254 pre-coated plates (0.25 
mm) from EMD Chemical Inc. and components were visualized by ultraviolet light (254 
nm). Silicycle silica gel 230-400 (particle size 40-63 μm) mesh was used for all flash 
column chromatography. 
Permeability Pe has been determined by a standard parallel artificial membrane 
permeability assay (PAMPA by pION). PAMPA was conducted on a Biomek FX lab 
automation workstation (Beckman Coulter, Inc., Fullerton, CA) with PAMPA evolution 
96 command software (pION Inc., Woburn, MA) as follows: 3 μL of 10μM test 
compound stock was mixed with 600 μL of system solution buffer, pH 7.4 or 4 (pION 
Inc., Woburn, MA) to make diluted test compound. Then 150 μL of diluted test 
compound was transferred to a UV plate (pION Inc., Woburn, MA), and the UV 
spectrum was read as the reference plate. The membrane on a preloaded PAMPA 
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sandwich (pION Inc., Woburn, MA) was painted with 4 μL of GIT lipid (pION Inc., 
Woburn, MA). The acceptor chamber was then filled with 200 μL of acceptor solution 
buffer (pION Inc., Woburn, MA), and the donor chamber was filled with 180 μL of 
diluted test compound. The PAMPA sandwich was assembled, placed on the Gut-Box 
controlled environment chamber and stirred for 30 min. The aqueous boundary layer was 
set to 40 μm for stirring. The UV spectrum (250–500 nm) of the donor and the acceptor 
were read. The permeability coefficient was calculated using PAMPA Evolution 96 
Command software (pION Inc., Woburn, MA) based on the AUC of the reference plate, 
the donor plate, and the acceptor plate. All compounds were tested in triplicate. Standards 
for this assay include Verapamil HCl (Pe = 1405 x10
-6
 cm/s at pH=7.4 and 39 x10
-6
 cm/s 
at pH=4.0), Carbamazepine (Pe = 112 x10
-6
 cm/s at pH=7.4 and 108 x10
-6
 cm/s at 
pH=4.0), and Ranitidine HCl (Pe = 0.5 x10
-6
 cm/s at pH=7.4 and 0 x10
-6
 cm/s at pH=4.0). 
Solubility has been determined via an in-house HPLC assay. A calibration curve 
was made by plotting the area under the curve at 254 nm (uv by HPLC) against the 
concentration of each compound injected after performing a serial dilution (25  to 
0.781 ) using a solvent in which the compound is soluble (DMSO).  A 100  
solution was then made for each compound in a buffer at pH 7.4, 4.0, and 2.0 by 
performing a 1:100 serial dilution using a 10mM DMSO stock solution of each 
compound. This solution was incubated at 21
o
C for 18 hours, filtered using a filter plate, 
and injected into the HPLC to compare the area found at wavelength 254 nm with the 
previously made calibration curve. Standards for this assay include carbamazepine and 
albendazole. Solubility for carbamazepine at pH 7.4, 4.0, and 2.0 is 95 and 
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100  respectively. Solubility for albendazole at pH 7.4, 4.0, and 2.0 is 6.1 , 12, 
and 100respectively 
Log D was also determined in-house via an HPLC method adapted from the 
strategy reported by Donovan and Pescatore.
1
 Two buffers were made at a concentration 
of 50 each: ammonium acetate at pH 7.4 and ammonium formate at pH 3.0. A set of 
compounds with known log D values between -0.36 and 5.68 were used to make a 
calibration curve at each pH by using a liner gradient between 0 and 100% acetonitrile, 
with buffer at the specific concentration used as the second solvent. The curve was made 
by plotting the log D value against the retention time. Compounds were then injected into 
the HPLC and the retention time compared to the calibration curve previously 
determined. Standards for this assay include Cinnarizine (LogD7.4 5.68), Hydrocortisone-
21-acetate (LogD7.4 2.19), Ketoconazole (LogD7.4 3.83), Metronidazole (LogD7.4 -0.02), 
Nadolol (LogD7.4 0.68), Pyrene (LogD7.4 4.88), Theophyline (LogD7.4 -0.05), and 
Tolnaftate (LogD7.4 5.40). 
The microsomal stability of 4(1H)-quinolones was determined by Susan Charman 
at the Monash University in Australia. The compounds are incubated at a concentration 
of 1 µM with human microsomes at 37ºC and 0.4 mg/mL of microsomal protein. The 
metabolic reaction was initiated with the addition of an NADPH-regenerating system (i.e. 
NADPH is the cofactor required for CYP450-mediated metabolism) and quenched at 
various time points over the incubation period by the addition of acetonitrile. Controls 
were incubated without the NADPH to assess the amount of degradation without 
metabolic initiation. The relative loss of compound was monitored by LC-MS using a 
Waters/Micromass ZQ mass spectrometer.  
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 The test compounds concentration versus time data was fitted to an exponential 
decay function to determine the first order rate constant for substrate degradation. Each 
rate constant was then used to calculate microsomal half-life (Table 6.2). Entries of 
C.N.C. (could not calculate) are compounds that displayed little to no observable 
degradation throughout the assay duration (typically 250 minutes), whereas N.D. entries 
were molecules that were not assayed. Endochin was used as a control for comparing 
half-lives of 4(1H)-quinolones. Endochin possesses half-lives of 7.9 minutes in Mouse 
and 10.2 in human microsomes. 
4.5.2 General Procedures 
General Procedure A: POCl3 cyclization of Anthranillic Acids. Anthranillic acid (0.25 
g, 1.7 mmol) is added to a dried flask, followed by cycloalkanone (0.23 g, 1.87 mmol). 
This flask is cooled to 0
o
C and POCl3 (1.4 mL) is added. The reaction is allowed to reflux 
for 1-8h. Upon completion the reaction is poured onto ice and water. The solution is 
brought to pH 10 using saturated K2CO3 . Next ethyl acetate or chloroform is added and 
the organic layer is removed and washed with brine (50 mL) followed by water (50 mL). 
Next the organic layer is dried over Na2SO4 and concentrated in vacuo. The crude oil is 
purified further further via flash chromatography (Hexane / EtOAc). A few representative 
examples of these compounds were characterized by NMR, however, the majority were 
considered as intermediates and were taken on to acetic acid hydrolysis upon 
identification using LC-MS. 
General Procedure B: Hydrolysis of 9-chloro-1,2,3,4-tetrahydroacridine. 9-chloro-
1,2,3,4-tetrahydroacridine (0.15 g, 0.69 mmol) was dissolved in AcOH (1.5 mL) and 
heated in a sealed-tube at 200
o
C for 24-48h. Upon completion via LC-MS analysis, the 
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crude material is poured onto ice and water. The mixture if filtered and the solid is 
recrystallized from either pyridine or DMF.  
General Procedure C: Conrad-Limpach cyclization using ethyl 2-
oxocyclohexanecarboxylate. An oven-dried 100 mLround-bottom flask attached to a 
Dean-Stark trap equipped with a reflux condenser was charged with an aniline 
(0.025mol), corresponding cyclohexanone carboxylate (0.025 - 0.05mol), benzene (25 
mL), and glacial acidic acid (1 mL). The mixture was heated at 100
o
C until no more 
water was separated (3-24 h). The benzene was distilled under reduced pressure, and the 
resulting crude intermediate was then used in the next step without further purification. 
Biphenyl ether (30 mL) was stirred and heated at reflux, while the crude intermediate was 
added rapidly through the dropping funnel. Stirring and refluxing continued for 10-15 
min until no more ethanol separated within the Dean-Stark trap. The mixture was then 
allowed to cool to room temperature while precipitation arose. The solid was filtered off 
and washed with hexane and acetone. Ice cold methanol washing may be necessary in 
some cases. No further purification was needed.  
General Procedure D: Suzuki-Coupling of halo-tetrahydroacridone. An oven-dried 
Schlenk tube was flame-dried and backfilled with argon (3X). The tube was then charged 
with 6-bromo-1,2,3,4-tetrahydroacridin-9(10H)-one (0.1 g, 0.36 mmol), Pd2(dba)3 (0.01g, 
7mol%), SPHOS (0.013 g, 14mol%), and boronic Acid (0.102g, 0.54 mmol). A rubber 
septum was then placed on the tube and 1M Na2CO3 (1mL), DMF (5mL), were added. 
The tube was then purged of air by argon for about 1 minute, while stirring and then 
heated at 80
o 
C until completion by HPLC analysis (3-24hrs). After completion, reaction 
was boiled with 1:1 MeOH/CHCl3, and filtered over celite. The celite was then rinsed 
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with boiling hot DMF.  The filtrate was then evaporated on silica gel purified via flash 
chromatography. 
4.5.3 Compound Characterization 
6-methoxy-2,3-dihydro-1H-cyclopenta[b]quinolin-9(4H)-one (4.5). Following general 
procedures A and B, the title compound was prepared to provide 54% yield as a brown 
powder.
 
 
1H NMR (400 MHz, DMSO) δ 7.92 (s, 1H), 6.83 (d, J = 32.8 Hz, 2H), 3.76 (s, 
3H), 2.87 (br s, 2H), 2.44 (br s, 2H), 1.95 (br s, 2H). 
13C NMR (101 MHz, DMSO) δ 
161.58, 153.93, 142.55, 126.95, 119.35, 112.52, 99.65, 55.40, 32.13, 28.09, 21.72. 
HRMS (ESI) calcd for C13H14NO2 [M+H]
+
: 216.1019, found: 216.1018. 
6-methoxy-1,2,3,4-tetrahydroacridin-9(10H)-one (4.6). Following general procedures 
A and B, the title compound was prepared to provide 43% yield as an off white powder, 
m.p. = 283 - 287
°
C.
 1H NMR (400 MHz, DMSO) δ 11.38 (s, 1H), 7.97 (d, J = 8.7 Hz, 
1H), 6.85 (d, J = 10.0 Hz, 2H), 3.83 (s, 3H), 2.66 (d, J = 5.8 Hz, 2H), 2.41 (t, J = 5.4 Hz, 
2H), 1.76 – 1.65 (m, 4H). 13C NMR (101 MHz, DMSO) δ 175.74, 162.10, 147.41, 
141.57, 127.25, 118.14, 115.67, 113.14, 98.86, 55.97, 27.79, 22.55, 22.24, 22.13. HRMS 
(ESI) calcd for C14H16NO2[M+H]
+
: 230.1176, found: 230.1171. 
3-methoxy-7,8,9,10-tetrahydro-5H-cyclohepta[b]quinolin-11(6H)-one (4.7). 
Following general procedures A and B, the title compound was prepared to provide 38% 
yield as a brown crystal, m.p. = 284 - 285
°
C.
 1H NMR (400 MHz, DMSO) δ 11.98 (s, 
1H), 8.04 (d, J = 8.6 Hz, 1H), 7.03 – 6.86 (m, 2H), 3.84 (s, 3H), 2.88 (br s, 2H), 2.79 (br 
s, 2H), 1.79 (br s, 2H), 1.66 (br s, 2H), 1.46 (br s, 2H).
  13C NMR (101 MHz, DMSO) δ 
172.38, 161.53, 154.31, 140.25, 126.79, 120.02, 117.02, 113.92, 98.63, 55.45, 33.51, 
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31.70, 27.00, 25.66, 23.06. HRMS (ESI) calcd for C15H18NO2 [M+H]
+
: 244.1332, found: 
244.1330. 
3-methoxy-6,7,8,9,10,11-hexahydrocycloocta[b]quinolin-12(5H)-one (4.8). Following 
general procedures A and B, the title compound was prepared to provide 32% yield as a 
brown powder, m.p. = 266 - 268
°
C. 
1H NMR (400 MHz, DMSO) δ 12.66 (s, 1H), 8.12 (d, 
J = 8.3 Hz, 1H), 7.12 (s, 1H), 6.99 (d, J = 8.0 Hz, 1H), 3.85 (s, 3H), 2.91 (br s, 2H), 2.74 
(br s, 2H), 1.75 (br s, 2H), 1.55 (br s, 2H), 1.35 (br s, 4H). 
13
C NMR (101 MHz, DMSO) 
δ 171.34, 161.68, 152.63, 140.83, 126.34, 117.78, 116.29, 114.60, 98.50, 55.48, 30.12, 
29.72, 29.15, 25.85, 25.45, 22.57. HRMS (ESI) calcd for C16H20NO2 [M+H]
+
: 258.1489, 
found: 258.1490.
 
6-trifluoromethyl-2,3-dihydro-1H-cyclopenta[b]quinolin-9(4H)-one (4.9). Following 
general procedures A and B, the title compound was prepared to provide 65% yield as a 
gray powder, m.p. = 283 - 284
°
C.
 1H NMR (400 MHz, DMSO) δ 12.57 (s, 1H), 8.29 (d, J 
= 8.0 Hz, 1H), 7.87 (s, 1H), 7.57 (d, J = 7.8 Hz, 1H), 3.03 (s, 2H), 2.73 (s, 2H), 2.07 (d, J 
= 6.2 Hz, 2H). 
19F NMR (376 MHz, DMSO) δ -61.82. 13C NMR (101 MHz, DMSO) δ 
172.41, 155.98, 139.50, 130.55 (q, J = 31.3 Hz), 126.54, 123.74 (q, J = 273.1 Hz),120.94, 
118.28, 115.44, 31.83, 27.49, 21.26. HRMS (ESI) calcd for C13H11F3NO [M+H]
+
: 
254.0787, found: 254.0785. 
6-trifluoromethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.10). Following general 
procedures A and B, the title compound was prepared to provide 62% yield as a brown 
crystal, m.p. = 324 - 328
°
C.
  1H NMR (400 MHz, DMSO) δ 12.09 (s, 1H), 8.26 (d, J = 8.4 
Hz, 1H), 7.88 (s, 1H), 7.52 (d, J = 8.4 Hz, 1H), 2.75 (t, J = 5.7 Hz, 2H), 2.46 (t, J = 5.8 
Hz, 2H), 1.80 – 1.66 (m, 4H). 19F NMR (376 MHz, DMSO) δ -62.16. 13C NMR (101 
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MHz, DMSO) δ 175.00, 164.60, 161.89, 149.63, 141.41, 139.16, 133.55, 131.50 (q, J = 
32.3 Hz), 130.08, 127.25, 125.26, 124.47 (q, J = 273.7 Hz,), 118.57, 117.76, 115.76, 
27.92, 22.32, 22.20, 21.85. HRMS (ESI) calcd. for C14H13F3NO [M+H]
+
: 268.0944, 
found: 268.0943. 
3-trifluoromethyl-7,8,9,10-tetrahydro-5H-cyclohepta[b]quinolin-11(6H)-one (4.11). 
Following general procedures A and B, the title compound was prepared to provide 57% 
yield as a brown crystal, m.p. =332 - 333
°
C.
 1
H NMR (500 MHz, DMSO) δ 8.27 (d, J = 
8.8 Hz, 1H), 8.23 (s, 1H), 7.88 (d, J = 7.6 Hz, 1H), 3.19 (dd, J = 15.4, 8.5 Hz, 4H), 1.83 
(dd, J = 11.1, 5.7 Hz, 2H), 1.69 (dd, J = 11.2, 5.4 Hz, 4H).
 13
C NMR (126 MHz, DMSO) 
δ 167.07, 145.26, 138.64, 136.72, 130.0 (q, J = 25 Hz), 127.01, 126.65 (q, J = 12.5 Hz), 
126.49, 124.3 (q, J = 275 Hz), 122.88 (q, J = 3.75 Hz), 39.79, 31.38, 30.22, 27.27, 26.69. 
HRMS (ESI) calcd for C15H15F3NO [M+H]
+
: 282.1100, found: 282.1099. 
3-trifluoromethyl-6,7,8,9,10,11-hexahydrocycloocta[b]quinolin-12(5H)-one (4.12). 
Following general procedures A and B, the title compound was prepared to provide 31% 
yield as a brown powder, m.p. = 241 - 242
°
C. 
1H NMR (400 MHz, DMSO) δ 11.94 (s, 
1H), 8.25 (d, J = 6.3 Hz, 1H), 7.88 (s, 1H), 7.52 (d, J = 6.4 Hz, 1H), 2.84 (s, 2H), 2.70 (s, 
2H), 1.55 (s, 2H), 1.37 (s, 4H). 
19F NMR (376 MHz, DMSO) δ -61.51. 13C NMR (101 
MHz, DMSO) δ 174.50, 151.87, 139.20, 131.09 (q, J = 27.3 Hz), 127.43, 125.53, 124.28 
(q, J = 273.7 Hz), 120.52, 118.32, 115.75, 30.70, 29.96, 29.57, 26.43, 25.97, 23.21. 
1,2,3,4-tetrahydroacridin-9(10H)-one (4.13). Following general procedures A and B, 
the title compound was prepared to provide 72% yield as an off-white powder, m.p. = 
341 - 343
°
C.
 1H NMR (400 MHz, DMSO) δ 11.30 (s, 1H), 8.05 (d, J = 7.9 Hz, 1H), 7.55 
(dd, J = 11.1, 4.0 Hz, 1H), 7.45 (d, J = 8.3 Hz, 1H), 7.21 (t, J = 7.4 Hz, 1H), 2.69 (t, J = 
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6.0 Hz, 2H), 2.43 (t, J = 6.0 Hz, 2H), 1.77 – 1.67 (m, 4H).13C NMR (101 MHz, DMSO) δ 
176.60, 147.41, 139.92, 131.57, 125.49, 123.88, 122.60, 118.00, 116.18, 27.79, 22.56, 
22.34, 22.18. HRMS (ESI) calcd for C13H14NO [M+H]
+
: 200.1070, found: 200.1073. 
5-methoxy-1,2,3,4-tetrahydroacridin-9(10H)-one (4.14). Following general procedures 
A and B, the title compound was prepared to provide 27% yield as a light yellow powder, 
m.p. = 273 - 276
°
C.
 1H NMR (400 MHz, DMSO) δ 10.69 (s, 1H), 7.64 – 7.58 (m, 1H), 
7.15 (d, J = 5.0 Hz, 2H), 3.97 (s, 3H), 2.76 (t, J = 5.8 Hz, 2H), 2.42 (t, J = 6.0 Hz, 2H), 
1.74 – 1.65 (m, 4H).13C NMR (101 MHz, DMSO) δ 175.66, 147.91, 146.72, 130.09, 
124.02, 121.64, 116.19, 116.01, 110.28, 56.00, 27.12, 21.80, 21.78, 21.51. HRMS (ESI) 
calcd for C14H16NO2 [M+H]
+
: 230.1176, found: 230.1171. 
7-methoxy-1,2,3,4-tetrahydroacridin-9(10H)-one (4.15). Following general procedure 
A, the title compound was prepared to provide 46% yield as a brown crystal, m.p. = 299 - 
301
°
C.
 1H NMR (400 MHz, DMSO) δ 11.29 (s, 1H), 7.45 (d, J = 2.8 Hz, 1H), 7.42 (d, J = 
9.0 Hz, 1H), 7.21 (dd, J = 9.0, 2.8 Hz, 1H), 3.80 (s, 3H), 2.68 (t, J = 5.8 Hz, 2H), 2.44 (t, 
J = 5.9 Hz, 2H), 1.77 – 1.67 (m, 4H).13C NMR (101 MHz, DMSO) δ 175.23, 154.64, 
145.85, 133.95, 123.99, 121.41, 119.06, 114.48, 104.05, 55.19, 27.05, 21.95, 21.79, 
21.54. HRMS (ESI) calcd for C14H16NO2 [M+H]
+
: 230.1176, found: 230.1179. 
8-methoxy-1,2,3,4-tetrahydroacridin-9(10H)-one (4.16). Following general procedures 
A and B, the title compound was prepared to provide 15% yield as a brown powder.
 1
H 
NMR (400 MHz, DMSO) δ11.1 (s, 1H), 7.37 – 7.30 (m, 1H), 7.16 (d, J = 8.0, 1H), 6.78 
(d, J = 6.8, 1H), 2.82 (s, 3H), 2.60 (t, J = 5.1, 2H), 2.43 (t, J = 5.0, 2H), 1.70 – 1.60 (m, 
4H).
 
HRMS (ESI) calcd for C14H16NO2 [M+H]
+
: 230.1176, found: 230.1167. 
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5-methyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.17). Following general procedures 
and B, the title compound was prepared to provide 29% yield as a brown powder, m.p. = 
314 - 317
°
C. 
1H NMR (400 MHz, DMSO) δ 10.16 (s, 1H), 7.94 (d, J = 7.9 Hz, 1H), 7.41 
(d, J = 6.8 Hz, 1H), 7.13 (t, J = 7.5 Hz, 1H), 2.80 (t, J = 5.6 Hz, 2H), 2.5 (s, 3H), 2.46 – 
2.42 (m, 2H), 1.72 (br m, J = 23.1, 5.0 Hz, 4H).
 13C NMR (101 MHz, DMSO) δ 176.00, 
147.35, 137.91, 131.89, 125.43, 123.28, 122.78, 121.81, 115.66, 27.32, 21.78, 21.76, 
21.57, 17.49. HRMS (ESI) calcd for C14H16NO [M+H]
+
: 214.1226, found: 214.1229. 
6-methyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.18). Following general procedures 
A and B, the title compound was prepared to provide 51% yield as a tan crystal, m.p. = 
330 - 332
°
C. 
1H NMR (250 MHz, DMSO) δ 11.17 (s, 1H), 7.92 (d, J = 8.2 Hz, 1H), 7.21 
(s, 1H), 7.03 (dd, J = 8.3, 1.1 Hz, 1H), 2.67 (t, J = 5.8 Hz, 2H), 2.45 – 2.35 (m, 5H), 1.78 
– 1.62 (m, 4H).13C NMR (63 MHz, DMSO) δ 175.83, 146.44, 140.87, 139.45, 124.85, 
123.74, 121.29, 116.57, 115.26, 27.11, 21.91, 21.65, 21.53, 21.33. HRMS (ESI) calcd for 
C14H16NO [M+H]
+
: 214.1226, found: 214.1226. 
7-methyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.19). Following general procedures 
A and B, the title compound was prepared to provide 55% yield as a beige crystal, m.p. = 
352 - 356
°
C. 
1H NMR (250 MHz, DMSO) δ 11.24 (s, 1H), 7.84 (s, 1H), 7.37 (s, 2H), 
2.67 (t, J = 5.4 Hz, 2H), 2.42 (t, J = 5.7 Hz, 2H), 2.37 (s, 3H), 1.83 – 1.61 (m, 4H).13C 
NMR (63 MHz, DMSO) δ 175.75, 146.37, 137.37, 132.36, 130.97, 124.02, 123.15, 
117.30, 115.20, 27.11, 21.95, 21.74, 21.54, 20.75. HRMS (ESI) calcd for C14H16NO 
[M+H]
+
: 214.1226, found: 214.1219. 
8-methyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.20). Following general procedures 
A and B, the title compound was prepared to provide 43% yield as an off-white powder, 
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m.p. = 340 - 342
°
C. 
1H NMR (250 MHz, DMSO) δ 11.06 (s, 1H), 7.39 – 7.32 (m, 1H), 
7.26 (d, J = 8.0, 1H), 6.88 (d, J = 6.8, 1H), 2.79 (s, 3H), 2.62 (t, J = 5.1, 2H), 2.36 (t, J = 
5.0, 2H), 1.75 – 1.65 (m, 4H).13C NMR (63 MHz, DMSO) δ 178.44, 145.16, 140.85, 
138.90, 130.01, 124.31, 121.55, 116.67, 115.53, 26.70, 23.34, 21.99, 21.76, 21.48. 
HRMS (ESI) calcd for C14H16NO [M+H]
+
: 214.1226, found: 214.1222. 
5-chloro-1,2,3,4-tetrahydroacridin-9(10H)-one (4.21). Following general procedures A 
and B, the title compound was prepared to provide 60% yield as a light yellow powder, 
m.p. = 265 - 266
°
C. 
1H NMR (400 MHz, DMSO) δ 10.46 (s, 1H), 8.05 (d, J = 8.0 Hz, 
1H), 7.74 (d, J = 7.6 Hz, 1H), 7.24 (t, J = 7.8 Hz, 1H), 2.82 (t, J = 5.9 Hz, 2H), 2.43 (t, J 
= 6.0 Hz, 2H), 1.75 – 1.67 (m, 4H).13C NMR (101 MHz, DMSO) δ 175.44, 148.06, 
135.79, 131.26, 124.69, 124.25, 122.38, 120.54, 116.59, 27.28, 21.71, 21.56, 21.39. 
HRMS (ESI) calcd for C13H13ClNO [M+H]
+
: 234.0680, found: 234.0681. 
6-chloro-1,2,3,4-tetrahydroacridin-9(10H)-one (4.22). Following general procedures A 
and B, the title compound was prepared to provide 65% yield as an off white crystal, m.p. 
= 362 - 365
°
C. 
1H NMR (250 MHz, DMSO) δ 11.38 (s, 1H), 8.03 (d, J = 8.6 Hz, 1H), 
7.46 (s, 1H), 7.22 (dd, J = 8.6, 1.8 Hz, 1H), 2.68 (t, J = 5.6 Hz, 2H), 2.41 (t, J = 5.7 Hz, 
2H), 1.79 – 1.66 (m, 4H).13C NMR (101 MHz, DMSO) δ 175.38, 147.31, 139.92, 135.51, 
127.22, 122.37, 121.77, 116.39, 116.30, 27.11, 21.70, 21.55, 21.36. HRMS (ESI) calcd 
for C13H13ClNO [M+H]
+
: 234.0680, found: 234.0683. 
7-chloro-1,2,3,4-tetrahydroacridin-9(10H)-one (4.23). Following general procedures A 
and B, the title compound was prepared to provide 68% yield as an off-white powder, 
m.p. = 359 - 361
°
C. 
1H NMR (400 MHz, DMSO) δ 11.51 (s, 1H), 7.97 (d, J = 2.2 Hz, 
1H), 7.59 (dd, J = 8.8, 2.2 Hz, 1H), 7.50 (d, J = 8.8 Hz, 1H), 2.70 (t, J = 5.8 Hz, 2H), 
237 
 
2.43 (t, J = 5.9 Hz, 2H), 1.76 (d, J = 5.1 Hz, 2H), 1.70 (d, J = 5.2 Hz, 2H).
13
C NMR (101 
MHz, DMSO) δ 174.70, 147.32, 137.77, 131.04, 126.51, 124.07, 123.68, 119.83, 116.01, 
27.10, 21.71, 21.63, 21.37. HRMS (ESI) calcd for C13H13ClNO[M+H]
+
: 234.0680, found: 
234.0677. 
8-chloro-1,2,3,4-tetrahydroacridin-9(10H)-one (4.24). Following general procedures A 
and B, the title compound was prepared to provide 43% yield as a tan powder, m.p. = 329 
- 330
°
C. 
1H NMR (400 MHz, DMSO) δ 11.35 (s, 1H), 7.48 – 7.38 (m, 2H), 7.16 (d, J = 
7.3, 1H), 2.65 (t, J = 5.9, 2H), 2.36 (t, J = 5.8, 2H), 1.78 – 1.66 (m, 4H).13C NMR (101 
MHz, DMSO) δ 175.16, 145.67, 141.72, 131.74, 130.65, 124.56, 119.07, 117.36, 116.94, 
26.71, 21.77, 21.31. HRMS (ESI) calcd for C13H13ClNO [M+H]
+
: 234.0680, found: 
234.0680. 
2,2-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.25). Following general 
procedures A and B, the title compound was prepared to provide 59% yield as a white 
crystal. 
1
H NMR (400 MHz, DMSO) δ 11.34 (s, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.56 (t, J 
= 8.1 Hz, 1H), 7.45 (d, J = 8.2 Hz, 1H), 7.21 (t, J = 7.4 Hz, 1H), 2.71 (t, J = 6.5 Hz, 2H), 
2.25 (s, 2H), 1.55 (t, J = 6.6 Hz, 2H), 0.97 (s, 6H). 
13
C NMR (101 MHz, DMSO) δ 
176.17, 145.59, 139.23, 130.91, 124.80, 123.11, 121.87, 117.30, 114.54, 35.42, 33.89, 
28.51, 27.93, 24.60. HRMS (ESI) calcd for C15H18NO [M+H]
+
: 228.1383, found: 
228.1376. 
5-methoxy-2,2-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.26). Following 
general procedures A and B, the title compound was prepared to provide 56% yield as a 
yellow powder solid. 
1
H NMR (400 MHz, DMSO) δ 10.75 (s, 1H), 7.67 – 7.58 (m, 1H), 
7.15 (s, 2H), 3.97 (s, 3H), 2.78 (s, 2H), 2.24 (t, J = 6.1 Hz, 2H), 1.51 (t, J = 6.1 Hz, 2H), 
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0.95 (s, 6H).
13
C NMR (101 MHz, DMSO) δ 175.91, 147.92, 145.58, 130.11, 123.94, 
121.61, 116.20, 115.09, 110.29, 56.02, 35.56, 33.93, 28.35, 27.91, 24.63.  HRMS (ESI) 
calcd for C16H20NO2 [M+H]
+
: 258.1487, found: 258.1478. 
6-methoxy-2,2-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.27). Following 
general procedures A and B, the title compound was prepared to provide 37% yield as a 
yellow powder solid, m.p. = 301 - 303.5
°
C. 
1H NMR (400 MHz, DMSO) δ 11.17 (s, 1H), 
7.94 (d, J = 8.6 Hz, 1H), 6.82 (d, J = 9.9 Hz, 2H), 3.82 (s, 3H), 2.66 (t, J = 6.1 Hz, 2H), 
2.22 (s, 2H), 1.52 (t, J = 6.2 Hz, 2H), 0.95 (s, 6H).
13C NMR (101 MHz, DMSO) δ 
175.81, 161.34, 145.04, 140.91, 126.65, 117.66, 114.06, 112.00, 98.15, 55.23, 35.30, 
33.89, 28.51, 27.92, 24.55.  HRMS (ESI) calcd for C16H20NO2 [M+H]
+
: 258.1489, found: 
258.1484. 
7-methoxy-2,2-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.28). Following 
general procedures A and B, the title compound was prepared to provide 61% yield as a 
yellow powder, m.p. = 206 - 208
°
C.  
1
H NMR (400 MHz, DMSO) δ 11.34 (s, 1H), 7.46 – 
7.40 (m, 2H), 7.22 (dt, J = 8.9, 3.2 Hz, 1H), 3.80 (s, 3H), 2.71 (s, 2H), 2.26 (s, 2H), 1.54 
(t, J = 6.1 Hz, 2H), 0.96 (s, 6H).
13
C NMR (101 MHz, DMSO) δ 175.51, 154.64, 144.74, 
133.98, 123.92, 121.50, 119.08, 113.58, 104.03, 55.22, 35.60, 33.95, 28.56, 27.97, 24.52.  
HRMS (ESI) calcd C16H20NO2 [M+H]
+
: 258.1489, found: 258.1492. 
8-methoxy-2,2-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.29). Following 
general procedures A and B, the title compound was prepared to provide 45% yield as a 
white powder. 
1
H NMR (400 MHz, DMSO) δ 11.04 (s, 1H), 7.39 (t, J = 8.2 Hz, 1H), 
6.96 (d, J = 8.3 Hz, 1H), 6.62 (d, J = 8.0 Hz, 1H), 3.76 (s, 3H), 2.62 (t, J = 6.4 Hz, 2H), 
2.14 (s, 2H), 1.50 (t, J = 6.5 Hz, 2H), 0.94 (s, 6H).
 13C NMR (101 MHz, DMSO) δ 
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176.72, 159.92, 143.99, 142.68, 131.75, 116.82, 114.31, 110.11, 103.72, 56.10, 36.33, 
34.54, 29.28, 28.68, 24.86.  HRMS (ESI) calcd for C16H20NO2 [M+H]
+
: 258.1489, found: 
258.1500. 
2,2,5-trimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.30). Following general 
procedures A and B, the title compound was prepared to provide 34% yield as a yellow 
crystal. 
1H NMR (400 MHz, DMSO) δ 10.15 (s, 1H), 7.93 (d, J = 7.9 Hz, 1H), 7.41 (d, J 
= 6.8 Hz, 1H), 7.12 (t, J = 7.4 Hz, 1H), 2.81 (t, J = 6.0 Hz, 2H), 2.50 (s, 3H), 2.25 (s, 
2H), 1.54 (t, J = 6.0 Hz, 2H), 0.96 (s, 6H). 
13
C NMR (101 MHz, DMSO) δ 176.47, 
145.99, 137.95, 131.86, 125.39, 123.31, 122.83, 121.68, 114.72, 35.51, 34.02, 28.37, 
27.93, 24.79, 17.53. HRMS (ESI) calcd for C16H20NO [M+H]
+
: 242.1539, found: 
242.1537. 
2,2,6-trimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.31). Following general 
procedures A and B, the title compound was prepared to provide 37% yield as a white 
crystal, m.p. = 329 - 330
°
C.  
1
H NMR (250 MHz, DMSO) δ 11.22 (s, 1H), 7.92 (d, J = 
8.2 Hz, 1H), 7.21 (s, 1H), 7.03 (dd, J = 8.3, 1.3 Hz, 1H), 2.69 (t, J = 6.5 Hz, 2H), 2.39 (s, 
3H), 2.23 (s, 2H), 1.53 (t, J = 6.6 Hz, 2H), 0.96 (s, 6H).
 13C NMR (101 MHz, DMSO) δ 
176.07, 145.26, 140.84, 139.43, 124.82, 123.65, 121.20, 116.53, 114.28, 35.40, 33.91, 
28.51, 27.94, 24.60, 21.30. HRMS (ESI) calcd for C16H20NO [M+H]
+
: 242.1539, found: 
242.1533. 
2,2,7-trimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.32). Following general 
procedures A and B, the title compound was prepared to provide 39% yield as a yellow 
crystal, m.p. = 334 - 335
°
C. 
1H NMR (400 MHz, DMSO) δ 11.28 (s, 1H), 7.83 (s, 1H), 
7.42 – 7.33 (m, 2H), 2.70 (t, J = 6.5 Hz, 2H), 2.37 (s, 3H), 2.25 (s, 2H), 1.54 (t, J = 6.5 
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Hz, 2H), 0.96 (s, 6H).
13C NMR (101 MHz, DMSO) δ 175.93, 145.22, 137.34, 132.34, 
130.92, 123.97, 123.02, 117.26, 114.23, 35.49, 33.91, 28.52, 27.95, 24.57, 20.71. HRMS 
(ESI) calcd for C16H20NO [M+H]
+
: 242.1539, found: 242.1547. 
2,2,8-trimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.33). Following general 
procedures A and B, the title compound was prepared to provide 44% yield as a yellow 
crystal, m.p. = 308 - 309
°
C. 
1H NMR (400 MHz, DMSO) δ 11.10 (s, 1H), 7.35 (t, J = 7.7 
Hz, 1H), 7.26 (d, J = 8.2 Hz, 1H), 6.88 (d, J = 7.0 Hz, 1H), 2.79 (s, 3H), 2.65 (t, J = 6.3 
Hz, 2H), 2.18 (s, 2H), 1.51 (t, J = 6.4 Hz, 2H), 0.95 (s, 6H).
13
C NMR (101 MHz, DMSO) 
δ 178.64, 143.98, 140.84, 138.88, 130.00, 124.24, 121.48, 115.72, 115.50, 35.54, 33.87, 
28.57, 27.99, 24.24, 23.31. HRMS (ESI) calcd for C16H20NO [M+H]
+
: 242.1539, found: 
242.1531. 
5-chloro-2,2-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.34). Following general 
procedures A and B, the title compound was prepared to provide 51% yield as a light 
yellow crystal, m.p. = 244 - 246
°
C. 
1H NMR (400 MHz, DMSO) δ 10.52 (s, 1H), 8.05 (s, 
1H), 7.75 (s, 1H), 7.24 (s, 1H), 2.84 (s, 2H), 2.25 (s, 2H), 1.53 (s, 2H), 0.96 (s, 6H).
13
C 
NMR (101 MHz, DMSO) δ 175.69, 146.96, 135.81, 131.29, 124.63, 124.28, 122.36, 
120.54, 115.65, 35.42, 33.83, 28.25, 27.85, 24.82. HRMS (ESI) calcd for C15H17ClNO 
[M+H]
+
: 262.0993, found: 262.0998. 
6-chloro-2,2-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.35). Following general 
procedures A and B, the title compound was prepared to provide 45% yield as a off white 
crystal, m.p. = 341 - 343
°
C. 
1H NMR (400 MHz, DMSO) δ 11.43 (s, 1H), 8.03 (d, J = 8.6 
Hz, 1H), 7.48 (d, J = 1.6 Hz, 1H), 7.23 (dd, J = 8.6, 1.7 Hz, 1H), 2.70 (t, J = 6.4 Hz, 2H), 
2.23 (s, 2H), 1.54 (t, J = 6.5 Hz, 2H), 0.96 (s, 6H).
 13C NMR (101 MHz, DMSO) δ 
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176.29, 146.87, 140.60, 136.19, 127.90, 122.99, 122.37, 117.07, 116.00, 35.96, 34.44, 
29.15, 28.58, 25.33. HRMS (ESI) calcd for  C15H17ClNO [M+H]
+
: 262.0993, found: 
262.0996. 
7-chloro-2,2-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.36). Following general 
procedures A and B, the title compound was prepared to provide 60% yield as an off-
white powder, m.p. = 324 - 325
°
C. 
1
H NMR (400 MHz, DMSO) δ 11.55 (s, 1H), 7.97 (s, 
1H), 7.59 (dd, J = 8.7, 1.8 Hz, 1H), 7.50 (d, J = 8.8 Hz, 1H), 2.72 (t, J = 6.2 Hz, 2H), 
2.25 (s, 2H), 1.54 (t, J = 6.3 Hz, 2H), 0.96 (s, 6H).
13C NMR (101 MHz, DMSO) δ 
174.98, 146.24, 137.78, 131.07, 126.48, 123.99, 123.70, 119.83, 115.07, 35.37, 33.77, 
28.47, 27.90, 24.62. HRMS (ESI) calcd for C15H16ClNONa [M+Na]
+
: 284.0813, found: 
284.0810. 
8-chloro-2,2-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.37). Following general 
procedures A and B, the title compound was prepared to provide 42% yield as a tan 
crystal. 
1
H NMR (400 MHz, DMSO) δ 11.38 (s, 1H), 7.47 – 7.38 (m, 2H), 7.16 (d, J = 
7.2 Hz, 1H), 2.67 (t, J = 6.2 Hz, 2H), 2.18 (s, 2H), 1.52 (t, J = 6.4 Hz, 2H), 0.96 (s, 
6H).
13
C NMR (101 MHz, DMSO) δ 175.38, 144.55, 141.73, 131.75, 130.66, 124.51, 
119.01, 116.93, 116.41, 35.49, 33.70, 28.54, 27.94, 24.28. HRMS (ESI) calcd for 
C15H17ClNO [M+H]
+
: 262.0993, found: 262.0987. 
3,3-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.38). Following general 
procedures A and B, the title compound was prepared to provide 43% yield as a white 
crystal, m.p. = 301 - 302
°
C.  
1
H NMR (400 MHz, DMSO) δ 11.27 (s, 1H), 8.05 (d, J = 
7.3 Hz, 1H), 7.56 (t, J = 7.6 Hz, 1H), 7.45 (d, J = 8.2 Hz, 1H), 7.22 (t, J = 7.5 Hz, 1H), 
2.48 – 2.43 (m, 4H), 1.50 (t, J = 6.6 Hz, 2H), 0.98 (s, 6H). 13C NMR (101 MHz, DMSO) 
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δ 175.77, 145.97, 139.39, 130.89, 124.77, 123.23, 121.98, 117.33, 114.04, 40.57, 34.48, 
28.99, 27.55, 19.48. HRMS (ESI) calcd for C15H18NO [M+H]
+
: 228.1383, found: 
228.1386. 
5-methoxy-3,3-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.39). Following 
general procedures A and B, the title compound was prepared to provide 21% yield as a 
tan powder, m.p. = decomp. 317
°
C.  
1
H NMR (400 MHz, DMSO) δ 10.65 (s, 1H), 7.63 (t, 
J = 4.5 Hz, 1H), 7.16 (d, J = 3.3 Hz, 2H), 3.97 (s, 3H), 2.57 (s, 2H), 2.45 (t, J = 6.1 Hz, 
2H), 1.48 (t, J = 6.1 Hz, 2H), 0.96 (s, 6H). 
13
C NMR (101 MHz, DMSO) δ 175.54, 
147.94, 145.99, 130.28, 124.05, 121.74, 116.14, 114.59, 110.28, 56.00, 40.54, 34.40, 
28.95, 27.63, 19.65.  HRMS (ESI) calcd for C16H20NO2 [M+H]
+
: 258.1489, found: 
258.1495. 
6-methoxy-3,3-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.40). Following 
general procedures A and B, the title compound was prepared to provide 39% yield as a 
tan crystal, m.p. = 309 - 311
°
C. 
1H NMR (400 MHz, DMSO) δ 11.10 (s, 1H), 7.94 (d, J = 
9.3 Hz, 1H), 6.83 (s, 2H), 3.82 (s, 3H), 2.42 (d, J = 9.5 Hz, 4H), 1.48 (t, J = 6.0 Hz, 2H), 
0.98 (s, 6H). 
13C NMR (101 MHz, DMSO) δ 175.43, 161.32, 145.42, 141.07, 126.62, 
117.76, 113.57, 112.13, 98.20, 55.25, 40.52, 34.53, 28.98, 27.56, 19.36.  HRMS (ESI) 
calcd for C16H20NO2 [M+H]
+
: 258.1489, found: 258.1483. 
7-methoxy-3,3-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.41). Following 
general procedures A and B, the title compound was prepared to provide 21% yield as a 
yellow crystal, m.p. = 318 - 320
°
C. 
1H NMR (400 MHz, DMSO) δ 11.27 (s, 1H), 7.47 – 
7.38 (m, 2H), 7.24 – 7.17 (m, 1H), 3.81 (s, 3H), 2.47 (s, 4H), 1.49 (t, J = 5.9 Hz, 2H), 
0.98 (s, 6H).
13C NMR (101 MHz, DMSO) δ 175.11, 154.71, 145.12, 134.12, 124.05, 
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121.40, 119.09, 113.03, 104.04, 55.21, 40.54, 34.55, 29.00, 27.55, 19.60.  HRMS (ESI) 
calcd for C16H19NO2 [M+H]
+
: 258.1489, found: 258.1485. 
8-methoxy-3,3-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.42). Following 
general procedures A and B, the title compound was prepared to provide 46% yield as a 
white powder, m.p. = decomp. 365
°
C.  
1
H NMR (400 MHz, DMSO) δ 10.95 (s, 1H), 7.40 
(t, J = 7.9 Hz, 1H), 6.96 (d, J = 8.0 Hz, 1H), 6.63 (d, J = 7.6 Hz, 1H), 3.76 (s, 3H), 2.37 
(d, J = 16.8 Hz, 4H), 1.46 (s, 2H), 0.97 (s, 6H).
13
C NMR (101 MHz, DMSO) δ 175.81, 
159.43, 143.63, 142.16, 131.17, 115.64, 113.95, 109.43, 103.15, 55.55, 40.44, 34.63, 
28.96, 27.58, 19.62.  HRMS (ESI) calcd for C16H20NO2 [M+H]
+
: 258.1489, found: 
258.1493. 
3,3,5-trimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.43). Following general 
procedures A and B, the title compound was prepared to provide 32% yield as a white 
powder, m.p. = decomp. 280
°
C.  
1H NMR (400 MHz, DMSO) δ 10.15 (s, 1H), 7.93 (d, J 
= 8.0 Hz, 1H), 7.41 (d, J = 6.8 Hz, 1H), 7.12 (t, J = 7.2 Hz, 1H), 2.81 (t, J = 6.0 Hz, 2H), 
2.25 (s, 3H), 1.54 (t, J = 6.0 Hz, 2H), 0.96 (s, 6H).
 13C NMR (101 MHz, DMSO) δ 
176.74, 147.02, 138.78, 132.48, 126.10, 124.10, 123.45, 122.43, 114.85, 41.43, 35.06, 
29.70, 28.33, 20.23, 18.11. HRMS (ESI) calcd for C16H20NO [M+H]
+
: 242.1539, found: 
242.1530. 
3,3,6-trimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.44). Following general 
procedures A and B, the title compound was prepared to provide 41% yield as a tan 
crystal, m.p. = 339 - 341
°
C.  
1
H NMR (400 MHz, DMSO) δ 11.13 (s, 1H), 7.93 (d, J = 
8.2 Hz, 1H), 7.21 (s, 1H), 7.04 (d, J = 8.2 Hz, 1H), 2.47 – 2.41 (m, 4H), 2.39 (s, 3H), 
1.49 (t, J = 6.5 Hz, 2H), 0.98 (s, 6H).
13
C NMR (101 MHz, DMSO) δ 175.48, 145.99, 
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141.02, 139.58, 124.78, 123.97, 121.21, 116.65, 113.83, 40.62, 34.50, 29.03, 27.60, 
21.34, 19.49. HRMS (ESI) calcd for C16H20NO [M+H]
+
: 242.1539, found: 242.1531. 
3,3,7-trimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.45). Following general 
procedures A and B, the title compound was prepared to provide 38% yield as a white 
crystal, m.p. = 342 - 344
°
C. 
1H NMR (400 MHz, DMSO) δ 11.20 (s, 1H), 7.84 (s, 1H), 
7.38 (q, J = 8.3 Hz, 2H), 2.44-2.48 (m, 4H), 2.38 (s, 3H), 1.49 (t, J = 6.0 Hz, 2H), 0.98 (s, 
6H).
13C NMR (101 MHz, DMSO) δ 175.57, 145.56, 137.49, 132.30, 131.01, 123.94, 
123.16, 117.28, 113.69, 40.55, 34.52, 28.98, 27.56, 20.71, 19.51. HRMS (ESI) calcd for 
C16H20NO [M+H]
+
: 242.1539, found: 242.1530. 
3,3,8-trimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.46). Following general 
procedures A and B, the title compound was prepared to provide 75% yield as a white 
crystal, m.p. = 327 - 329
°
C. 
1H NMR (400 MHz, DMSO) δ 11.03 (s, 1H), 7.36 (t, J = 7.7 
Hz, 1H), 7.26 (d, J = 8.2 Hz, 1H), 6.89 (d, J = 7.0 Hz, 1H), 2.80 (s, 3H), 2.39 (dd, J = 
13.1, 6.4 Hz, 4H), 1.47 (t, J = 6.5 Hz, 2H), 0.97 (s, 6H).
13C NMR (101 MHz, DMSO) δ 
178.31, 144.39, 141.02, 138.92, 129.99, 124.35, 121.58, 115.54, 115.21, 40.21, 34.64, 
28.95, 27.56, 23.29, 19.60. HRMS (ESI) calcd for C16H20NO [M+H]
+
: 242.1539, found: 
242.1529. 
5-chloro-3,3-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.47). Following general 
procedures A and B, the title compound was prepared to provide 26% yield as an off-
white powder, m.p. = 255 - 256
°
C. 
1
H NMR (400 MHz, DMSO) δ 10.52 (s, 1H), 8.05 (s, 
1H), 7.75 (s, 1H), 7.24 (s, 1H), 2.84 (s, 2H), 2.25 (s, 2H), 1.53 (s, 2H), 0.96 (s, 6H).
13
C 
NMR (101 MHz, DMSO) δ 175.32, 147.30, 135.97, 131.26, 124.73, 124.22, 122.47, 
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120.61, 115.17, 40.64, 34.15, 28.96, 27.60, 19.55. HRMS (ESI) calcd for C15H17ClNO 
[M+H]
+
: 262.0993, found: 262.0993. 
6-chloro-3,3-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.48). Following general 
procedures A and B, the title compound was prepared to provide 52% yield as a white 
powder, m.p. = 346 - 349
°
C. 
1H NMR (400 MHz, DMSO) δ 11.36 (s, 1H), 8.04 (d, J = 
8.6 Hz, 1H), 7.47 (d, J = 1.7 Hz, 1H), 7.24 (dd, J = 8.6, 1.7 Hz, 1H), 3.17 (s, 2H), 2.43 (d, 
J = 6.5 Hz, 2H), 1.49 (t, J = 6.5 Hz, 2H), 0.98 (s, 6H).
13C NMR (101 MHz, DMSO) δ 
175.26, 146.54, 140.09, 135.52, 127.20, 122.44, 121.82, 116.44, 114.87, 48.58, 34.34, 
28.99, 27.54, 19.40. HRMS (ESI) calcd for C15H17ClNO [M+H]
+
: 262.0993, found: 
262.0998. 
7-chloro-3,3-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.49). Following general 
procedures A and B, the title compound was prepared to provide 53% yield as a white 
crystal, m.p. = 337 - 339
°
C. 
1H NMR (400 MHz, DMSO) δ 11.48 (s, 1H), 7.98 (d, J = 2.1 
Hz, 1H), 7.60 (dd, J = 8.8, 2.1 Hz, 1H), 7.50 (d, J = 8.8 Hz, 1H), 2.48 – 2.44 (m, 4H), 
1.49 (t, J = 6.4 Hz, 2H), 0.98 (s, 6H).
13C NMR (101 MHz, DMSO) δ 174.61, 146.61, 
137.95, 131.07, 126.61, 124.13, 123.68, 119.88, 114.61, 40.54, 34.33, 28.99, 27.54, 
19.48. HRMS (ESI) calcd for C15H17ClNO [M+H]
+
: 262.0993, found: 262.0989. 
8-chloro-3,3-dimethyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.50). Following general 
procedures A and B, the title compound was prepared to provide 45% yield as an off-
white powder, m.p. = 339 - 341
°
C. 
1H NMR (400 MHz, DMSO) δ 11.30 (s, 1H), 7.48 – 
7.38 (m, 2H), 7.17 (d, J = 7.0 Hz, 1H), 2.43 (s, 2H), 2.39 (t, J = 6.2 Hz, 2H), 1.48 (t, J = 
6.4 Hz, 2H), 0.97 (s, 6H). 
13C NMR (101 MHz, DMSO) δ 175.05, 144.91, 141.90, 
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131.76, 130.64, 124.62, 119.10, 116.97, 115.95, 40.16, 34.43, 28.90, 27.52, 19.62. 
HRMS (ESI) calcd for C15H17ClNO [M+H]
+
: 262.0993, found: 262.0995. 
6-nitro-1,2,3,4-tetrahydroacridin-9(10H)-one (4.51). Following general procedures A 
and B, the title compound was prepared to provide 54% yield as a yellow powder, m.p. = 
330 – 331°C. 1H NMR (400 MHz, DMSO) δ 11.74 (s, 1H), 8.29 (s, 1H), 8.22 (d, J = 8.7 
Hz, 1H), 7.93 (d, J = 8.6 Hz, 1H), 2.71 (br s, 2H), 2.43 (br s, 2H), 1.74 (dd, J = 25.7, 5.0 
Hz, 4H). HRMS (ESI) calcd for C13H13N2O3 [M+H]
+
: 245.0921, found: 245.0925. 
7-nitro-1,2,3,4-tetrahydroacridin-9(10H)-one (4.52). Following general procedures A 
and B, the title compound was prepared to provide 61% yield as a yellow powder, m.p. = 
358 - 359
°
C. 
1H NMR (400 MHz, DMSO) δ 11.82 (s, 1H), 8.77 (s, 1H), 8.31 (d, J = 8.8 
Hz, 1H), 7.56 (d, J = 9.0 Hz, 1H), 2.69 (s, 2H), 2.42 (s, 2H), 1.73 (dd, J = 26.3, 4.1 Hz, 
4H).
13C NMR (101 MHz, DMSO) δ 175.49, 148.16, 142.76, 141.74, 125.15, 121.86, 
121.70, 119.06, 117.53, 27.08, 21.46, 21.20. HRMS (ESI) calcd for C13H13N2O3 [M+H]
+
: 
245.0921, found: 245.0926. 
5-Fluoro-1,3,4,10-tetrahydro-2H-acridin-9-one (4.53). Following general procedure C, 
the title compound was prepared to provide 25% yield as an off white powder, m.p. = 308 
- 310
°
C.  
1H NMR (400 MHz, DMSO) δ 11.21 (s, 1H), 7.82 (d, J = 8.1 Hz, 1H), 7.44 (dd, 
J = 11.4, 7.9 Hz, 1H), 7.17 – 7.12 (m, 1H), 2.70 (t, J = 5.7 Hz, 2H), 2.39 (t, J = 5.7 Hz, 
2H), 1.71 – 1.62 (m, 4H). 19F NMR (376 MHz, DMSO) δ -131.26. 13C NMR (101 MHz, 
DMSO) δ 175.09, 151.14 (d, J = 248.5 Hz), 147.40, 128.54 (d, J = 13.13 Hz), 125.24, 
121.40 (d, J = 6.1 Hz), 120.53, 116.45, 115.45 (d, J = 17.2 Hz), 27.08, 21.68, 21.65, 
21.34. HRMS (ESI) calcd for C13H13FNO [M+H]
+
: 218.0976, found: 218.0969. 
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6-fluoro-1,2,3,4-tetrahydroacridin-9(10H)-one (4.54). Following general procedures A 
and B, the title compound was prepared to provide 55% yield as a white powder, m.p. = 
decomp. 359
°
C. 
1H NMR (400 MHz, DMSO) δ 11.35 (s, 1H), 8.08 (dd, J = 8.8, 6.6 Hz, 
1H), 7.15 (dd, J = 10.3, 2.2 Hz, 1H), 7.06 (td, J = 8.8, 2.2 Hz, 1H), 2.67 (t, J = 6.0 Hz, 
2H), 2.40 (t, J = 6.0 Hz, 2H), 1.76 – 1.66 (m, 4H). 19F NMR (376 MHz, DMSO) δ -
109.41. 
13C NMR (101 MHz, DMSO) δ 175.38, 163.46 (d, J = 247.5 Hz) , 147.24, 
140.45 (d, J = 12.12 Hz), 128.12 (d, J = 10.1 Hz), 120.27, 115.78, 110.79 (d, J = 24.24 
Hz), 102.22 (d, J = 25.25 Hz), 27.05, 21.75, 21.49, 21.38. HRMS (ESI) calcd for 
C13H13FNO [M+H]
+
: 218.0976, found: 218.0967. 
7-iodo-1,2,3,4-tetrahydroacridin-9(10H)-one (4.55). Following general procedures A 
and B, the title compound was prepared to provide 49% yield as a white powder. 
1
H 
NMR (400 MHz, DMSO) δ 11.45 (s, 1H), 8.32 (s, 1H), 7.82 (d, J = 8.5 Hz, 1H), 7.28 (d, 
J = 8.7 Hz, 1H), 2.68 (s, 2H), 2.41 (s, 2H), 1.72 (d, J = 18.6 Hz, 4H). 
13
C NMR (101 
MHz, DMSO) δ 174.39, 147.29, 138.89, 138.36, 133.30, 124.99, 119.94, 116.22, 86.02, 
27.12, 21.70, 21.65, 21.35. HRMS (ESI) calcd for C13H12INONa [M+Na]
+
: 347.9856, 
found: 347.9851  
6-bromo-1,2,3,4-tetrahydroacridin-9(10H)-one (4.56). Following general procedures A 
and B, the title compound was prepared to provide 51% yield as a yellow powder. 
1
H 
NMR (400 MHz, DMSO) δ 11.37 (s, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.63 (s, 1H), 7.35 (d, 
J = 8.3 Hz, 1H), 2.68 (s, 2H), 2.41 (s, 2H), 1.72 (d, J = 20.6 Hz, 4H).
13
C NMR (101 
MHz, DMSO) δ 175.36, 147.34, 140.08, 127.23, 125.09, 124.32, 121.95, 119.48, 116.32, 
27.13, 21.69, 21.57, 21.35. HRMS (ESI) calcd for C13H13BrNO [M+H]
+
: 278.0175, 
found: 287.0179. 
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7-bromo-1,2,3,4-tetrahydroacridin-9(10H)-one (4.57). Following general procedure C, 
the title compound was prepared to provide 48% yield as a yellow crystal, m.p. = 252 - 
253
°
C. 
1H NMR (400 MHz, DMSO) δ 11.50 (s, 1H), 8.12 (s, 1H), 7.70 (d, J = 8.8 Hz, 
1H), 7.43 (d, J = 8.7 Hz, 1H), 2.69 (t, J = 6.0 Hz, 2H), 2.42 (t, J = 6.1 Hz, 2H), 1.72 (dd, 
J = 24.8, 5.7 Hz, 4H). 
13C NMR (101 MHz, DMSO) δ 174.53, 147.39, 138.04, 133.64, 
126.90, 124.47, 120.05, 116.13, 114.45, 27.12, 21.70, 21.65, 21.36. HRMS (ESI) calcd 
for C13H13BrNO [M+H]
+
: 278.0175, found: 287.0167. 
5-tert-butyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.58). Following general procedure 
C, the title compound was prepared to provide 49% yield as an off white crystal, m.p. 
=176 - 177
°
C. 
1H NMR (400 MHz, DMSO) δ 8.74 (s, 1H), 8.05 (d, J = 7.9 Hz, 1H), 7.55 
(d, J = 7.0 Hz, 1H), 7.17 (d, J = 7.4 Hz, 1H), 2.87 (d, J = 5.4 Hz, 2H), 2.44 (s, 2H), 1.78 – 
1.66 (m, 4H), 1.50 (s, 9H). 
13C NMR (101 MHz, DMSO) δ 177.11, 147.11, 137.58, 
136.90, 128.98, 125.30, 124.44, 122.61, 115.94, 34.81, 31.16, 28.56, 22.40, 22.25, 22.20. 
HRMS (ESI) calcd for C17H22NO [M+H]
+
: 256.1696, found: 256.1703. 
7-tert-butyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.59). Following general procedure 
C, the title compound was prepared to provide 84% yield as a white crystal, m.p. = 316 - 
319
°
C. 
1
H NMR (400 MHz, DMSO) δ 11.25 (s, 1H), 8.04 – 7.97 (m, 1H), 7.66 (ddd, J = 
8.7, 2.3, 1.4 Hz, 1H), 7.40 (dd, J = 8.7, 0.8 Hz, 1H), 2.67 (t, J = 5.9 Hz, 2H), 2.43 (t, J = 
6.0 Hz, 2H), 1.77 – 1.67 (m, 4H), 1.32 (s, 9H). 13C NMR (101 MHz, DMSO) δ 175.97, 
146.32, 144.25, 137.30, 129.03, 122.64, 119.78, 117.19, 115.17, 34.27, 31.14, 27.07, 
21.93, 21.72, 21.53. HRMS (ESI) calcd for C17H22NO [M+H]
+
: 256.1696, found: 
256.1700. 
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5-(trifluoromethyl)-1,2,3,4-tetrahydroacridin-9(10H)-one (4.60). Following general 
procedure C, the title compound was prepared to provide 39% yield as a yellow powder, 
m.p. = 226 - 230
°
C. 
1H NMR (400 MHz, DMSO) δ 10.00 (s, 1H), 8.40 (d, J = 7.9 Hz, 
1H), 7.99 (d, J = 7.3 Hz, 1H), 7.39 (t, J = 7.6 Hz, 1H), 2.84 (s, 2H), 2.44 (s, 2H), 1.72 
(dd, J = 14.8, 6.6 Hz, 4H). 
19F NMR (376 MHz, DMSO) δ -59.13. 13C NMR (101 MHz, 
DMSO) δ 175.18, 148.45, 135.21, 130.51, 129.57 (d, J = 5.05 Hz), 124.41, 123.79 (d, J = 
276.7 Hz), 121.42, 117.16, 27.61, 21.59, 21.43. HRMS (ESI) calcd for C14H13F3NO 
[M+H]
+
: 268.0944, found: 268.0940. 
7-isopropyl-1,2,3,4-tetrahydroacridin-9(10H)-one (4.61). Following general procedure 
C, the title compound was prepared to provide 11% yield as a tan powder, m.p. = 275 - 
277
°
C.
 1H NMR (400 MHz, DMSO) δ 11.24 (s, 1H), 7.88 (s, 1H), 7.48 (d, J = 7.9 Hz, 
1H), 7.39 (d, J = 8.0 Hz, 1H), 2.96 (d, J = 6.0 Hz, 1H), 2.68 (s, 2H), 2.43 (s, 2H), 1.72 (d, 
J = 19.1 Hz, 4H), 1.23 (d, J = 5.9 Hz, 6H).
13C NMR (101 MHz, DMSO) δ 176.54, 
147.00, 142.62, 138.31, 130.68, 123.74, 121.75, 118.06, 115.81, 33.69, 27.76, 24.59, 
22.61, 22.40, 22.21.HRMS (ESI) calcd for C16H20NO [M+H]
+
: 242.1539, found: 
242.1540. 
7-ethoxy-1,2,3,4-tetrahydroacridin-9(10H)-one (4.62). Following general procedure C, 
the title compound was prepared to provide 51% yield as a yellow powder, m.p. = 291 - 
292
°
C.  
1
H NMR (400 MHz, DMSO) δ 11.28 (s, 1H), 7.42 (dd, J = 11.0, 5.8 Hz, 2H), 
7.19 (dd, J = 8.9, 2.8 Hz, 1H), 4.05 (q, J = 6.9 Hz, 2H), 2.68 (t, J = 5.7 Hz, 2H), 2.43 (d, J 
= 5.5 Hz, 2H), 1.75 – 1.63 (m, 4H), 1.35 (t, J = 6.9 Hz, 3H). 13C NMR (101 MHz, 
DMSO) δ 175.93, 154.57, 146.51, 134.56, 124.69, 122.41, 119.72, 115.13, 105.38, 63.87, 
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27.74, 22.65, 22.49, 22.24, 15.29. HRMS (ESI) calcd for C15H18NO2 [M+H]
+
: 244.1332, 
found: 244.1323. 
9-oxo-5,6,7,8,9,10-hexahydro-acridine-2-carboxylic acid ethyl ester (4.63). Following 
general procedure C, the title compound was prepared to provide 32% yield as an off 
white crystal, m.p. = 325 - 326
°
C. 
1H NMR (400 MHz, DMSO) δ 11.60 (s, 1H), 8.68 (d, J 
= 1.3 Hz, 1H), 8.06 (dd, J = 8.6, 1.5 Hz, 1H), 7.52 (d, J = 8.7 Hz, 1H), 4.33 (q, J = 7.0 
Hz, 2H), 2.69 (d, J = 5.9 Hz, 2H), 2.42 (d, J = 5.4 Hz, 2H), 1.73 (dd, J = 25.3, 4.9 Hz, 
4H), 1.34 (t, J = 7.0 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 176.57, 166.08, 148.25, 
142.67, 131.42, 128.12, 123.83, 122.98, 118.58, 117.55, 61.31, 27.77, 22.31, 22.25, 
22.02, 14.90. HRMS (ESI) calcd C16H18NO3 [M+H]
+
: 272.1281, found: 272.1275. 
5,8-Dimethyl-1,3,4,10-tetrahydro-2H-acridin-9-one (4.64). Following general 
procedure C, the title compound was prepared to provide 74% yield as a yellow crystal, 
m.p. = 246 - 248
°
C. 
1H NMR (400 MHz, DMSO) δ 9.66 (s, 1H), 7.20 (d, J = 7.3 Hz, 1H), 
6.80 (d, J = 7.3 Hz, 1H), 2.74 (br. m, 5H), 2.41 (s, 3H), 2.37 (t, J = 5.9 Hz, 2H), 1.69 (br. 
m, 4H). 
13
C NMR (101 MHz, DMSO) δ 178.77, 145.46, 139.30, 136.53, 130.96, 124.10, 
122.78, 121.68, 116.94, 26.92, 23.49, 21.93, 21.81, 21.57, 17.56. HRMS (ESI) calcd 
C15H18NO [M+H]
+
: 228.1383, found: 228.1376. 
5,7-Dimethyl-1,3,4,10-tetrahydro-2H-acridin-9-one (4.65). Following general 
procedure C, the title compound was prepared to provide 78% yield as an off white 
crystal, m.p. = 323 - 326
°
C.  
1H NMR (400 MHz, DMSO) δ 10.97 (s, 1H), 7.06 (s, 1H), 
6.74 (s, 1H), 2.79 (s, 3H), 2.64 (s, 2H), 2.38 (s, 2H), 2.34 (s, 3H), 1.72 (br. d, J = 15.4 Hz, 
4H). 
13C NMR (101 MHz, DMSO) δ 178.28, 144.84, 141.08, 139.66, 138.73, 126.06, 
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119.63, 116.40, 114.83, 26.72, 23.18, 22.04, 21.74, 21.52, 21.01. HRMS (ESI) calcd for 
C15H18NO [M+H]
+
: 228.1383, found: 228.1377. 
6,8-Dimethyl-1,3,4,10-tetrahydro-2H-acridin-9-one (4.66). Following general 
procedure C, the title compound was prepared to provide 31% yield as a white powder, 
m.p. = 292 - 294
°
C. 
1H NMR (400 MHz, DMSO) δ 10.97 (s, 1H), 7.06 (s, 1H), 6.74 (s, 
1H), 2.79 (s, 3H), 2.64 (s, 2H), 2.38 (s, 2H), 2.34 (s, 3H), 1.72 (br. d, J = 15.4 Hz, 4H). 
13C NMR (101 MHz, DMSO) δ 178.28, 144.84, 141.08, 139.66, 138.73, 126.06, 119.63, 
116.40, 114.83, 26.72, 23.18, 22.04, 21.74, 21.52, 21.01. HRMS (ESI) calcd for 
Chemical Formula: C15H18NO [M+H]
+
: 228.1383, found: 228.1381. 
5,6-Dimethyl-1,3,4,10-tetrahydro-2H-acridin-9-one (4.67). Following general 
procedure C, the title compound was prepared to provide 27% yield as a white crystal, 
m.p. = 340 - 343
°
C. 
1H NMR (400 MHz, DMSO) δ 9.93 (s, 1H), 7.83 (d, J = 8.2 Hz, 1H), 
7.06 (d, J = 8.2 Hz, 1H), 3.32 (d, J = 0.9 Hz, 3H), 2.78 (t, J = 5.9 Hz, 2H), 2.42 (t, J = 5.5 
Hz, 2H), 2.39 (s, 2H), 2.36 (s, 2H), 1.72 (dd, J = 23.8, 5.9 Hz, 4H). 
13
C NMR (101 MHz, 
DMSO) δ 176.21, 146.99, 138.82, 138.00, 124.46, 122.77, 122.05, 121.91, 114.99, 27.33, 
21.84, 21.66, 21.63, 20.39, 12.94. HRMS (ESI) calcd C15H17NONa [M+Na]
+
: 250.1202, 
found: 250.1195. 
6,7-Dimethyl-1,3,4,10-tetrahydro-2H-acridin-9-one (4.68). Following general 
procedure C, the title compound was prepared to provide 34% yield as a white powder. 
1H NMR (400 MHz, DMSO) δ 11.13 (s, 1H), 7.78 (s, 1H), 7.20 (s, 1H), 2.66 (s, 2H), 
2.41 (s, 2H), 2.29 (d, J = 9.1 Hz, 6H), 1.75 – 1.67 (m, 4H). 13C NMR (101 MHz, DMSO) 
δ 146.69, 141.04, 138.51, 131.36, 125.19, 122.28, 117.82, 115.62, 27.77, 22.64, 22.38, 
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22.23, 20.57, 19.86. HRMS (ESI) calcd for C15H18NO [M+H]
+
: 228.1383, found: 
228.1379. 
5,8-Dimethoxy-1,3,4,10-tetrahydro-2H-acridin-9-one (4.69). Following general 
procedure C, the title compound was prepared to provide 84% yield as a yellow-green 
powder, m.p. = 215 - 219
°
C. 
1H NMR (400 MHz, DMSO) δ 10.25 (s, 1H), 7.03 (d, J = 
8.6 Hz, 1H), 6.55 (d, J = 8.6 Hz, 1H), 3.89 (s, 3H), 3.71 (s, 3H), 2.70 (s, 2H), 2.34 (s, 
2H), 1.66 (br. d, 4H). 
13C NMR (101 MHz, DMSO) δ 175.66, 152.65, 144.61, 141.47, 
132.17, 117.75, 114.67, 110.58, 102.85, 56.16, 26.71, 21.90, 21.47. HRMS (ESI) calcd 
for C15H18NO3 [M+H]
+
: 260.1281, found: 260.1272. 
5,7-Dimethoxy-1,3,4,10-tetrahydro-2H-acridin-9-one (4.70). Following general 
procedure C, the title compound was prepared to provide 23% yield as a tan powder, m.p. 
= 226 - 230
°
C. 
1H NMR (400 MHz, DMSO) δ 10.67 (s, 1H), 7.04 (s, 1H), 6.79 (s, 1H), 
3.95 (s, 3H), 3.80 (s, 3H), 2.74 (t, J = 5.3 Hz, 2H), 2.43 (t, J = 5.3 Hz, 2H), 1.68 (d, J = 
3.6 Hz, 4H). 
13C NMR (101 MHz, DMSO) δ 174.94, 154.78, 149.16, 145.77, 125.34, 
124.31, 115.14, 101.88, 95.19, 56.16, 55.21, 27.04, 21.92, 21.89, 21.54. HRMS (ESI) 
calcd for C15H18NO3 [M+H]
+
: 260.1281, found: 260.1283. 
6,8-Dimethoxy-1,3,4,10-tetrahydro-2H-acridin-9-one (4.71). Following general 
procedure C, the title compound was prepared to provide 11% yield as a white powder, 
m.p. = 267 - 270
°
C. 
1H NMR (400 MHz, DMSO) δ 10.89 (s, 1H), 6.44 (s, 1H), 6.24 (s, 
1H), 3.82 (s, 3H), 3.77 (s, 3H), 2.59 (s, 2H), 2.33 (s, 2H), 1.71 (br. d, J = 15.8 Hz, 4H). 
13C NMR (101 MHz, DMSO) δ 175.40, 161.27, 160.78, 143.77, 143.25, 116.56, 109.04, 
93.46, 90.60, 55.46, 55.05, 26.49, 21.99, 21.58, 21.45. HRMS (ESI) calcd for C15H18NO3 
[M+H]
+
: 260.1281, found: 260.1273. 
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5,6-Dimethoxy-1,3,4,10-tetrahydro-2H-acridin-9-one (4.72). Following general 
procedure C, the title compound was prepared to provide 35% yield as a light yellow 
powder, m.p. = 206 - 207
°
C. 
1H NMR (400 MHz, DMSO) δ 10.59 (s, 1H), 7.82 (d, J = 
9.0 Hz, 1H), 7.10 (d, J = 9.0 Hz, 1H), 3.95 (s, 3H), 3.87 (s, 3H), 2.79 (s, 2H), 2.44 (s, 
2H), 1.73 (br. d, J = 14.5 Hz, 4H). 
13C NMR (101 MHz, DMSO) δ 175.70, 152.76, 
147.14, 134.98, 134.04, 120.67, 118.58, 114.75, 108.68, 60.57, 56.08, 27.22, 21.84, 
21.67, 21.53. HRMS (ESI) calcd for C15H18NO3 [M+H]
+
: 260.1281, found: 260.1280. 
6,7-dimethoxy-1,2,3,4-tetrahydroacridin-9(10H)-one (4.73). Following general 
procedures A and B, the title compound was prepared to provide 40% yield as a yellow 
powder, m.p. = 252 - 254
°
C. 
1H NMR (400 MHz, DMSO) δ 11.15 (s, 1H), 7.40 (s, 1H), 
6.88 (s, 1H), 3.82 (d, J = 14.2 Hz, 6H), 2.65 (t, J = 5.5 Hz, 2H), 2.41 (t, J = 5.8 Hz, 2H), 
1.71 (dd, J = 21.9, 5.1 Hz, 4H). 
13C NMR (101 MHz, DMSO) δ 175.51, 153.13, 146.48, 
145.85, 135.57, 117.71, 115.03, 104.89, 99.12, 56.20, 56.07, 27.68, 22.68, 22.41, 22.23. 
HRMS (ESI) calcd for C15H18NO3 [M+H]
+
: 260.1281, found: 260.1284. 
5,8-Dichloro-1,3,4,10-tetrahydro-2H-acridin-9-one (4.74). Following general 
procedure C, the title compound was prepared to provide 15% yield as a off white 
powder, m.p. = 229 - 231
°
C. 
1H NMR (400 MHz, DMSO) δ 10.23 (s, 1H), 7.65 (d, J = 
8.3 Hz, 1H), 7.18 (d, J = 8.3 Hz, 1H), 2.76 (d, J = 5.7 Hz, 2H), 2.36 (t, J = 5.3 Hz, 2H), 
1.69 (dd, J = 11.3, 5.3 Hz, 4H). 
13C NMR (101 MHz, DMSO) δ 174.77, 146.66, 137.78, 
131.09, 130.81, 124.67, 120.09, 119.61, 118.45, 26.92, 21.77, 21.48, 21.21. HRMS (ESI) 
calcd for C13H12Cl2NO [M+H]
+
: 268.0291, found: 268.0281. 
5,7-Dichloro-1,3,4,10-tetrahydro-2H-acridin-9-one (4.75). Following general 
procedure C, the title compound was prepared to provide 39% yield as a yellow 
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crystalline powder, m.p. = 302 – 305°C. 1H NMR (400 MHz, DMSO) δ 10.68 (s, 1H), 
7.96 (d, J = 24.3 Hz, 2H), 2.84 (s, 2H), 2.44 (s, 2H), 1.73 (d, J = 16.2 Hz, 4H). 
13
C NMR 
(101 MHz, DMSO) δ 174.89, 149.30, 135.41, 131.50, 126.92, 125.65, 123.97, 122.87, 
117.70, 27.97, 22.40, 22.10, 21.98. HRMS (ESI) calcd for C19H12Cl2NO [M+H]
+
: 
268.0291, found: 268.0286. 
6,8-Dichloro-1,3,4,10-tetrahydro-2H-acridin-9-one (76). Following general procedure 
C, the title compound was prepared to provide 47% yield as a white powder. 
1
H NMR 
(400 MHz, DMSO) δ 11.38 (s, 1H), 7.41 (s, 1H), 7.23 (s, 1H), 2.63 (s, 2H), 2.34 (s, 2H), 
1.70 (d, J = 17.9 Hz, 4H). 
13C NMR (101 MHz, DMSO) δ 203.73, 175.33, 146.66, 
142.67, 135.02, 134.25, 124.69, 118.78, 116.66, 27.39, 22.32, 21.88. HRMS (ESI) calcd 
for C13H12Cl2NO [M+H]
+
: 268.0290, found: 268.0278. 
5,6-Dichloro-1,3,4,10-tetrahydro-2H-acridin-9-one (4.77). Following general 
procedure C, the title compound was prepared to provide 36% yield as a white powder, 
m.p. = 320 - 322
°
C. 
1H NMR (400 MHz, DMSO) δ 10.56 (s, 1H), 8.05 (d, J = 8.7 Hz, 
1H), 7.47 (d, J = 8.7 Hz, 1H), 2.85 (s, 2H), 2.45 (s, 2H), 1.75 (br. d, J = 17.2 Hz, 4H). 
13
C 
NMR (101 MHz, DMSO) δ 175.02, 148.58, 136.99, 134.43, 125.14, 125.06, 123.15, 
122.89, 117.09, 27.28, 21.58, 21.40, 21.29. HRMS (ESI) calcd for C13H12Cl2NO [M+H]
+
: 
268.0290, found: 268.0286. 
6,7-Dichloro-1,3,4,10-tetrahydro-2H-acridin-9-one (4.78). Following general 
procedure C, the title compound was prepared to provide 21% yield as a brown powder.  
1
H NMR (400 MHz, DMSO) δ 9.93 (s, 1H), 7.83 (1H), 7.06 (1H), 2.78 (d, J = 5.8 Hz, 
2H), 2.34 (d, J = 4.9 Hz, 2H),  1.78 – 1.66 (m, 4H). HRMS (ESI) calcd for C13H12Cl2NO 
[M+H]
+
: 268.0290, found: 268.0296. 
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5,8-Difluoro-1,3,4,10-tetrahydro-2H-acridin-9-one (4.79). Following general 
procedure C, the title compound was prepared to provide 19% yield as a yellow powder, 
m.p. = 304.4 – 306.3°C. 1H NMR (400 MHz, DMSO) δ 11.20 (s, 1H), 7.56 – 7.39 (m, 
1H), 6.94 – 6.79 (m, 1H), 2.71 (t, J = 5.8 Hz, 2H), 2.36 (t, J = 5.8 Hz, 2H), 1.73 – 1.64 
(m, 4H). 
19F NMR (376 MHz, DMSO) δ -119.28, -134.70. 13C NMR (101 MHz, DMSO) 
δ 174.02, 156.28 (d, J = 256.5 Hz), 147.04 (dd, J = 245.4, 5.05 Hz) 146.72, 118.22, 
115.47 (dd, J = 19.19, 10.1 Hz), 106.64 (dd, J = 24.24, 7.07 Hz) 26.83, 21.56, 21.22. 
HRMS (ESI) calcd for C13H12F2NO [M+H]
+
: 236.0882, found: 236.0880. 
5,7-Difluoro-1,3,4,10-tetrahydro-2H-acridin-9-one (4.80). Following general 
procedure C, the title compound was prepared to provide 97% yield as a white powder, 
m.p. = 328 – 331°C. 1H NMR (400 MHz, DMSO) δ 11.38 (s, 1H), 7.66 – 7.58 (m, 1H), 
7.53 (dd, J = 9.1, 0.9 Hz, 1H), 2.73 (t, J = 5.8 Hz, 2H), 2.42 (t, J = 5.8 Hz, 2H), 1.76 – 
1.64 (m, 4H). 
19F NMR (376 MHz, DMSO) δ -117.71, -125.75. 13C NMR (101 MHz, 
DMSO) δ 174.15, 156.13 (dd, J = 244.4, 11.11 Hz), 151.42 (dd, J = 252.5, 12.12 Hz),  
147.70, 125.66 (d, J = 12.12 Hz), 124.94 (d, J = 6.06 Hz), 116.00, 106.07 (dd, J = 29.3, 
20.0 Hz), 106.5 (d, J = 22.2 Hz), 27.06, 21.68, 21.57, 21.27. HRMS (ESI) calcd for 
C13H12F2NO [M+H]
+
: 236.0882, found: 236.0874. 
6,8-Difluoro-1,3,4,10-tetrahydro-2H-acridin-9-one (4.81). Following general 
procedure C, the title compound was prepared to provide 30% yield as an off-white 
powder, m.p. = Decomp. 315
°
C.  
1
H NMR (400 MHz, DMSO) δ 11.45 (s, 1H), 6.99 (dd, 
J = 24.9, 10.2 Hz, 2H), 2.67 (s, 2H), 2.38 (s, 2H), 1.74 (d, J = 19.6 Hz, 2H), 0.00 (dd, J = 
24.9, 10.2 Hz, 2H). 
19F NMR (376 MHz, DMSO) δ -106.67, -109.20. HRMS (ESI) calcd 
for C13H12F2NO [M+H]
+
: 236.0882, found: 236.0871. 
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5,6-Difluoro-1,3,4,10-tetrahydro-2H-acridin-9-one (4.82). Following general 
procedure C, the title compound was prepared to provide 51% yield as an off-white 
powder, m.p. = 327 - 331
°
C. 
1H NMR (400 MHz, DMSO) δ 11.42 (s, 1H), 7.95 – 7.85 
(m, 1H), 7.28 (dd, J = 16.9, 9.0 Hz, 1H), 2.76 (s, 2H), 2.44 (s, 2H), 1.74 (br. d, J = 15.9 
Hz, 4H). 
13
C NMR (101 MHz, DMSO) δ 174.64, 150.21 (dd, J = 248.5, 9.09 Hz), 
147.97, 138.51 (dd, J = 250.5, 15.15 Hz), 129.97, 121.45, 121.04, 116.47, 110.94 (d, J = 
19.19 Hz), 27.05, 21.52, 21.23. HRMS (ESI) calcd for C13H11F2NONa (M+Na)
+
: 
258.0701, found: 258.0700. 
6,7-difluoro-1,2,3,4-tetrahydroacridin-9(10H)-one (4.83). Following general 
procedures A and B, the title compound was prepared to provide 42% yield as a tan 
powder, m.p. = 357 - 358
°
C. 
1H NMR (400 MHz, DMSO) δ 11.47 (s, 1H), 7.86 (t, J = 9.7 
Hz, 1H), 7.37 (dd, J = 10.6, 6.8 Hz, 1H), 2.67 (s, 2H), 2.40 (s, 2H), 1.71 (d, J = 19.1 Hz, 
5H). 
19F NMR (376 MHz, DMSO) δ -133.05, -144.44. 13C NMR (101 MHz, DMSO) δ 
174.55, 151.68 (dd, J = 255.53, 15.15 Hz), 147.54, 146.08 (dd, J = 245.43, 14.14 Hz), 
136.08 (d, J = 11.11 Hz), 119.93, 115.38, 111.77 (d, J = 16.16 Hz), 105.26 (d, J = 20.2 
Hz), 27.03, 21.65, 21.50, 21.29. HRMS (ESI) calcd for C13H12F2NO [M+H]
+
: 236.0882, 
found: 236.0885. 
4-chloro-3-methoxyaniline (4.84). 900 ml of ammonia is condensed at -78
o
C. 1g of 
thinly shaven strips of sodium was added followed by 1.0g of iron (III) nitrate 
nonahydrate. Upon disappearance of the deep blue color 25g of thinly shaven strips of 
sodium was added. After 30 minutes of stirring at -78
o
C 50g of 2,5-dichloroanisole is 
added as a solution in hexane (70 ml) dropwise and the reaction is warmed to -45
o
C for 
2h. Upon completion the ammonia is allowed to evaporate. The crude pot is then diluted 
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in chloroform and 100g of NH4Cl is added slowly. The combines are taken up in a 
separatory funnel and washed with H2O (X3) followed by brine (X1). The organic layer 
is dried over Na2SO4 and concentrated in vacuo. The resulting solid can be used without 
further purification. Yield: 99%. 
1
H NMR (400 MHz, DMSO) δ 6.98 (d, J = 8.4, 1H), 
6.34 (d, J = 1.8, 1H), 6.16 (dd, J = 8.4, 1.9, 1H), 5.23 (s, 2H), 3.74 (s, 3H). 
13
C NMR 
(101 MHz, DMSO) δ 154.90, 149.16, 129.68, 107.02, 106.74, 98.66, 55.38. HRMS (ESI) 
calcd for C7H8ClNO [M+H]
+
: 157.0367, found: 157.0361. 
4-chloro-3-isopropoxyaniline (4.85). To 13.9 mmoles of 5-Amino-2-chlorophenol 1.3 
mL of acetic anhydride and 8 mL of acetic acid was added. After 5 minutes at reflux, the 
reaction was allowed to cool. Product was filtered and used without purification. To the 
product described above, 25.6 mmoles of isopropyl iodide, 25.6 mmoles of Cs2CO3, and 
65 mL of DMF. After 18 hours of reflux, the product was purified via flash 
chromatography. This product was refluxed with 121.5 mmoles of KOH, 15 mL of water, 
and 135 mL of ethanol overnight. Flash chromatography afforded 4-chloro-3-
isopropoxyaniline in 75% yield over 3 steps. 
1
H NMR (250 MHz, CDCl3) δ 7.07 (d, J = 
8.4, 1H), 6.28 (d, J = 2.5, 1H), 6.21 (dd, J = 8.4, 2.6, 1H), 4.45 (dt, J = 12.2, 6.1, 1H), 
3.62 (s, 2H), 1.34 (d, J = 6.1, 3H). 
3-methoxy-4-methylaniline (4.86). A solution of 2-Methoxy-1-methyl-4-nitro-benzene 
(12 mmoles) in 30 mL of ethyl acetate was stirred with 75 mg of 10% palladium on 
carbon under 1.4 atm of hydrogen for 5 hours. The catalyst was filtered and the solution 
was concentrated to afford 93% yield. 
1
H NMR (400 MHz, CDCl3) δ 6.91 (d, J = 8.0 Hz, 
1H), 6.29 – 6.16 (m, 2H), 3.79 (s, 3H), 3.57 (s, 2H), 2.12 (s, 3H). 13C NMR (101 MHz, 
DMSO) δ 158.54, 145.66, 131.08, 116.62, 106.91, 98.66, 55.27, 15.44. 
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Ethyl 4-oxotetrahydro-2H-thiopyran-3-carboxylate (4.87). To 15 mmoles of 3-(2-
Carboxy-ethylsulfanyl)-propionic acid 5 ml of concentrated sulfuric acid in 900 mL of 
ethanol was added. The mixture was allowed to reflux for 4 hours. After cooling, the 
reaction was concentrated to ~20% of its initial concentration followed by the addition of 
600 mL of EA. The solution was extracted using 50% sodium bicarbonate twice and once 
with brine. After flash chromatography, the resulting compound was added in 30 mL of 
Et2O to a flamed dried flask containing 193 mmoles of 60% NaH, 350 mL of Et2O, and 
catalytic ethanol. After 8 hours of reflux, the reaction was quenched with 200 mL of 3.1 
N aqueous AcOH. After extraction with ether 3 times, the organic layers were washed 
with sodium bicarbonate, dried, and concentrated. After purification via flash 
chromatography, the titled compound was afforded in 68% yield over 2 steps as a 
mixture of keto and enol forms. 
1
H NMR (400 MHz, cdcl3) δ 12.51 (d, J = 3.6 Hz, 2H), 
4.16 (qd, J = 7.0, 3.4 Hz, 8H), 3.59 (ddd, J = 7.7, 3.8, 3.1 Hz, 1H), 3.28 – 3.25 (m, 4H), 
3.25 – 3.16 (m, 1H), 3.02 – 2.92 (m, 1H), 2.92 – 2.73 (m, 4H), 2.70 (td, J = 6.0, 3.5 Hz, 
6H), 2.53 – 2.48 (m, 4H), 1.28 – 1.12 (m, 15H). 13C NMR (101 MHz, cdcl3) δ 172.27, 
171.46, 168.54, 97.29, 61.42, 60.66, 60.58, 60.53, 58.59, 43.50, 37.42, 32.50, 32.44, 
30.76, 30.31, 29.61, 25.17, 24.63, 23.44, 14.17, 14.05. 
Ethyl 5,5-difluoro-2-oxocyclohexanecarboxylate (4.88). To a flamed-dried flask, 7.5 
mmoles of 4,4-Difluoro-cyclohexanone in 3 mL of benzene was added along with 22.3 
mmoles of NaH in 30 mL of benzene, and 18.6 mmoles of diethyl carbonate. After 
refluxing for 2 hours, the reaction was quenched by the addition of crushed ice, brine, and 
6 mL of acetic acid. The reaction was washed with DCM twice and the organic layers 
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were dried and concentrated. The oil was purified via column chromatography to afford 
the titled compound in 22% yield. 
6-Chloro-7-methoxy-1,3,4,10-tetrahydro-2H-acridin-9-one (4.89). Following general 
procedure C, the title compound was prepared to provide 36% yield as a mixture of 
isomers. The desired compound was further purified by preparative HPLC. 
1
H NMR (400 
MHz, DMSO) δ 11.19 (s, 1H), 7.49 – 7.39 (m, 2H), 3.86 (s, 3H), 2.62 (d, J = 5.6 Hz, 
3H), 2.35 (t, J = 5.6 Hz, 2H), 1.74 – 1.64 (m, 4H). 13C NMR (101 MHz, DMSO) δ 
175.90, 150.85, 145.83, 136.52, 120.60, 118.85, 118.10, 117.77, 116.81, 57.48, 27.39, 
22.60, 22.57, 22.04. HRMS (ESI) calc. for Chemical Formula: C14H15ClNO2 (M+H)
+
: 
264.0786, found: 264.0777. 
7-Chloro-6-methoxy-1,3,4,10-tetrahydro-2H-acridin-9-one (4.90). Following general 
procedure C, the title compound was prepared to provide 42% yield as a mixture of 
isomers. The desired compound was further purified by preparative HPLC to afford an 
off white powder, m.p. = 316-317
°
C. 
1H NMR (400 MHz, DMSO) δ 11.31 (s, 1H), 7.96 
(s, 1H), 6.99 (s, 1H), 3.93 (s, 1H), 2.66 (s, 2H), 2.40 (s, 2H), 1.72 (br. d, J = 20.3 Hz, 
4H). 
13C NMR (101 MHz, DMSO) δ 174.46, 156.27, 146.66, 139.43, 125.63, 117.69, 
117.22, 115.41, 99.07, 56.20, 27.03, 21.75, 21.49, 21.37. HRMS (ESI) calcd for 
C14H15ClNO2 [M+H]
+
: 264.0786, found: 264.0781. 
7-Chloro-6-isopropoxy-1,3,4,10-tetrahydro-2H-acridin-9-one (4.91). Following 
general procedure C, the title compound was prepared to provide 35% yield as a white 
powder, m.p. = 345 - 346
°
C. 
1H NMR (400 MHz, DMSO) δ 11.22 (s, 1H), 7.95 (s, 1H), 
7.01 (s, 1H), 4.66 (s, 1H), 2.65 (s, 2H), 2.39 (s, 2H), 1.75 – 1.68 (m, 4H), 1.38 (d, J = 5.7 
Hz, 6H). 
13C NMR (101 MHz, DMSO) δ 175.19, 155.24, 147.37, 140.10, 126.50, 118.85, 
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118.26, 115.98, 101.48, 72.16, 40.83, 40.62, 40.41, 40.20, 39.99, 39.78, 39.57, 27.74, 
22.49, 22.15. HRMS (ESI) calcd for C16H19ClNO2 [M+H]
+
: 292.1099, found: 292.1097. 
7-Chloro-6-methoxy-1,3,4,10-tetrahydro-2-thia-10-aza-anthracen-9-one (4.92). 
Following general procedure C, the title compound was prepared to provide 16% yield as 
a brown powder, m.p. = Decomp 324°C. 1H NMR (400 MHz, DMSO) δ 11.46 (s, 1H), 
7.96 (s, 1H), 6.98 (s, 1H), 3.93 (s, 3H), 3.54 (s, 2H), 2.91 (dd, J = 13.5, 4.5 Hz, 4H). 13C 
NMR (101 MHz, DMSO) δ 174.02, 157.29, 147.38, 140.03, 126.42, 118.45, 118.28, 
114.49, 99.86, 56.98, 29.27, 24.25, 23.01. 
7-Chloro-2,2-difluoro-6-methoxy-1,3,4,10-tetrahydro-2H-acridin-9-one  (4.93). 
Following general procedure C, the title compound was prepared to provide 4% yield as a 
dark brown powder. 
1H NMR (400 MHz, DMSO) δ 11.66 (s, 1H), 7.97 (s, 1H), 7.00 (s, 
1H), 3.93 (s, 3H), 2.90 (d, J = 15.6 Hz, 4H), 2.29 (s, 2H). 
19
F NMR (376 MHz, DMSO) δ 
-94.75. 
13C NMR (101 MHz, DMSO) δ 174.01, 157.13, 144.74, 139.80, 126.03, 124.13, 
118.42, 117.67, 99.64, 56.84, 31.67 (t, J = 25.3 Hz), 29.08 (t, J = 25.3 Hz), 25.74. HRMS 
(ESI) calcd for C14H13ClF2NO2 [M+H]
+
: 300.06029, found: 300.06024. 
7-Chloro-2,2-difluoro-1,3,4,10-tetrahydro-2H-acridin-9-one  (4.94). Following 
general procedures A and B, the title compound was prepared to provide 55% yield as a 
brown powder, m.p. = decomp. 351°C. 
1H NMR (400 MHz, DMSO) δ 11.83 (s, 1H), 
7.98 (d, J = 2.1 Hz, 1H), 7.64 (dd, J = 8.8, 2.1 Hz, 1H), 7.52 (d, J = 8.8 Hz, 1H), 2.96 (d, 
J = 5.9 Hz, 4H), 2.34 – 2.27 (m, 2H). 19F NMR (376 MHz, DMSO) δ -94.75. 13C NMR 
(101 MHz, DMSO) δ 174.69, 145.68, 138.34, 132.14, 127.63, 124.22, 124.03, 120.52, 
111.66, 31.75 (t, J = 25.3 Hz), 29.25 (t, J = 25.3 Hz), 25.70 (t, J = 5 Hz).  HRMS (ESI) 
calcd for C13H11ClF2NO [M+H]
+
: 270.04972, found: 270.04968.  
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2,2-difluoro-6-methoxy-1,3,4,10-tetrahydro-2H-acridin-9-one  (4.95). Following 
general procedures A and B, the title compound was prepared to provide 36% yield as a 
light brown powder, m.p. = decomp. 327°C. 
1H NMR (400 MHz, DMSO) δ 11.48 (s, 
1H), 7.96 (d, J = 8.8 Hz, 1H), 6.86 (dt, J = 6.8, 2.3 Hz, 2H), 3.84 (s, 3H), 2.96 – 2.87 (m, 
4H), 2.27 (dt, J = 20.6, 7.0 Hz, 2H). 
19F NMR (376 MHz, DMSO) δ -94.73. 13C NMR 
(101 MHz, DMSO) δ 175.05, 161.78, 144.18, 141.11, 126.58, 117.24, 112.74, 110.36, 
98.40, 55.35, 31.25 (t, J = 25.3 Hz), 28.50 (t, J = 25.2 Hz ), 25.23. HRMS (ESI) calcd for 
C14H14F2NO2 [M+H]
+
: 266.09926, found: 266.09933. 
6-Methoxy-7-methyl-1,3,4,10-tetrahydro-2H-acridin-9-one (4.96). Following general 
procedure C, the title compound was prepared to provide 38% yield as a white powder. 
1
H NMR (400 MHz, DMSO) δ 11.09 (s, 1H), 7.77 (s, 1H), 6.81 (s, 1H), 3.85 (s, 3H), 
2.64 (s, 2H), 2.39 (s, 2H), 2.20 (s, 3H), 1.71 (d, J = 19.9 Hz, 4H). 
13
C NMR (101 MHz, 
DMSO) δ 175.33, 159.92, 145.62, 139.46, 125.89, 121.81, 117.16, 114.86, 96.44, 55.39, 
27.03, 21.98, 21.60, 21.53, 16.00. HRMS (ESI) calcd for C15H18NO2 [M+H]
+
: 244.1332, 
found: 244.1326. 
6-Methoxy-7-methyl-1,3,4,10-tetrahydro-2-thia-10-aza-anthracen-9-one (4.97). 
Following general procedure C, the title compound was prepared to provide 9% yield as a 
pink crystalline powder, m.p. = Decomp. 328
°
C. 
1
H NMR (400 MHz, DMSO) δ 11.27 (s, 
1H), 7.79 (s, 1H), 6.83 (s, 1H), 3.87 (s, 3H), 3.52 (d, J = 19.9 Hz, 2H), 2.90 (dd, J = 14.6, 
5.0 Hz, 4H), 2.21 (s, 3H). 
13
C NMR (101 MHz, DMSO) δ 174.12, 160.25, 145.68, 
139.37, 125.97, 122.48, 117.07, 113.24, 96.54, 55.47, 28.54, 23.67, 22.43, 15.98. HRMS 
(ESI) calcd for C14H16NO2S [M+H]
+
: 262.0896, found: 262.0895. 
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7-bromo-3,4-dihydro-1H-thiopyrano[4,3-b]quinolin-10(5H)-one (4.98). Following 
general procedure C, the title compound was prepared to provide 34% yield as a yellow 
crystal, m.p. = decomp. 298
°
C. 
1
H NMR (400 MHz, DMSO) δ 11.66 (s, 1H), 8.13 (d, J = 
2.2 Hz, 1H), 7.74 (dd, J = 8.8, 2.3 Hz, 1H), 7.45 (d, J = 8.8 Hz, 1H), 3.57 (s, 2H), 2.97 (d, 
J = 5.6 Hz, 2H), 2.90 (t, J = 5.8 Hz, 2H).
 13
C NMR (101 MHz, DMSO) δ 173.45, 147.35, 
137.90, 134.11, 127.00, 124.48, 120.16, 114.94, 114.44, 28.66, 23.57, 22.40. HRMS 
(ESI) calcd for C12H10BrNOSNa [M+Na]
+
: 317.9556, found: 317.9571. 
2-Methyl-1,3,4,5-tetrahydro-2H-benzo[b][1,6]naphthyridin-10-one (4.99). Following 
general procedure C, the title compound was prepared to provide 26% yield as a yellow 
powder. 
1H NMR (400 MHz, DMSO) δ 12.31 (s, 1H), 8.07 (d, J = 7.9 Hz, 1H), 7.66 (dd, 
J = 11.0, 4.0 Hz, 1H), 7.60 (d, J = 8.1 Hz, 1H), 7.31 (t, J = 7.2 Hz, 1H), 4.07 (s, 2H), 3.48 
(s, 2H), 3.16 (s, 2H), 2.93 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 174.24, 143.62, 
139.38, 124.62, 124.54, 123.22, 122.86, 118.11, 109.49, 49.65, 49.13, 42.76, 24.79. 
HRMS (ESI) calcd. for C13H15N2O [M+H]
+
: 215.1179, found: 215.1170. 
7-(4-Fluoro-phenoxy)-1,3,4,10-tetrahydro-2H-acridin-9-one (4.100). Following 
general procedure C, the title compound was prepared to provide 55% yield as an off 
white powder, m.p. = 306 – 308°C. 1H NMR (400 MHz, DMSO) δ 11.42 (s, 1H), 7.51 (s, 
1H), 7.44 (s, 1H), 7.36 (dd, J = 8.7, 2.0 Hz, 1H), 7.23 (t, J = 8.5 Hz, 2H), 7.08 (dd, J = 
8.5, 4.4 Hz, 2H), 2.67 (d, J = 5.7 Hz, 2H), 2.40 (s, 2H), 1.70 (dd, J = 24.6, 5.0 Hz, 4H). 
13
C NMR (101 MHz, DMSO) δ 175.12, 158.19 (d, J = 249.47 Hz), 152.80, 152.31, 
146.61, 135.49, 123.98, 123.30, 120.64, 119.72, 116.57 (d, J = 24.24 Hz), 114.90, 
111.09, 27.08, 21.83, 21.67, 21.47. HRMS (ESI) calcd for C19H17FNO2 [M+H]
+
: 
310.1238, found: 310.1232. 
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7-Chloro-6-methoxy-2-oxo-1,3,4,10-tetrahydro-2H-2l4-thia-10-aza-anthracen-9-one 
(4.101). A flame-dried 5ml round-bottom flask was charged with 2mL of 27% aq. H2O2 
and 7-Chloro-6-methoxy-1,3,4,10-tetrahydro-2-thia-10-aza-anthracen-9-one (.142mmol). 
The reaction was heated at 40
o
C for 10hrs and the resulting solid was filtered and purified 
by preparatory HPLC to give a white crystal.  
1
H NMR (400 MHz, DMSO) δ 11.80 (s, 
1H), 7.97 (s, 1H), 7.05 (s, 1H), 3.95 (s, 3H), 3.84 (d, J = 16.0 Hz, 2H), 3.65 (d, J = 16.6 
Hz, 2H), 3.20 (d, J = 12.1 Hz, 2H).
  13
C NMR (101 MHz, DMSO) δ 174.36, 156.85, 
145.41, 139.42, 125.66, 118.12, 117.54, 105.92, 99.39, 56.40, 42.86, 41.15, 19.64. 
HRMS (ESI) calcd for C13H13ClNO3S [M+H]
+
: 298.0299, found: 298.0295. 
7-Chloro-6-methoxy-2,2-dioxo-1,3,4,10-tetrahydro-2H-2l6-thia-10-aza-anthracen-9-
one (4.102). A flame-dried 25ml round-bottom flask was charged with m-CPBA 
(.553mmol), 4.7mL of anhydrous CHCl3, and 7-Chloro-6-methoxy-1,3,4,10-tetrahydro-2-
thia-10-aza-anthracen-9-one (.142mmol). The reaction slurry was allowed to stir at room 
temperature for 22hrs. It was then quenched by adding a few drops of water and filtered. 
The resulting solid was then purified by preparatory HPLC to give a white crystal. 
1
H 
NMR (400 MHz, DMSO) δ 11.92 (s, 1H), 7.99 (s, 1H), 7.05 (s, 1H), 4.06 (s, 2H), 3.95 (s, 
3H), 3.49 (d, J = 6.5 Hz, 2H), 3.30 (d, J = 6.3 Hz, 2H). 
13
C NMR (101 MHz, DMSO) δ 
173.23, 157.05, 144.24, 139.76, 125.60, 118.51, 117.05, 108.82, 99.60, 56.44, 46.71, 
45.62, 28.02. HRMS (ESI) calcd for C13H13ClNO4S [M+H]
+
: 314.0248, found: 314.0244. 
7-Pyridin-4-yl-1,3,4,10-tetrahydro-2-thia-10-aza-anthracen-9-one (4.103). Following 
general procedure D, the title compound was prepared to provide 31% yield as a yellow 
powder, m.p. = decomp. 348
°
C. 
1
H NMR (400 MHz, DMSO) δ 11.66 (s, 1H), 8.65 (s, 
2H), 8.44 (s, 1H), 8.05 (d, J = 8.2 Hz, 1H), 7.76 (s, 2H), 7.61 (d, J = 8.5 Hz, 1H), 3.61 (s, 
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2H), 3.00 (s, 2H), 2.92 (d, J = 5.1 Hz, 2H). 
13
C NMR (101 MHz, DMSO) δ 175.15, 
150.56, 147.58, 140.06, 140.03, 131.41, 130.27, 123.70, 123.59, 121.43, 119.13, 114.97, 
29.12, 24.08, 22.92. HRMS (ESI) calcd for C17H15N2OS [M+H]
+
: 295.0900, found: 
295.0904. 
7-Pyridin-3-yl-1,3,4,10-tetrahydro-2-thia-10-aza-anthracen-9-one (4.104). Following 
general procedure D, the title compound was prepared to provide 82% yield as a yellow 
powder, m.p. = decomp. 327
°
C. 
1
H NMR (400 MHz, DMSO) δ 11.64 (s, 1H), 8.94 (s, 
1H), 8.58 (s, 1H), 8.33 (s, 1H), 8.13 (d, J = 7.1 Hz, 1H), 8.00 (d, J = 8.6 Hz, 1H), 7.61 (d, 
J = 8.8 Hz, 1H), 7.58 – 7.30 (m, 1H), 3.61 (s, 2H), 3.01 (d, J = 5.2 Hz, 2H), 2.93 (d, J = 
5.3 Hz, 2H). 
13
C NMR (101 MHz, DMSO) δ 174.67, 148.29, 147.42, 146.99, 138.87, 
135.00, 134.02, 131.17, 130.12, 123.97, 123.40, 122.80, 118.62, 114.29, 28.68, 23.66, 
22.49. HRMS (ESI) calcd for C17H15N2OS [M+H]
+
: 295.0900, found: 295.0889. 
8-(2,4-difluorophenyl)-3,4-dihydro-1H-thiopyrano[4,3-b]quinolin-10(5H)-one 
(4.105). Following general procedure D, the title compound was prepared to provide 74% 
yield as a yellow powder, m.p. = decomp. 341
°
C.  
1
H NMR (400 MHz, DMSO) δ 11.64 
(s, 1H), 8.19 (s, 1H), 7.82 – 7.74 (m, 1H), 7.65 (td, J = 8.9, 6.7 Hz, 1H), 7.59 (d, J = 8.6 
Hz, 1H), 7.42 – 7.35 (m, 1H), 7.21 (td, J = 8.5, 2.7 Hz, 1H), 3.61 (s, 2H), 3.02 (t, J = 5.5 
Hz, 2H), 2.92 (t, J = 5.6 Hz, 2H). 
13
C NMR (101 MHz, DMSO) δ 174.60, 161.62 (dd, J = 
241.9, 6.8 Hz), 159.09 (dd, J = 242.9, 7.3 Hz), 147.03, 138.56, 133.05 – 130.30 129.10 – 
127.80 (m), 124.90 (d, J = 3.3 Hz), 124.24 (dd, J = 13.1, 3.6 Hz), 123.05, 118.04, 114.24, 
112.15 (dd, J = 21.2, 3.7 Hz), 104.56 (dd, J = 26.9, 25.9 Hz), 28.65, 23.67, 22.46.  
HRMS (ESI) calcd for C18H14F2NOS [M+H]
+
: 330.0759, found: 330.0749. 
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7-(4-Chloro-2-methyl-phenyl)-1,3,4,10-tetrahydro-2-thia-10-aza-anthracen-9-one 
(4.106). Following general procedure D, the title compound was prepared to provide 70% 
yield as an orange powder, m.p. = decomp. 329
°
C. 
1
H NMR (400 MHz, DMSO) δ 11.62 
(s, 1H), 7.96 (s, 1H), 7.65 – 7.58 (m, 1H), 7.56 (d, J = 8.6 Hz, 1H), 7.41 (s, 1H), 7.33 (d, 
J = 8.1 Hz, 1H), 7.26 (d, J = 8.2 Hz, 1H), 3.60 (s, 2H), 3.00 (d, J = 5.4 Hz, 2H), 2.92 (d, J 
= 5.2 Hz, 2H), 2.23 (s, 3H). 
13
C NMR (101 MHz, DMSO) δ 174.64, 146.94, 139.51, 
138.20, 137.39, 134.10, 132.35, 131.81, 131.30, 129.91, 125.92, 124.78, 122.91, 117.61, 
114.11, 28.67, 23.69, 22.45, 19.97. HRMS (ESI) calcd for C19H16ClNOSNa [M+Na]
+
: 
364.0533, found: 364.0532. 
8-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-1H-thiopyrano[4,3-b]quinolin-10(5H)-
one (4.107). Following general procedure D, the title compound was prepared to provide 
72% yield as a yellow powder, m.p. = decomp. 319°C.  
1
H NMR (400 MHz, DMSO) δ 
11.63 (s, 1H), 8.31 (s, 1H), 7.95 (d, J = 8.6 Hz, 1H), 7.84 (d, J = 8.1 Hz, 2H), 7.59 (d, J = 
8.6 Hz, 1H), 7.46 (d, J = 8.2 Hz, 2H), 3.61 (s, 2H), 3.00 (d, J = 5.2 Hz, 2H), 2.92 (t, J = 
5.5 Hz, 2H). 
19F NMR (376 MHz, DMSO) δ -56.96. 13C NMR (101 MHz, DMSO) δ 
174.67, 147.70, 146.95, 138.77, 138.69, 132.80, 130.10, 128.35, 123.30, 122.56, 121.50, 
δ 120.10 (q, J = 256.2 Hz,) 118.48, 114.19, 28.67, 23.65, 22.47. HRMS (ESI) calcd for 
C19H15F3NO2S [M+H]+: 378.0770, found: 378.0764. 
8-(3-(4-fluorophenoxy)phenyl)-3,4-dihydro-1H-thiopyrano[4,3-b]quinolin-10(5H)-
one (4.108). Following general procedure D, the title compound was prepared to provide 
79% yield as an off white powder, m.p. = decomp. 338°C. 
1
H NMR (400 MHz, DMSO) δ 
11.61 (s, 1H), 8.26 (d, J = 2.1 Hz, 1H), 7.92 (dd, J = 8.7, 2.1 Hz, 1H), 7.57 (d, J = 8.7 Hz, 
1H), 7.55 – 7.44 (m, 2H), 7.34 – 7.21 (m, 3H), 7.21 – 7.11 (m, 2H), 7.11 – 6.83 (m, 2H), 
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3.60 (s, 2H), 3.13 – 2.91 (m, 4H), 2.90 (s, 1H). 19F NMR (376 MHz, DMSO) δ -119.90. 
13
C NMR (101 MHz, DMSO) δ 174.69, 157.81, 158.27 (d, J= 239.4 Hz),  152.43, 146.89, 
141.51, 138.68, 133.44, 130.72, 130.09, 123.26, 122.39, 121.50, 120.85 (d, J = 8.5 Hz,), 
118.42, 116.80 (d, J = 13.4 Hz,), 116.50, 115.93, 114.13, 28.65, 23.64, 22.46. HRMS 
(ESI) calcd for C24H19FNO2S [M+H]+: 404.1115, found: 404.1122.  
7-[2-Methyl-4-(4-trifluoromethoxy-phenoxy)-phenyl]-1,3,4,10-tetrahydro-2-thia-10-
aza-anthracen-9-one (4.109). Following general procedure D, the title compound was 
prepared to provide 56% yield as an off white powder, m.p. = decomp. 350
°
C. 
1
H NMR 
(400 MHz, DMSO) δ 11.61 (s, 1H), 7.97 (s, 1H), 7.63 (d, J = 8.2, 1H), 7.56 (d, J = 8.6, 
1H), 7.40 (d, J = 8.4, 2H), 7.29 (d, J = 8.2, 1H), 7.17 (d, J = 9.0, 2H), 7.05 (s, 1H), 6.96 
(d, J = 8.0, 1H), 3.60 (s, 2H), 2.97 (d, J = 37.9, 4H), 2.23 (s, 3H). 
13
C NMR (101 MHz, 
DMSO) δ 174.67, 155.73, 155.23, 146.87, 143.58, 138.02, 137.21, 136.57, 134.66, 
132.55, 131.33, 124.81, 122.93, 120.71, 119.73, 117.51, 116.54, 114.02, 28.67, 23.69, 
22.45, 20.26. HRMS (ESI) calcd. for C26H21F3NO3S [M+H]
+
: 484.1189, found: 
484.1173. 
8-(4-((4-(trifluoromethoxy)phenoxy)methyl)phenyl)-3,4-dihydro-1H-thiopyrano[4,3-
b]quinolin-10(5H)-one (4.110). Following general procedure D, the title compound was 
prepared to provide 68% yield as a light yellow powder, m.p. = decomp. 301
°
C.
 1
H NMR 
(400 MHz, DMSO) δ 11.60 (s, 1H), 8.33 (s, 1H), 7.96 (d, J = 8.5 Hz, 1H), 7.75 (d, J = 
7.8 Hz, 2H), 7.57 (dd, J = 12.5, 8.6 Hz, 3H), 7.31 (d, J = 8.7 Hz, 2H), 7.13 (d, J = 8.9 Hz, 
2H), 5.18 (s, 2H), 3.62 (s, 2H), 3.00 (d, J = 5.2 Hz, 2H), 2.92 (d, J = 5.2 Hz, 2H). 
19
F 
NMR (376 MHz, DMSO) δ -57.38.  13C NMR (101 MHz, DMSO) δ 174.76, 157.16, 
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146.82, 141.85, 139.08, 138.54, 135.75, 133.86, 130.09, 128.44, 126.57, 123.36, 122.50, 
122.26, 120.15 (d, J = 255.2 Hz), 118.38, 116.00, 114.08, 69.35, 28.67, 23.67, 22.50. 
7-(4-Phenoxymethyl-phenyl)-1,3,4,10-tetrahydro-2-thia-10-aza-anthracen-9-one 
(4.111). Following general procedure D, the title compound was prepared to provide 68% 
yield as a off white powder, m.p. = decomp. 323
°
C. 
1
H NMR (400 MHz, DMSO) δ 11.60 
(s, 1H), 8.32 (d, J = 2.0 Hz, 1H), 7.96 (dd, J = 8.7, 2.1 Hz, 1H), 7.74 (d, J = 8.1 Hz, 2H), 
7.57 (dd, J = 12.9, 8.5 Hz, 3H), 7.30 (t, J = 7.9 Hz, 2H), 7.03 (d, J = 8.0 Hz, 2H), 6.95 (s, 
1H), 5.16 (s, 2H), 3.61 (s, 2H), 3.00 (d, J = 5.2 Hz, 2H), 2.92 (t, J = 5.6 Hz, 2H).  
13
C 
NMR (101 MHz, DMSO) δ 174.74, 158.28, 146.82, 138.92, 138.51, 136.23, 133.91, 
130.10, 129.47, 128.35, 126.52, 123.36, 122.23, 120.70, 118.37, 114.77, 114.07, 68.72, 
28.67, 23.67, 22.49. HRMS (ESI) calcd for C25H22NO2S [M+H]
+
: 400.1366, found: 
400.1357. 
8-(4-(benzyloxy)phenyl)-3,4-dihydro-1H-thiopyrano[4,3-b]quinolin-10(5H)-one 
(4.112). Following general procedure D, the title compound was prepared to provide 62% 
yield as a yellow powder, m.p. = decomp. 310
°
C. 
1
H NMR (400 MHz, DMSO) δ 11.57 
(s, 1H), 8.25 (s, 1H), 7.90 (d, J = 8.1 Hz, 1H), 7.65 (d, J = 8.1 Hz, 2H), 7.56 (d, J = 8.7 
Hz, 1H), 7.48 (d, J = 7.0 Hz, 2H), 7.42 – 7.39 (m, 2H), 7.35 (d, J = 6.9 Hz, 1H), 7.12 (d, 
J = 7.7 Hz, 2H), 5.16 (s, 2H), 3.61 (s, 2H), 3.00 (s, 2H), 2.91 (s, 2H). 
13
C NMR (101 
MHz, DMSO) δ 174.54, 157.91, 146.81, 138.02, 137.02, 134.10, 132.04, 129.89, 128.41, 
127.80, 127.63, 127.61, 123.30, 121.41, 118.29, 115.38, 113.90, 69.25, 28.68, 23.66, 
22.49.  HRMS (ESI) calcd for C25H22NO2S [M+H]
+
: 400.1366, found: 400.1377. 
7-(4-Trifluoromethyl-phenyl)-1,3,4,10-tetrahydro-2-thia-10-aza-anthracen-9-one 
(4.113). Following general procedure D, the title compound was prepared to provide 71% 
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yield as a dark green powder, m.p. = decomp. 304
°
C. 
1
H NMR (400 MHz, DMSO) δ 8.38 
(d, J = 2.2 Hz, 1H), 8.00 (dd, J = 8.7, 2.2 Hz, 1H), 7.94 (d, J = 8.2 Hz, 2H), 7.82 (d, J = 
8.4 Hz, 2H), 7.62 (d, J = 8.7 Hz, 1H), 3.62 (s, 2H), 3.01 (t, J = 5.5 Hz, 2H), 2.92 (t, J = 
5.7 Hz, 2H).  
19F NMR (376 MHz, DMSO) δ -61.09. 13C NMR (101 MHz, DMSO) δ 
174.57, 147.44, 143.49, 139.47, 132.39, 129.98, 127.18, 125.88, 125.84, 123.43, 123.02, 
118.96, 114.28, 28.91, 23.73, 22.52. 
7-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroacridin-9(10H)-one (4.114). 
Following general procedure D, the title compound was prepared to provide 78% yield as 
a white solid, m.p. > 364
°
C. 
1
H NMR (400 MHz, DMSO) δ 11.48 (s, 1H), 8.37 (d, J = 2.2 
Hz, 1H), 7.97 (dd, J = 8.7, 2.3 Hz, 1H), 7.94 (d, J = 8.2 Hz, 2H), 7.82 (d, J = 8.3 Hz, 2H), 
7.59 (d, J = 8.7 Hz, 1H), 2.72 (t, J = 6.0 Hz, 2H), 2.46 (t, J = 6.1 Hz, 2H), 1.81 – 1.69 (m, 
4H).
13
C NMR (101 MHz, DMSO) δ 175.86, 147.06, 143.61, 139.24, 132.08, 129.72, 
127.15, 125.86, 123.32, 122.95, 118.48, 116.05, 109.55, 27.15, 21.81, 21.71, 21.46.
19
F 
NMR (376 MHz, DMSO) δ -60.89. HRMS (ESI) calcd for C20H16F3NONa [M+Na]
+
: 
366.1076, found: 366.1076. 
6-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroacridin-9(10H)-one (4.115). 
Following general procedure D, the title compound was prepared to provide 81% yield as 
a yellow powder, m.p. = 352 - 354
°
C. 
1H NMR (400 MHz, DMSO) δ 11.43 (s, 1H), 8.15 
(d, J = 8.5 Hz, 1H), 7.90 (dd, J = 19.8, 8.3 Hz, 4H), 7.73 (s, 1H), 7.57 (d, J = 8.4 Hz, 1H), 
2.72 (t, J = 5.9 Hz, 2H), 2.45 (t, J = 6.0 Hz, 2H), 1.74 (dd, J = 25.2, 6.0 Hz, 4H). 
19
F 
NMR (376 MHz, DMSO) δ -61.09. HRMS (ESI) calcd. for C20H17F3NO[M+H]
+
: 
344.1257, found: 344.1251. 
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6-(2,6-difluorophenyl)-1,2,3,4-tetrahydroacridin-9(10H)-one (4.116). Following 
general procedure D, the title compound was prepared to provide 10% yield as a yellow 
powder, m.p. = 318 - 320
°
C. 
1H NMR (400 MHz, DMSO) δ 11.42 (s, 1H), 8.14 (d, J = 
8.3 Hz, 1H), 7.53 (dd, J = 9.9, 3.1 Hz, 2H), 7.28 (t, J = 8.2 Hz, 3H), 2.71 (d, J = 6.2 Hz, 
2H), 2.46 (t, J = 5.9 Hz, 2H), 1.75 (dd, J = 23.2, 4.8 Hz, 4H).
 19
F NMR (376 MHz, 
DMSO) δ -114.70. 13C NMR (101 MHz, DMSO) δ 176.01, 160.88, 147.69, 139.46, 
131.37, 131.03, 125.48, 124.26, 123.16, 119.38, 116.52, 112.76, 112.51, 27.61, 22.26, 
22.11, 21.90. HRMS (ESI) calcd for C19H16F2NO [M+H]
+
: 312.1195, found: 312.1183. 
6-(4-(dimethylamino)phenyl)-1,2,3,4-tetrahydroacridin-9(10H)-one (4.117).  
Following general procedure D, the title compound was prepared to provide 33% yield as 
a light brown powder, m.p. > 364
°
C. 
1H NMR (400 MHz, DMSO) δ 11.24 (s, 1H), 8.04 
(d, J = 8.5 Hz, 1H), 7.58 (d, J = 1.9 Hz, 2H), 7.56 (s, 1H), 7.47 (dd, J = 8.5, 1.7 Hz, 1H), 
6.84 (d, J = 8.9 Hz, 2H), 2.96 (s, 6H), 2.70 (t, J = 6.0 Hz, 2H), 2.44 (t, J = 5.9 Hz, 2H), 
1.73 (dd, J = 25.6, 4.8 Hz, 4H). 
13
C NMR (101 MHz, DMSO) δ 175.74, 150.30, 146.68, 
142.67, 139.86, 127.35, 126.32, 125.45, 121.32, 120.18, 115.45, 112.78, 112.60, 27.16, 
21.92, 21.67, 21.52. HRMS (ESI) calcd for C21H23N2O [M+H]
+
: 319.1805, found: 
319.1795. 
6-(4-(4-(trifluoromethoxy)phenoxy)phenyl)-1,2,3,4-tetrahydroacridin-9(10H)-one 
(4.118). Following general procedure D, the title compound was prepared to provide 37% 
yield as a yellow powder, m.p. = 311 - 313
°
C. 
1H NMR (400 MHz, DMSO) δ 11.39 (s, 
1H), 8.11 (d, J = 8.4 Hz, 1H), 7.76 (s, 1H), 7.74 (s, 1H), 7.66 (s, 1H), 7.52 (d, J = 8.5 Hz, 
1H), 7.44 (s, 1H), 7.41 (s, 1H), 7.24 – 7.17 (m, 4H), 2.72 (t, J = 5.9 Hz, 2H), 2.45 (t, J = 
5.9 Hz, 2H), 1.74 (dd, J = 25.5, 6.1 Hz, 4H).
13C NMR (101 MHz, DMSO) δ 175.62, 
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156.49, 155.29, 147.09, 143.92, 141.73, 139.67, 134.92, 128.70, 125.71, 123.04, 122.07, 
120.87, 120.24, 119.30, 115.82, 114.55, 27.20, 21.86, 21.68, 21.48. HRMS (ESI) calcd 
for C26H21F3NO3 [M+H]
+
: 452.1468, found: 452.1467.  
4-((4-(trifluoromethoxy)phenoxy)methyl)phenylboronic acid (4.119). To a flame-
dried flask back-filled with argon (X2) is added 4-(trifluoromethoxy)phenol (20 mmol, 
3.64 g), anhydrous DMF (3 mL), and NaH (32.3 mmol, 0.77 g) at 0
°
C. This suspension is 
allowed to stir for 30 min at which time a solution of 1-bromo-4-(chloromethyl)benzene 
(19 mmol, 4 g) dissolved in 3 mL of DMF is added dropwise. The reaction is stirred 
overnight at 80
°
C, and quenched by pouring onto ice and water. The resulting slurry is 
extracted by EtOAc (X3) and washed with water followed by brine and subsequently 
dried over Na2SO4. The crude bromide is purified further via flash chromatography 
(Hexane:EtOAc 10:1) to afford 1-bromo-4-((4-
(trifluoromethoxy)phenoxy)methyl)benzene as a colorless oil in 90% yield. To a solution 
of 1-bromo-4-((4-(trifluoromethoxy)phenoxy)methyl)benzene (7.2 mmol, 2.5 g) and 
triisopropyl borate (9.4 mmol, 2.15 mL) in dry THF (65 mL) at -78
°
C was added 
dropwise 1.6M BuLi (5.4 mL) in Hexanes over 10 minutes. The reaction was stirred for 
3h at -78
°
C at which point 10 mL of 6M HCl is added and the solution is allowed to 
warm up to room temperature and stir overnight. The reaction mixture was diluted with 
EtOAc (150 mL) and water (150 mL). The organic layer is taken separately and rinsed 
with water (150 mL), followed by brine (150 mL) and then dried over Na2SO4.  The 
EtOAc is then concentrated in vacuo to afford a waxy solid which is then treated with 2M 
NaOH (40 mL) and stirred for 15 min diluted with water (300 mL) and stirred for 20 
minutes. The solution is then filtered and the filtrate washed with hexane (3 x 100 mL). 
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The aqueous layer was carefully acidified to pH 1 with 6m HCl. The resulting white solid 
was filtered and dried on a high vacuum overnight to afford the titled compound in 67% 
yield.  
4-(4-(trifluoromethoxy)phenoxy)phenylboronic acid (4.120). The titled compound was 
prepared exactly as Yeates et al.
16
 describe. In a flame-dried 25 mL schlenk tube 
backfilled with argon (X3) a solution of 4-bromophenol (0.346 g, 2 mmol) in N-
methylpyrrolidine (8 mL) under an argon atmosphere was added 4-
(trifluoromethoxy)iodobenzene (0.626 mL, 4 mmol), 2,2,6,6-tetramethylheptane-3,5-
dione (0.092 mL, 0.44 mmol) and cesium carbonate (1.30 g, 4mmol). The slurry was 
degassed by bubbling argon for 15 min and CuCl (0.099 g, 1mmol) was then added. The 
reaction mixture was again degassed and then warmed to 100º C for 7h. After cooling to 
room temperature, Et2O (75 mL) was added slowly. The resulting slurry was filtered and 
the solid washed with Et2O (3 x 50 mL). The combined filtrates were washed with 2 M 
NaOH (100 mL), water (100 mL), 1 M aq HCl (100 mL), water (100 mL) and saturated 
brine (100 mL), the subsequently dried over Na2SO4 and concentrated under reduced 
pressure. The residue was purified via flash chromatography with 100% Hexane. This 
column was repeated three times combining the purest fractions each column to obtain 
pure material due to similarly eluting 4-(trifluoromethoxy)iodobenzene to afford 1-
bromo-4-(4-(trifluoromethoxy)phenoxy)benzene (0.15 g, 45%) as a colorless liquid. 1H 
NMR (300MHz, CDCl3): δ 7.45 (m, 2H), 7.20 (m 2H), 6.99 (m 2H), 6.90 (m 2H). To a 
solution of 1-bromo-4-(4-(trifluoromethoxy)phenoxy)benzene (2.1 mmol, 0.7 g) and 
triisopropyl borate (2.7 mmol, 0.63 mL) in dry THF (15 mL) at -78
°
C was added 
dropwise 2.5M BuLi (6.5 mL) in Hexanes over 5 minutes. The reaction was stirred for 3h 
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at -78
°
C at which point 10 mL of 6M HCl is added and the solution is allowed to warm 
up to room temperature and stir overnight. The reaction mixture was diluted with EtOAc 
(150 mL) and water (150 mL). The organic layer is taken separately and rinsed with 
water (150 mL), followed by brine (150 mL) and then dried over Na2SO4.  The EtOAc is 
then concentrated in vacuo to afford a waxy solid which is then treated with 2M NaOH 
(40 mL) and stirred for 15 min diluted with water (300 mL) and stirred for 20 minutes. 
The solution is then filtered and the filtrate washed with hexane (3 x 100 mL). The 
aqueous layer was carefully acidified to pH 1 with 6m HCl. The resulting white solid was 
filtered and dried on a high vacuum overnight to afford the titled compound in 67% yield. 
1H NMR (300 MHz, CDCl3): δ 8.01 (bs, 2H), 7.85-7.78 (m, 2H), 7.43-7.33 (m, 2H), 
7.15-7.07 (m, 2H), 7.02-6.94 (m, 2H).  
2-methyl-4-(4-(trifluoromethoxy)phenoxy)phenylboronic acid (4.121). The titled 
compound is prepared the same as 120 in 36% yield over two steps as an off-white solid. 
1H NMR (400 MHz, DMSO) δ 7.92 (d, J = 7.9 Hz, 1H), 7.36 (d, J = 8.9 Hz, 2H), 7.12 – 
7.07 (m, 2H), 6.82 (d, J = 9.0 Hz, 2H), 2.64 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 
156.91, 155.63, 146.05, 143.50, 136.70, 135.43, 122.82, 120.03, 119.75, 119.57, 114.87, 
21.97. 
 
 
 
 
 
 
273 
 
4.6 References Cited 
1. Kesten, S. J.; Degnan, M. J.; Hung, J.; McNamara, D. J.; Ortwine, D. F.; 
Uhlendorf, S. E.; Werbel, L. M. Antimalarial drugs. 64. Synthesis and antimalarial 
properties of 1-imino derivatives of 7-chloro-3-substituted-3,4-dihydro-1,9(2H,10H)-
acridinediones and related structures. J. Med. Chem. 1992, 35, 3429-3447. 
2. Cross, R. M.; Monastyrskyi, A.; Mutka, T. S.; Burrows, J. N.; Kyle, D. E.; 
Manetsch, R. Endochin optimization: structure-activity and structure-property 
relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial 
activity. J. Med. Chem. 2010, 53, 7076-7094. 
3. Tiedtke, H. Tetrahydroacridone. Ber. Dtsch. Chem. Ges. 1909, 42, 621-626. 
4. Reed, R. A. Hydroacridones. Synthesis and dehydrogenation. J. Chem. Soc. 1944, 
425-426. 
5. Reed, R. A. Hydroacridones. Synthesis and dehydrogenation. II. J. Chem. Soc. 
1945, 186-189. 
6. Frideling, A.; Faure, R.; Galy, J.-P.; Kenz, A.; Alkorta, I.; Elguero, J. 
Tetrahydroacridin-9-ones, 9-chlorotetrahydroacridines, 9-amino-tetrahydroacridines and 
9-(pyrazol-1-yl)-tetrahydroacridines derived from chiral cyclanones. Eur. J. Med. Chem. 
2004, 39, 37-48. 
7. Apelt, J.; Ligneau, X.; Pertz, H. H.; Arrang, J.-M.; Ganellin, C. R.; Schwartz, J.-
C.; Schunack, W.; Stark, H. Development of a new class of nonimidazole histamine H3 
receptor ligands with combined inhibitory histamine N-methyltransferase activity. J. 
Med. Chem. 2002, 45, 1128-1141. 
274 
 
8. Manetsch, R.; Krasinski, A.; Radic, Z.; Raushel, J.; Taylor, P.; Sharpless, K. B.; 
Kolb, H. C. In situ click chemistry: enzyme inhibitors made to their own specifications. J. 
Am. Chem. Soc. 2004, 126, 12809-12818. 
9. Topliss, J. G. Utilization of operational schemes for analog synthesis in drug 
design. J. Med. Chem. 1972, 15, 1006-1011. 
10. Topliss, J. G. A manual method for applying the Hansch approach to drug design. 
J. Med. Chem. 1977, 20, 463-469. 
11. Savini, L.; Gaeta, A.; Fattorusso, C.; Catalanotti, B.; Campiani, G.; Chiasserini, 
L.; Pellerano, C.; Novellino, E.; McKissic, D.; Saxena, A. Specific targeting of 
acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, 
selective, and highly potent cholinesterase inhibitors. J. Med. Chem. 2003, 46, 1-4. 
12. Conrad-Limpach reactions have 2-regioisomeric outcomes when a non-
symmetrical aniline is used. 
13. Benkeser, R. A.; Schroll, G. The reaction of dihaloanisoles with sodium amide in 
liquid ammonia. J. Am. Chem. Soc. 1953, 75, 3196-3197. 
14. Sridharan, V.; Martin, M. A.; Menendez, J. C. Acid-free synthesis of carbazoles 
and carbazolequinones by intramolecular Pd-catalyzed, microwave-assisted oxidative 
biaryl coupling reactions - efficient syntheses of murrayafoline A, 2-methoxy-3-
methylcarbazole, and glycozolidine. Eur. J. Org. Chem. 2009, 4614-4621, S4614/1-
S4614/39. 
15. Philipp, A.; Jirkovsky, I.; Martel, R. R. Synthesis and antiallergic properties of 
some 4H,5H-pyrano[3,2-c][1]benzopyran-4-one, 4H,5H-[1]benzothiopyrano[4,3-
275 
 
b]pyran-4-one, and 1,4-dihydro-5H-[1]benzothiopyrano[4,3-b]pyridin-4-one derivatives. 
J. Med. Chem. 1980, 23, 1372-1376. 
16. Yeates, C. L.; Batchelor, J. F.; Capon, E. C.; Cheesman, N. J.; Fry, M.; Hudson, 
A. T.; Pudney, M.; Trimming, H.; Woolven, J.; Bueno, J. M.; Chicharro, J.; Fernandez, 
E.; Fiandor, J. M.; Gargallo-Viola, D.; Gomez de las Heras, F.; Herreros, E.; Leon, M. L. 
Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials. J. 
Med. Chem. 2008, 51, 2845-2852. 
17. Fiandor Roman, J. M.; Bueno Calderon, J. M.; Mallo Rubio, A. Preparation of 
novel heterocyclic compounds, particularly 4-pyridones, as antimalarial agents. 2006-
EP21602006094799, 20060302., 2006. 
18. Berman, J.; Brown, L.; Miller, R.; Andersen, S. L.; McGreevy, P.; Schuster, B. 
G.; Ellisk, W.; Ager, A.; Rossan, R. Antimalarial activity of WR 243251, a 
dihydroacridinedione. Antimicrob. Agents Chemother. 1994, 38, 1753-1756. 
19. Raether, W.; Enders, B.; Hofmann, J.; Schwannecke, U.; Seidenath, H.; Hanel, 
H.; Uphoff, M. Antimalarial activity of new floxacrine-related acridinedione derivatives: 
studies on blood schizontocidal action of potential candidates against P. berghei in mice 
and P. falciparum in vivo and in vitro. Parasitol. Res. 1989, 75, 619-626. 
20. Winkelmann, E.; Raether, W. Antimalarial and anticoccidial activity of 3-aryl-7-
chloro-3,4-dihydroacridine-1,9-(2H,10H)-diones. 1-Imines, 1-amines, 1-oximes, 1-
hydrazones and related compounds. Arzneim.-Forsch. 1987, 37, 647-661. 
21. Suswam, E.; Kyle, D.; Lang-Unnasch, N. Plasmodium falciparum: the effects of 
atovaquone resistance on respiration. Exp. Parasitol. 2001, 98, 180-187. 
276 
 
22. Schmidt, L. H. Antimalarial properties of floxacrine, a dihydroacridinedione 
derivative. Antimicrob. Agents Chemother. 1979, 16, 475-485. 
23. Stephen, J. M. L.; Tonkin, I. M.; Walker, J. Tetrahydroacridones and related 
compounds as antimalarials. J. Chem. Soc. 1947, 1034-1039. 
24. Milhous, W. K.; Gerena, L.; Kyle, D. E.; Oduola, A. M. J. In vitro strategies for 
circumventing antimalarial drug resistance. Prog. Clin. Biol. Res. 1989, 313, 61-72. 
25. Looareesuwan, S.; Viravan, C.; Webster, H. K.; Kyle, D. E.; Hutchinson, D. B.; 
Canfield, C. J. Clinical studies of atovaquone, alone or in combination with other 
antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am. J. 
Trop. Med. Hyg. 1996, 54, 62-66. 
 
 
277 
 
 
 
Chapter 5: Synthesis and Anti-malarial Activity for Analogs of 7-(2-phenoxyethoxy)-
4(1H)-quinolones 
5.1 Overview 
 The extinction of all Plasmodium species that infect humans is a lofty goal set 
forth by the Bill and Melinda Gates Foundation. One avenue of discovery that could help 
achieve this goal would be the design of a drug capable of acting on the liver and blood 
stage parasites simultaneously within the same host as well as inhibiting the sexual stages 
within the mosquito. Compound 5.1 was initially discovered in 1968 for its anti-
coccidostatic activity (Figure 5.1). It was later discovered in 1970 by Riley and Peters 
that this compound  possessed anti-malarial activity.
1
 This compound displayed causal 
prophylactic (single dose of 30 mg/kg subcutaneous) and blood schizonticidal activity 
(ED50 = 0.05 mg/kg) in rodent malaria models but produced high levels of chemical 
resistance after one pass in P. berghei.
1
 In 1990 follow-up studies with monkeys infected 
with sporozoite induced P. cynomologi revealed that 5.1, amongst other known 
antimalarials such as endochin and WR194905 had curative effects (Figure 5.1). When 
5.1 was administered intravenously for 7 consecutive days radical cure was realized and 
no relapse of malaria was evident by 120 days.
2
 The in vivo activity of 5.1 with the 
excellent in vitro activity of EC50s of 0.05 nM against W2 is accompanied with poor 
solubility and a high level of chemical resistance amongst W2 and TM90C2B strains.
1
 
These features compelled us to examine compound 5.1 through SAR by preparing a small 
library of 7-(2-phenoxyethoxy)-4(1H)-quinolones (PEQs). 
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Figure 5.1. Antimalarials Utilized for P. cynomologi In Vivo Studies 
 
5.2 Synthetic Chemistry 
 Compound 5.1 was patented in 1968 by Bowie and later reported as an anti-
coccidiostat in 1970 by Mizzoni et al.
3, 4
 Compound 5.1 was first synthesized in our 
laboratory in order to obtain preliminary data on the core PEQ scaffold. A slightly 
modified route to obtain 5.1 was employed because the key step in the reduction of N-(4-
butyryl-3-hydroxyphenyl)acetamide to N-(4-butyl-3-hydroxyphenyl)acetamide involved 
a hydrogenation step at ~500 psi. Without access to these pressures at the scale we were 
hoping to achieve, a two-step alternative was successfully employed (Figure 5.2).  
Figure 5.2. Alternative Synthetic Route 
 
 Previous SAR and SPR studies on the 3-aryl-4(1H)-quinolone series and THA 
series revealed the 3-position to be critical for antimalarial activity as well as the 6- and 
7-position (Chapter 2). The 5- and 8- positions were shown to be more important in terms 
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of solubility, while maintaining a proton in these positions was optimal for activity 
(Chapter 4). The carbonyl and N-H center had to remain intact to retain potency, as 
alkylation to either of these centers resulted in loss of biological activity. The goal would 
be to prepare in the upwards of 100g of the aniline 5.7 to funnel into Conrad Limpach 
reaction sequences to generate other alkyl analogs of 5.1 (Scheme 5.1).  
Scheme 5.1. Synthesis of the PEQ 5.1 via Key Intermediate Aniline 5.7
a
  
a
Reaction conditions: (a) butyryl chloride, pyr. r.t. (b) AlCl3, 150-175°C 45min then 3h; (c) NaBH4, THF 
anhy., 0°C; (d) AcOH, 10% Pd/C, 60 psi, 36h; (e) NaH, DMF 30 min then (2-bromoethoxy)benzene, 3h; (f) 
KOH (14 eq.), EtOH:H2O (9:1), reflux, 4h; (g) dimethyl 2-(methoxymethylene)malonate, EtOH, reflux; (h) 
Ph2O, reflux, 12 min 
 
Iodination of a common quinolone scaffold to prepare 3-aryl analogs would be achieved 
using a recently developed protocol in our laboratory (Scheme 5.2).
5
 Furthermore, robust 
aniline precursors would be used in several iterative sequences to prepare vastly different 
analogs in the 6- and 7-positions (Figure 5.4).  
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 The route to generate compound 5.1 began with 450 g of commercially available 
N-(3-hydroxyphenyl)acetamide that was transformed to 5.2 with butyryl chloride in 
pyridine (Scheme 5.1). Next a Fries-rearrangement was employed to arrive at compound 
5.3 using AlCl3. The reaction was initially heated to approximately 150°C at which point 
a brittle cake evolved. This material was removed from the vessel carefully and mortared 
with pestle back into a homogenous powder, the material was then placed back to the 
heat for another 3h. Compound 5.3 was taken directly to compound 5.5 in the original 
report, whereas without access to 500 psi hydrogenation apparatus and the reaction 
failing to work at 75 psi, an alternative route was employed. Conjugated ketones are 
much more stable to hydrogenolysis as compared to a benzylic alcohol.
6
 Therefore, 
compound 5.3 was reduced using NaBH4, resulting in a black-tar that was exhaustively 
columned to obtain 5.4 in moderate yield and high purity. Compound 5.4 was now much 
more prone to hydrogenolysis than the conjugated ketone previously, the hydrogenolysis 
in acetic acid at 60 psi occurred relatively smoothly to yield compound 5.5. Compound 
5.6 was prepared through a simple alkylation using (2-bromoethoxy)benzene in high 
yield. Next, the key intermediate 5.7 was prepared via hydrolysis of the acetamido 
moiety. In order to avoid room temperature de-composition of 5.7, albeit minor amounts, 
bulk material was stored as compound 5.6 at -20ºC. Finally, compound 5.1 was prepared 
in a two-step Gould-Jacobs sequence from 5.7.
4, 7
 The final compound was recrystallized 
from a mixture of DMF: methanol (4:1). Many solvent systems were screened and this 
solvent mixture was necessary in order to obtain a proper dissolution. 
 A small library of 3-aryl PEQs were prepared by employing 5.7 as the starting 
aniline for the Conrad-Limpach protocol followed by regioselective iodination to 
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generate 3-iodo-4(1H)-quinolone 5.8 (Scheme 5.2). Next, the quinolone was subjected to 
Suzuki-Miyaura cross-coupling conditions to arrive at compounds 5.11-5.23. The 3-halo-
4(1H)-quinolone core can tolerate coupling with or without alkyl protection, however, in 
some instances depending on the nature of the boronic acid used, an alkylated quinolone 
may be necessary to achieve coupling.
5
 Therefore, using O-methyl or O-ethyl-3-iodo-
quinolines 5.9-5.10 the coupling could be employed successfully followed by 
chemoselective de-alkylation using HBr in refluxing acetic acid. It is worthy to note that 
this de-alkylation is a very time sensitive reaction and depending on the substituents of 
the 6- or 7-position, unwanted de-alkylations may occur. A 7-(2-phenoxyethoxy) 
substituent can be displaced by a bromide ion if the reaction is allowed to proceed too 
long. A variety of electron poor and electron rich boronic acids were coupled resulting in 
quinolones 5.11-5.23. Some of the cross-couplings were carried out in a microwave 
reactor in very good yield and short reaction times.  
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Scheme 5.2. Synthesis of 3-Aryl PEQs
a 
a
Reaction conditions: (a) ethyl acetoacetate, AcOH, benzene, Dean-Stark trap, reflux, overnight then Ph2O, 
reflux, 15min; (b) KI (20% aq.), I2, 2M NaOH, r.t. 2h (c) Cs2CO3, DMF, EtI / MeI, 0°C to r.t. 5h (d) 
Pd2(dba)3, SPHOS, K3PO4, DMF, ArB(OH)2, 110
o
C or Pd(PPh3)4, 2M Na2CO3, DMF, ArB(OH)2, 110°C 
(MW)  (e) HBr / AcOH, reflux 1-2h 
 
 A subset of 5.1 was prepared to determine the necessity of substituents (Scheme 
5.3). The placement of a proton, methyl, or ethyl group in the 3-postion as compared to a 
3-methyl ester would determine whether the β-dicarbonyl motif present in 5.1 was 
necessary for biological activity (5.24-5.26). Aniline 5.7 was subjected to Conrad-
Limpach conditions using various 2-substituted β-ketoesters to generate compounds 5.24-
5.26. Starting from aniline 5.27, prepared in a previous report, a 6-chloro-7-methoxy-
4(1H)-quinolone bearing the β-dicarbonyl moiety was synthesized using 1-ethyl-3-
methyl-2-acetylmalonate.
8
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Scheme 5.3. Preparation of PEQ Analogs Lacking a Di-carbonly Motif
a 
 
a
2-substituted ethyl acetoacetate, AcOH, benzene, Dean-Stark trap, reflux, overnight then Ph2O, reflux, 
15min; (b) 1-ethyl 3-methyl 2-acetylmalonate, AcOH, benzene, Dean-Stark trap, reflux, overnight then 
Ph2O, reflux, 15min 
 
 Finally, a set of 4(1H)-quinolones bearing either a 3-ethyl or 3-phenyl substituent 
were prepared with various 6- and 7-substitutions. Additionally, the 3-carboxymethyl 
substituent would not be further studied, as many of these have been tirelessly screened 
as antimicrobials, additionally many of these 3-carboxymethyl analogs have shown to 
induce chemical resistance as antimalarials.
9
 The 6- and 7-substitutions contained various 
solubilizing groups with different length linkers. Starting from 5-amino-2-chlorophenol, 
the 4(1H)-quinolones 5.30b-5.40b were prepared (Scheme 5.4). N-acylation of 5-amino-
2-chlorophenol produced intermediate 5.29. Varying alkyl halides were employed to 
generate acetamides 5.30a-5.40a. These intermediates were then hydrolyzed using KOH 
to arrive at the necessary anilines. The anilines could then be subsequently cyclized using 
either 2-ethyl or 2-phenyl-β-ketoester to generate the corresponding 4(1H)-quinolones 
5.30b-5.40b (Table 5.1). An alternative route was used to prepare compounds 5.41-5.43 
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utilizing a di-substituted nitro precursor due to complications in the alkylation using the 
route depicted in Scheme 5.4 (Scheme 5.5). Synthesis of compound 5.43 was initially 
attempted using several standard heterogeneous Pd/C hydrogenation conditions to reduce 
the carbon-chlorine bond, 5.32b however, was prone to reduction and all attempts 
produced a partially hydrogenated benzene ring. During the synthesis of compounds 
5.11-5.23 it was observed that the major side product of the 3-halo cross-coupling was 
the reduction of the carbon-iodine bond to the carbon-hydrogen bond, furthermore the 
cross-coupling of bis-ortho substituted boronic acids such as mesitylboronic acid only 
produced trace amounts of product and large amounts of the reduced side product. Thus, 
5.32b was heated in a schlenk tube for 36 hours with several additions of mesitylboronic 
acid until the chloride was completely reduced, resulting in compound 5.43 in moderate 
yield. 
Scheme 5.4. Synthesis of 4(1H)-Quinolones 5.30b-5.40b
a 
 
a
Ac2O, AcOH; (b) corresponding alkyl halide, Cs2CO3, DMF, 4-8h;  (c) KOH, EtOH:H2O (9:1), reflux;(d) 
2-ethyl or 2-phenyl-β-ketoester, AcOH, benzene, Dean-Stark trap, reflux, overnight then Ph2O, reflux, 
15min 
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Scheme 5.5. Synthesis of 4(1H)-Quinolones 5.41-5.43
a 
 
a
(a) BBr3; (b) corresponding alkyl halide, Cs2CO3, DMF, 4-8h;  (c) Zn, AcOH, r.t., 4h; (d) 2-ethyl-β-
ketoester, AcOH, benzene, Dean-Stark trap, reflux, overnight then Ph2O, reflux, 15min; (e) 1,3-dibromo 
propane, Cs2CO3, r.t.; (f) N-Phenylpiperazine, K2CO3, DMF, r.t.;  (g) Pd2(dba)3, SPHOS, K3PO4, DMF, 
Mesitylboronicacid, 130
o
C 
 
5.3 Antimalarial Activity 
5.3.1. Structure-Activity Studies 
 All compounds underwent in vitro screening against P. falciparum as previously 
described in Chapter 2 (Section 2.3 Antimalarial Activity).
8
 Compound 5.1 showed 
excellent in vitro activity against W2 and TM90-C2B with EC50s of 0.05 nM and 11.17 
nM respectively (Table 5.1). However, the difference in activity between the two strains, 
RI = 223, may be indicative for the emergence of resistance in one pass of P. berghei.
1
 It 
was found that varying the  6- and 7-positions of compound 5.1 to a 6-chloro-7-methoxy 
analog in an attempt to increase activity and reduce RI, a significant decrease in 
antimalarial activity was observed with EC50s of 134 nM against W2 and 765 nM against 
TM90-C2B.
8
 If the 3-position is exchanged by a proton 5.24, a 4000-fold decrease in 
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activity is observed for W2 as compared to only a 4-fold decrease against TM90-C2B. 
Placement of an ethyl at the 3-position 5.26 generated the most potent compound in the 
synthetic library with EC50 values of 1.92 nM against W2 and 0.15 nM against TM90-
C2B. This stands in sharp contrast when compared to 5.1 that inhibits the W2 strain much 
more than the TM90-C2B, whereas compound 5.26 has the exact opposite effect 
inhibiting TM90-C2B much more than W2. As seen before, the nature of the 3-position 
manifested itself as the most important site for antimalarial activity.
8
 With this in mind, a 
variety of 6- and 7-substituted-4(1H)-quinolones were prepared containing either an ethyl 
or phenyl substituent aat the 3-position. By removing the butyl group as in compound 
5.43, EC50s of 131 nM and 104 nM against W2 and TM90-C2B respectively were 
observed. The 3-phenyl analogs 5.30b and 5.31b displayed diminished activity when 
compared to 5.1, however, the 7-hydroxy analog 5.31 was far more active. The 3-ethyl 
analogs exhibited superior potency, thus analogs 5.32b-5.34b, and 5.41 were prepared 
and tested for activity. These analogs contained the 7-(2-phenoxyethoxy) substituent 
while varying the 6-position. These 4 analogs were approximately 2-7 fold more potent 
against TM90-C2B. Compound 5.34b bearing a methoxy group at the 6-postion was the 
most active with EC50s of 184 nM and 19.5 against W2 and TM90-C2B respectively. 
Several other groups at the 7-position were screened for activity, including several amino 
containing moieties. Surprisingly, the majority of these compounds showed an increase in 
potency against TM90-C2B but not W2. Compound 5.36b bearing a dimethoxymethane 
moiety displayed EC50s of 914 nM against W2 and 70.3 nM against TM90-C2B. 
Compound 5.36b was the most potent non-7-(2-phenoxyethoxy) compound against the 
TM90-C2B strain. Compounds 5.37b-5.40b, and 5.42 were shown to be greatly 
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diminished in activity against W2 with EC50 ranges between 976 nM – 6129 nM, while 
5.42 showed some promise against TM90-C2B with an EC50 of 91.7 nM. These results 
indicate that the 7-(2-phenoxyethoxy) moiety greatly effects the level of antimalarial 
activity of the 4(1H)-quinolone. Depending on the nature of the 3- and 6-position the 7-
(2-phenoxyethoxy) group will lead to very potent molecules, with the 3-ethyl analogs 
being more potent. Moreover, these analogs inhibit the drug-resistant strain 
approximately 10-20 times more than the W2 strain, highlighting that these compounds 
may be capable of inducing resistance in P. falciparum. 
 While retaining the 7-(2-phenoxyethoxy) moiety, a small series of 3-aryl analogs 
was prepared and tested against W2 and TM90-C2B (Table 5.2). Roughly half of the 
analogs were more potent against W2 than TM90-C2B. However, PEQs containing an 
ortho-substituted aryl ring were more potent against the W2 strain whereas analogs 
without ortho-aryl substitution were more potent against TM90-C2B. Initially, the 3-
phenyl analog 5.11 was prepared, which displayed poor EC50s of 1072 nM against W2, 
and 764 nM against TM90-C2B. Next, 3-para- and 3-meta-pyridyl analogs 5.12 and 5.13 
were screened. Compound 5.12 possessed activity in the micromolar range while 5.13 
showed moderate activity against TM90-C2B with an EC50 of 588 nM. Trifluoromethyl 
phenyl and trifluoromethoxy phenyl analogs 5.14 and 5.15 were both greatly diminished 
in activity with 5.14 only possessing an EC50 of 509 nM against W2. The bi-aryl and 
benzyl aryl analogs 5.16 and 5.17 were also inactive. Based upon unpublished results in 
which ortho-substituted aryl analogs greatly increase activity and solubility, analogs 5.18-
5.23 were screened. RIs ranged from 1.11 to 8.12, much more acceptable than many of 
the analogs in the PEQ library. Compound 5.20 was the least active of the ortho-
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substituted aryl analogs. Compound 5.21 displayed excellent activities of 27.96 nM and 
30.99 nM against W2 and TM90-C2B respectively, possessing an RI of 1.11. 
Interestingly, the 3-(3,5-dimethylisoxazol-4-yl) analog 5.23 was also very potent against 
W2 (27.0 nM), however, ~5 fold less potent against TM90-C2B (127.6 nM). Overall, the 
3-aryl series displayed greatly reduced antimalarial activity when compared to compound 
5.1 nevertheless, analogs 5.21 and 5.23 showed promise in developing 3-aryl PEQs. 
Furthermore, it was very interesting that the ortho-substituted-aryl analogs displayed 
greater affinity toward the W2 strain whereas aryl analogs lacking ortho-substitution had 
an affinity toward the TM90-C2B. This supports our findings in the endochin 
optimization studies, where it was shown that a 3-aryl pharmacophore would be the most 
robust for the development of a lead devoid of chemical resistance.
8
 
Table 5.1. EC50 Values of PEQs 5.1, 5.24-5.26, 5.28, 5.30b-5.40b, and 5.41-.5.43 
 
Compound R
1 
R
2 
R
3 
EC50 
W2 
(nM) 
EC50 
TM90-C2B 
(nM) 
RI 
EC50 
J774 
(μM) 
5.1 -CO2Me 
 
-Bu 0.05 11.17 223 46.0 
5.28 -CO2Me -MeO -Cl 134.3 764.8 5.7 37.3 
5.24 -H 
 
-Bu 216.1 44.14 0.20 28.4 
5.26 -Et 
 
-Bu 1.92 0.15 0.08 0.90 
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5.43 -Et 
 
-H 130.7 103.9 0.79 3.8 
5.30b -Ph 
 
-Cl 6379 6379 1.0 20.0 
5.31b -Ph -OH -Cl 1167 383.0 0.32 34.9 
5.32b -Et 
 
-Cl 255.64 72.12 0.28 27.9 
5.41 -Et 
 
-Br 202.5 43.52 0.21 24.8 
5.33b -Et 
 
-Me 255.4 27.7 0.11 29.6 
5.34b -Et 
 
-MeO 184.2 19.45 0.11 28.2 
5.35b -Et 
 
-Cl 907.5 79.65 0.09 19.3 
5.36b -Ph 
 
-Cl 914.4 70.34 0.08 30.3 
5.37b -Et 
 
-H 8452 775.9 0.09 20.0 
5.38b -Et 
 
-Cl 6129 6129 1.0 20.0 
5.39b -Et 
 
-Cl 5087 725.9 0.14 20.0 
5.40b -Et 
 
-Cl 5055 604.4 0.12 20.0 
5.42 -Et 
 
-Cl 975.9 91.67 0.09 22.7 
a
Dihydroartemisinin
 
(DHA) and chloroquine (CQ) are internal controls for each in vitro assay. 
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DHA (1.8 nM W2 and 0.9 nM TM90C2B) and CQ (131 nM W2 and 162 nM TM90-C2B) 
Table 5.2. EC50 Values of PEQs 5.11-5.23 
 
Compound Ar
 
EC50 
W2 
(nM) 
EC50 
TM90-C2B 
(nM) 
RI 
EC50 
J774 
(μM) 
5.11 
 
1072 764 0.71 23.4 
5.12 
 
3146 1016 0.32 23.3 
5.13 
 
1349 587.9 0.44 23.3 
5.14 
 
508.8 2448 4.82 20.2 
5.15 
 
3219 2514 0.78 19.5 
5.16 
 
1392 1002 0.72 18.6 
5.17 
 
4047 4047 1.00 16.2 
5.18 
 
58.52 475.4 8.12 16.1 
5.19 
 
71.78 139.7 1.95 19.6 
5.20 
 
906.6 1627 1.79 21.9 
5.21 
 
27.96 30.99 1.11 19.4 
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5.22 
 
68.67 541.7 7.89 21.0 
5.23 
 
26.95 127.6 4.73 22.3 
a
Dihydroartemisinin
 
(DHA) and chloroquine (CQ) are internal controls for each in vitro assay. 
DHA (1.8 nM W2 and 0.9 nM TM90C2B) and CQ (131 nM W2 and 162 nM TM90-C2B) 
 
5.4 Conclusions 
 Synthesis of 7-(2-phenoxyethoxy)-4(1H)-quinolones (PEQ) 5.1 and related 
analogs was completed to compare the effect on biological activity of several positions of 
the scaffold. A total of 42 novel PEQ analogs with varying substitution at the 2-,3-,6-, 
and 7- positions were synthesized and tested for anti-malarial activity against the 
clinically relevant strains TM90C2B and W2 with the objective to ascertain SAR insight. 
The most potent anti-malarial activities were obtained if (a) the 3-position contained an 
ethyl group, or fluoro aryl moiety, (b) when the compound contained an ethyl at the 3-
poistion and was 7-(2-phenoxyethoxy) substituted the 6-psotion produced the following 
order of activities against TM90-C2B (Bu>>MeO>Me>Br>Cl>H) and against W2 
(Bu>H>MeO>Br>Me>Cl) showing there is a strain preference amongst the 6-position (c) 
the 3-aryl ring contained an ortho-substitution, and (d) the 7-position was devoid of any 
nitrogen atoms or free OH. Many of the analogs showed large differences in RI amongst 
the two strains. Typically, analogs with several heteroatoms at the 7-position other than 
the 7-(2-phenoxyethoxy) substitution pattern exhibited this RI difference. Furthermore, 
RI amongst the 3-aryl series was dependent on the nature of the aryl moiety. Analogs not 
containing an ortho-substituted aryl ring were typically more potent against TM90-C2B 
whereas analogs with an ortho-substituted aryl ring were more potent against the W2 
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strain with RI’s closer to 1. This fluctuation in strain selectivity suggests that an alternate 
target to bc1 complex may be likely amongst some of the PEQ analogs.
10
 These results 
suggest that these compounds are suitable for advancement to in vivo studies which are 
currently ongoing. 
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5.5 Experimental Section 
5.5.1 General Information 
 All reagents and anhydrous solvents were obtained from Aldrich Chemical Co. 
and used without further purification unless otherwise noted. The identity of all title 
compounds was verified via 
1
H NMR, 
13
C NMR, and HPLC/HRMS. The chemical purity 
of the titled compounds was determined using the following conditions: an Agilent 1100 
series LC/MSD with a Eclipse XDB-C18 (4.6mm x 100 mm, 5 μm) reversed phase 
column; method: 10% (v/v) of acetonitrile (+0.05% TFA) in 90% (v/v) of H2O (+0.05% 
TFA), ramped to 100% acetonitrile (+0.05% TFA) over 9 min, and holding at 100% 
acetonitrile for 4 min with a flow rate of 0.7 mL/min, UV detector, 254 nm. The purity of 
each compound was ≥95% in this analysis. NMR spectra were recorded at ambient 
temperature on a 400 or 500 MHz Varian NMR spectrometer in the solvent indicated. All 
1H NMR experiments are reported in ≥ units, parts per million (ppm) downfield of TMS 
and were measured relative to the signals for chloroform (7.26 ppm) and 
dimethylsulfoxide (2.50 ppm). All 
13
C NMR spectra were reported in ppm relative to the 
signals for chloroform (77 ppm) and dimethylsulfoxide (39.5 ppm) with 
1
H decoupled 
observation. Data for 
1H NMR are reported as follows: chemical shift (δ ppm), 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), integration 
and coupling constant (Hz), whereas 
13
C-NMR analyses were obtained at 101 MHz and 
reported in terms of chemical shift. NMR data was analyzed by using MestReNova 
Software ver. 5.3.2-4936. High resolution mass spectra (HRMS) were performed on an 
Agilent LC/MSD TOF system G3250AA. Silicycle silica gel 230-400 (particle size 40-63 
μm) mesh was used for all flash column chromatography.  
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5.5.2 General Procedures 
General Procedure A: Preparation of 3-substituted 2-methylquinolin-4(1H)-ones 
(5.1, 5.8, 5.24-5.26, 5.28, 5.30b-5.40b, 5.41, and 5.42). Quinolin-4-ones were prepared 
by using one of the standard procedures for Conrad-Limpach reaction.
11
 An oven-dry 100 
ml rbf attached to a Dean-Stark trap equipped with a reflux condenser was charged with 
an aniline (0.025 mol), corresponded ethyl acetoacetate (0.25-0.05 mol)
12-14
, benzene (25 
ml) and glacial acidic acid (1 ml). The mixture was heated at 100ºC until no more water 
was separated (3-24 hours). The benzene was distilled under the reduced pressure and 
resulting enamine was then used in the next step without further purification.  Biphenyl 
ether (30 ml) was stirred and heated at reflux while enamine was added rapidly through 
the dropping funnel. Stirring and refluxing continued for 10-15 minutes until no more 
ethanol separates within the Dean-Stark trap. The mixture was then allowed to cool down 
to room temperature while precipitation arises. The solid was filtered off and washed 
with hexane and acetone. Ice cold methanol washing may be necessary in some cases. 
The solid was typically recrystallized with DMF if necessary.  
General Procedure B: Halogenation of substituted 2-methylquinolin-4(1H)-one 
(5.8). The halogenation was done following a similar procedure reported by Renault et 
al.
15
 Thus 5 eq. of iodine was added dropwise to a stirred solution or slurry of 
2‐methylquinolin‐4(1H)‐one in 2M solution of sodium hydroxide and MeOH (~1:1) at r.t. 
Stirring was continued until LCMS indicates absence of starting material (3‐24 hours). In 
some cases more than 8 eq of iodine was needed. The mixture was then acidified with 
acetic acid; precipitation was collected by filtration, washed with water, and 
recrystallized from DMF. 
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General Procedure C: Alkylation of 2-methylquinolin-4(1H)-one (5.9-5.10). 
To a flame dried-backfilled round bottom flask is added quinolone (0.72 g, 2.8 mmol) 
and Cs2CO3 (1.37 g, 4.2 mmol). DMF (14.5 ml) is added and this slurry is allowed to stir 
at r.t. for 1h. Next, Iodomethane (0.88 ml, 14 mmol) is added dropwise and the reaction is 
left until completion is observed via HPLC analysis. The reaction is the poured onto 
water (20 ml) and then diluted with chloroform (20 ml). The organic layer is then washed 
with water (20 ml) twice followed by brine (20 ml). The organic layer is then dried over 
sodium sulfate and concentrated in vacuo. The crude compound is columned via flash 
chromatography (Hex / EtOAc gradient). 
General Procedure D: Suzuki-Coupling of 3-iodo-2-methylquinolin-4(1H)-one (5.11-
5.23). 
An oven-dried schlenk tube is flame-dried and backfilled with argon(x3). The tube is then 
charged with 4(1H)-quinolone (100 mg, 0.4 mmol), Pd2(dba)3 (14.5 mg, 0.016 mmol), 
SPHOS (13 mg, 0.032 mmol), boronic acid (97mg, 0.6 mmol), and anhydrous powdered 
K3PO4 (168 mg, 0.79 mmol). The schlenk tube was fitted with a rubber septum and then 
evacuated and backfilled with argon (this process was repeated three times). Dry solvent 
(Toluene, DMF, or 2-butanol, 3mL) was added through the septum via syringe and the 
resulting solution was stirred for 1 min while purging with argon before replacing the 
rubber septum with the Teflon screwcap. The reaction was set to the oil bath until 
completion was observed via HPLC analysis. The reaction is cooled to room temperature 
and then diluted with 20 ml chloroform and 20 ml of methanol. This mixture was brought 
to a boil with a heat gun and then filtered over a pad of celite. The eluent was 
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concentrated under reduced pressure and the residual oil was purified further via flash 
chromatography. 
General Procedure E: Suzuki-Coupling of 3-iodo-2-methylquinolin-4(1H)-one (5.11-
5.23). 
An oven-dried microwave reactor tube is flame-dried and backfilled with argon(x3). The 
tube is then charged with 4(1H)-quinolone (125 mg, 0.26 mmol), Pd2(dba)3 (3.5 mg, 
0.004 mmol), SPHOS (3.2 mg, 0.008 mmol), boronic acid (52 mg, 0.39 mmol). The 
schlenk tube was fitted with a rubber septum and then evacuated and backfilled with 
argon (this process was repeated three times). Dry DMF 5 mL and 1M Na2CO3 1 mL was 
added through the septum via syringe and the resulting solution was placed in a 
microwave reactor for 20 minutes at 140ºC. The reaction was monitored via HPLC 
analysis. The reaction is cooled to room temperature and then diluted with 2 ml 
chloroform and 2 ml of methanol. This mixture was brought to a boil with a heat gun and 
then filtered over a pad of celite. The eluent was concentrated under reduced pressure and 
the residual oil was purified further via flash chromatography. 
General Procedure F: Suzuki-Coupling of 6-butyl-4-ethoxy-3-iodo-2-methyl-7-(2-
phenoxyethoxy)quinoline (5.11-5.23). 
An oven-dried schlenk tube is flame-dried and backfilled with argon(x3). The tube is then 
charged with 6-butyl-4-ethoxy-3-iodo-2-methyl-7-(2-phenoxyethoxy)quinoline (100 mg, 
0.4 mmol), Pd2(dba)3 (14.5 mg, 0.016 mmol), SPHOS (13 mg, 0.032 mmol), boronic acid 
(97mg, 0.6 mmol), and anhydrous powdered K3PO4 (168 mg, 0.79 mmol). The schlenk 
tube was fitted with a rubber septum and then evacuated and backfilled with argon (this 
process was repeated three times). Dry solvent (Toluene, DMF, or 2-butanol, 3mL) was 
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added through the septum via syringe and the resulting solution was stirred for 1 min 
while purging with argon before replacing the rubber septum with the Teflon screwcap. 
The reaction was set to the oil bath until completion was observed via HPLC analysis. 
The reaction is cooled to room temperature and then diluted with 20 ml chloroform and 
20 ml of methanol. This mixture was brought to a boil with a heat gun and then filtered 
over a pad of celite. The eluent was concentrated under reduced pressure and the residual 
oil was purified further via flash chromatography. 
General Procedure G: O-ethyl Hydrolysis 
6-Butyl-4-methoxy-2-methyl-7-(2-phenoxyethoxy)-3-phenylquinoline (100 mg, 0.226 
mmol) was dissolved in 1 mL of acetic acid and 1mL of HBr. The reaction was refluxed 
for 1.5h and checked via LC-MS to determine completion. Upon completion, the reaction 
is poured onto ice and water and filtered. The solid is then dried in an oven for 1h and 
recrystallized from DMF. 
General Procedure H: Acylation of Aniline 
To a solution of 4-chloro-3-hydroxy aniline (4.0 g, 28 mmol) in acetic acid (20 mL), 
acetic anhydride (3 mL, 42 mmol) was added and the reaction was refluxed for 5 
minutes. Then the reaction mixture was cooled to room temperature and the product was 
solidified. It was isolated via filtration and washed with water (10 mL) and dried to 
obtain the product in 93% yield (4.8 g). No further purification was necessary. 
General Procedure I: Alkylation of Acyl Aniline 
To a DCM (15 mL) solution of N-(4-chloro-3-hydroxyphenyl)acetamide  (1.07 g, 5.78 
mmol) was added the MOMCl (0.6 mL, 7.51 mmol). DIPEA (1.8 mL, 10.4 mmol) was 
added at 0
o
C to the reaction mixture. The mixture was warmed to room temperature and 
298 
 
stirred over night. Water (5 mL) was added and extracted with DCM (20 mL X 3). The 
combined extracts were shaken with brine (10 mL) and dried over Na2SO4. The product 
was obtained (0.860 g, 65% yield) after flash column chromatography. 
General Procedure J: Hydrolysis of Acetamide 
N-(4-Chloro-3-(methoxymethoxy)phenyl)acetamide (700 mg, 3.05 mmol) and KOH 
(2.39 gr, 42.8 mmol) was added to a flame-dried flask and subsequently dissolved in 10 
mL of 9:1 ethanol: water solution. The mixture was refluxed over night. The ethanol was 
concentrated in vacuo, diluted with water (5 mL) and extracted with EA (3 X 20 mL). 
The combined extracts were dried over Na2SO4 and purified by flash column 
chromatography to get the product (0.480 g) in 84% yield. 
5.5.3 Compound Characterization 
3-acetamidophenyl butyrate (5.2).  N-(3-Hydroxyphenyl)acetamide (300 g) was stirred 
in pyridine ( 990 mL) followed by the addition of butyryl chloride ( 246 mL). This 
reaction was stirred at r.t. for 30 min until stirring stopped. The resulting crystalline 
suspension was left for 18h to ensure completion. The mixture was dissolved in H2O and 
EA (1:1, 1000 mL), the organic layer is separated and washed with brine (3X 1000 mL). 
The organic layer is dried over Na2SO4 and concentrated in vacuo at 70ºC to remove 
pyridine. Upon cooling the oil become a very low melting solid. This solid is carefully 
added to a coarse 500 mL frit and dried, minimal washing with ice cold hexane was used 
to cake the solid. The final compound was collected to provide the title compound in 75% 
yield (440 g) as a light-yellow solid. 
1
H NMR (250 MHz, CDCl3) δ 7.92 (s, 1H), 7.37 (s, 
1H), 7.17 (d, J = 8.1 Hz, 1H), 7.03 (d, J = 7.5 Hz, 1H), 6.70 (d, J = 7.8 Hz, 1H), 2.46 (t, J 
= 7.4 Hz, 2H), 1.96 (s, 3H), 1.70 (dd, J = 14.7, 7.4 Hz, 2H), 0.96 (t, J = 7.4 Hz, 3H). 
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N-(4-butyryl-3-hydroxyphenyl)acetamide (5.3). 3-Acetamidophenyl butyrate (440 g, 
1.98 mol) was added to a 2-neck 1-L round bottom flask. Finely mortared AlCl3 (560 g, 
4.15 mol) was added to the flask and the two solids were heated to approximately 150ºC 
at which point a glassy brittle solid forms. This process is extremely exothermic and a 
large amount of HCl gas is formed. This solid was removed from the reaction flask and 
re-mortared into a very fine orange powder. This powder was then re-heated at 175ºC 
overnight. Upon cooling the solid is added to 2N H2SO4 and ice and stirred for several 
hours. The solid is then filtered off and wash liberally with water. Next, 1M NaOH is 
used to dissolve the solid completely, followed by acidification of this solution with 
acetic acid. This resulting solid is filtered and recrystallized with benzene to obtain the 
title compound in 75% yield (330 g). 
1
H NMR (500 MHz, CDCl3) δ 12.66 (s, 1H), 8.12 
(s, 1H), 7.70 (d, J = 8.8 Hz, 1H), 7.17 (d, J = 8.8 Hz, 1H), 7.13 (s, 1H), 2.90 (t, J = 7.4 
Hz, 2H), 2.21 (s, 3H), 1.77 (dt, J = 14.8, 7.4 Hz, 2H), 1.02 (t, J = 7.4 Hz, 3H). 
13
C NMR 
(126 MHz, CDCl3) δ 205.51, 169.15, 163.75, 144.90, 131.35, 115.73, 110.35, 107.37, 
39.89, 24.81, 18.12, 13.85. 
N-(3-hydroxy-4-(1-hydroxybutyl)phenyl)acetamide (5.4). N-(4-Butyryl-3-
hydroxyphenyl)acetamido (330 g, 1.48 mol) was dissolved in 2 L of DCM and 1 L of 
MeOH. This solution was chilled to 0ºC and NaBH4 (33g, 0.87 mol) was added portion-
wise over 30 minutes. Upon completion by TLC the reaction is quenched by the slow 
addition of ice. The resulting mixture is slowly evaporated to remove the methanol. The 
resulting solution is taken up in 1L of EA and washed with 1M HCl. The organic layer is 
then washed with water (X3) and brine (X1). The organic layer is dried over Na2SO4 
concentrated in vacuo to give a brown viscous oil. This oil was exhaustively columned on 
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a 1L column and eluted with EA:H (2:1) over the course of approximately 12 column 
loads to obtain the title compound in 56% yield (184 g).  
N-(4-butyl-3-hydroxyphenyl)acetamide (5.5). N-(3-Hydroxy-4-(1-
hydroxybutyl)phenyl)acetamide (184 g) was reduced in 20g batches by dissolving it in 
de-oxygenated acetic acid (210 mL) in the presence of 10% Pd/C (7g) at 60 Psi in a Parr 
hydrogenator for eleven hours. Upon completion the reaction was filtered over celite and 
diluted. The acetic acid was removed in vacuo. The resulting oil was diluted with EA and 
was washed with water (X3) followed by brine (X1). The organic layer was dried over 
Na2SO4 and concentrated in vacuo. The crude compound was purified via flash 
chromatography with 100% EA to obtain the title compound in 70% yield (120 g) as a 
waxy tan solid.  
N-(4-butyl-3-(2-phenoxyethoxy)phenyl)acetamide (5.6). To a flame dried flask back-
filled with argon (X2) was added NaH (26.5 g, 1.1 mol) and 325 mL of anhydrous DMF. 
A solution of N-(4-butyl-3-hydroxyphenyl)acetamide (120 g, 0.58 mol) dissolved in 325 
mL of anhydrous DMF was added via dropping funnel over 30 min at 0ºC. The reaction 
was then brought to 75ºC and held for 4h. Upon completion the reaction was cooled to r.t. 
and filtered over celite. The resulting solution was diluted with EA (600 mL) and washed 
with ice cold water (X3) and brine (X1). The organic layer was dried over Na2SO4 and 
concentrated in vacuo. The crude oil was purified further via flash chromatography with 
Hex:EA (2:1) to obtain the title compound in 71% yield (132 g) as a light brown solid.  
4-butyl-3-(2-phenoxyethoxy)aniline (5.7). N-(4-Butyl-3-(2-
phenoxyethoxy)phenyl)acetamide (132 g, 0.41 mol) was dissolved in EtOH (897 mL) 
and H2O (104 mL). KOH (312 g, 5.57 mol) was added at 0ºC and the solution was 
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allowed to reflux for 18h. Upon completion the reaction is cooled to room temperature 
and diluted with 2L of water and 2L of DCM. The organic layer was washed with water 
(X2) and dried over Na2SO4. The crude compound was purified further via flash 
chromatography with Hex:EA (1:1) to obtain the title compound in 80% yield (92 g) as a 
pink solid.  
methyl 6-butyl-4-oxo-7-(2-phenoxyethoxy)-1,4-dihydroquinoline-3-carboxylate (5.1). 
4-butyl-3-(2-phenoxyethoxy)aniline (1g, 3.5 mmol) was dissolved in EtOH (7 mL) 
followed by the addition of dimethyl 2-(methoxymethylene)malonate (0.73 g, 4.2 mmol). 
This solution was refluxed for 3h. Upon completion the reaction is concentrated in vacuo 
and the resulting oil is further purified via flash chromatography with Hex:EA (2:1) to 
obtain the eneamino intermediate in 90% yield (1.34 g) as a yellow oil. The resulting oil 
was added dropwise to refluxing biphenyl ether (13 mL) and refluxed for 8 min to obtain 
the title compound in 12% yield (0.18 g) as a white powder. 
1
H NMR (400 MHz, DMSO) 
δ 12.10 (s, 1H), 8.48 (s, 1H), 7.87 (s, 1H), 7.31 (t, J = 8.0 Hz, 2H), 7.05 (s, 1H), 6.98 (dd, 
J = 12.5, 7.7 Hz, 3H), 4.40 (s, 4H), 3.72 (s, 3H), 2.61 (t, J = 7.5 Hz, 2H), 1.52 (dd, J = 
15.1, 7.9 Hz, 2H), 1.27 – 1.21 (m, 2H), 0.84 (t, J = 7.3 Hz, 3H). 
6-butyl-3-iodo-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (5.8). Following 
general procedure A methyl 6-chloro-7-methoxy-2-methyl-4-oxo-1,4-dihydroquinoline-
3-carboxylate was obtained in 18% yield. 
1H NMR (400 MHz, DMSO) δ 11.35 (s, 1H), 
7.74 (s, 1H), 7.31 (t, J = 7.8 Hz, 2H), 7.05 – 6.87 (m, 4H), 5.79 (s, 1H), 4.38 (d, J = 6.7 
Hz, 4H), 2.58 (t, J = 7.4 Hz, 2H), 2.29 (s, 3H), 1.58 – 1.47 (m, 2H), 1.25 (dd, J = 14.6, 
7.3 Hz, 2H), 0.83 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 176.87, 159.75, 
159.09, 149.21, 140.85, 130.18, 127.88, 125.94, 121.45, 119.12, 115.23, 108.68, 98.82, 
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67.50, 66.77, 32.03, 29.87, 22.51, 20.02, 14.42. Chemical Formula: C22H25NO3. 
Following general procedure B the title compound was prepared from methyl 6-chloro-7-
methoxy-2-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate in 89% yield as a light 
yellow powder. 
1H NMR (400 MHz, DMSO) δ 7.78 (s, 1H), 7.31 (t, J = 7.7 Hz, 2H), 
7.02 – 6.92 (m, 4H), 4.40 (s, 4H), 2.61 (d, J = 10.1 Hz, 5H), 1.57 – 1.49 (m, 2H), 1.26 
(dt, J = 14.6, 7.3 Hz, 2H), 0.83 (t, J = 7.3 Hz, 3H). 
6-butyl-4-ethoxy-3-iodo-2-methyl-7-(2-phenoxyethoxy)quinolone (5.10). Following 
general procedure C the title compound was prepared in 77% yield as a beige solid. 
1
H 
NMR (400 MHz, cdcl3) δ 7.68 (s, 1H), 7.35 – 7.24 (m, 3H), 6.95 (t, J = 7.1 Hz, 3H), 4.40 
(dd, J = 17.5, 5.0 Hz, 4H), 4.16 (q, J = 7.0 Hz, 2H), 2.89 (s, 3H), 2.77 – 2.71 (m, 2H), 
1.62 (dt, J = 14.0, 7.3 Hz, 5H), 1.34 (dt, J = 14.5, 7.4 Hz, 2H), 0.90 (t, J = 7.3 Hz, 3H). 
13
C NMR (101 MHz, cdcl3) δ 162.58, 160.66, 158.99, 158.66, 149.45, 133.56, 129.48, 
121.57, 121.09, 117.57, 114.71, 106.65, 87.05, 70.66, 66.76, 66.22, 31.64, 30.44, 30.38, 
22.46, 15.81, 13.95.   
6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-phenylquinolin-4(1H)-one (5.11). Following 
general procedure E the title compound was prepared in 49% yield. 
1
H NMR (400 MHz, 
DMSO) δ 11.44 (s, 1H), 7.80 (s, 1H), 7.37 (t, J = 7.2 Hz, 2H), 7.33 – 7.25 (m, 3H), 7.22 
(d, J = 7.6 Hz, 2H), 7.02 – 6.93 (m, 4H), 4.40 (d, J = 4.9 Hz, 4H), 2.60 (t, J = 7.4 Hz, 
2H), 2.17 (s, 3H), 1.57 – 1.49 (m, 2H), 1.25 (dd, J = 14.6, 7.3 Hz, 2H), 0.83 (dd, J = 7.8, 
6.7 Hz, 3H). 
13
C NMR (101 MHz, DMSO) δ 174.34, 159.14, 158.42, 145.43, 139.42, 
136.46, 131.02, 129.51, 127.66, 127.36, 126.27, 125.86, 120.78, 120.46, 118.35, 114.54, 
97.88, 66.84, 66.09, 31.41, 29.26, 21.81, 18.76, 13.74.  
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6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(pyridin-4-yl)quinolin-4(1H)-one (5.12). 
Following general procedure E the title compound was prepared in 41% yield. 
1
H NMR 
(400 MHz, DMSO) δ 11.62 (s, 1H), 8.56 (d, J = 4.2 Hz, 2H), 7.80 (s, 1H), 7.30 (dd, J = 
13.1, 5.8 Hz, 4H), 7.04 – 6.90 (m, 4H), 4.40 (s, 4H), 2.60 (t, J = 7.5 Hz, 2H), 1.57 – 1.48 
(m, 2H), 1.24 (dt, J = 14.4, 7.4 Hz, 2H), 0.83 (t, J = 7.3 Hz, 3H). 
13
C NMR (101 MHz, 
DMSO) δ 173.70, 159.38, 158.42, 148.96, 145.97, 144.53, 139.43, 129.52, 127.81, 
126.35, 125.79, 120.80, 118.25, 117.87, 114.55, 98.04, 66.91, 66.09, 31.35, 29.25, 21.81, 
18.71, 13.74.  
6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(pyridin-3-yl)quinolin-4(1H)-one (5.13). 
Following general procedure E the title compound was prepared in 41% yield. 
1
H NMR 
(400 MHz, DMSO) δ 11.59 (s, 1H), 8.46 (d, J = 11.9 Hz, 2H), 7.81 (s, 1H), 7.67 (d, J = 
7.6 Hz, 1H), 7.45 – 7.37 (m, 1H), 7.31 (t, J = 7.6 Hz, 2H), 6.98 (dd, J = 21.4, 9.4 Hz, 
4H), 4.41 (s, 4H), 2.61 (t, J = 7.5 Hz, 2H), 1.53 (dt, J = 15.1, 7.6 Hz, 2H), 1.25 (dd, J = 
14.6, 7.4 Hz, 2H), 0.83 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 174.69, 
159.76, 158.85, 151.91, 147.70, 146.62, 139.93, 138.94, 132.54, 129.95, 128.14, 126.23, 
123.35, 121.22, 118.61, 117.33, 114.98, 98.44, 67.32, 66.52, 31.80, 29.69, 22.25, 19.20, 
14.18.  
6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(4-(trifluoromethyl)phenyl)quinolin-4(1H)-
one (5.14). Following general procedure D the title compound was prepared in 60% 
yield. 
1H NMR (400 MHz, DMSO) δ 11.56 (s, 1H), 7.80 (s, 1H), 7.72 (d, J = 8.1 Hz, 
2H), 7.48 (d, J = 8.0 Hz, 2H), 7.31 (t, J = 7.9 Hz, 2H), 7.03 – 6.94 (m, 4H), 4.41 (s, 4H), 
2.61 (t, J = 7.4 Hz, 2H), 2.21 (s, 3H), 1.58 – 1.49 (m, 2H), 1.24 (dt, J = 14.6, 7.3 Hz, 2H), 
0.83 (t, J = 7.3 Hz, 3H). 
19F NMR (376 MHz, DMSO) δ -61.19. 13C NMR (101 MHz, 
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DMSO) δ 174.69, 160.01, 159.10, 146.52, 141.69, 140.13, 132.60, 130.20, 128.37, 
127.55 (q, J = 31.31 Hz), 126.50, 125.13, 123.84, 121.47, 119.72, 118.95, 115.22, 98.67, 
67.56, 66.76, 32.06, 29.94, 22.49, 19.42, 14.42. 
6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(4-(trifluoromethoxy)phenyl)quinolin-
4(1H)-one (5.15). Following general procedure E the title compound was prepared in 
37% yield. 
1
H NMR (400 MHz, DMSO) δ 11.53 (s, 1H), 7.80 (s, 1H), 7.37 – 7.29 (m, 
6H), 7.02 – 6.94 (m, 4H), 4.40 (d, J = 2.7 Hz, 4H), 2.63 – 2.57 (m, 2H), 2.19 (s, 3H), 1.54 
(dd, J = 14.9, 7.3 Hz, 2H), 1.25 (dd, J = 14.8, 7.4 Hz, 2H), 0.83 (t, J = 7.3 Hz, 3H). 
19
F 
NMR (376 MHz, DMSO) δ -56.62. 13C NMR (101 MHz, DMSO) δ 174.18, 159.28, 
158.43, 146.84, 145.77, 139.45, 135.79, 132.93, 129.53, 127.59, 125.82, 121.46, 120.80, 
120.27, 119.00, 118.92, 118.25, 114.54, 97.94, 66.88, 66.09, 31.41, 29.29, 21.83, 18.79, 
13.76.  
6-butyl-3-(3-(4-fluorophenoxy)phenyl)-2-methyl-7-(2-phenoxyethoxy)quinolin-
4(1H)-one (5.16). Following general procedure E the title compound was prepared in 
71% yield. 
1H NMR (400 MHz, DMSO) δ 11.48 (s, 1H), 7.79 (s, 1H), 7.38 (t, J = 7.9 Hz, 
1H), 7.30 (dd, J = 11.9, 4.1 Hz, 2H), 7.22 (t, J = 8.8 Hz, 2H), 7.11 – 7.06 (m, 2H), 7.01 – 
6.86 (m, 7H), 4.39 (d, J = 5.4 Hz, 4H), 2.59 (t, J = 7.5 Hz, 2H), 2.20 (s, 3H), 1.52 (dt, J = 
14.8, 7.4 Hz, 2H), 1.24 (dd, J = 14.7, 7.4 Hz, 2H), 0.83 (t, J = 7.3 Hz, 3H). 
19
F NMR (376 
MHz, DMSO) δ -120.09. 13C NMR (101 MHz, DMSO) δ 174.10, 159.18, 158.05 (d, J = 
240.4 Hz), 158.40, 156.46, 152.72 (d, J = 2.02 Hz), 145.59, 139.37, 138.40, 129.48, 
129.15, 127.46, 126.20, 125.80, 120.89, 120.76, 120.41 (d, J = 7.07 Hz), 119.66, 118.29, 
116.81 (d, J = 23.23 Hz), 116.15, 114.53, 97.89, 66.84, 66.08, 31.36, 29.21, 21.78, 18.76, 
13.70.  
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6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(4-((4-(trifluoromethoxy)phenoxy)methyl) 
phenyl)quinolin-4(1H)-one (5.17). Following general procedure E the title compound 
was prepared in 69% yield. 
1H NMR (400 MHz, DMSO) δ 11.41 (s, 1H), 7.76 (s, 1H), 
7.42 (d, J = 8.0 Hz, 2H), 7.30 – 7.25 (m, 4H), 7.22 (d, J = 7.9 Hz, 2H), 7.11 (d, J = 9.0 
Hz, 2H), 7.01 – 6.87 (m, 5H), 5.11 (s, 2H), 4.37 (d, J = 3.4 Hz, 4H), 2.59 – 2.54 (m, 2H), 
2.16 (s, 3H), 1.54 – 1.47 (m, 2H), 1.24 – 1.17 (m, 2H), 0.80 (t, J = 7.3 Hz, 3H). 19F NMR 
(376 MHz, DMSO) δ -57.31. 13C NMR (101 MHz, DMSO) δ 174.61, 159.63, 158.84, 
157.76, 146.22, 146.00, 142.25, 139.84, 136.60, 134.97, 131.56, 129.96, 127.90, 127.74, 
126.29, 122.95, 121.23, 120.50, 118.73, 116.37, 114.97, 98.33, 70.19, 67.30, 66.53, 
31.83, 29.70, 22.24, 19.22, 14.17.  
6-butyl-2-methyl-3-(2-methyl-4-(4-(trifluoromethoxy)phenoxy)phenyl)-7-(2-
phenoxyethoxy)quinolin-4(1H)-one (5.18). Following general procedures F and G the 
title compound was prepared in 49% yield over two steps. 
1H NMR (400 MHz, DMSO) δ 
11.44 (s, 1H), 7.75 (s, 1H), 7.37 (d, J = 8.7 Hz, 2H), 7.28 (t, J = 7.6 Hz, 2H), 7.11 (d, J = 
9.0 Hz, 2H), 7.02 – 6.91 (m, 6H), 6.83 (d, J = 8.1 Hz, 1H), 4.37 (s, 4H), 2.59 – 2.54 (m, 
2H), 2.03 (s, 3H), 1.98 (s, 3H), 1.54 – 1.47 (m, 2H), 1.22 (dd, J = 14.7, 7.5 Hz, 2H), 0.80 
(t, J = 7.2 Hz, 3H). 
19F NMR (376 MHz, DMSO) δ -57.31. 13C NMR (101 MHz, DMSO) 
δ 170.34, 159.91, 158.35, 155.68, 155.55, 149.41, 143.58, 139.93, 139.59, 132.55, 
130.11, 130.04, 129.47, 124.82, 122.80, 121.35, 120.78, 120.09, 119.70, 118.79, 118.52, 
116.20, 114.45, 98.20, 67.16, 65.98, 31.24, 29.42, 21.84, 19.36, 18.67, 13.67. 
6-butyl-2-methyl-3-(2-methyl-4-(trifluoromethyl)phenyl)-7-(2-phenoxyethoxy) 
quinolin-4(1H)-one (5.19). Following general procedure E the title compound was 
prepared in13% yield. 
1H NMR (400 MHz, DMSO) δ 11.57 (s, 1H), 7.79 (s, 1H), 7.63 (s, 
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1H), 7.53 (d, J = 8.0 Hz, 1H), 7.33 – 7.25 (m, 3H), 7.03 – 6.94 (m, 4H), 4.41 (s, 4H), 2.60 
(t, J = 7.4 Hz, 2H), 2.12 (s, 3H), 2.04 (s, 3H), 1.57 – 1.49 (m, 2H), 1.26 (dd, J = 14.6, 7.3 
Hz, 2H), 0.83 (t, J = 7.2 Hz, 3H). 
19F NMR (376 MHz, DMSO) δ -57.51. 13C NMR (101 
MHz, DMSO) δ 174.29, 159.77, 158.81, 146.33, 141.56, 140.02, 139.65, 132.33, 129.97, 
128.30, 128.19, 127.88, 126.38, 126.34, 126.27, 126.13, 123.56, 122.64, 122.60, 121.26, 
119.26, 118.45, 114.96, 98.45, 67.37, 66.51, 31.86, 29.71, 22.28, 19.63, 18.69, 14.14.  
6-butyl-3-(2,4-dimethylphenyl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one 
(5.20). Following general procedures F and G the title compound was prepared in 64% 
yield over two steps. 
1H NMR (400 MHz, DMSO) δ 11.56 (s, 1H), 7.81 (s, 1H), 7.35 – 
7.27 (m, 3H), 7.22 (d, J = 8.3 Hz, 1H), 7.05 – 6.93 (m, 5H), 4.38 (d, J = 5.9 Hz, 4H), 2.60 
(t, J = 7.3 Hz, 2H), 2.03 (s, 6H), 1.52 (dd, J = 14.8, 7.6 Hz, 2H), 1.27 – 1.21 (m, 2H), 
0.82 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 173.96, 159.21, 158.41, 145.82, 
140.19, 139.59, 135.53, 132.69, 131.32, 129.49, 129.09, 127.61, 125.75, 125.34, 120.78, 
118.81, 118.12, 114.53, 97.98, 66.86, 66.07, 31.46, 29.28, 21.88, 19.18, 18.29, 13.74.  
6-butyl-3-(2-fluoro-4-(trifluoromethyl)phenyl)-2-methyl-7-(2-phenoxyethoxy) 
quinolin-4(1H)-one (5.21). Following general procedures F and G the title compound 
was prepared in 48% yield over two steps. 
1H NMR (400 MHz, DMSO) δ 12.38 (s, 1H), 
7.90 (s, 1H), 7.71 (d, J = 9.3 Hz, 1H), 7.66 – 7.46 (m, 2H), 7.31 (t, J = 7.8 Hz, 2H), 7.11 
(s, 1H), 7.05 – 6.79 (m, 3H), 4.43 (s, 4H), 2.74 – 2.52 (m, 2H), 2.23 (s, 3H), 1.53 (dd, J = 
14.6, 7.5 Hz, 2H), 1.28 – 1.19 (m, 2H), 0.82 (t, J = 7.3 Hz, 3H). 19F NMR (376 MHz, 
DMSO) δ -61.11, -110.84. 13C NMR (101 MHz, DMSO) δ 172.39, 160.41 (d, J = 247.45 
Hz), 160.31, 158.83, 148.67, 140.11, 135.08, 130.16, 129.92, 129.69, 128.20 (d, J = 
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16.16), 125.70, 123.90 (q, J = 273.71 Hz) 121.38, 121.23, 117.38, 114.98, 113.41, 
113.22, 98.69, 67.52, 66.47, 31.69, 29.76, 22.25, 18.92, 14.13. 
6-butyl-3-(4-chloro-2-methylphenyl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-
on (5.22). Following general procedures F and G the title compound was prepared in 
52% yield over two steps. 
1H NMR (400 MHz, DMSO) δ 11.44 (s, 1H), 7.79 (s, 1H), 
7.31 (t, J = 7.6 Hz, 2H), 7.01 (dd, J = 23.2, 14.6 Hz, 5H), 6.88 (d, J = 7.8 Hz, 2H), 4.39 
(d, J = 6.0 Hz, 4H), 2.64 – 2.55 (m, 2H), 2.29 (s, 3H), 2.00 (d, J = 14.3 Hz, 6H), 1.53 (dt, 
J = 14.8, 7.5 Hz, 2H), 1.25 (dd, J = 14.8, 7.3 Hz, 2H), 0.83 (t, J = 7.3 Hz, 3H). 
13
C NMR 
(101 MHz, DMSO) δ 174.65, 159.50, 158.85, 146.04, 139.97, 137.59, 136.15, 133.93, 
131.21, 130.61, 129.94, 127.77, 126.48, 126.25, 121.22, 120.41, 118.60, 114.98, 98.34, 
67.28, 66.52, 31.93, 29.72, 22.31, 21.15, 19.76, 18.78, 14.18. Chemical Formula: 
C29H30ClNO3 
6-butyl-3-(3,5-dimethylisoxazol-4-yl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-
on (5.23). Following general procedures F and G the title compound was prepared in 
10% yield over two steps. 
1H NMR (400 MHz, DMSO) δ 11.70 (s, 1H), 7.79 (s, 1H), 
7.30 (dd, J = 8.4, 7.5 Hz, 2H), 7.01 – 6.92 (m, 4H), 4.39 (d, J = 2.3 Hz, 4H), 2.63 – 2.57 
(m, 2H), 2.16 (d, J = 2.8 Hz, 6H), 1.98 (s, 3H), 1.55 – 1.50 (m, 2H), 1.24 (d, J = 7.5 Hz, 
2H), 0.84 (d, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 174.30, 165.72, 160.26, 
159.35, 158.41, 147.95, 139.57, 129.50, 127.91, 125.68, 120.79, 117.75, 114.55, 110.87, 
107.78, 98.12, 66.94, 66.08, 31.41, 29.24, 21.85, 18.21, 13.73, 11.24, 10.23.  
methyl 6-chloro-7-methoxy-2-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate 
(5.24). Following general procedure A the title compound was prepared in 18% yield. 
1
H 
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NMR (400 MHz, DMSO) δ 11.35 (s, 1H), 7.74 (s, 1H), 7.31 (t, J = 7.8 Hz, 2H), 7.05 – 
6.87 (m, 4H), 5.79 (s, 1H), 4.38 (d, J = 6.7 Hz, 4H), 2.58 (t, J = 7.4 Hz, 2H), 2.29 (s, 3H), 
1.58 – 1.47 (m, 2H), 1.25 (dd, J = 14.6, 7.3 Hz, 2H), 0.83 (t, J = 7.3 Hz, 3H). 13C NMR 
(101 MHz, DMSO) δ 176.87, 159.75, 159.09, 149.21, 140.85, 130.18, 127.88, 125.94, 
121.45, 119.12, 115.23, 108.68, 98.82, 67.50, 66.77, 32.03, 29.87, 22.51, 20.02, 14.42.  
6-butyl-3-ethyl-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (5.26). Following 
general procedure A the title compound was prepared in 43% yield. 
1
H NMR (400 MHz, 
DMSO) δ 11.15 (s, 1H), 7.76 (s, 1H), 7.31 (t, J = 7.9 Hz, 2H), 7.02 – 6.93 (m, 3H), 6.87 
(s, 1H), 4.38 (d, J = 9.8 Hz, 4H), 2.58 (t, J = 7.4 Hz, 2H), 2.49 – 2.43 (m, 2H), 2.34 (s, 
3H), 1.51 (dd, J = 14.8, 7.5 Hz, 2H), 1.25 (dd, J = 14.7, 7.3 Hz, 2H), 0.98 (t, J = 7.3 Hz, 
3H), 0.83 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 175.53, 159.43, 159.10, 
145.05, 139.87, 130.67, 130.16, 127.57, 126.24, 121.43, 120.52, 119.25, 118.23, 115.22, 
98.32, 67.42, 66.78, 32.09, 29.92, 22.50, 18.59, 17.86, 14.42.  
methyl 6-chloro-7-methoxy-2-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate 
(5.28). Following general procedure A the title compound was prepared in 23% yield. 
6-chloro-2-methyl-7-(2-phenoxy-ethoxy)-3-phenyl-1 H-quinolin-4-one (5.30b). 
Following general procedures H, then I, then J, followed by general procedure A the final 
4(1H)-quinolone was prepared in 19% over the 4 steps. 
1H NMR (400 MHz, DMSO) δ 
11.69 (s, 1H), 8.00 (s, 1H), 7.39 (t, J = 7.5 Hz, 2H), 7.35 – 7.29 (m, 3H), 7.25 – 7.22 (m, 
2H), 7.15 (s, 1H), 7.04 (d, J = 8.3 Hz, 2H), 6.97 (t, J = 7.4 Hz, 1H), 4.524.47 (m, J = 5.5 
Hz, 2H), 4.46-4.41 (m, J = 5.0 Hz, 2H), 2.20 (s, 3H). 
309 
 
6-chloro-7-hydroxy-2-methyl-3-phenyl-1H-quonolin-4-one (5.31b). Following general 
procedure A the final 4(1H)-quinolone was prepared in 16% directly from 5-amino-2-
chloro phenol. The reaction generated a mixture of two isomers. The title compound was 
separated by preparative HPLC by dissolving in minimal amount of methanol. 
1
H NMR 
(400 MHz, DMSO) δ 11.43 (s, 1H), 11.04 (s, 1H), 7.92 (s, 1H), 7.36 (t, J = 7.3 Hz, 2H), 
7.28 (d, J = 7.0 Hz, 1H), 7.20 (d, J = 7.5 Hz, 2H), 7.04 (s, 1H), 2.15 (s, 3H). 
13
C NMR 
(101 MHz, DMSO) δ 174.23, 156.33, 146.94, 140.20, 136.72, 131.66, 128.37, 127.09, 
126.97, 120.83, 118.96, 118.32, 102.86, 19.46. 
6-chloro-3-ethyl-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (5.32b). 
Following general procedures H, then I, then J, followed by general procedure A the final 
4(1H)-quinolone was prepared in 12% over the 4 steps. 
1H NMR (400 MHz, DMSO) δ 
11.38 (s, 1H), 7.97 (s, 1H), 7.31 (t, J = 7.9 Hz, 2H), 7.06 (s, 1H), 7.02 (d, J = 8.0 Hz, 2H), 
6.96 (t, J = 7.3 Hz, 1H), 4.49-4.37 (m, 4H), 2.47 (q, J = 7.3 Hz, 2H), 2.36 (s, 3H), 0.98 (t, 
J = 7.3 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 173.94, 158.23, 155.36, 145.43, 139.21, 
129.50, 126.02, 120.84, 120.36, 118.09, 117.64, 114.58, 100.15, 67.77, 65.92, 17.87, 
17.23, 13.38. 
3-ethyl-2,6-dimethyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (5.33b). Following 
general procedures H, then I, then J, followed by general procedure A the final 4(1H)-
quinolone was prepared in 37% over the 4 steps. 
1H NMR (250 MHz, DMSO) δ 11.16 (s, 
1H), 7.79 (s, 1H), 7.31 (t, J = 7.8 Hz, 2H), 6.98 (m, 3H), 6.86 (s, 1H), 4.38 (m, 4H), 2.47 
(q, J = 7.15 Hz, 2H), 2.34 (s, 3H), 2.18 (s, 3H), 0.97 (t, J = 7.2 Hz, 3H). 
13
C NMR (101 
MHz, DMSO) δ 175.43, 159.59, 159.07, 145.03, 139.88, 130.19, 126.97, 122.92, 121.48, 
120.52, 118.22, 115.29, 98.15, 67.53, 66.77, 18.57, 17.86, 16.62, 14.25. 
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3-ethyl-6-methoxy-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (5.34b). 
Following general procedures H, then I, then J, followed by general procedure A the final 
4(1H)-quinolone was prepared in 44% over the 4 steps starting from 5-amino-2-methoxy 
phenol.
1H NMR (400 MHz, DMSO) δ 11.15 (s, 1H), 7.40 (s, 1H), 7.27 (t, J = 7.7 Hz, 
2H), 7.05 – 6.77 (m, 4H), 4.36-4.28 (m, 4H), 3.77 (s, 3H), 2.45 (q, J = 7.3 Hz, 2H), 2.31 
(s, 3H), 0.94 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 174.26, 158.21, 151.33, 
145.95, 143.85, 134.56, 129.53, 120.79, 119.36, 117.56, 114.48, 104.73, 99.51, 67.10, 
65.93, 55.35, 18.01, 17.17, 13.57. 
6-chloro-3-ethyl-7-(methoxymethoxy)-2-methylquinolin-4(1H)-one (5.35b).  
Following general procedures H, then I, then J, followed by general procedure A the final 
4(1H)-quinolone was prepared in 9% over the 4 steps starting from 4-chloro-3-hydroxy 
aniline. 
1H NMR (400 MHz, DMSO) δ 11.39 (s, 1H), 7.99 (s, 1H), 7.22 (s, 1H), 5.37 (s, 
2H), 3.45 (d, J = 1.2 Hz, 3H), 2.46 (q, J = 7.2 Hz, 2H), 2.34 (s, 3H), 0.98 (t, J = 7.1 Hz, 
3H).
 13C NMR (101 MHz, DMSO) δ 173.91, 153.88, 145.66, 138.97, 125.98, 120.31, 
118.67, 118.11, 102.52, 94.83, 56.02, 17.87, 17.19, 13.36. 
6-chloro-7-(methoxymethoxy)-2-methyl-3-phenylquinolin-4(1H)-one (5.36b). 
Following general procedures H, then I, then J, followed by general procedure A the final 
4(1H)-quinolone was prepared in 10% over the 4 steps starting from 4-chloro-3-hydroxy 
aniline. 
1H NMR (400 MHz, DMSO) δ 11.65 (s, 1H), 8.02 (s, 1H), 7.37 (t, J = 7.3 Hz, 
2H), 7.29 (d, J = 6.0 Hz, 2H), 7.22 (d, J = 7.5 Hz, 2H), 5.39 (s, 2H), 3.46 (s, 3H), 2.17 (s, 
3H). 
13C NMR (101 MHz, DMSO) δ 173.44, 154.32, 146.75, 139.25, 135.79, 130.92, 
127.76, 126.54, 126.28, 120.74, 119.54, 118.59, 102.74, 94.90, 56.10, 18.82. 
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6-chloro-3-ethyl-7-(3-hydroxypropoxy)-2-methylquinolin-4(1H)-one (5.37b).  
Following general procedures H, then I, then J, followed by general procedure A the final 
4(1H)-quinolone was prepared in 8% over the 4 steps starting from 4-chloro-3-hydroxy 
aniline. 
1H NMR (400 MHz, DMSO) δ 11.31 (br s, 1H), 7.94 (s, 1H), 6.98 (s, 1H), 4.60 
(br s, 1H), 4.15 (t, J = 6.2 Hz, 2H), 3.59 (d, J = 5.0 Hz, 2H), 2.45 (q, J = 7.4 Hz, 2H), 
2.33 (s, 3H), 1.97 – 1.88 (m, 2H), 0.96 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, DMSO) 
δ 173.97, 155.60, 145.34, 139.31, 125.85, 120.27, 117.82, 117.73, 99.75, 65.82, 57.01, 
31.68, 17.87, 17.25, 13.40. 
3-(6-chloro-3-ethyl-2-methyl-4-oxo-1,4-dihydroquinolin-7-yloxy)propyl 2-ethyl-3-
oxobutanoate (5.38b). Following general procedures H, then I, then J, followed by 
general procedure A the final 4(1H)-quinolone was prepared in 5 % over the 3steps. 
1
H 
NMR (400 MHz, CDCl3) δ 9.46 (s, 1H), 8.31 (s, 1H), 6.68 (s, 1H), 4.36 (dt, J = 11.1, 5.5 
Hz, 1H), 4.25 (dt, J = 11.3, 5.6 Hz, 1H), 4.15 (t, J = 6.6 Hz, 2H), 3.45 (t, J = 7.4 Hz, 1H), 
2.62 (q, J = 7.83 Hz, 2H), 2.43 (s, 3H), 2.27 (s, 3H), 2.21 – 2.09 (m, 2H), 2.01 – 1.83 (m, 
2H), 1.09 (t, J = 7.3 Hz, 3H), 0.95 (t, J = 7.4 Hz, 3H). 
13
C NMR (101 MHz, CDCl3) δ 
175.90, 168.89, 156.24, 144.63, 139.00, 127.74, 122.08, 119.77, 118.87, 98.85, 65.33, 
61.67, 61.52, 29.41, 27.98, 21.82, 18.68, 18.25, 13.45, 11.97. 
6-chloro-3-ethyl-2-methyl-7-(2-morpholinoethoxy)quinolin-4(1H)-one (5.39b). 
Following general procedures H, then I, then J, followed by general procedure A the final 
4(1H)-quinolone was prepared in 9% over the 4 steps. 
1H NMR (400 MHz, DMSO) δ 
11.29 (s, 1H), 7.93 (s, 1H), 6.95 (s, 1H), 4.18 (t, J = 5.4 Hz, 2H), 3.65 – 3.47 (m, 4H), 
2.76 (t, J = 5.2 Hz, 2H), 2.60 – 2.37 (m, 6H), 2.32 (s, 3H), 0.94 (t, J = 7.3 Hz, 3H). 13C 
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NMR (101 MHz, DMSO) δ 174.65, 156.10, 146.08, 139.93, 126.60, 121.01, 118.63, 
118.37, 100.60, 67.96, 66.88, 57.04, 54.40, 18.55, 17.92, 14.08. 
6-chloro-7-(2-(dimethylamino)ethoxy)-3-ethyl-2-methylquinolin-4(1H)-one (5.40b). 
Following general procedures H, then I, then J, followed by general procedure A the final 
4(1H)-quinolone was prepared in 7% over the 4 steps starting from 4-chloro-3-hydroxy 
aniline. 
1H NMR (250 MHz, DMSO) δ 11.34 (s, 1H), 7.92 (s, 1H), 6.96 (s, 1H), 4.15 (t, J 
= 5.7 Hz, 2H), 2.71 (t, J = 5.7 Hz, 2H), 2.43 (q, J = 7.54 Hz, 2H), 2.32 (s, 3H), 2.24 (s, 
6H), 0.94 (t, J = 7.54 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 173.93, 155.39, 145.41, 
139.28, 125.87, 120.26, 117.90, 117.65, 99.82, 67.45, 57.05, 45.66, 17.87, 17.18, 13.39. 
6-bromo-3-ethyl-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (5.41). To a 
solution of of 1-bromo-2methoxy-4-nitrobenzene (1.0 gr, 4.3 mmol) in DCM (10 mL) 
was added BBr3 (8.58 mL of 1.0 M solution, 8.6 mmol) at 0
o
C. The reaction mixture 
warmed to room temperature and stirred overnight. The mixture was quenched with 
water and extracted with EA (3 X 20 mL). The combined extracts were dried and the 
crude was purified by flash column chromatography to obtain 2-bromo-5-nitrophenol  in 
65% yield (600 mg). Next, 1-bromo-4-nitro-2-(2-phenoxyethoxy)benzene was prepared 
from 2-bromo-5-nitrophenol following general procedure I in 80%. 
1
H NMR (400 MHz, 
CDCl3) δ 7.86 (d, J = 2.3 Hz, 1H), 7.77 – 7.66 (m, 2H), 7.33-7.26 (m, 2H), 7.00-6.93 (m, 
3H), 4.49 (dd, J = 5.6, 3.5 Hz, 2H), 4.41 (dd, J = 6.0, 3.5 Hz, 2H). 
13
C NMR (101 MHz, 
CDCl3) δ 158.37, 133.68, 129.55, 121.38, 120.28, 116.91, 114.73, 108.08, 68.58, 66.18. 
Next, 4-bromo-3-(2-phenoxyethoxy)phenylamine was prepared from 1-bromo-4-nitro-2-
(2-phenoxyethoxy)benzene (600 mg, 1.8 mmol) and zinc dust (1.157 g, 18.0 mmol) 
which was dissolved in ethanol (10 mL) and acetic acid (1.068 mL, 18 mmol) at 0
o
C. The 
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reaction mixture was warmed to room temperature and stirred for 4 hours. Then the 
mixture was filtered off, the solvent was distilled off under reduced pressure and the 
crude was purified by flash column chromatography to obtain the pure product in 84% 
yield. 
1H NMR (400 MHz, DMSO) δ 7.33 – 7.26 (m, 2H), 7.11 (d, J = 8.5 Hz, 1H), 7.02 
– 6.98 (m, 2H), 6.97 - 6.92 (m, 1H), 6.37 (d, J = 2.4 Hz, 1H), 6.13 (dd, J = 8.5, 2.4 Hz, 
1H), 5.28 (s, 2H), 4.31 (dd, J = 5.3, 3.0 Hz, 2H), 4.24 (dd, J = 5.8, 2.8 Hz, 2H). 
13
C NMR 
(101 MHz, DMSO) δ 158.77, 155.38, 150.21, 133.10, 129.94, 121.20, 115.06, 108.45, 
100.28, 67.56, 66.64. Finally, following general procedure A, the titled compound was 
prepared in 15% yield as a mixture of two isomers. The titled compound was isolated by 
preparative HPLC by dissolving the mixture in minimal amount of methanol. 
1
H NMR 
(400 MHz, DMSO) δ 11.32 (s, 1H), 8.11 (s, 1H), 7.27 (t, J = 7.8 Hz, 2H), 7.11 – 6.78 (m, 
4H), 4.39 (m, 4H), 2.43 (q, J = 7.3 Hz, 2H), 2.32 (s, 3H), 0.94 (t, J = 7.3 Hz, 3H). 
6-chloro-3-ethyl-2-methyl-7-(3-(4-phenylpiperazin-1-yl)propoxy)quinolin-4(1H)-one 
(5.42).  Following general procedures H, then I, then J, followed by general procedure A 
the final 4(1H)-quinolone was prepared in 10% over the 4 steps. 
13
C NMR (101 MHz, 
DMSO) δ 173.98, 155.57, 150.99, 145.34, 139.29, 128.87, 125.88, 120.29, 118.73, 
117.86, 117.73, 115.30, 99.84, 67.22, 54.20, 52.75, 48.19, 25.78, 19.77, 17.87, 17.26, 
13.41.  
3-ethyl-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (5.43). An oven-dried 
schlenk tube is flame-dried and backfilled with argon(x3). The tube is then charged with 
6-chloro-3-ethyl-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (100 mg, 0.4 mmol), 
Pd2(dba)3 (14.5 mg, 0.016 mmol), SPHOS (13 mg, 0.032 mmol), mesityleneboronic acid 
(299mg, 1.8 mmol), and anhydrous powdered K3PO4 (168 mg, 0.79 mmol). The schlenk 
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tube was fitted with a rubber septum and then evacuated and backfilled with argon (this 
process was repeated three times). Dry DMF was added through the septum via syringe 
and the resulting solution was stirred for 1 min while purging with argon before replacing 
the rubber septum with the Teflon screwcap. The reaction was set to the oil bath until 
completion was observed via HPLC analysis. The reaction is cooled to room temperature 
and then diluted with 20 ml chloroform and 20 ml of methanol. This mixture was brought 
to a boil with a heat gun and then filtered over a pad of celite. The eluent was 
concentrated under reduced pressure and the residual oil was purified further via flash 
chromatography. 
1
H NMR (400 MHz, CDCl3) δ 11.20 (s, 1H), 8.03 – 7.88 (m, 1H), 7.31 
(t, J = 7.8 Hz, 2H), 6.97 (dd, J = 20.1, 7.7 Hz, 3H), 6.89 (d, J = 6.9 Hz, 2H), 4.36 (s, 4H), 
2.47 (d, J = 7.5 Hz, 2H), 2.35 (s, 3H), 0.98 (t, J = 7.3 Hz, 3H). 
13
C NMR (101 MHz, 
DMSO) δ 175.01, 160.32, 158.23, 144.95, 140.72, 129.53, 127.01, 120.79, 120.00, 
118.06, 114.60, 114.48, 112.45, 99.07, 66.57, 66.01, 17.87, 17.21, 13.53.  
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Chapter 6: Identification of an Early Lead and Optimization Strategies Toward the 
Development of an Orally Bio-Available Late Lead 4(1H)-Quinolone with Antimalarial 
Activity 
6.1 Overview 
 Previous studies on the 4(1H)-quinolone series identified 6-chloro-7-methoxy-3-
phenyl-4(1H)-quinolone 6.2 as an initial candidate for in vivo efficacy studies. The 
compound failed to reduce the parasitemia levels in P. berghei infected mice although it 
was shown to have acceptable aqueous solubility (6 µM at pH 7.4). Detailed SAR and 
SPR studies were conducted simultaneously to identify a compound with improved 
solubility while maintaining or improving antimalarial activity. In vivo efficacy testing 
showed that compound 6.3 had a 3-fold increase in solubility (19 µM) and 3-4 fold 
increase in antimalarial activity with EC50s of 5.8 nM and 4.0 nM against W2 and TM90-
C2B respectively. Compound 6.3 displayed a 17% parasitemia suppression on day six 
post-exposure (PE) at 10 mg/kg doses and a 41% parasitemia suppression on day six PE 
at 50 mg/kg doses. Degradation studies revealed that microsomal stability of the 4(1H)-
quinolone series was equally important as solubility when compound 6.23 was identified 
to have greater in vivo activity (92% parasitemia suppression on day six PE at 10 mg/kg 
doses and a 97% parasitemia suppression on day 6 PE at 50 mg/kg doses) in comparison 
to the more soluble compound 6.3. Follow-up SAR and SPR identified several 
compounds with increased microsomal stability, very low EC50s in the picomolar range, 
and with 99% parasitemia suppression on day six PE at 10 mg/kg doses and 99% 
parasitemia suppression on day six PE at 50 mg/kg doses. The best compounds were 
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found to be curative with five out of five mice surviving the infection of P. berghei after 
30 days. In total 71 compounds were prepared and tested for anti-malarial activity as well 
as solubility, permeability, log D and microsomal stability. Currently, a thorough 
pharmacokinetic analysis of selected 4(1H)-quinolones is being conducted to determine 
which candidate will be advanced to pre-clinical development.  
6.2 Synthetic Chemistry 
 Previously, a small set of 3-aryl and 3-alkyl 6-chloro-7-methoxy-4(1H)-
quinolones were synthesized and identified to possess anti-malarial activity.
1
 A more 
thorough optimization study of the 3-position was conducted (Scheme 6.1 and Table 6.1 
for structures and activities). 
Scheme 6.1. Synthesis of 3-Substituted 6-Chloro-7-methoxy-4(1H)-quinolones 
 
3-Aryl analogs (6.2-6.9, and 6.21-6.72) were prepared from the previously described 3-
halo intermediate 6.1 (Scheme 6.1).
1, 2
 Similarly, compounds 6.11-6.20 were prepared 
from Conrad-Limpach cyclization of 4-chloro-3-methoxyaniline (6.10) (Scheme 6.1).
1, 2
 
The early stages of the Suzuki-Miyaura cross-coupling with intermediate 6.1 followed the 
same approach as our previous methodology with 4(1H)-quinolones (Chapter 3). These 
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products (6.2-6.9) were prepared solely from aliphatic arylboronic acids. However, 
several classes of boronic acids were envisioned to be cross-coupled for the generation of 
a diverse library including: (a) fluoroarylboronic acids (6.21-6.34), (b) heteroaromatic / 
oxygen-containing arylboronic acids (6.35-6.49), (c) heteroaromatic / nitrogen-containing 
arylboronic acids (6.50-6.59), and (d) bi-cyclic / bi-arylboronic acids (6.60-6.72).  
Figure 6.1. Various Routes/Conditions for the Preparation of 3-Aryl-4(1H)-quinolones 
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In order to prepare this diverse set of analogs for in vitro testing, several modifications to 
the standard procedure were implemented. One of these procedures included the 
utilization of O-ethyl intermediate 6.19. There was not an individual reaction screening 
optimization study as in Chapter 3 (Table 3.3), however, if required, the preparation of 
individual substrates was optimized on a molecule by molecule basis. When a substrate 
was isolated in amounts of greater than 5 mgs (typically 5% yield or more) and greater 
than 95% purity, the molecule was sent for testing and no further synthetic optimization 
was pursued. Nevertheless, several of the analogs were scaled up to obtain the amounts 
required for in vivo and pharmacokinetic studies. Using the procedures depicted in Figure 
6.1, analogs 6.21–6.72 were synthesized and tested for antimalarial activity. In some 
cases, the cross-coupling reaction failed to achieve high yields during scale-up and 
subsequently the Conrad-Limpach protocol was employed as an alternative using the 
corresponding 2-aryl β-ketoester. 
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Table 6.1. EC50s and Synthetic Details of Compounds 6.2-6.72
 
 
Compound R
1
 
EC50 
W2
a 
(nM) 
EC50  
T90-C2B
a 
(nM) 
RI Procedure Yield 
6.2 
 
26.2 15.3 0.58 C 71% 
6.3 
 
5.8 4.0  0.69 A or F 33% 
6.4 
 
24.5 7.3 0.29 A 78% 
6.5 
 
9.1 3.2 0.35 A 28% 
6.6 
 
46.0 46.3 1.00 Conrad-
Limpach 
6% 
6.7 
 
61.7 159 2.57 A 6% 
6.8 
 
6.7 2.7 0.40 A 66% 
6.9 
 
66.8 116 1.73 A 35% 
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6.11 -methyl 
 
56.6 27.3 0.48 Conrad-
Limpach 
48% 
6.12 -ethyl 48.2 27.6 0.57 Conrad-
Limpach 
70% 
6.13 -isopropyl 112 193 1.73 Conrad-
Limpach 
52% 
6.14 -isobutyl 86.4 63.3 0.73 C 14% 
6.15 -cyclohexyl 236 397 1.68 Conrad-
Limpach 
21% 
6.16 -benzyl 93.7 68.6 0.73 Conrad-
Limpach 
40% 
6.17 -heptyl 12.4 2.90 0.23 Conrad-
Limpach 
30% 
6.18 -nonyl 6.1 1.6 0.26 Conrad-
Limpach 
27% 
6.20 -CO2Me 134 764 5.70 Conrad-
Limpach 
15% 
6.21 
 
20.8 35.8 1.72 B 52% 
6.22 
 
7.7 7.7 1.0 B 
(Microwave) 
47% 
6.23 
 
12.0 <6.0 <2.0 G 86% 
6.24 
 
193 25.8 0.13 A 77% 
6.25 
 
26.3 44.6 1.69 A 20% 
6.26 
 
7.52 8.06 1.07 B 34% 
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6.27 
 
1.18 0.93 0.79 B 10% 
6.28 
 
14.2 4.9 0.35 A 17% 
6.29 
 
442 1910 4.32 A 25% 
6.30 
 
21.4 10.3 0.48 F 74% 
6.31 
 
157 403 2.57 E 41% 
6.32 
 
35.7 8.7 0.24 A 5% 
6.33 
 
4244 3417 0.80 A <1% 
6.34 
 
1675 448 0.26 A 7% 
6.35 
 
132 137 1.03 A 59% 
6.36 
 
71.8 24.8 0.35 C 53% 
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6.37 
 
13.3 1.85 0.13 B 
(Microwave) 
45% 
6.38 
 
34.2 8.4 0.24 A 72% 
6.39 
 
1061 628 0.59 A 16% 
6.40 
 
258 174 0.67 A 32% 
6.41 
 
5402 828 0.16 A 23% 
6.42 
 
154 93.9 0.61 A 61% 
6.43 
 
2864 467 0.16 A 44% 
6.44 
 
54.0 11.3 0.21 A 68% 
6.45 
 
58.4 12.6 0.21 A 62% 
6.46 
 
5521 3813 0.69 B 
(Microwave) 
15% 
6.47 
 
777 48.4 0.06 A 13% 
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6.48 
 
22.5 25.9 1.15 A 32% 
6.49 
 
516 73.1 0.14 F 48% 
6.50 
 
60.7 15.3 0.25 E 49% 
6.51 
 
748 91 0.12 E 16% 
6.52 
 
128 219 1.71 B 19% 
6.53 
 
747 120 0.16 D 12% 
6.54 
 
928 213 0.23 H 
 
41% 
6.55 
 
2986 2986 1.0 A 12% 
6.56 
 
1965 80.6 0.04 B 
(Microwave) 
22% 
6.57 
 
1579 536 0.33 B 
(Microwave) 
10% 
326 
 
6.58 
 
277 93.5 0.34 E 12% 
6.59 
 
1892 151 0.08 A 34% 
6.60 
 
49.0 33.5 0.68 B 
(Microwave) 
24% 
6.61 
 
173 92 0.53 A 61% 
6.62 
 
22.8 21.1 0.92 A 62% 
6.63 
 
73.4 10.8 0.15 A 69% 
6.64 
 
6.4 1.2 0.19 A 30% 
6.65 
 
1312 496 0.37 B 
(Microwave) 
10% 
6.66 
 
1.3 0.6 0.46 A 57% 
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6.67 
 
7.74 1.58 0.20 B 
(Microwave) 
5% 
6.68 
 
5.18 1.56 0.30 B 
(Microwave) 
25% 
6.69 
 
1.55 0.9 0.58 A 65% 
6.70 
 
9.01 1.75 0.19 B 
(Microwave) 
58% 
6.71 
 
1.27 0.32 0.25 B 20% 
6.72 
 
5.6 
 
2.3 0.41 A 53% 
a
Dihydroartemisinin
 
(DHA) and chloroquine (CQ) are internal controls for each in vitro assay. 
DHA (1.8 nM W2 and 0.9 nM TM90C2B) and CQ (131 nM W2 and 162 nM TM90-C2B) 
One particular analog of interest was compound 6.52 which contains a 2-pyridyl 
moiety. 2-Pyridylboronic acids have been shown to be problematic in Suzuki-Miyaura 
cross-coupling due to an elongation of the carbon-boron bond which facilitates 
protodeboronation. Protodeboronation is also observed in the 3- and 4-pyridylboronic 
acid systems, albeit at a slower rate. Furthermore, it is believed that transmetalation from 
boron to palladium of an electron-deficient 2-heterocyclic boronate is slower than the 
protodeboronation. Nevertheless, in the past decade, several research groups have aimed 
to accomplish this transformation in a higher yielding fashion through the use of several 
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co-catalysts, unique phosphine ligands, and the use of tri-isopropyl borate salts as 
opposed to neutral boronic acids.
3-8
 Tri-isopropyl borate salts are more stable than the 
boronic acid analogs, thus their increased stability allows the rate determining 
transmetalation to palladium to occur. After several unsuccessful attempts using the 
aforementioned protocols, an alternative procedure published by Frontier Scientific Corp. 
was invoked (Scheme 6.2). This concise report was easy to reproduce generating the 
desired transformation in moderate yield (64%). 
Scheme 6.2. Synthesis of Pyridyl Analog 6.52 
 
6.3 Antimalarial Activity  
6.3.1 Structure-Activity Relationship Studies 
 All compounds underwent in vitro screening against P. falciparum as previously 
described in Chapter 2 (Section 2.3 Antimalarial Activity).
1
 The initial set of compounds 
contained two sub-series (6.2-6.20) which included aliphatic-substituted aryl analogs 
(6.2-6.9) and alkyl analogs (6.11-6.20). These compounds lead us to the following 
observations: (a) aryl analogs possessing substitution at the ortho position displayed 
lower EC50s, (b) long chain aliphatic substituents displayed the lowest EC50s amongst the 
alkyl analogs, (c) branching of either alkyl or aryl substituents was less effective for 
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potency (6.9, 6.13, and 6.14) as compared to the other analogs. With these findings, the 
aryl motif was chosen to be investigated with more detail. 
 Throughout the work, four major series of compounds were synthesized and 
designated as such: (Series 1) 3-fluoroaryl-4(1H)-quinolones (6.21-6.34), (Series 2) 3-
aryl-4(1H)-quinolones containing oxygen based functionalities such as carbonyl, 
alcohols, and furans (6.35-6.49), (Series 3) 3-aryl-4(1H)-quinolones containing nitrogen 
based functionalities such as amines, pyrimidines, and pyridines (6.50-6.59), and (Series 
4) 3-bi-cyclic-4(1H)-quinolones such as bi-aryl ethers, aryl benzyl ethers, and biphenyls 
(6.60-6.72). 
 Series 1 (6.21-6.34) included the synthesis of fluoro aryl, trifluoromethoxy aryl, 
and trifluoromethyl aryl analogs (Table 6.1). Para-substituted analogs 6.21-6.23 showed 
that fluoro, trifluoromethoxy, and trifluoromethyl substituents to be viable with EC50s 
between 35.8 nM and 6.0 nM against W2 and TM90-C2B. Meta-substituted analogs 6.24 
and 6.34 were less potent against the W2 strain with EC50s of 193 nM and 1675 nM 
respectively. Finally, the fluoro-aryl analogs containing either a methyl- or a fluoro-
substituent at the ortho position (6.26-6.33) were prepared. With the exception of 
compound 6.33, which displayed poor potency, the analogs had EC50 ranges of 1.18 nM 
to 442 nM against W2 and 0.93 nM to 1910 nM against TM90-C2B. Analogs 6.26-6.28 
containing a methyl in the ortho-position were very potent with EC50s ranging from 930 
pM to 14.2 nM. In contrast compounds 6.27-6.29 were more potent than compounds 
6.30-6.33 which contained fluoro-substitution in the ortho-positions or di-fluoro 
substitution in both ortho-positions (6.32-6.33). Compounds 6.31-6.34 displayed EC50 
ranges from 35.7 nM to 4244 nM against W2 and 8.7 nM to 3417 nM against TM90-
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C2B. The majority of this series falls within the acceptable RI range of 0.3 to 3.0. Series 
1 appears to tolerate all three fluoro aryl substitutions fluoro, trifluoromethoxy, and 
trifluoromethyl, however, analogs containing a methyl in the ortho-position in addition to 
the fluoro, trifluoromethoxy, and trifluoromethyl were the most potent analogs in the 
series. 
 Series 2 (6.35-6.49) included the synthesis of 3-aryl-4(1H)-quinolones with 
oxygen-containing functionalities such as benzyl alcohols, furans, benzofurans, 
isoxazoles and phenols (Table 6.1). Benzofuran and benzothiofuran (6.35-6.36) displayed 
good activities with EC50 ranges of 71.8 nM to 132 nM against W2 and 24.8 nM to 137 
nM against TM90-C2B. Compounds 6.37-6.38 possessed both connectivities of furan 
moiety to the central quinolone ring. Both analogs displayed single digit nM EC50s 
against TM90-C2B, however the compounds were approximately 4-fold less active 
against the W2 strain. Benzyl alcohol containing compounds 6.40-6.42 displayed 
moderate to poor activity ranges, with EC50s of 154 nM to 5402 nM against W2 and 93.9 
nM to 828 nM against TM90-C2B. The para-substituted benzyl alcohol 6.42 was more 
potent than the ortho-substituted analog 6.40 which in turn was more potent than meta-
substituted compound 6.41. Phenol 6.43 was less potent than its methylated version 6.44. 
Methoxy-substituted analog 6.44 displayed a 50-fold increase in activity as compared to 
the phenol analog 6.43 with EC50s of 11.3 nM against TM90-C2B and 54.0 against W2. 
Interestingly, compound 6.45 bearing an isopropoxy-substituent behaved similarly to 
compound 6.44 with EC50s of 58.4 nM against W2 and 12.6 nM against TM90-C2B. 
Next, para-substituted carbonyl-containing aryl functionalities (aldehyde, ketone, ester, 
and carboxylic acid) were prepared (6.46-6.49). The benzaldehyde containing analog 
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6.46 was the least potent with µM EC50s followed by the acetylphenyl analog 6.47 which 
displayed EC50s of 777 nM against W2 and 48.4 nM against TM90-C2B. Ester 6.48 was 
the most active of the para-substituted carbonyl-containing aryl functionalities with EC50s 
of 22.5 nM against W2 and 25.9 nM against TM90-C2B. Furthermore, this compound 
displayed almost equipotent EC50s resulting in a RI of 1.15. Amongst the carbonyl 
containing analogs, an activity trend emerged which suggests that a more oxidized 
carbonyl carbon atom would be preferred. In addition, seven out of the 15 compounds in 
series 2 exhibited acceptable RIs of 0.3 to 3.0 suggesting that the oxygen-containing 
functionalities may inherit the potential to induce resistance. The furan based analogs 
(6.37-6.38) and the para-substituted analogs (6.44-6.45, and 6.48) were the most potent 
analogs amongst the compounds of this series.  
 Series 3 (6.50-6.69) included the synthesis of aryls with amino-based 
functionalities such as pyridines, pyrimidines, and sulfonamides (Table 6.1). 3-
Dimethylaminophenyl compound 6.50 and 3-dimethylaminopyridine 6.51 displayed 
EC50s of 60.7 nM and 748 nM against W2 respectively. These compounds were more 
potent against TM90-C2B with EC50s of 15.3 nM and 91 nM respectively. The pyridine 
analogs (6.52-6.54) did not follow obvious potency trends with the meta- and ortho-
pyridine analogs (6.53-6.54) having poor EC50s against W2. All three analogs however 
display moderate potency against TM90-C2B with EC50s ranging from 120 nM to 219 
nM. Pyrimidine analog 6.55 was completely inactive. Analog 6.56 was also inactive 
against W2 while showing moderate activity with an EC50 of 80.6 nM. The morpholino- 
and piperazino-pyridine analogs (6.57-6.58) displayed poor to moderate EC50 ranging 
from 1579 nM to 277 nM against W2 respectively. In contrast, the potency of these two 
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compounds was improved against TM90-C2B with EC50 of 536 nM and 93.5 nM 
respectively. Finally, compound 6.59 bearing an aryl-sulfonamide functionality displayed 
EC50 values of 1892 nM against W2 and 151 nM against TM90-C2B, which created an 
unacceptable RI of 0.08. Series 3 had a more disproportionate level of RI, where many of 
the compounds were more potent against TM90-C2B than W2. This observation is 
interesting considering that the TM90-C2B has more drug-resistance than W2. The most 
potent analog in the series was 6.50 displaying similar potencies as analogs 6.44 and 6.45 
of series 2.  
 Series 4 contained substituents such as bi-aryl ethers, aryl benzyl ethers, and 
biphenyls (6.60-6.75). The design of this series was based on the better substituents of 
Series 1-3 while adding a second ring as a cap to probe the size and nature of the 
biological target. Compounds 6.60-6.61 were designed to see whether extended furan 
systems (6.60) or extended methoxy aryl groups (6.61) would be more potent than the 
original furan analogs (6.37, 6.38) or methoxy aryl quinolone 6.44. Furan 6.60 displayed 
EC50s of 49.0 nM and 33.5 nM against W2 and TM90-C2B, while compound 6.61 
displayed 173 nM against W2 and 92 against TM90-C2B. Next, para-substituted O-
benzyl ethers were prepared (6.62-6.65). The compound 6.64 containing an ortho-methyl 
substitution on the innermost aryl ring (6.64) with EC50s of 6.4 nM against W2 and 1.2 
nM against TM90-C2B was the most potent. Importantly, even though this compound 
was very potent with single digit EC50s against both strains, the RI was 0.19 and was not 
optimal for further development. Compound 6.62 was also potent with EC50s less than 22 
nM against both strains but containing an acceptable RI of 0.92. Next, ortho- and para-
substituted C-benzyl ethers were prepared (6.65-6.67). Compound 6.65 was an ortho-
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substituted C-benzyl ethers which was amongst the least active in the series. Contrarily, 
compounds 6.66-6.67 were very potent. Para-substituted C-benzyl ether 6.66 which has 
the reverse ether connectivity of compound 6.62, was 22-fold more potent than 6.62 
against W2 and 35-fold more potent against TM90-C2B with EC50s of 1.3 nM against 
W2 and 600 pM against TM90-C2B. In contrast, compound 6.67, the trifluoromethoxy 
substituted analog of 6.66, was 2-3 fold less potent against W2 and TM90-C2B. Bi-aryl 
ethers (6.69-6.71) were previously identified by GSK to be extremely potent side-chains 
in the 4-pyridone antimalarials.
9
 In analogy, these substitutions were also observed to 
produce very potent 4(1H)-quinolones. The simple bi-aryl ether 6.69 was first 
synthesized and shown to inhibit at EC50s of 1.55 nM against W2 and 0.9 nM against 
TM90-C2B. Its meta-substituted version 6.70 was prepared with comparable potency. 
Compound 6.72 alleviated the bridging of the rings by fusing them into a biphenyl 
system, which displayed EC50s of 5.6 nM and 2.3 nM against W2 and TM90-C2B 
respectively. In conclusion, the majority of this series against both strains displayed the 
following trends of antimalarial activity: Series 4 > Series 1 > Series 2 >> Series 3 and all 
four series displayed RIs in the acceptable range. Para-substituted aryl analogs were 
generally superior in antimalarial activity as compared to meta-substituted analogs and 
analogs containing a 3-ortho-substituted aryl ring experienced increases in activity as 
compared to analogs without this ortho-substitution. 
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6.4 Physicochemical Properties 
6.4.1 Microsomal Stability 
 The microsomal stability of approximately half of the analogs was determined by 
Susan Charman at the Monash University in Australia. The compounds are incubated at a 
concentration of 1 µM with human microsomes at 37ºC and 0.4 mg/mL of microsomal 
protein. The metabolic reaction was initiated with the addition of an NADPH-
regenerating system (i.e. NADPH is the cofactor required for CYP450-mediated 
metabolism) and quenched at various time points over the incubation period by the 
addition of acetonitrile. Controls were incubated without the NADPH to assess the 
amount of degradation without metabolic initiation. The relative loss of compound was 
monitored by LC-MS using a Waters/Micromass ZQ mass spectrometer.  
 The test compounds concentration versus time data was fitted to an exponential 
decay function to determine the first order rate constant for substrate degradation. Each 
rate constant was then used to calculate microsomal half-life (Table 6.2). Entries of 
C.N.C. (could not calculate) are compounds that displayed little to no observable 
degradation throughout the assay duration (typically 250 minutes), whereas N.D. entries 
were molecules that were not assayed. Endochin was used as a control for comparing 
half-lives of 4(1H)-quinolones. Endochin possesses half-lives of 7.9 minutes in Mouse 
and 10.2 in human microsomes.  
 Solubility, permeability, and LogD7.4 were obtained as previously described in 
Chapter 2. 
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Table 6.2. Physicochemical Properties 6.2-6.72 
 
Compound R1 
Human 
Microsome 
½ Life 
(min) 
Solubility 
pH 7.4a 
(µM) 
Pe 
pH 7.4b 
(x10-6 
cm/s) 
Log D 
pH 7.4c 
6.2 
 
100  6.0 48 1.65 
6.3 
 
N.D. 19.1 191 2.51 
6.4 
 
83 0.2 N.D. 2.83 
6.5 
 
N.D. 0.6 549 2.97 
6.6 
 
N.D. 2.6 406 3.31 
6.7 
 
N.D. 3.6 443 2.93 
6.8 
 
51 0.4 N.D. 3.56 
6.9 
 
N.D. 0.1 N.D. 3.79 
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6.11 -methyl N.D. 6.2 59 1.86 
6.12 -ethyl 31 0.4 57 2.43 
6.13 -isopropyl N.D. 11.8 187 2.84 
6.14 -isobutyl N.D. 1.0 367 2.99 
6.15 -cyclohexyl N.D. 6.7 630 3.04 
6.16 -benzyl N.D. 3.8 566 1.99 
6.17 -heptyl 12 0.9 N.D. 3.83 
6.18 -nonyl 9 1.6 63 2.61 
6.20 -CO2Me N.D. 3.4 69 1.34 
6.21 
 
56.3 6.4 65 2.56 
6.22 
 
C.N.C. 0.1 6.0 3.42 
6.23 
 
C.N.C. 0.3 3.0 2.35 
6.24 
 
N.D. 0.9 147 2.86 
6.25 
 
202 8.5 316 2.61 
6.26 
 
116 1.1 N.D. 2.70 
6.27 
 
236 0.4 N.D. 2.69 
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6.28 
 
C.N.C. 0.9 369 2.88 
6.29 
 
N.D. 15.8 411 2.96 
6.30 
 
N.D. N.D. N.D. N.D. 
6.31 
 
N.D. 24.8 N.D. 2.69 
6.32 
 
N.D. 6.8 151 2.07 
6.33 
 
N.D. 24.8 N.D. 2.54 
6.34 
 
N.D. <0.1 0.0 4.00 
6.35 
 
60 0.1 73 3.20 
6.36 
 
N.D. 0.1 241 3.46 
6.37 
 
19 4.6 N.D. 2.02 
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6.38 
 
29 43.0 0.9 2.15 
6.39 
 
C.N.C. 30.4 24 1.79 
6.40 
 
N.D. 28.6 20 1.82 
6.41 
 
C.N.C. 3.7 8.5 3.46 
6.42 
 
C.N.C. 2.3 N.D. 1.75 
6.43 
 
297 2.9 7.6 1.79 
6.44 
 
C.N.C. 1.4 97 2.39 
6.45 
 
218 0.4 427 3.32 
6.46 
 
N.D. 1.3 N.D. 2.17 
6.47 
 
155 1.1 N.D. 2.28 
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6.48 
 
N.D. N.D. N.D. N.D. 
6.49 
 
N.D. N.D. N.D. N.D. 
6.50 
 
119 2.6 238 2.62 
6.51 
 
89 8.6 1356 1.89 
6.52 
 
117 7.4 N.D. 1.78 
6.53 
 
160 20.4 9.6 4.13 
6.54 
 
N.D. N.D. N.D. N.D. 
6.55 
 
N.D. 29.2 11 N.D. 
6.56 
 
N.D. N.D. N.D. N.D. 
6.57 
 
51 43 N.D. 1.86 
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6.58 
 
82 0.7 125 1.99 
6.59 
 
159 0.3 119 2.18 
6.60 
 
N.D. 0.7 N.D. 3.52 
6.61 
 
N.D. 0.7 178 2.36 
6.62 
 
N.D. 0.1 N.D. 3.45 
6.63 
 
23 1.1 N.D. 3.76 
6.64 
 
23 0.2 0.0 3.78 
6.65 
 
N.D. 0.3 N.D. 4.18 
6.66 
 
78 3.7 N.D. 3.72 
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6.67 
 
129 N.D. N.D. 4.40 
6.68 
 
N.D. 1.3 N.D. 3.72 
6.69 
 
91 0.3 41 3.66 
6.70 
 
N.D. N.D. N.D. 3.71 
6.71 
 
C.N.C. 2.2 N.D. 2.05 
6.72 
 
125 0.1 0.0 3.67 
a
Standards for the solubility assay include carbamazepine and albendazole. Solubility for carbamazepine at 
pH 7.4, 4.0, and 2.0 is 95 and 100  respectively. Solubility for albendazole at pH 7.4, 4.0, 
and 2.0 is 6.1 , 12, and 100respectively 
b
Standards for the permeability assay include verapamil HCl (Pe = 1405 x10-6 cm/s at pH=7.4 and 39 x10-
6 cm/s at pH=4.0), carbamazepine (Pe = 112 x10-6 cm/s at pH=7.4 and 108 x10-6 cm/s at pH=4.0), and 
ranitidine HCl (Pe = 0.5 x10-6 cm/s at pH=7.4 and 0 x10-6 cm/s at pH=4.0). 
c
Standards for the LogD7.4 assay include cinnarizine (LogD7.4 5.68), hydrocortisone-21-acetate (LogD7.4 
2.19), ketoconazole (LogD7.4 3.83), metronidazole (LogD7.4 -0.02), nadolol (LogD7.4 0.68), pyrene (LogD7.4 
4.88), theophyline (LogD7.4 -0.05), and tolnaftate (LogD7.4 5.40). 
 
 Amongst the initial sub-set of compounds (6.2-6.20) compound 6.2 had the best 
stability with a 100 minute half-life, as compared to the branched isopropyl analog 6.8 
having only a 51 minute half-life. Nonyl and ethyl analogs (6.12 and 6.18) displayed very 
poor half-lives of 31 minutes and 9 minutes respectively.  
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 Series 1 (6.21-6.34) highlighted the importance of the study as several compounds 
emerged with minimal degradation. Compounds 6.22, 6.23, and 6.28 showed minimal 
degradation (C.N.C.) while compound 6.25 nearly approached the same level of stability 
at 202 minutes. It became apparent that the para-position substitution of the 3-aryl 
substituent greatly influenced the stability as well as the potency of the compounds. 
Interestingly, ortho-methyl substituted aryl analogs that had displayed excellent potencies 
possessed decreased stability. This may have arose due to oxidation of the methyl group. 
Some of the compounds subjected to the microsomal stability testing were also probed 
for potential metabolites through LC-MS analysis of the degradation mixture. 
Compounds 6.26-6.27 were identified to contain metabolites corresponding to P+16 and 
or P-14 [M+H]
+
. These metabolites are believed to be the result of methyl oxidation or 
de-methylation of the 7-methoxy substituent.  
 Series 2 did not display quite the same levels of stability. Compounds 6.35, 6.37-
6.38 displayed half-lives of 60, 19, and 29 minutes respectively. However, the benzyl 
alcohol compounds 6.42 and 6.43 showed minimal degradation, which further supported 
our hypothesis of compounds 6.26-6.27 experiencing oxidation of the ortho-methyl 
group. Isoxazole 6.39 also displayed minimal degradation as well as methyl ether 6.44. 
The ketone containing compound 6.47 displayed improved stability, with a 155 minute 
half-life, as compared to 3-aryl analogs with alkyl substituents (6.2-6.9).  
 Series 3 did not contain any compounds that experienced minimal degradation, 
however, the most stable compound was 6.51 with a 119 minute half-life.  
 Series 4 had a range of stabilities from 23 minutes to minimal degradation 
(C.N.C.). Compounds 6.63 and 6.64 containing an O-benzyl ether were the least stable, 
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both with a 23 minute half-life. Nevertheless, compounds 6.66 and 6.67 had improved 
half-lives of 78 minutes and 129 minutes. Bi-aryl ether 6.71 showed minimal 
degradation, which to some extent is somewhat contradictory to the previous hypothesis 
of methyl oxidation; however, the nature of the electron rich system may prevent the 
biochemical oxidation. The bi-phenyl compound 6.72 did not have the same levels of 
stability with only a 125 minute half-life.  
 In summary, the para-position and the nature of its substitution were critical in 
determining the microsomal stability of the molecule. Para-substituted aryl compounds 
with fluoro, trifluoromethyl, and methoxy substituents displayed the best microsomal 
stabilities. Furthermore, oxidized substrates such as 6.42 and 6.43 experienced minimal 
degradations. The nitrogen-based compounds (Series 3) displayed the poorest stabilities. 
Series 4 had a range of stabilities depending on the arrangement of the bi-cyclic system. 
These studies proved critical in the selection process of identifying an in vivo active 
compound. Without the use of these studies, a large number of compounds would have 
needed to be screened for in vivo activity before a candidate could have emerged.  
6.4.2 Log D, Solubility, and Permeability 
 Solubility was determined for the majority of the compounds in the library (6.2-
6.72) at pH 7.4, pH 4.0, and pH 2.4. Permeability was also determined at pH 7.4 and pH 
4.0. For clarity, however, solubilities and permeabilities at pH 4.0 and pH 2.4 have been 
omitted from Table 6.2. Finally, Log D7.4Mwas determined for the majority of the 
compounds at pH 7.4 in our laboratory (Table 6.2).  
 Log D7.4 is the logarithm of the distribution coefficient of the compound between 
an organic phase (octanol) and an aqueous phase (water or buffer) at a specified pH. 
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Compounds with Log D7.4 <1 have good solubility and poor permeability while 
molecules with a Log D7.4 >5 have poor bioavailability due to a very poor solubility.  Log 
D7.4 between 1 and 3 is ideal for compounds, since these have a good balance of solubility 
and permeability leading to a favorable absorption.
10
 The LogD7.4 parameters is more of a 
guide in the overall chemical series when the solubility and permeability of the individual 
compound is available. Series 1 had LogD7.4 ranging from 2.56-3.42. Series 2 Log D7.4 
1.79-3.46. Series 3 had LogD7.4 1.78-4.13. Series 4 had LogD7.4 1.86 to 4.40. These 
values are almost ideal, however, there a few compounds that do not fall between 1 and 
3.  
 Solubility of compound 6.2 (6.0 µM) was identified as being a liability in 
advancing the 4(1H)-quinolone series to an orally bio-available candidate. Amongst the 
preliminary compounds (6.2-6.20) the solubilities ranged from 0.1 µM to 11.8 µM with 
the exception of compound 6.3 which had a marked increase up to 19.1 µM. It was 
hypothesized that this analog was more soluble due to an out-of-plane flexing of the 3-
aryl ring, which was shown by X-ray crystal analysis of 6.3 (Figure 6.2). 
Figure 6.2. X-ray Crystal Structure of 6.3 
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The angle between C2-C11-C12 is approximately 100º showing an orthogonal 
arrangement. This compound as well as several other ortho-methyl substituted analogs 
experienced an increase in solubility indicating a decrease in lattice energy.  
 Series 1 had solubilities ranging from <0.1 µM to 24.8 µM. Para-substituted 
compounds 6.22-6.24 possessed poor solubilities of 6.4, 0.13, and 0.3 µM respectively. 
Improvements were observed when a fluoro or methyl ortho-substitution was present 
(6.25-6.28). The most soluble compounds in the series were 6.31 and 6.32 which both 
contained two fluorine atoms, albeit in slightly different arrangements. Interestingly these 
two compounds are constitutional isomers and both possess the exact same solubility. 
The bis-meta substituted compound 6.34 displayed the poorest solubility of less than 0.1 
µM. 
 Series 2 had a wide range of solubilities from 0.1 to 43.0 µM. This range was to 
be expected based on the wide range of functionalities preset within this series. The furan 
compounds 6.37 and 6.38 had very different solubilities of 4.6 µM and 43.0 µM 
respectively. This increase observed for 6.38 is believed to be due to a chelating effect 
that the carbonyl and the oxygen atom of the furan ring can simultaneously participate in. 
Comparatively, because of the spatial arrangement of the atoms, compound 6.37 is not as 
capable of chelating with solvent. Surprisingly two of the three benzyl alcohols (6.41-
6.42) showed poor solubilities of 3.7 µM and 2.3 µM. However, as expected compound 
6.40 displayed a solubility of 28.6 µM due to out-of-plane flexing of the 3-aryl ring. 
Para-substituted compounds 6.43-6.47 all displayed poor solubilities regardless of the 
functionality present (phenol, alkyl aryl ether, benzaldehyde, and acetylphenyl).  
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 Series 3 included some of the more soluble compounds in the library and 
possessed a range from 0.3 µM to 29.2 µM unfortunately, compounds 6.50 and 6.51 
displayed poor solubility of only 2.6 µM and 8.6 µM respectively. The meta-pyridyl 
compound 6.53 displayed a 20.4 µM, which was an improvement of 6.3. Surprisingly, 
compounds 6.52 and 6.54 did not achieve the solubilities that were expected. The most 
soluble compound in the series was 6.55, which interestingly, possess two meta-nitrogen 
atoms, giving approximately a 50% increase in comparison to 6.53. Overall, series 3 
possessed improved solubilities, however, the extent of the series suffered from poor 
antimalarial activities.  
Finally, series 4 displayed a range of solubilities from 0.1 µM to 3.7 µM. The 
compounds in series 4 were expected to be poor in solubility, however, some of the 
compounds low solubility values were surprising such as 6.71 due to the internal 
substitution at the ortho-position of the 3-aryl ring. Nevertheless, this could easily be 
expected from the higher molecular weight and increased non-polar carbons and 
hydrogens. Surprisingly, the combination of microsomal stability and extremely potent 
EC50s allowed these compounds to achieve high levels of in vivo activity despite their 
poor solubilities.  
 Permeability is defined as the velocity of a molecule through a membrane barrier 
and it is measured through a PAMPA assay previously described in Chapter 2. 
Compounds with permeabilities (Pe) between 0.1 x10
-6
 cm/s and 1.0 x10
-6
 cm/s are poor. 
Compounds with Pe between 50 x10
-6
 cm/s and 500 x10
-6
 cm/s are good, while 
compounds with Pe greater than 1000 x10
-6
 cm/s are excellent. Another aspect of the 
PAMPA measurement is the % retention in the artificial membrane, this value is often 
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looked at for compounds with extremely low Pe values because the compound may have 
gotten caught in the membrane. 
 Amongst the initial sub-set of compounds (6.2-6.20) Pe values ranged from 0.1 
x10
-6
 cm/s to 630 x10
-6
 cm/s. The majority of the series was in the acceptable range, 
however the most permeable compounds were those with several mono-substituted 
branches (6.5 and 6.6) as compared to analogs with one highly branched substitution such 
as 6.8 and 6.9. In contrast alkyl analogs with branched substitution (6.13-6.16) had higher 
values of Pe as compared to 6.8 and 6.9.  
 Series 1 had a range of 0.1 x10
-6
 cm/s to 411 x10
-6
 cm/s. Di-substituted 
compounds 6.24-6.25, 6.28 and ortho-substituted compound 6.29 displayed Pe of greater 
than 50 x10
-6
 cm/s. Compound 6.34 displayed a poor solubility as well as poor 
permeability. This compound was perhaps the worst compound of the entire series.  
 Series 2 had a range of 0.1 x10
-6
 cm/s to 427 x10
-6
 cm/s. Compound 6.45 
displayed the greatest permeability with a Pe of 427 x10
-6
 cm/s due to the branched 
isopropyl chain. Whereas, the benzyl alcohol compounds as well as the phenol (6.40-
6.43) all displayed poor Pe less than 20 x10
-6
 cm/s.  
 Series 3 had a wide range of permeabilities from 0.1 x10
-6
 cm/s to 1356 x10
-6
 
cm/s. The pyridyl and pyrimidine compounds 6.52-6.55 were expected to have poor 
permeabilities due to the possible charge developed on the nitrogen. Compound 6.51 had 
an excellent Pe of 1356 x10
-6
 cm/s due to the branched amine chain in conjunction with 
the sterically shielded internal nitrogen of the aryl ring. This result was surprising 
however, there must be a synergy of the electronic density in the amino moiety and the 
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pyridine nitrogen that make this compound extremely permeable. Structurally similar 
analogs 6.58 had a good Pe of 125 x10
-6
 cm/s but 10-fold less than 6.51.  
 The majority of series 4 was not tested due to accessibility to the instrumentation 
needed to complete the analysis, however, some of the compounds were screened. The 
majority of the compounds possess a Pe of 0.1 x10
-6
 cm/s due to trapping in the 
membrane (high % retention values). 
6.5 In Vivo Efficacy Models 
 Compound 6.2 was our initial quinolone to be tested in vivo, with no efficacy 
being achieved in these studies. However, upon identification of the potency and 
increased solubility due to the out of plane conformation of 6.3, this compound was 
evaluated in P. berghi infected mice using the Thompson test (see experimental section 
6.7.1. for experimental details). Dosing of compound 6.3 at 10 mg/kg and 50 mg/kg at 
day six PE provided a 17% parasitemia suppression and 41% parasitemia suppression 
respectively with the average day of death for the mice at seven days. Although this was 
a success in terms of advancement, these numbers were less than satisfactory to the long 
term goal of a bio-orally available compound that could produce radical curative 
treatments.  
 An opportunity to utilize an alternative in vivo efficacy model that makes use of 
shorter time frames and less dosing known as the Schmatz efficacy scouting protocol (see 
experimental section 6.7.1. experimental for details) presented itself. The assay used one 
dose of 50 mg/kg and the mice were monitored for parasitemia at day six PE and for 
average day of death. Compounds 6.5, 6.8, 6.9, 6.22, 6.24, 6.25, 6.35, 6.44, 6.45, 6.57, 
6.63, 6.64, 6.68, 6.69, and 6.73 were tested (Table 6.3).  
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Table 6.3. Results of Schmatz Efficacy Scouting Protocol
 
Compound R1 Mice Vehicle Route 
% 
Inhibition 
Day 6
a 
Avg. 
Day 
Death 
6.5 
 
5 Peg400 Oral 28 7.0 
6.8 
 
5 Peg400 Oral 10 7.0 
6.9 
 
5 Peg400 Oral 13 7.00 
6.22 
 
5 Peg400 Oral 28 7.00 
6.24 
 
5 Peg400 Oral -11 6.00 
6.25 
 
5 Peg400 Oral 29 8.50 
6.35 
 
5 Peg400 Oral 5 7.00 
6.44 
 
5 Peg400 Oral 27 7.00 
6.45 
 
5 Peg400 Oral 27 7.00 
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6.57 
 
5 Peg400 Oral -58 N.D. 
6.63 
 
5 Peg400 Oral 27 7.00 
6.64 
 
5 Peg400 Oral 2 7.00 
6.68 
 
5 Peg400 Oral 16 N.D. 
6.69 
 
5 Peg400 Oral 69 7.00 
6.72 
 
5 Peg400 Oral 61 7.00 
a
Standards for the Schmatz efficacy scouting protocol include amodiaquine (99%  Inhibition on Day 6 PE) 
and Atovaquone (99%  Inhibition on Day 6 PE) both at 10mg/kg dosages. 
 Compounds that exhibited a negative parasitemia reduction actually increased 
levels of parasitemia due to a number of complications related to the exposure and 
treatment of the compound. Several of the analogs emerged as very promising in terms of 
activity such as 6.69 and 6.70 which both had inhibitions of 60-70%. Despite the 
underwhelming solubility and permeabilities of these compounds, they were capable of 
inhibiting the P. berghei in the mouse model.  
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 Simultaneous to this assay, several Thompson tests were on-going (Table 6.4). 
These assays are more detailed with a different dosing regimen and are considered the 
standard for identifying in vivo active compounds. These were not the first Thompson 
tests as compounds 6.2 and 6.3 had already experienced several rounds of testing with 
various vehicles, however, these were considered to be the frontier assays in search of a 
lead candidate. The vehicle for all compounds was PEG400.  
Table 6.4. First Round of In Vivo Thompson Tests 
Compound R1 Mice 
Dose 
(mg/kg) 
% 
Inhibition 
Day 6 
Avg. 
Day 
Death 
6.3 
 
5 10 17 7.0 
6.3 
 
5 50 41 7.0 
6.21 
 
5 10 63 8.0 
6.21 
 
5 50 30 8.0 
6.23 
 
5 10 92 9.0 
6.23 
 
5 50 97 10.0 
6.28 
 
5 10 95 11.0 
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6.28 
 
5 50 71 11.0 
6.51 
 
5 10 -5 7 
6.51 
 
5 50 22 7 
6.42 
 
5 10 0 7 
6.42 
 
5 50 -5 7 
6.38 
 
5 10 -37 7 
6.38 
 
5 50 -35 7 
6.66 
 
5 10 -5 8 
6.66 
 
5 50 -19 7 
a
Standards for the Thompson Test include atovaquone (99%  Inhibition on Day 6 PE at 10 mg/kg) with 
curative dosage (5/5 mice survive beyond day 30). 
 The results of this assay were very encouraging, especially for compounds 6.23 
and 6.28 which exhibited parasitemia reductions in the >90% range. At this point it 
became apparent that microsomal stability was a key physicochemical property allowing 
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for the high levels of in vivo activities. The exact reason for the in vivo efficacy with 
such stable yet insoluble compounds is not fully know but is currently being investigated.  
Taking the encouraging results of the Thompson test as well as the Schmatz 
efficacy scouting protocol while analyzing the physicochemical data (Table 6.2), it was 
determined that the bi-aryl ether and bi-phenyl containing compounds 6.69 and 6.71 with 
the high level of microsomal stability and very potent EC50 values would be further 
assessed for in vivo efficacy. These studies are summarized in Table 6.5. Compound 6.69 
and 6.72 exhibited excellent parasitemia reduction, however the compounds were not 
curative as the mice did not live to 30 days. However, compound 6.71 did in fact produce 
radical curative treatments in which all five mice survived 30 days PE, with parasitemia 
reductions of 99%. 
Table 6.5. In Vivo Thompson Tests 
Compound R1 Mice 
Dose 
(mg/kg) 
% 
Inhibition 
Day 6 
Avg. 
Day 
Death 
6.69 
 
5 10 87 N.D. 
6.69 
 
5 50 70 N.D. 
6.71 
 
5 10 99 30 
6.71 
 
5 50 98 30 
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6.72 
 
5 10 80 N.D. 
6.72 
 
5 50 79 N.D. 
a
Standards for the Thompson Test include atovaquone (99%  Inhibition on Day 6 PE at 10 mg/kg) with 
curative dosage (5/5 mice survive beyond day 30). 
 
Compound 6.71 emerged as the late lead and is under detailed pharmacokinetic 
investigations by our collaborators in Australia.  
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6.6 Conclusions 
 Studies on the 4(1H)-quinolone series identified 6-chloro-7-methoxy-3-phenyl-
4(1H)-quinolone 6.2 as an initial candidate for in vivo studies however the compound 
failed to reduce the parasitemia levels. A small set of similar analogs (6.2-6.20) revealed 
that compound 6.3 had a 3-fold increase in solubility (19 µM) and 3-4 fold increase in 
antimalarial activity with EC50s of 5.8 nM and 4.0 nM against W2 and TM90C2B 
respectively. Compound 6.3 displayed a 17% parasitemia suppression 10 mg/kg doses 
and a 41% parasitemia suppression at 50 mg/kg doses on day six PE. Follow-up SAR and 
SPR studies revealed the following trends: (a) 3-alkyl analogs while potent displayed 
poor solubilities and had little potential for further optimization, (b) 3-aryl-4(1H)-
quinolones possessing para-substitution at the 3-aryl ring were typically more potent than 
4(1H)-quinolones with meta- and / or ortho-substituted 3-aryl moieties, (c) electron-rich 
and electron-poor functionalities were tolerated in the para-position of the aryl 
substitution, (d) compounds with ortho-substituted aryl rings typically experienced an 
increase in solubility and permeability, (e) compounds possessing greater levels of 
microsomal stability displayed marked improvements within in vivo efficacy models. 
 Degradation studies revealed that microsomal stability of the 4(1H)-quinolone 
series was equally important as solubility when compound 6.23 was identified to have 
greater in vivo activity (92% parasitemia suppression at 10 mg/kg doses and a 97% 
parasitemia suppression at 50 mg/kg doses at day six PE). A follow-up Schmatz efficacy 
scouting protocol was utilized to rapidly evaluate 14 4(1H)-quinolones for in vivo 
efficacy. Several compounds displayed promising reductions in parasitemia. A final 
round of in vivo testes provided several efficacious compounds (6.69, 6.71-6.72). 
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Especially compound 6.71 which provided a 99% parasitemia suppression at 10 mg/kg 
and 98% parasitemia suppression at 50 mg/kg doses on day 30 PE. Thus, compound 6.71 
provided a radical curative activity with five out of five mice surviving beyond 30 days. 
In summary, the library presented here (6.2-6.72) which eventually lead to the 
identification of compound 6.71 which was the result of detailed investigations of the 
three scaffolds: (a) 4(1H)-quinolones, (b) THAs, and (c) PEQs. Further work is on-going 
to optimize 6.71 to develop a preclinical candidate. 
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6.7 Experimental Section 
6.7.1 General Information 
All palladium catalysts and ligands were purchased from Strem. All boronic acids 
were purchased from Frontier Scientific. The identity of all title compounds were verified 
via 
1
H NMR, 
13
C NMR, and HPLC/HRMS. The chemical purity of the titled compounds 
was determined using the following conditions: an Agilent 1100 series LC/MSD with a 
Eclipse XDB-C18 (4.6mm x 100 mm, 5 μm) reversed phase column; method: 10% (v/v) 
of acetonitrile (+0.05% TFA) in 90% (v/v) of H2O (+0.05% TFA), ramped to 100% 
acetonitrile (+0.05% TFA) over 9 min, and holding at 100% acetonitrile for 4 min with a 
flow rate of 0.7 mL/min, UV detector, 254 nm. The purity of each compound was ≥95% 
in this analysis. NMR spectra were recorded at ambient temperature on a 400 or 500 
MHz Varian NMR spectrometer in the solvent indicated. All 
1
H NMR experiments are 
reported in ≥ units, parts per million (ppm) downfield of TMS and were measured 
relative to the signals for chloroform (7.26 ppm) and dimethylsulfoxide (2.50 ppm). All 
13
C NMR spectra were reported in ppm relative to the signals for chloroform (77 ppm) 
and dimethylsulfoxide (39.5 ppm) with 
1
H decoupled observation. Data for 
1
H NMR are 
reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet), integration and coupling constant (Hz), whereas 
13
C-
NMR analyses were obtained at 101 MHz and reported in terms of chemical shift. NMR 
data was analyzed by using MestReNova Software ver. 5.3.2-4936. High resolution mass 
spectra (HRMS) were performed on an Agilent LC/MSD TOF system G3250AA. 
Isomers were separated by reverse phase HPLC system (Waters Prep LC 4000 system 
with Waters 996 Photodiode Array Detector, Agilent column Eclipse XDB-C18, 5 μM, 
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9.4x250 mm). Compounds were eluted using a gradient elution of 70/30 to 50/50 A/B 
over 30 minutes at a flow rate of 5.0 mL/min, where solvent A was water and solvent B 
was acetonitrile. Analytical thin layer chromatography (TLC) was performed on silica gel 
60 F254 pre-coated plates (0.25 mm) from EMD Chemical Inc. and components were 
visualized by ultraviolet light (254 nm). Silicycle silica gel 230-400 (particle size 40-63 
μm) mesh was used for all flash column chromatography. 
Permeability Pe has been determined by a standard parallel artificial membrane 
permeability assay (PAMPA by pION). PAMPA was conducted on a Biomek FX lab 
automation workstation (Beckman Coulter, Inc., Fullerton, CA) with PAMPA evolution 
96 command software (pION Inc., Woburn, MA) as follows: 3 μL of 10μM test 
compound stock was mixed with 600 μL of system solution buffer, pH 7.4 or 4 (pION 
Inc., Woburn, MA) to make diluted test compound. Then 150 μL of diluted test 
compound was transferred to a UV plate (pION Inc., Woburn, MA), and the UV 
spectrum was read as the reference plate. The membrane on a preloaded PAMPA 
sandwich (pION Inc., Woburn, MA) was painted with 4 μL of GIT lipid (pION Inc., 
Woburn, MA). The acceptor chamber was then filled with 200 μL of acceptor solution 
buffer (pION Inc., Woburn, MA), and the donor chamber was filled with 180 μL of 
diluted test compound. The PAMPA sandwich was assembled, placed on the Gut-Box 
controlled environment chamber and stirred for 30 min. The aqueous boundary layer was 
set to 40 μm for stirring. The UV spectrum (250–500 nm) of the donor and the acceptor 
were read. The permeability coefficient was calculated using PAMPA Evolution 96 
Command software (pION Inc., Woburn, MA) based on the AUC of the reference plate, 
the donor plate, and the acceptor plate. All compounds were tested in triplicate. Standards 
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for this assay include Verapamil HCl (Pe = 1405 x10
-6
 cm/s at pH=7.4 and 39 x10
-6
 cm/s 
at pH=4.0), Carbamazepine (Pe = 112 x10
-6
 cm/s at pH=7.4 and 108 x10
-6
 cm/s at 
pH=4.0), and Ranitidine HCl (Pe = 0.5 x10
-6
 cm/s at pH=7.4 and 0 x10
-6
 cm/s at pH=4.0). 
Solubility has been determined via an in-house HPLC assay. A calibration curve 
was made by plotting the area under the curve at 254 nm (uv by HPLC) against the 
concentration of each compound injected after performing a serial dilution (25  to 
0.781 ) using a solvent in which the compound is soluble (DMSO).  A 100  
solution was then made for each compound in a buffer at pH 7.4, 4.0, and 2.0 by 
performing a 1:100 serial dilution using a 10mM DMSO stock solution of each 
compound. This solution was incubated at 21
o
C for 18 hours, filtered using a filter plate, 
and injected into the HPLC to compare the area found at wavelength 254 nm with the 
previously made calibration curve. Standards for this assay include carbamazepine and 
albendazole. Solubility for carbamazepine at pH 7.4, 4.0, and 2.0 is 95 and 
100  respectively. Solubility for albendazole at pH 7.4, 4.0, and 2.0 is 6.1 , 12, 
and 100respectively 
Log D was also determined in-house via an HPLC method adapted from the 
strategy reported by Donovan and Pescatore.
1
 Two buffers were made at a concentration 
of 50 each: ammonium acetate at pH 7.4 and ammonium formate at pH 3.0. A set of 
compounds with known log D values between -0.36 and 5.68 were used to make a 
calibration curve at each pH by using a liner gradient between 0 and 100% acetonitrile, 
with buffer at the specific concentration used as the second solvent. The curve was made 
by plotting the log D value against the retention time. Compounds were then injected into 
the HPLC and the retention time compared to the calibration curve previously 
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determined. Standards for this assay include Cinnarizine (LogD7.4 5.68), Hydrocortisone-
21-acetate (LogD7.4 2.19), Ketoconazole (LogD7.4 3.83), Metronidazole (LogD7.4 -0.02), 
Nadolol (LogD7.4 0.68), Pyrene (LogD7.4 4.88), Theophyline (LogD7.4 -0.05), and 
Tolnaftate (LogD7.4 5.40). 
The microsomal stability of 4(1H)-quinolones was determined by Susan Charman 
at the Monash University in Australia. The compounds are incubated at a concentration 
of 1 µM with human microsomes at 37ºC and 0.4 mg/mL of microsomal protein. The 
metabolic reaction was initiated with the addition of an NADPH-regenerating system (i.e. 
NADPH is the cofactor required for CYP450-mediated metabolism) and quenched at 
various time points over the incubation period by the addition of acetonitrile. Controls 
were incubated without the NADPH to assess the amount of degradation without 
metabolic initiation. The relative loss of compound was monitored by LC-MS using a 
Waters/Micromass ZQ mass spectrometer.  
 The test compounds concentration versus time data was fitted to an exponential 
decay function to determine the first order rate constant for substrate degradation. Each 
rate constant was then used to calculate microsomal half-life (Table 6.2). Entries of 
C.N.C. (could not calculate) are compounds that displayed little to no observable 
degradation throughout the assay duration (typically 250 minutes), whereas N.D. entries 
were molecules that were not assayed. Endochin was used as a control for comparing 
half-lives of 4(1H)-quinolones. Endochin possesses half-lives of 7.9 minutes in Mouse 
and 10.2 in human microsomes. 
In Vivo Thomson Test: The in vivo efficacies of the new compounds were determined 
by a modified Thompson test. This test measures the survivability of mice and parasite 
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clearance following administration of the drug on days 3 to 5 post-exposure. In brief, 
1x10
6
 P. berghei-infected erythrocytes (KBG-173 strain) were inoculated into the 
intraperitoneal cavity of male mice that weighed 24 to 30 g. By day 3 post-exposure, 
parasitemia ranged from 1.0 to 3.7%. Each drug, suspended in 0.5% 
hydroxyethylcellulose–0.1% Tween 80, was administered orally (p.o.) once daily from 
days 3 to 5 post-exposure. The volume of drug suspension given depends on the weight 
of the mouse and the drug concentration of the suspension. In general, the volume is 
given at 0.01 mL/gram of body weight. Five mice were used in each dosage group. Blood 
films were taken on day 6 and biweekly for 30 days. Mice that were blood-film negative 
on day 30 post-exposure were considered cured. Compounds were considered active 
when the survival time of the treated mice was greater than twice that of the control mice 
(i.e., 12 to 14 days). Mice losing >20% of their body weight were sacrificed.  
Schmatz Efficacy Scouting Protocol: As Thompson test except mouse is treated with 
the drug at day 1 post-exposure. Parasitemia is measured at day 3 post-exposure and day 
6 post-exposure. Compounds with >90% parasitemia reduction are advanced to the 
Thompson test.  
6.7.3 General Procedures 
General Procedure A: Preparation of 3-aryl-6-chloro-7-methoxy-4(1H)-quinolones 
via Suzuki-Miyaura cross-coupling. 
An oven-dried schlenk tube was flame-dried and backfilled with argon (x3). The tube is 
then charged with quinolone (100 mg, 0.4 mmol), Pd2(dba)3 (14.5 mg, 0.016 mmol), 
SPHOS (13 mg, 0.032 mmol), boronic acid (97 mg, 0.6 mmol), and anhydrous powdered 
K3PO4 (168 mg, 0.79 mmol). The schlenk tube was fitted with a rubber septum and then 
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evacuated and backfilled with argon (this process was repeated three times). Dry solvent 
(Toluene, DMF, or 2-butanol) (1 mL) was added through the septum via syringe and the 
resulting solution was stirred for 1 min while purging with argon before replacing the 
rubber septum with the Teflon screwcap. The reaction was set to the oil bath until 
completion was observed via HPLC analysis. The reaction is cooled to room temperature 
and then diluted with 20 ml chloroform and 20 ml of methanol. This mixture was brought 
to a boil with a heat gun and then filtered over a pad of celite. Then, 10-30 ml of boiling 
DMF is passed through the celite pad. The eluent was concentrated under reduced 
pressure and the residual oil was purified further via flash chromatography. Some 4(1H)-
quinolones required two columns. The columned solids were then collected and placed in 
a 2-ml fritted funnel and washed with ice cold methanol, followed by diethyl ether then 
dried in vacuo to obtain the NMR pure samples. Some 4(1H)-quinolones could be 
triturated with cold ether upon in vacuo removal of the chloroform / methanol / DMF and 
placed in a 2-ml frit and washed with ~30 ml of diethyl ether and ~30 ml of ice cold 
methanol without any further purification. 
General Procedure B: Preparation of 3-aryl-6-chloro-7-methoxy-4(1H)-quinolones 
via Suzuki-Miyaura cross-coupling. 
An oven-dried schlenk tube was flame-dried and backfilled with argon(x3). The tube is 
then charged with quinolone (100 mg, 0.4 mmol), Pd(PPh3)4 (14.5 mg, 0.016 mmol), 
boronic acid (97mg, 0.6 mmol), and degassed 1-2M Na2CO3(1 mL). The schlenk tube 
was fitted with a rubber septum and then evacuated and backfilled with argon (this 
process was repeated three times). DMF (5 mL) was added through the septum via 
syringe and the resulting solution was stirred for 1 min while purging with argon before 
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replacing the rubber septum with the Teflon screwcap. The reaction was set to the oil 
bath until completion was observed via HPLC analysis. The reaction is cooled to room 
temperature and then diluted with 20 ml chloroform and 20 ml of methanol. This mixture 
was brought to a boil with a heat gun and then filtered over a pad of celite. Then, 10-30 
ml of boiling DMF is passed through the celite pad. The eluent was concentrated under 
reduced pressure and the residual oil was purified further via flash chromatography. 
Some 4(1H)-quinolones required two columns. The columned solids were then collected 
and placed in a 2-ml fritted funnel and washed with ice cold methanol, followed by 
diethyl ether then dried in vacuo to obtain the NMR pure samples. Some 4(1H)-
quinolones could be triturated with cold ether upon in vacuo removal of the chloroform / 
methanol / DMF and placed in a 2-ml fritted funnel and washed with ~30 ml of diethyl 
ether and ~30 ml of ice cold methanol without any further purification. 
General Procedure C: Preparation of 3-aryl-6-chloro-7-methoxy-4(1H)-quinolones 
via Suzuki-Miyaura cross-coupling. 
An oven-dried schlenk tube was flame-dried and backfilled with argon(x3). The tube is 
then charged with quinolone (100 mg, 0.4 mmol), Pd(PPh3)4 (14.5 mg, 0.016 mmol), 
boronic acid (97 mg, 0.6 mmol), and K3PO4 (168 mg, 0.79 mmol). The schlenk tube was 
fitted with a rubber septum and then evacuated and backfilled with argon (this process 
was repeated three times). A degassed mixture of toluene/H2O (9:1) was added through 
the septum via syringe and the resulting solution was stirred for 1 min while purging with 
argon before replacing the rubber septum with the Teflon screwcap. The reaction was set 
to the oil bath until completion was observed via HPLC analysis. The reaction is cooled 
to room temperature and then diluted with 20 ml chloroform and 20 ml of methanol. This 
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mixture was brought to a boil with a heat gun and then filtered over a pad of celite. Then, 
10-30 ml of boiling DMF is passed through the celite pad. The eluent was concentrated 
under reduced pressure and the residual oil was purified further via flash 
chromatography. Some 4(1H)-quinolones required two columns. The columned solids 
were then collected and placed in a 2-ml fritted funnel and washed with ice cold 
methanol, followed by diethyl ether then dried in vacuo to obtain the NMR pure samples. 
Some 4(1H)-quinolones could be triturated with cold ether upon in vacuo removal of the 
chloroform / methanol / DMF and placed in a 2-ml fritted funnel and washed with ~30 ml 
of diethyl ether and ~30 ml of ice cold methanol without any further purification. 
General Procedure D: Preparation of 3-aryl-6-chloro-7-methoxy-4(1H)-quinolones 
via Suzuki-Miyaura cross-coupling. 
An oven-dried schlenk tube was flame-dried and backfilled with argon(x3). The tube is 
then charged with quinolone (100 mg, 0.4 mmol), Pd2(dba)3 (14.5 mg, 0.016 mmol), 
SPHOS (13 mg, 0.032 mmol), boronic acid (97mg, 0.6 mmol), and anhydrous powdered 
K3PO4 (168 mg, 0.79 mmol). The schlenk tube was fitted with a rubber septum and then 
evacuated and backfilled with argon (this process was repeated three times). A degassed 
mixture of toluene/H2O (9:1) was added through the septum via syringe and the resulting 
solution was stirred for 1 min while purging with argon before replacing the rubber 
septum with the Teflon screwcap. The reaction was set to the oil bath until completion 
was observed via HPLC analysis. The reaction is cooled to room temperature and then 
diluted with 20 ml chloroform and 20 ml of methanol. This mixture was brought to a boil 
with a heat gun and then filtered over a pad of celite. Then, 10-30 ml of boiling DMF is 
passed through the celite pad. The eluent was concentrated under reduced pressure and 
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the residual oil was purified further via flash chromatography. Some 4(1H)-quinolones 
required two columns. The columned solids were then collected and placed in a 2-ml frit 
and washed with ice cold methanol, followed by diethyl ether then dried in vacuo to 
obtain the NMR pure samples. Some 4(1H)-quinolones could be triturated with cold ether 
upon in vacuo removal of the chloroform / methanol / DMF and placed in a 2-ml fritted 
funnel and washed with ~30 ml of diethyl ether and ~30 ml of ice cold methanol without 
any further purification. 
General Procedure E: Preparation of 3-aryl-6-chloro-7-methoxy-4(1H)-quinolones 
via Suzuki-Miyaura cross-coupling. 
An oven-dried schlenk tube was flame-dried and backfilled with argon(x3). The tube is 
then charged with quinolone (100 mg, 0.4 mmol), Pd2(dba)3 (14.5 mg, 0.016 mmol), 
SPHOS (13 mg, 0.032 mmol), boronic acid (97mg, 0.6 mmol), and degassed 1-2M 
Na2CO3(1 mL). The schlenk tube was fitted with a rubber septum and then evacuated and 
backfilled with argon (this process was repeated three times). Dry solvent (Toluene, 
DMF, or 2-butanol) (5 mL) was added through the septum via syringe and the resulting 
solution was stirred for 1 min while purging with argon before replacing the rubber 
septum with the Teflon screwcap. The reaction was set to the oil bath until completion 
was observed via HPLC analysis. The reaction is cooled to room temperature and then 
diluted with 20 ml chloroform and 20 ml of methanol. This mixture was brought to a boil 
with a heat gun and then filtered over a pad of celite. Then, 10-30 ml of boiling DMF is 
passed through the celite pad. The eluent was concentrated under reduced pressure and 
the residual oil was purified further via flash chromatography. Some 4(1H)-quinolones 
required two columns. The columned solids were then collected and placed in a 2-ml frit 
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and washed with ice cold methanol, followed by diethyl ether then dried in vacuo to 
obtain the NMR pure samples. Some 4(1H)-quinolones could be triturated with cold ether 
upon in vacuo removal of the chloroform / methanol / DMF and placed in a 2-ml fritted 
funnel and washed with ~30 ml of diethyl ether and ~30 ml of ice cold methanol without 
any further purification. 
General Procedure F: Preparation of 3-aryl-6-chloro-7-methoxy-4(1H)-quinolones 
via Suzuki-Miyaura cross-coupling. 
An oven-dried schlenk tube was flame-dried and backfilled with argon(x3). The tube is 
then charged with O-ethyl quinolone (100 mg, 0.39 mmol), Pd2(dba)3 (14.5 mg, 0.016 
mmol), SPHOS (13 mg, 0.032 mmol), boronic acid (97mg, 0.6 mmol), and anhydrous 
powdered K3PO4 (168 mg, 0.79 mmol). The schlenk tube was fitted with a rubber septum 
and then evacuated and backfilled with argon (this process was repeated three times). Dry 
solvent (toluene, DMF, or 2-butanol) (1 mL) was added through the septum via syringe 
and the resulting solution was stirred for 1 min while purging with argon before replacing 
the rubber septum with the Teflon screwcap. The reaction was set to the oil bath until 
completion was observed via HPLC analysis. The reaction is cooled to room temperature 
and then diluted with 20 ml chloroform and 20 ml of methanol. This mixture was brought 
to a boil with a heat gun and then filtered over a pad of celite. Then, 10-30 ml of boiling 
DMF is passed through the celite pad. The eluent was concentrated under reduced 
pressure and the residual oil was purified further via flash chromatography. Some 4(1H)-
quinolones required two columns. The columned solids were then collected and placed in 
a 2-ml fritted funnel and washed with ice cold methanol, followed by diethyl ether then 
dried in vacuo to obtain the NMR pure samples. Some 4(1H)-quinolones could be 
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triturated with cold ether upon in vacuo removal of the chloroform / methanol / DMF and 
placed in a 2-ml frit and washed with ~30 ml of diethyl ether and ~30 ml of ice cold 
methanol without any further purification. The resulting Suzuki adduct is then dissolved 
in 1:1 AcOH/HBr and refluxed for 1.5 hours. The solution is allowed to cool to room 
temperature and is then poured onto ice and water. Next, the crude compound is isolated 
via filtration and washed with 100 mL of water. The 2-ml fritted funnel is placed in a 
60ºC oven and dried for 1 hour, and then re-crystallized from DMF. 
General Procedure G: Preparation of 3-aryl-6-chloro-7-methoxy-4(1H)-quinolones 
via Suzuki-Miyaura cross-coupling. 
An oven-dried schlenk tube was flame-dried and backfilled with argon(x3). The tube is 
then charged with O-ethyl quinolone (100 mg, 0.39 mmol), Pd2(dba)3 (14.5 mg, 0.016 
mmol), SPHOS (13 mg, 0.032 mmol), boronic acid (97mg, 0.6 mmol), and degassed 1-
2M Na2CO3(1 mL). The schlenk tube was fitted with a rubber septum and then evacuated 
and backfilled with argon (this process was repeated three times).  DMF (5 mL) was 
added through the septum via syringe and the resulting solution was stirred for 1 min 
while purging with argon before replacing the rubber septum with the Teflon screwcap. 
The reaction was set to the oil bath until completion was observed via HPLC analysis. 
The reaction is cooled to room temperature and then diluted with 20 ml chloroform and 
20 ml of methanol. This mixture was brought to a boil with a heat gun and then filtered 
over a pad of celite. Then, 10-30 ml of boiling DMF is passed through the celite pad. The 
eluent was concentrated under reduced pressure and the residual oil was purified further 
via flash chromatography. Some 4(1H)-quinolones required two columns. The columned 
solids were then collected and placed in a 2-ml fritted funnel and washed with ice cold 
368 
 
methanol, followed by diethyl ether then dried in vacuo to obtain the NMR pure samples. 
Some 4(1H)-quinolones could be triturated with cold ether upon in vacuo removal of the 
chloroform / methanol / DMF and placed in a 2-ml fritted funnel and washed with ~30 ml 
of diethyl ether and ~30 ml of ice cold methanol without any further purification. The 
resulting Suzuki adduct is then dissolved in 1:1 AcOH/HBr and refluxed for 1.5 hours. 
The solution is allowed to cool to room temperature and is then poured onto ice and 
water. Next, the crude compound is isolated via filtration and washed with 100 mL of 
water. The frit is placed in a 60ºC oven and dried for 1 hour, and then re-crystallized from 
DMF. 
General Procedure H: Preparation of 6-chloro-7-methoxy-3-substituted 2-
methylquinolin-4(1H)-ones (6.11-6.20) 
Quinolin-4-ones were prepared by using one of the standard procedures for Conrad-
Limpach reactions. An oven-dry 100 ml rbf attached to a Dean-Stark trap equipped with 
a reflux condenser was charged with an aniline (0.025 mol), corresponded ethyl 
acetoacetate (0.25-0.05 mol), benzene (25 ml) and glacial acidic acid (1 ml). The mixture 
was heated at 100
°
C until no more water was separated (3-24 hours). The benzene was 
distilled under the reduced pressure and resulting enamine was then used in the next step 
with no further purification.  Biphenyl ether (30 ml) was stirred and heated at reflux 
while enamine was added rapidly through the dropping funnel. Stirring and refluxing 
continued for 10-15 minutes until no more ethanol is separates by using the Dean-Stark 
trap. The mixture was then allowed to cool down to room temperature while precipitation 
arises. The solid was filtered off and washed with hexane and acetone. No further 
purification was needed. The yield is reported over the two steps. 
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General Procedure I: Ethylation of 3-benzyl-2-methylquinolin-4(1H)-one. 
 To a flame dried-backfilled round bottom flask was added quinolone (0.72 g, 2.8 mmol) 
and Cs2CO3 (1.37 g, 4.2 mmol). DMF (14.5 ml) was added and this slurry is allowed to 
stir at r.t. for 1h. Next, ethyl iodide (0.88 ml, 14 mmol) was added dropwise and the 
reaction is left until completion was observed via HPLC analysis. The reaction was then 
poured onto water (20 ml) and then diluted with chloroform (20 ml). The organic layer 
was then washed with water (20 ml) twice followed by brine (20 ml). The organic layer 
was then dried over sodium sulfate and concentrated in vacuo. The crude compound was 
columned via flash chromatography (Hex / EtOAc gradient). 
6.7.3 Compound Characterization 
6-chloro-7-methoxy-2-methyl-3-phenylquinolin-4(1H)-one (6.2). Compound 6.2 was 
prepared using general procedure C in 71% yield as a white solid, m.p. = 329 - 330°C. 
1
H 
NMR (400 MHz, DMSO) δ 11.63 (s, 1H), 7.99 (s, 1H), 7.38 (t, J = 7.4 Hz, 2H), 7.29 (t, J 
= 7.4 Hz, 1H), 7.23 (d, J = 6.9 Hz, 2H), 7.06 (s, 1H), 3.96 (s, 3H), 2.19 (s, 3H). 
13
C NMR 
(101 MHz, DMSO) δ 173.48, 156.66, 146.42, 139.59, 135.85, 130.94, 127.75, 126.53, 
126.17, 120.78, 118.78, 117.94, 99.40, 56.37, 18.85. HRMS calc. for C17H14BrNO2 
(M+H)
+
: 300.0785, found: 300.07936. 
6-chloro-7-methoxy-2-methyl-3-o-tolylquinolin-4(1H)-one (6.3). Compound 6.3 was 
prepared using general procedure A in 31% yield as a white powder, m.p. = 337 - 339°C. 
1H NMR (400 MHz, DMSO) δ 11.66 (s, 1H), 7.99 (s, 1H), 7.22 (dt, J = 22.4, 7.1, 3H), 
7.08 (s, 1H), 7.03 (d, J = 6.9, 1H), 3.96 (s, 3H), 2.05 (s, 3H), 2.02 (s, 3H). 
13
C NMR (101 
MHz, DMSO) δ 173.16, 156.63, 146.50, 139.71, 137.35, 135.92, 130.81, 129.48, 127.04, 
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126.11, 125.46, 120.44, 118.58, 117.91, 99.44, 56.37, 19.30, 18.39. HRMS calc for  
C18H16ClNO2 (M+H)
+
: 314.09423, found: 314.09470. 
6-chloro-7-methoxy-2-methyl-3-p-tolylquinolin-4(1H)-one (6.4). Compound 6.4 was 
prepared using general procedure A in 78% as a tan solid, m.p. = 336 - 341°C. 
1
H NMR 
(400 MHz, DMSO) δ 11.59 (s, 1H), 7.99 (s, 1H), 7.18 (d, J = 7.7 Hz, 2H), 7.10 (d, J = 
7.7 Hz, 2H), 7.03 (s, 1H), 3.94 (s, 3H), 2.33 (s, 3H), 2.18 (s, 3H). 
13
C NMR (101 MHz, 
DMSO) δ 173.57, 156.58, 146.33, 139.54, 135.51, 132.79, 130.75, 128.34, 126.16, 
120.64, 118.74, 117.86, 99.35, 56.32, 20.80, 18.83. HRMS calc for C18H16ClNO2 
(M+H)
+
: 314.09423, found: 314.09456. 
6-chloro-3-(2,4-dimethylphenyl)-7-methoxy-2-methylquinolin-4(1H)-one (6.5). 
Compound 6.5 was a prepared using general procedure A in 28%. 
1
H NMR (400 MHz, 
DMSO) δ 11.63 (s, 1H), 7.98 (s, 1H), 7.06 (s, 2H), 6.99 (d, J = 7.6 Hz, 1H), 6.89 (d, J = 
7.6 Hz, 1H), 3.95 (s, 3H), 2.29 (s, 3H), 2.04 (s, 3H), 1.97 (s, 3H). 
13
C NMR (101 MHz, 
DMSO) δ 173.98, 157.27, 147.26, 140.39, 137.77, 136.64, 133.58, 131.36, 130.91, 
126.79, 121.02, 119.27, 118.54, 100.12, 57.04, 21.40, 19.95, 19.11. 
6-chloro-3-mesityl-7-methoxy-2-methylquinolin-4(1H)-one (6.6). Compound 6.6 was 
prepared using general procedure G in 10% as a tan solid, m.p. = 350 - 352°C. 
1
H NMR 
(250 MHz, DMSO) δ 11.68 (s, 1H), 7.99 (s, 1H), 7.07 (s, 1H), 6.89 (s, 2H), 3.95 (s, 3H), 
2.25 (s, 3H), 1.93 (d, J = 13.5 Hz, 9H). HRMS calc for C20H20ClNO2 (M+H)
+
: 
342.12553, found: 342.12447. 
6-chloro-3-(2-ethylphenyl)-7-methoxy-2-methylquinolin-4(1H)-one (6.7). Compound 
6.7 was prepared following general procedure A in 8% yield. 
1
H NMR (400 MHz, 
DMSO) δ 7.99 (s, 1H), 7.27 (d, J = 12.6 Hz, 2H), 7.21 (d, J = 5.2 Hz, 1H), 7.08 (s, 1H), 
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7.00 (d, J = 7.3 Hz, 1H), 3.96 (s, 3H), 2.35 (dd, J = 14.8, 7.3 Hz, 2H), 2.05 (s, 3H), 0.99 
(t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 174.16, 157.31, 147.28, 143.90, 
140.44, 136.02, 131.70, 129.25, 128.53, 128.00, 126.80, 126.24, 121.09, 119.26, 118.60, 
100.17, 57.05, 26.49, 19.26, 15.54. 
6-chloro-3-(4-isopropylphenyl)-7-methoxy-2-methylquinolin-4(1H)-one (6.8). 
Compound 6.8 was prepared using general procedure A in 66% as a white solid, m.p. = 
359 - 360°C. 
1H NMR (400 MHz, DMSO) δ 11.60 (s, 1H), 7.99 (s, 1H), 7.24 (d, J = 7.8 
Hz, 2H), 7.14 (d, J = 7.8 Hz, 2H), 7.05 (s, 1H), 3.95 (s, 3H), 2.91 (dt, J = 13.6, 6.7 Hz, 
1H), 2.19 (s, 3H), 1.24 (d, J = 6.8 Hz, 6H). 
13C NMR (101 MHz, DMSO) δ 173.61, 
164.24, 156.60, 146.41, 139.54, 133.16, 130.80, 126.17, 125.64, 120.65, 118.73, 117.87, 
99.35, 56.34, 33.17, 23.91, 18.89. HRMS calc for C20H20ClNO2 (M+H)
+
: 342.12553, 
found: 342.12436. 
3-(4-tert-butylphenyl)-6-chloro-7-methoxy-2-methylquinolin-4(1H)-one (6.9). 
Compound 6.9 was prepared using general procedure A in 35% as a white solid, m.p. = 
360 - 362°C. 
1
H NMR (400 MHz, DMSO) δ 11.60 (s, 1H), 7.99 (s, 1H), 7.40 (d, J = 8.1 
Hz, 2H), 7.15 (d, J = 8.1 Hz, 2H), 7.06 (s, 1H), 3.96 (s, 3H), 2.20 (s, 3H), 1.32 (s, 9H). 
13C NMR (101 MHz, DMSO) δ 174.30, 157.31, 149.34, 147.07, 140.24, 133.48, 131.24, 
126.86, 125.16, 121.26, 119.42, 118.57, 100.06, 57.05, 34.90, 31.88, 19.60. HRMS calc 
for C21H22ClNO2 (M+H)
+
: 356.14118, found: 356.14311. 
6-chloro-7-methoxy-2,3-dimethylquinolin-4(1H)-one (6.11). Compound 6.11 was 
prepared using general procedure G in 48% as a tan solid, m.p. = 337 - 338°C. 
1
H NMR 
(500 MHz, DMSO) δ 11.39 (s, 1H), 7.96 (s, 1H), 6.98 (s, 1H), 3.92 (s, 3H), 2.33 (s, 3H), 
1.93 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 174.37, 156.18, 145.72, 139.21, 125.86, 
372 
 
117.50, 113.99, 99.17, 56.24, 17.96, 10.31. HRMS calc for C12H12ClNO2 (M+H)
+
: 
238.06293, found: 238.06241. 
6-chloro-3-ethyl-7-methoxy-2-methylquinolin-4(1H)-one (6.12). Compound 6.12 was 
prepared using general procedure G in 70% as a white solid, m.p. = 326 - 328°C. 
1
H 
NMR (400 MHz, DMSO) δ 11.36 (s, 1H), 7.96 (s, 1H), 6.99 (s, 1H), 3.92 (s, 3H), 2.49 – 
2.42 (m, 2H), 2.35 (s, 3H), 0.98 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 
173.97, 156.25, 145.39, 139.33, 125.91, 120.35, 117.93, 117.49, 99.19, 56.27, 17.90, 
17.26, 13.47. HRMS calc for C13H14ClNO2 (M+H)
+
: 252.07858, found: 252.07977. 
6-chloro-3-isopropyl-7-methoxy-2-methylquinolin-4(1H)-one (6.13). Compound 6.13 
was prepared using general procedure G in 52% as a white solid, m.p. = 289 - 291°C. 
1
H 
NMR (400 MHz, DMSO) δ 11.23 (s, 1H), 7.94 (s, 1H), 6.95 (s, 1H), 3.91 (s, 3H), 3.04 
(dt, J = 13.4, 6.7 Hz, 1H), 2.35 (s, 3H), 1.27 (d, J = 7.0 Hz, 6H). 
13
C NMR (101 MHz, 
DMSO) δ 174.32, 156.19, 144.99, 139.15, 125.92, 122.80, 118.85, 117.41, 98.95, 56.24, 
26.76, 20.13, 18.06. HRMS calc for C14H16ClNO2 (M+H)
+
: 266.09423, found: 
266.09413. 
6-chloro-3-isobutyl-7-methoxy-2-methylquinolin-4(1H)-one (6.14). Compound 6.14 
was prepared using general procedure A in ~3% as a white amorphous solid. Purified via 
preparative HPLC. 
1H NMR (400 MHz, DMSO) δ 11.82 (s, 1H), 8.03 (s, 1H), 7.08 (s, 
1H), 3.94 (s, 3H), 2.39 (s, 5H), 1.90 – 1.80 (m, 1H), 0.85 (d, J = 6.6 Hz, 6H). 13C NMR 
(101 MHz, DMSO) δ 174.12, 159.07, 158.70, 157.12, 147.93, 139.97, 126.46, 118.78, 
99.98, 56.90, 34.23, 28.36, 23.14, 18.81. HRMS calc for C15H18ClNO2 (M+H)
+
: 
280.10988, found: 280.11035. 
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6-chloro-3-cyclohexyl-7-methoxy-2-methylquinolin-4(1H)-one (6.15). Compound 6.15 
was prepared using general procedure G in 21% as a beige solid, m.p. = 313 - 314°C. 
1
H 
NMR (400 MHz, DMSO) δ 11.23 (s, 1H), 7.94 (s, 1H), 6.96 (s, 1H), 3.91 (s, 3H), 2.37 (s, 
3H), 2.23 (d, J = 11.1 Hz, 2H), 1.70 (dd, J = 33.1, 9.4 Hz, 3H), 1.44 – 1.13 (m, 6H). 13C 
NMR (101 MHz, DMSO) δ 174.38, 156.18, 145.33, 139.11, 125.98, 122.36, 118.92, 
117.38, 98.97, 56.25, 37.65, 28.92, 26.85, 25.72, 18.25. HRMS calc for C17H20ClNO2 
(M+H)
+
: 342.08915, found: 342.08955. 
3-benzyl-6-chloro-7-methoxy-2-methylquinolin-4(1H)-one (6.16). Compound 6.16 
was prepared using general procedure G in 40% as a brown solid, m.p. = 254 – 255°C. 
1H NMR (500 MHz, DMSO) δ 11.49 (s, 1H), 8.02 (s, 1H), 7.20 (dd, J = 8.9, 5.3 Hz, 4H), 
7.10 (ddd, J = 8.6, 6.3, 2.5 Hz, 1H), 6.99 (s, 1H), 3.92 (s, 3H), 3.86 (s, 2H), 2.30 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 174.26, 156.40, 146.89, 141.15, 139.41, 128.09, 127.99, 
126.05, 126.02, 125.46, 118.04, 117.82, 99.31, 56.27, 29.84, 17.83. HRMS calc for 
C18H16ClNO2 (M+H)
+
: 314.09423, found: 314.09466. 
6-chloro-3-heptyl-7-methoxy-2-methylquinolin-4(1H)-one (6.17). Compound 6.17 was 
prepared using general procedure G in 30% as a white solid, m.p. = 238 - 239°C. 
1
H 
NMR (400 MHz, DMSO) δ 11.34 (s, 1H), 7.95 (s, 1H), 6.98 (s, 1H), 3.92 (s, 3H), 2.45 – 
2.41 (m, 2H), 2.34 (s, 3H), 1.25 (d, J = 10.4 Hz, 10H), 0.84 (d, J = 7.0 Hz, 3H). 
13
C NMR 
(101 MHz, DMSO) δ 174.16, 156.23, 145.52, 139.31, 125.92, 119.08, 117.86, 117.47, 
99.16, 56.25, 31.31, 29.23, 28.68, 28.56, 24.70, 22.10, 17.45, 13.94. HRMS calc for 
C18H24ClNO2 (M+H)
+
: 322.15683, found: 322.15608. 
6-chloro-7-methoxy-2-methyl-3-nonylquinolin-4(1H)-one (6.18). Compound 6.18 was 
prepared using general procedure G in 27% as a tan solid, m.p. = 219 – 221°C. 1H NMR 
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(400 MHz, DMSO) δ 11.33 (s, 1H), 7.95 (s, 1H), 6.97 (s, 1H), 3.91 (s, 3H), 2.45 – 2.39 
(m, 2H), 2.33 (s, 3H), 1.35 – 1.20 (m, 14H), 0.84 (t, J = 6.3 Hz, 3H). 13C NMR (101 
MHz, DMSO) δ 174.16, 156.22, 145.48, 139.31, 125.92, 119.07, 117.86, 117.46, 99.14, 
56.23, 31.28, 29.25, 29.01, 28.71, 28.53, 24.69, 22.07, 17.43, 13.91. HRMS calc for 
C20H28ClNO2 (M+H)
+
: 350.18813, found: 350.18856. 
Methyl 6-chloro-7-methoxy-2-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate 
(6.20). Compound 6.20 was prepared using general procedure G in 15% as a brown solid, 
m.p. = 303 – 308°C. 
6-chloro-3-(4-fluorophenyl)-7-methoxy-2-methylquinolin-4(1H)-one (6.21). 
Compound 6.21 was prepared using general procedure B in 52% as a grey solid, m.p. = 
344 - 345°C. 
1H NMR (400 MHz, DMSO) δ 11.66 (s, 1H), 7.99 (s, 1H), 7.27 (dd, J = 8.5, 
5.9, 2H), 7.20 (t, J = 8.9, 2H), 7.07 (s, 1H), 3.96 (s, 3H), 2.20 (s, 3H). 
19
F NMR (376 
MHz, DMSO) δ -116.51. 13C NMR (101 MHz, DMSO) δ 171.50, 160.26 (d, J = 242.4), 
154.66, 152.60, 145.84, 135.60, 132.845 (d, J = 7.07), 125.55, 120.67, 118.38, 115.66, 
113.93 (d, J = 21.21), 104.47, 55.83, 22.45. HRMS calc for  C17H13ClFNO2 (M+H)
+
: 
318.06916, found: 318.06988. 
6-chloro-7-methoxy-2-methyl-3-(4-(trifluoromethoxy)phenyl)quinolin-4(1H)-one 
(6.22). Compound 6.22 was prepared using general procedure B in 47% as a white solid, 
m.p. = 321 - 322°C. 
1H NMR (400 MHz, DMSO) δ 11.69 (s, 1H), 7.99 (s, 1H), 7.37 (s, 
4H), 7.05 (s, 1H), 3.96 (s, 3H), 2.21 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 173.31, 
156.75, 146.97, 146.71, 139.57, 135.15, 132.83, 126.10, 120.30, 119.29, 118.65, 118.12, 
99.43, 56.37, 18.83. HRMS calc for C18H13ClF3NO3 (M+H)
+
: 384.06088, found: 
384.06184. 
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6-chloro-7-methoxy-2-methyl-3-(4-(trifluoromethyl)phenyl)quinolin-4(1H)-one 
(6.23). Compound 6.23 was prepared using general procedure A in 31% as a yellow 
solid, m.p. = 322 - 323°C. 
1H NMR (400 MHz, DMSO) δ 11.79 (s, 1H), 8.00 (s, 1H), 
7.74 (d, J = 8.1, 2H), 7.49 (d, J = 8.0, 2H), 7.09 (s, 1H), 3.97 (s, 3H), 2.22 (s, 3H). 
19
F 
NMR (376 MHz, DMSO) δ -61.24 13C NMR (101 MHz, DMSO) δ 173.84, 157.51, 
147.60, 141.13, 140.40, 132.53, 127.77 (q, J = 31.61), 126.80, 125.215 (d, J = 3.03), 
123.79, 120.04, 119.42, 118.90, 100.30, 57.10, 19.54. HRMS calc for C18H13ClF3NO2 
(M+H)
+
: 368.06597, found: 368.06445. 
6-chloro-3-(3-ethoxy-4-fluorophenyl)-7-methoxy-2-methylquinolin-4(1H)-one (6.24). 
Compound 6.24 was prepared using general procedure A in 77% as a tan solid, m.p. = 
328 - 329°C. 
1H NMR (400 MHz, DMSO) δ 11.64 (s, 1H), 7.98 (s, 1H), 7.16 – 7.03 (m, 
3H), 6.97 (d, J = 8.0 Hz, 1H), 4.13 (q, J = 6.6 Hz, 2H), 3.95 (s, 3H), 2.21 (s, 3H), 1.37 (t, 
J = 6.7 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 174.12, 157.34, 151.76 (d, J  = 243.41), 
147.38, 145.62 (d, J = 11.11), 140.19, 129.15, 127.81, 126.82, 120.04, 119.28 (d, J = 
15.15), 119.03, 118.66, 114.75, 100.06, 64.90, 57.03, 19.54, 15.33. HRMS calc for 
C19H17ClFNO3 (M+H)
+
: 362.09538, found: 362.09390. 
6-chloro-3-(2,4-difluorophenyl)-7-methoxy-2-methylquinolin-4(1H)-one (6.25). 
Compound 6.25 was prepared using general procedure A in 20% as a tan solid, m.p. = 
318 - 323°C. 
1H NMR (400 MHz, DMSO) δ 11.79 (s, 1H), 7.98 (s, 1H), 7.32 – 7.26 (m, 
2H), 7.12 – 7.07 (m, 2H), 3.97 (s, 3H), 2.16 (s, 3H). 13C NMR (101 MHz, DMSO) δ 
173.73, 162.32 (dd, J = 246.44, 12.12), 160.81 (dd, J = 247.45, 13.13), 157.53, 148.29, 
140.40, 134.95, 126.72, 120.37 (d, J = 17.17), 118.99 (d, J = 7.07), 114.51, 111.78 (d, J = 
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202.20), 104.52 (d, J = 26.26), 104.26 (d, J = 26.26), 100.24, 57.10, 19.12. HRMS calc 
for C17H12ClF2NO2 (M+H)
+
: 336.05974, found: 336.06018. 
6-chloro-3-(4-fluoro-2-methylphenyl)-7-methoxy-2-methylquinolin-4(1H)-one (6.26). 
Compound 6.26 was prepared using general procedure B in 34% yield. 
1
H NMR (400 
MHz, DMSO) δ 7.95 (s, 1H), 7.07 (d, J = 2.6 Hz, 1H), 7.04 – 7.00 (m, 3H), 3.92 (s, 3H), 
2.00 (d, J = 12.1 Hz, 6H). 
19
F NMR (376 MHz, DMSO) δ -116.63. 13C NMR (101 MHz, 
DMSO) δ 173.64, 162.92, 160.51, 157.12, 147.33, 140.75, 140.67, 140.18, 133.01, 
132.93, 132.54, 126.54, 119.78, 118.98, 118.45, 116.52, 116.31, 112.66, 112.45, 99.92, 
56.83, 19.78, 18.86. 
6-chloro-7-methoxy-2-methyl-3-(2-methyl-4-(trifluoromethyl)phenyl)quinolin-
4(1H)-one (6.27). Compound 6.27 was prepared using general procedure B in 10% yield. 
1
H NMR (400 MHz, DMSO) δ 11.73 (s, 1H), 7.96 (d, J = 2.4 Hz, 1H), 7.61 (s, 1H), 7.51 
(d, J = 8.3 Hz, 1H), 7.25 (d, J = 8.1 Hz, 1H), 7.05 (d, J = 2.1 Hz, 1H), 3.93 (d, J = 2.2 Hz, 
3H), 2.08 (s, 3H), 2.03 (d, J = 2.2 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 173.31, 157.25, 
147.17, 141.07, 140.22, 139.64, 132.28, 128.35, 128.04, 126.49, 126.25, 123.55, 122.67, 
122.64, 119.59, 118.94, 118.65, 100.00, 56.87, 19.61, 18.84. 
6-chloro-3-(4-chloro-2-methylphenyl)-7-methoxy-2-methylquinolin-4(1H)-one (6.28). 
Compound 6.28 was prepared using general procedure A in 17% as a tan solid, m.p. = 
340 – 341°C. 1H NMR (400 MHz, DMSO) δ 11.68 (s, 1H), 7.95 (s, 1H), 7.32 (s, 1H), 
7.22 (d, J = 7.9 Hz, 1H), 7.03 (d, J = 10.3 Hz, 2H), 3.93 (s, 3H), 2.01 (d, J = 15.7 Hz, 
6H). 
13C NMR (101 MHz, DMSO) δ 173.71, 157.40, 147.46, 140.82, 140.42, 135.62, 
133.30, 132.18, 129.84, 126.76, 126.09, 119.83, 119.19, 118.75, 100.18, 57.08, 19.80, 
19.08. HRMS calc for C18H15Cl2NO2 (M+H)
+
: 348.05526, found: 348.05562. 
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6-chloro-7-methoxy-2-methyl-3-(2-(trifluoromethoxy)phenyl)quinolin-4(1H)-one 
(6.29). Compound 6.29 was prepared using general procedure A in 25% as a grey solid, 
m.p. = 312 - 316°C. 
1H NMR (400 MHz, DMSO) δ 11.87 – 11.79 (s, 1H), 7.99 (s, 1H), 
7.46 (dt, J = 18.2, 8.8 Hz, 3H), 7.34 (d, J = 7.3 Hz, 1H), 7.10 (s, 1H), 3.97 (s, 3H), 2.12 
(s, 3H).19F MISSING
13C NMR (101 MHz, DMSO) δ 172.83, 156.83, 147.15, 139.74, 
133.53, 129.49, 129.12, 128.13, 127.14, 126.05, 121.30, 120.67, 118.74, 118.28, 115.78, 
99.65, 56.40, 18.28. HRMS calc for C18H13ClF3NO3 (M+H)
+
: 384.06088, found: 
384.06162. 
6-chloro-3-(2-fluoro-4-(trifluoromethyl)phenyl)-7-methoxy-2-methylquinolin-4(1H)-
one (6.30). Compound 6.30 was prepared using general procedure F in 75% over two 
steps. 
1
H NMR (400 MHz, DMSO) δ 11.88 (s, 1H), 7.99 (d, J = 0.8 Hz, 1H), 7.70 (d, J = 
9.5 Hz, 1H), 7.62 (d, J = 8.5 Hz, 1H), 7.55 (t, J = 7.5 Hz, 1H), 7.09 (s, 1H), 3.97 (s, 3H), 
2.19 (s, 3H). 
13
C NMR (101 MHz, DMSO) δ 173.20, 161.57, 159.12, 157.41, 148.12, 
140.19, 135.09, 135.05, 130.53, 129.63, 128.66, 127.98, 126.44, 121.28, 118.93, 118.74, 
113.88, 113.36, 113.06, 100.08, 56.88, 18.87. 
6-chloro-3-(2-fluoro-4-(trifluoromethyl)phenyl)-7-methoxy-2-methylquinolin-4(1H)-
one (6.31). Compound 6.31 was prepared using general procedure E in 41%. 
1
H NMR 
(400 MHz, DMSO) δ 7.94 (s, 1H), 7.00 (d, J = 6.7 Hz, 3H), 3.93 (s, 3H), 3.87 (s, 3H), 
2.15 (s, 3H). 
13C NMR (101 MHz, dmso) δ 173.51, 157.29, 148.26, 140.14, 127.20, 
126.50, 118.77, 118.72, 117.44, 117.30, 114.12, 108.98, 100.00, 56.95, 56.86, 18.93. 
3-(3,5-bis(trifluoromethyl)phenyl)-6-chloro-7-methoxy-2-methylquinolin-4(1H)-one 
(6.34). Compound 6.34 was prepared using general procedure A in 7% as a yellow solid. 
1H NMR (400 MHz, DMSO) δ 11.88 (s, 1H), 8.12 – 7.81 (m, 4H), 7.10 (s, 1H), 3.98 (s, 
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3H), 2.28 (s, 3H). 
19F NMR (376 MHz, DMSO) δ -61.54. 13C NMR (101 MHz, DMSO) δ 
172.99, 156.99, 147.62, 139.63, 138.52, 131.83, 129.73 (q, J = 32.32), 126.08, 124.84, 
122.13, 120.24, 118.54 (d, J = 12.12), 117.67, 99.60, 56.43, 18.84. HRMS calc for 
C19H12ClF6NO2 (M+H)
+
: 356.14118, found: 356.14311. 
3-(benzofuran-2-yl)-6-chloro-7-methoxy-2-methylquinolin-4(1H)-one (6.35). 
Compound 6.35 was prepared using general procedure A in 59%. 
1
H NMR (400 MHz, 
DMSO) δ 11.94 (s, 1H), 8.06 (s, 1H), 7.67 – 7.62 (m, 1H), 7.54 (d, J = 7.8 Hz, 1H), 7.29 
– 7.21 (m, 3H), 7.09 (s, 1H), 3.97 (s, 3H), 2.56 (s, 3H). 13C NMR (101 MHz, DMSO) δ 
172.67, 156.95, 153.40, 151.64, 149.42, 139.08, 128.58, 126.15, 123.60, 122.59, 120.60, 
118.73, 118.50, 110.67, 109.95, 106.91, 99.74, 56.44, 19.66. 
3-(benzo[b]thiophen-2-yl)-6-chloro-7-methoxy-2-methylquinolin-4(1H)-one (6.36). 
Compound 6.36 was prepared using general procedure C in 53%, m.p. = 345 - 346°C. 
1
H 
NMR (500 MHz, DMSO) δ 11.91 (s, 1H), 8.04 (s, 1H), 7.93 (d, J = 7.7, 1H), 7.82 (d, J = 
7.2, 1H), 7.38 – 7.30 (m, 3H), 7.09 (s, 1H), 3.98 (s, 3H), 2.47 (s, 3H). 13C NMR (126 
MHz, DMSO) δ 173.60, 157.43, 149.08, 140.43, 139.77, 139.62, 138.12, 126.68, 124.70, 
124.36, 124.29, 123.60, 122.33, 119.04, 118.83, 113.76, 100.10, 56.95, 20.08. HRMS 
calc for  C19H14ClNO2S (M+H)
+
: 356.05065, found: 356.05077. 
6-chloro-3-(furan-3-yl)-7-methoxy-2-methylquinolin-4(1H)-one (6.37). Compound 
6.37 was prepared using general procedure B in 45%. 
1
H NMR (400 MHz, DMSO) δ 
11.59 (s, 1H), 7.96 (s, 1H), 7.79 (s, 1H), 7.64 (d, J = 0.8 Hz, 1H), 6.99 (s, 1H), 6.61 (d, J 
= 0.8 Hz, 1H), 3.91 (s, 3H), 2.36 (s, 3H). 
13
C NMR (101 MHz, DMSO) δ 173.73, 164.99, 
157.05, 147.35, 142.33, 142.14, 139.56, 126.59, 118.68, 118.54, 113.11, 111.95, 99.74, 
56.79, 19.76. 
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6-chloro-3-(furan-2-yl)-7-methoxy-2-methylquinolin-4(1H)-one (6.38). Compound 
6.38 was prepared using general procedure A in 72% as a yellow solid, m.p. = 300 - 
301°C. 
1H NMR (400 MHz, DMSO) δ 11.78 (s, 1H), 8.03 (s, 1H), 7.68 (s, 1H), 7.07 (s, 
1H), 6.78 (d, J = 3.0 Hz, 1H), 6.55 (s, 1H), 3.96 (s, 3H), 2.45 (s, 3H). 
13
C NMR (101 
MHz, DMSO) δ 173.17, 157.42, 149.37, 148.82, 141.91, 139.68, 126.81, 119.17, 119.09, 
111.42, 111.27, 111.06, 100.24, 57.06, 20.11. HRMS calc for C15H12ClNO3 (M+H)
+
: 
290.05785, found: 290.05890. 
6-chloro-3-(3,5-dimethylisoxazol-4-yl)-7-methoxy-2-methylquinolin-4(1H)-one 
(6.39). Compound 6.39 was prepared using general procedure A in 16% as a red solid, 
m.p. = 274 - 275°C. 
1H NMR (400 MHz, DMSO) δ 11.82 (s, 1H), 7.99 (s, 1H), 7.08 (s, 
1H), 3.96 (s, 3H), 2.17 (s, 6H), 1.98 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 174.14, 
166.58, 160.84, 157.54, 149.51, 140.41, 126.74, 118.98, 118.87, 111.11, 108.96, 100.24, 
57.12, 19.00, 11.94, 10.89. HRMS calc for C16H15ClN2O3 (M+H)
+
: 319.08440, found: 
319.08290. 
6-chloro-3-(2-(hydroxymethyl)phenyl)-7-methoxy-2-methylquinolin-4(1H)-one 
(6.40). Compound 6.40 was prepared using general procedure A in 32% as a white solid, 
m.p. = 267 - 269°C. 
1H NMR (400 MHz, DMSO) δ 11.74 (s, 1H), 7.99 (s, 1H), 7.53 (d, J 
= 7.5 Hz, 1H), 7.34 (t, J = 7.4 Hz, 1H), 7.26 (t, J = 7.3 Hz, 1H), 7.09 (s, 1H), 7.03 (d, J = 
7.3 Hz, 1H), 4.90 (s, 1H), 4.28 (d, J = 13.4 Hz, 1H), 4.17 (d, J = 13.5 Hz, 1H), 3.96 (s, 
3H), 2.06 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 173.50, 156.70, 147.16, 141.69, 
139.74, 134.08, 130.70, 127.12, 126.80, 126.49, 126.09, 119.60, 118.49, 118.11, 99.51, 
61.05, 56.41, 18.73. HRMS calc for C18H16ClNO3 (M+H)
+
: 330.08915, found: 
330.08830. 
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6-chloro-3-(3-(hydroxymethyl)phenyl)-7-methoxy-2-methylquinolin-4(1H)-one 
(6.41). Compound 6.41 was prepared using general procedure A in 23%. 
1
H NMR (250 
MHz, DMSO) δ 11.64 (s, 1H), 7.99 (s, 1H), 7.34 (t, J = 7.4 Hz, 1H), 7.24 (d, J = 7.6 Hz, 
1H), 7.16 (s, 1H), 7.08 (d, J = 6.9 Hz, 2H), 5.19 (s, 1H), 4.51 (d, J = 4.2 Hz, 2H), 3.96 (s, 
3H), 2.19 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 174.19, 157.30, 147.08, 142.64, 
140.29, 136.30, 129.90, 129.69, 128.18, 126.83, 125.41, 121.60, 119.46, 118.57, 100.11, 
63.62, 57.03, 19.53. HRMS calc for C18H16ClNO3 (M+H)
+
: 330.08915, found: 
330.09014. 
6-chloro-3-(4-(hydroxymethyl)phenyl)-7-methoxy-2-methylquinolin-4(1H)-one 
(6.42). Compound 6.42 was prepared using general procedure A in 49% as a yellow 
solid, m.p. = 310 - 315°C. 
1H NMR (400 MHz, DMSO) δ 11.61 (s, 1H), 7.99 (s, 1H), 
7.32 (d, J = 8.0 Hz, 2H), 7.17 (d, J = 8.0 Hz, 2H), 7.05 (s, 1H), 5.17 (s, 1H), 4.52 (d, J = 
3.7 Hz, 2H), 3.95 (s, 3H), 2.19 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 173.56, 156.62, 
146.37, 140.71, 139.58, 134.15, 130.60, 126.17, 125.94, 125.61, 120.70, 118.77, 117.89, 
99.39, 62.87, 56.34, 18.85. HRMS calc for C18H16ClNO3 (M+H)
+
: 330.08915, found: 
330.09001. 
6-chloro-3-(4-hydroxyphenyl)-7-methoxy-2-methylquinolin-4(1H)-one (6.43). 
Compound 6.43 was prepared using general procedure A in 44% as a grey solid, m.p. = 
270 - 274°C. 
1H NMR (400 MHz, DMSO) δ 11.54 (s, 1H), 9.32 (s, 1H), 7.98 (s, 1H), 
7.04 (s, 1H), 7.01 (d, J = 8.1 Hz, 2H), 6.76 (d, J = 8.0 Hz, 2H), 3.95 (s, 3H), 2.19 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 174.44, 157.22, 156.64, 146.98, 140.18, 132.55, 126.87, 
126.74, 121.40, 119.40, 118.43, 115.28, 100.00, 57.02, 19.58. HRMS calc for 
C17H14ClNO3 (M+H)
+
: 316.07350, found: 316.07254. 
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6-chloro-7-methoxy-3-(4-methoxyphenyl)-2-methylquinolin-4(1H)-one (6.44). 
Compound 6.44 was prepared using general procedure A in 68% as an off-white solid, 
m.p. = 297 - 298°C. 
1H NMR (400 MHz, DMSO) δ 11.59 (s, 1H), 7.99 (s, 1H), 7.14 (d, J 
= 7.8 Hz, 2H), 7.05 (s, 1H), 6.94 (d, J = 7.9 Hz, 2H), 3.95 (s, 3H), 3.78 (s, 3H), 2.20 (s, 
3H). 
13C NMR (101 MHz, DMSO) δ 173.73, 157.92, 156.61, 146.46, 139.55, 131.99, 
127.82, 126.21, 120.39, 118.74, 117.88, 113.25, 99.38, 56.37, 55.01, 18.90. HRMS calc 
for C18H16ClNO3 (M+H)
+
: 330.08915, found: 330.08983. 
6-chloro-3-(4-isopropoxyphenyl)-7-methoxy-2-methylquinolin-4(1H)-one (6.45). 
Compound 6.45 was prepared using general procedure A in 62% as a brown solid, m.p. = 
342 - 343°C. 
1H NMR (400 MHz, DMSO) δ 11.59 (s, 1H), 7.99 (s, 1H), 7.12 (d, J = 8.6 
Hz, 2H), 7.05 (s, 1H), 6.90 (d, J = 8.6 Hz, 2H), 4.61 (dd, J = 12.0, 6.0 Hz, 1H), 3.95 (s, 
3H), 2.20 (s, 3H), 1.29 (d, J = 6.0 Hz, 6H). HRMS calc for C20H20ClNO3 (M+H)
+
: 
358.12045, found: 358.11946. 
4-(6-chloro-7-methoxy-2-methyl-4-oxo-1,4-dihydroquinolin-3-yl)benzaldehyde 
(6.46). Compound 6.46 was prepared using general procedure B in 15%. 
1
H NMR (400 
MHz, DMSO) δ 11.72 (s, 1H), 10.00 (s, 1H), 7.96 (s, 1H), 7.88 (d, J = 7.8 Hz, 2H), 7.47 
(s, 2H), 7.03 (s, 1H), 3.92 (s, 3H), 2.20 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 197.97, 
178.31, 162.03, 152.00, 147.81, 144.78, 139.73, 137.01, 134.08, 131.33, 124.86, 123.92, 
123.44, 104.71, 61.60, 24.06. 
3-(4-acetylphenyl)-6-chloro-7-methoxy-2-methylquinolin-4(1H)-one (6.47). 
Compound 6.47 was prepared using general procedure A in 13% as a yellow solid, m.p. = 
266 - 269°C. 
1H NMR (250 MHz, DMSO) δ 11.65 (s, 1H), 7.94 – 7.80 (m, 3H), 7.30 (d, 
J = 8.0 Hz, 2H), 6.96 (s, 1H), 3.85 (s, 3H), 2.39 (s, 3H), 2.11 (s, 3H). 
13
C NMR (101 
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MHz, DMSO) δ 198.28, 173.87, 157.48, 147.38, 141.81, 140.28, 135.75, 131.99, 128.32, 
126.84, 120.46, 119.41, 118.86, 100.18, 57.09, 27.38, 19.54. HRMS calc for 
C19H16ClNO3 (M+H)
+
: 342.08915, found: 342.08955. 
Methyl 4-(6-chloro-7-methoxy-2-methyl-4-oxo-1,4-dihydroquinolin-3-yl)benzoate 
(6.48). Compound 6.48 was prepared using general procedure A in 32%.  
1
H NMR (400 
MHz, DMSO) δ 11.73 (s, 1H), 7.98 (dd, J = 9.5, 1.8 Hz, 2H), 7.89 (d, J = 10.4 Hz, 1H), 
7.43 – 7.34 (m, 2H), 7.05 (s, 1H), 3.95 (s, 3H), 3.87 (s, 3H), 2.21 (s, 3H). 13C NMR (101 
MHz, DMSO) δ 173.16, 166.23, 156.81, 146.74, 141.23, 139.60, 131.41, 128.55, 127.75, 
126.14, 119.68, 118.73, 118.22, 99.51, 95.86, 56.40, 52.07, 18.85. 
4-(6-chloro-7-methoxy-2-methyl-4-oxo-1,4-dihydroquinolin-3-yl)benzoic acid (6.49).  
1
H NMR (400 MHzDMSO) δ 12.86 (s, 1H), 11.71 (s, 1H), 7.96 (dd, J = 13.4, 10.2 Hz, 
3H), 7.37 (d, J = 8.1 Hz, 2H), 7.05 (s, 1H), 3.95 (s, 3H), 2.21 (s, 3H). 
13
C NMR (101 
MHz, DMSO) δ 173.22, 167.32, 162.28, 156.79, 146.70, 140.75, 139.60, 131.22, 128.92, 
128.73, 126.15, 119.85, 118.73, 118.19, 99.49, 90.23, 56.39, 18.85. 
6-chloro-3-(4-(dimethylamino)phenyl)-7-methoxy-2-methylquinolin-4(1H)-one 
(6.50). Compound 6.50 was prepared using general procedure E in 49% as a tan solid, 
m.p. = 324 - 325°C. 
1H NMR (400 MHz, DMSO) δ 11.52 (s, 1H), 7.99 (s, 1H), 7.03 (s, 
2H), 6.72 (d, J = 8.0 Hz, 2H), 3.94 (s, 3H), 2.91 (s, 6H), 2.20 (s, 3H). 
13
C NMR (101 
MHz, DMSO) δ 173.86, 156.46, 149.07, 146.14, 139.45, 131.36, 126.21, 123.29, 120.83, 
118.72, 117.65, 111.81, 99.29, 56.30, 40.19, 18.92. HRMS calc for C19H19ClN2O2 
(M+H)
+
: 343.12078, found: 343.12216. 
6-chloro-3-(6-(dimethylamino)pyridin-3-yl)-7-methoxy-2-methylquinolin-4(1H)-one 
(6.51). Compound 6.51 was prepared using general procedure E in 16%. 
1
H NMR (400 
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MHz, DMSO) δ 11.61 (s, 1H), 7.98 (s, 1H), 7.94 (d, J = 1.9 Hz, 1H), 7.39 (dd, J = 8.7, 
2.2 Hz, 1H), 7.03 (s, 1H), 6.64 (d, J = 8.7 Hz, 1H), 3.95 (s, 3H), 3.04 (s, 6H), 2.24 (s, 
3H). 
13C NMR (101 MHz, DMSO) δ 173.90, 157.69, 156.58, 148.91, 146.65, 139.75, 
139.49, 126.17, 118.68, 118.52, 117.84, 104.83, 99.35, 56.33, 37.72, 18.93. HRMS calc 
for C18H18ClN3O2 (M+H)
+
: 344.11603, found: 344.12216. 
6-chloro-7-methoxy-2-methyl-3-(pyridin-4-yl)quinolin-4(1H)-one (6.52). Compound 
6.52 was prepared using general procedure B in 19% as a tan solid, m.p. = 307 - 309°C. 
1H NMR (400 MHz, DMSO) δ 11.80 (s, 1H), 8.58 (d, J = 5.8, 2H), 8.00 (s, 1H), 7.31 – 
7.28 (m, 2H), 7.07 (s, 1H), 3.96 (s, 3H), 2.25 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 
172.85, 156.90, 149.05, 146.95, 143.94, 139.60, 126.21, 126.11, 118.68, 118.34, 118.18, 
99.55, 56.42, 18.78. HRMS calc for  C16H13ClN2O2 (M+H)
+
: 301.07383, found: 
301.07303. 
6-chloro-7-methoxy-2-methyl-3-(pyridin-3-yl)quinolin-4(1H)-one (6.53). Compound 
6.53 was prepared using general procedure D in 12% as a purple solid, m.p. = 301 - 
304°C. 
1H NMR (400 MHz, DMSO) δ 11.85 (s, 1H), 8.49 (s, 1H), 8.45 (s, 1H), 8.00 (s, 
1H), 7.68 (d, J = 6.7, 1H), 7.43 (d, J = 4.5, 1H), 7.10 (s, 1H), 3.96 (s, 3H), 2.24 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 173.40, 156.83, 151.34, 147.48, 147.24, 139.72, 138.44, 
131.58, 126.10, 122.96, 118.62, 118.23, 117.24, 99.60, 56.42, 18.85. HRMS calc for  
C16H13ClN2O2 (M+H)
+
: 301.07383, found: 314.07266. 
6-chloro-7-methoxy-2-methyl-3-(pyridin-2-yl)quinolin-4(1H)-one (6.54). Compound 
6.54 was prepared using general procedure F in 29% over two steps. 
1
H NMR (400 MHz, 
DMSO) δ 11.69 (s, 1H), 8.56 (s, 1H), 7.98 (s, 1H), 7.75 (td, J = 7.7, 1.7 Hz, 1H), 7.43 (d, 
J = 7.8 Hz, 1H), 7.24 (dd, J = 6.6, 5.1 Hz, 1H), 7.05 (s, 1H), 3.93 (s, 3H), 2.22 (s, 3H). 
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13
C NMR (101 MHz, DMSO) δ 173.74, 157.23, 155.44, 149.10, 148.55, 139.97, 135.88, 
127.29, 126.55, 122.03, 120.53, 119.50, 118.68, 100.05, 56.83, 19.03. 
6-chloro-7-methoxy-2-methyl-3-(pyrimidin-5-yl)quinolin-4(1H)-one (6.55). 
Compound 6.55 was prepared using general procedure A in 12%. 
1
H NMR (400 MHz, 
DMSO) δ 11.90 (s, 1H), 9.11 (s, 1H), 8.74 (s, 2H), 8.01 (s, 1H), 7.09 (s, 1H), 3.97 (s, 
3H), 2.30 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 173.88, 159.05, 157.73, 157.12, 
148.56, 140.37, 130.39, 126.76, 119.27, 114.44, 108.95, 100.35, 57.15, 19.52. 
3-([1,2,5]oxadiazolo[3,4-b]pyridin-5-yl)-6-chloro-7-methoxy-2-methylquinolin-
4(1H)-one (6.56). Compound 6.56 was prepared using general procedure B in 22%. 
1
H 
NMR (400 MHz, DMSO) δ 11.87 (s, 1H), 8.03 – 7.94 (m, 2H), 7.90 (s, 1H), 7.50 (d, J = 
9.3 Hz, 1H), 7.08 (s, 1H), 3.97 (s, 3H), 2.34 (s, 3H). 
6-chloro-7-methoxy-2-methyl-3-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)quinolin-
4(1H)-one (6.57). Compound 6.57 was prepared using general procedure B in 10%. 
1
H 
NMR (400 MHz, DMSO) δ 11.70 (s, 1H), 8.04 (s, 1H), 7.99 (d, J = 1.2 Hz, 1H), 7.52 (d, 
J = 8.6 Hz, 1H), 7.08 (s, 1H), 6.98 (d, J = 8.5 Hz, 1H), 3.97 (s, 3H), 2.80 (s, 3H), 2.26 (s, 
3H). 
13
C NMR (101 MHz, DMSO) δ 174.20, 157.12, 156.91, 149.45, 147.35, 140.91, 
139.97, 126.57, 122.05, 118.94, 118.47, 117.73, 107.18, 99.86, 56.85, 52.74, 42.87, 
42.72, 19.35. 
4-(6-chloro-7-methoxy-2-methyl-4-oxo-1,4-dihydroquinolin-3-yl)-N,N-
dimethylbenzenesulfonamide (6.59). Compound 6.59 was prepared using general 
procedure A in 34% as a brown solid, m.p. = 335 - 337°C. 
1
H NMR (400 MHz, DMSO) 
δ 11.78 (s, 1H), 8.01 (s, 1H), 7.75 (d, J = 8.2 Hz, 2H), 7.54 (d, J = 8.2 Hz, 2H), 7.08 (s, 
1H), 3.97 (s, 3H), 2.66 (s, 6H), 2.24 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 173.06, 
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156.87, 146.98, 140.84, 139.60, 132.84, 131.88, 126.92, 126.09, 119.14, 118.69, 118.28, 
99.54, 56.42, 37.60, 18.87. HRMS calc for C19H19ClN2O4S (M+H)
+
: 407.08268, found: 
407.08128. 
6-chloro-3-(dibenzo[b,d]furan-4-yl)-7-methoxy-2-methylquinolin-4(1H)-one (6.60). 
Compound 6.60 was prepared using general procedure B in 24%. 
1
H NMR (400 MHz, 
DMSO) δ 11.86 (s, 1H), 8.14 (dd, J = 18.0, 6.8 Hz, 2H), 8.02 (s, 1H), 7.62 (d, J = 8.2 Hz, 
1H), 7.50 – 7.37 (m, 4H), 7.13 (s, 1H), 3.99 (s, 3H), 2.17 (s, 3H). 13C NMR (101 MHz, 
DMSO) δ 173.70, 157.28, 155.66, 154.51, 148.05, 140.25, 130.71, 127.79, 126.59, 
124.30, 123.89, 123.38, 123.25, 121.47, 120.86, 120.39, 119.04, 118.69, 115.80, 112.07, 
100.03, 96.27, 56.88, 19.05. 
 
6-chloro-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-7-methoxy-2-methylquinolin-
4(1H)-one (6.61). Compound 6.61 was prepared using general procedure A in 61%, m.p. 
= 330 - 332°C. 
1H NMR (400 MHz, DMSO) δ 11.58 (s, 1H), 7.98 (s, 1H), 7.03 (s, 1H), 
6.84 (d, J = 8.2 Hz, 1H), 6.74 – 6.59 (m, 2H), 4.25 (s, 4H), 3.94 (s, 3H), 2.20 (s, 3H). 13C 
NMR (101 MHz, DMSO) δ 174.29, 157.26, 147.21, 143.39, 142.77, 140.18, 129.37, 
126.84, 124.46, 120.90, 120.20, 119.38, 118.56, 116.97, 100.02, 64.74, 64.69, 57.01, 
19.54. HRMS calc for C19H16ClNO4 (M+H)
+
: 358.08406, found: 358.08474. 
3-(4-(benzyloxy)phenyl)-6-chloro-7-methoxy-2-methylquinolin-4(1H)-one (6.62). 
Compound 6.62 was prepared using general procedure A in 62%. 
1
H NMR (400 MHz, 
DMSO) δ 11.60 (s, 1H), 7.99 (s, 1H), 7.48 (d, J = 6.9 Hz, 2H), 7.41 (t, J = 6.9 Hz, 2H), 
7.35 (d, J = 6.7 Hz, 1H), 7.15 (d, J = 7.7 Hz, 2H), 7.05 (s, 1H), 7.02 (d, J = 7.9 Hz, 2H), 
5.13 (s, 2H), 3.95 (s, 3H), 2.20 (s, 3H). 
13
C NMR (101 MHz, DMSO) δ 173.64, 157.03, 
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156.59, 146.38, 139.53, 137.23, 131.98, 128.41, 128.04, 127.76, 127.64, 126.18, 120.32, 
118.72, 117.83, 114.06, 99.36, 69.15, 56.35, 18.89. HRMS calc for C24H20ClNO3 
(M+H)
+
: 406.12045, found: 406.12204.  
3-(4-(benzyloxy)-3-fluorophenyl)-6-chloro-7-methoxy-2-methylquinolin-4(1H)-one 
(6.63). Compound 6.63 was prepared using general procedure A in 41%, m.p. = 302 - 
303°C. 
1H NMR (400 MHz, DMSO) δ 11.65 (s, 1H), 7.98 (s, 1H), 7.42 (ddd, J = 33.2, 
19.1, 7.1 Hz, 5H), 7.24 (t, J = 8.7 Hz, 1H), 7.13 – 6.94 (m, 3H), 5.21 (s, 1H), 3.96 (s, 
3H), 2.22 (s, 3H). 
19F NMR (376 MHz, DMSO) δ -136.41. 13C NMR (101 MHz, DMSO) 
δ 174.09, 157.37, 151.87 (d, J = 244.42), 147.40, 145.50, 140.20, 137.36, 129.57, 129.16, 
128.69, 128.47, 127.79, 126.83, 119.98, 119.35, 119.24 (d, J = 17.17), 118.68, 115.29, 
100.08, 70.88, 57.05, 19.56. HRMS calc for C24H19ClFNO3 (M+H)
+
: 424.11103, found: 
424.10894. 
3-(4-(benzyloxy)-2-methylphenyl)-6-chloro-7-methoxy-2-methylquinolin-4(1H)-one 
(6.64). Compound 6.64 was prepared using general procedure A in 30% as a white solid, 
m.p. = 318 - 319°C. 
1H NMR (400 MHz, DMSO) δ 11.65 (s, 1H), 7.98 (s, 1H), 7.48 (d, J 
= 7.2 Hz, 2H), 7.41 (t, J = 7.4 Hz, 2H), 7.34 (t, J = 7.2 Hz, 1H), 7.08 (s, 1H), 6.96 – 6.90 
(m, 2H), 6.83 (dd, J = 8.3, 2.4 Hz, 1H), 5.11 (s, 2H), 3.95 (s, 3H), 2.06 (s, 3H), 1.99 (s, 
3H). 
13C NMR (101 MHz, DMSO) δ 174.10, 158.10, 157.25, 147.51, 140.37, 139.45, 
138.00, 132.42, 129.08, 128.99, 128.42, 128.29, 126.82, 120.71, 119.26, 118.51, 116.52, 
112.34, 100.11, 69.76, 57.04, 20.28, 19.16. HRMS calc for C25H22ClNO3 (M+H)
+
: 
420.13610, found: 420.13487. 
6-chloro-7-methoxy-2-methyl-3-(2-((4-(trifluoromethoxy)phenoxy)methyl)phenyl)-
quinolin-4(1H)-one (6.65). Compound 6.65 was prepared using general procedure B in 
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10% as a white solid. 
1
H NMR (400 MHz, DMSO) δ 11.70 (s, 1H), 8.00 (d, J = 0.6 Hz, 
1H), 7.56 – 7.47 (m, 1H), 7.37 (dd, J = 5.3, 3.1 Hz, 2H), 7.27 – 7.10 (m, 3H), 7.05 (s, 
1H), 6.92 (d, J = 8.7 Hz, 2H), 4.88 (dd, J = 33.6, 12.4 Hz, 2H), 3.95 (s, 3H), 2.10 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 173.62, 157.54, 157.16, 147.89, 142.06, 140.10, 136.73, 
135.80, 131.80, 128.26, 128.07, 127.81, 126.53, 122.78, 119.56, 118.89, 118.59, 116.15, 
99.90, 68.69, 56.80, 19.14. 
6-chloro-7-methoxy-2-methyl-3-(4-(phenoxymethyl)phenyl)quinolin-4(1H)-one 
(6.66). Compound 6.66 was prepared using general procedure A in 57% as a beige solid, 
m.p. = 301 - 302°C. 
1H NMR (400 MHz, DMSO) δ 11.60 (s, 1H), 7.96 (s, 1H), 7.42 (d, J 
= 7.6 Hz, 2H), 7.35 – 7.20 (m, 4H), 7.06 – 6.87 (m, 4H), 5.08 (s, 2H), 3.92 (s, 3H), 2.17 
(s, 3H). 
13C NMR (101 MHz, DMSO) δ 174.17, 159.11, 157.35, 147.15, 140.25, 136.07, 
135.95, 131.67, 130.16, 127.90, 126.85, 121.34, 121.09, 119.43, 118.65, 115.39, 100.09, 
69.74, 57.04, 19.55. HRMS calc for C24H20ClNO3 (M+H)
+
: 406.12045, found: 
406.12223. 
6-chloro-7-methoxy-2-methyl-3-(4-((4-(trifluoromethoxy)phenoxy)methyl)phenyl)-
quinolin-4(1H)-one (6.67). Compound 6.67 was prepared using general procedure B in 
3%. 
1
H NMR (400 MHz, DMSO) δ 11.66 (s, 1H), 8.01 (s, 1H), 7.48 (d, J = 8.0 Hz, 2H), 
7.33 (d, J = 9.1 Hz, 2H), 7.28 (d, J = 7.9 Hz, 2H), 7.16 (d, J = 9.1 Hz, 2H), 7.08 (s, 1H), 
5.17 (s, 2H), 3.98 (s, 3H), 2.23 (s, 3H). 
6-chloro-3-(4-(4-fluorobenzyloxy)phenyl)-7-methoxy-2-methylquinolin-4(1H)-one 
(6.68). Compound 6.68 was prepared using general procedure B in 25%. 
1
H NMR (400 
MHz, DMSO) δ 11.59 (s, 1H), 7.99 (s, 1H), 7.53 (dd, J = 8.3, 5.7 Hz, 2H), 7.24 (t, J = 8.7 
388 
 
Hz, 2H), 7.15 (d, J = 8.3 Hz, 2H), 7.06 – 7.00 (m, 3H), 5.11 (s, 2H), 3.96 (s, 3H), 2.20 (s, 
3H).  
6-chloro-7-methoxy-2-methyl-3-(4-phenoxyphenyl)quinolin-4(1H)-one (6.69). 
Compound 6.69 was prepared using general procedure A in 65% as a white solid, m.p. = 
303 - 305°C. 
1H NMR (400 MHz, DMSO) δ 11.64 (s, 1H), 8.00 (s, 1H), 7.41 (t, J = 7.9 
Hz, 2H), 7.24 (d, J = 8.5 Hz, 2H), 7.15 (t, J = 7.4 Hz, 1H), 7.03 (dd, J = 22.4, 8.1 Hz, 
5H), 3.95 (s, 3H), 2.23 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 173.53, 156.64, 155.31, 
146.54, 139.55, 132.52, 130.80, 130.02, 126.15, 123.43, 120.00, 118.71, 117.94, 117.78, 
99.38, 56.35, 18.90. HRMS calc for C23H18ClNO3 (M+H)
+
: 392.10480, found: 
392.10580. 
6-chloro-3-(3-(4-fluorophenoxy)phenyl)-7-methoxy-2-methylquinolin-4(1H)-one 
(6.70). Compound 6.70 was prepared using general procedure B in 58%. 
1
H NMR (400 
MHz, DMSO) δ 11.65 (s, 1H), 7.98 (s, 1H), 7.39 (t, J = 7.9 Hz, 1H), 7.22 (dd, J = 12.9, 
4.6 Hz, 2H), 7.12 – 7.07 (m, 2H), 7.04 (s, 1H), 7.01 (dd, J = 7.6, 1.0 Hz, 1H), 6.95 – 6.90 
(m, 1H), 6.87 (d, J = 1.2 Hz, 1H), 3.94 (s, 3H), 2.21 (s, 3H). 
13
C NMR (101 MHz, 
DMSO) δ 173.80, 159.71, 157.15, 157.00, 153.08, 147.19, 139.95, 138.16, 129.76, 
126.56, 126.51, 121.16, 120.97, 120.89, 120.44, 119.09, 118.56, 117.05, 116.81, 99.79, 
56.80, 19.24. 
6-chloro-7-methoxy-2-methyl-3-(2-methyl-4-(4-(trifluoromethoxy)phenoxy)phenyl)-
quinolin-4(1H)-one (6.71). Compound 6.71 was prepared using general procedure B in 
20%. 
1
H NMR (400 MHz, DMSO) δ 7.98 (s, 1H), 7.40 (d, J = 9.0 Hz, 2H), 7.14 (d, J = 
9.0 Hz, 2H), 7.06 (d, J = 10.5 Hz, 2H), 6.98 (s, 1H), 6.88 (s, 1H), 3.96 (s, 3H), 2.08 (s, 
3H), 2.01 (s, 3H). 
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3-(biphenyl-4-yl)-6-chloro-7-methoxy-2-methylquinolin-4(1H)-one (6.72). Compound 
6.72 was prepared using general procedure A in 53% as a grey solid, m.p. = 352 - 353°C. 
1H NMR (400 MHz, DMSO) δ 11.63 (s, 1H), 7.99 (s, 1H), 7.65 (dd, J = 15.1, 7.6 Hz, 
4H), 7.54 – 7.16 (m, 5H), 7.03 (s, 1H), 3.92 (s, 3H), 2.22 (s, 3H). 13C NMR (101 MHz, 
DMSO) δ 174.21, 157.36, 147.21, 140.75, 140.26, 138.98, 135.73, 132.22, 129.61, 
127.97, 127.23, 126.87, 126.70, 120.95, 119.44, 118.68, 100.10, 57.05, 19.61. HRMS 
calc for C23H18ClNO2 (M+H)
+
: 376.10988, found: 376.10541. 
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Chapter 7: Development of a Species Specific Acetylcholinesterase (AChE) Inhibitor via 
In Situ Click Chemistry 
7.1 Overview 
 Initial in situ click chemistry proof of concept experiments revealed that the 
approach has great potential for lead discovery and optimization.
1-3
 Potent triazole 
inhibitors such as syn/anti-TZ2PA6 could be produced within the enzyme’s binding site 
through the binding of individual fragments bearing azide and alkyne functionalities 
(Figures 1.15 and 1.18). These triazole containing inhibitors were the most potent known 
inhibitors of AChE to date with low-femtomolar dissociation constants for both mouse 
and eel AChE. However, new understanding of AChEs binding conformation, binding 
potential, and thermodynamic equilibrium towards bound molecules also emerged 
through the use of detailed X-ray analysis of this enzyme via the inhibitors generated 
using in situ click chemistry.
4-7
 In essence, this approach has allowed for the elaboration 
of a detailed molecular-protein probe. 
 Species specific inhibitor generation is a necessity in drug design, especially in 
antimicrobials and pesticides. The capability of designing a species specific AChE 
inhibitor would be desirable for extending the scope of in situ click chemistry in lead 
discovery as well as as a model for vector control of malaria.  
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7.2 X-Ray Analysis of mAChE and dmAChE 
 By using X-ray crystal structure studies Bourne and co-workers revealed very 
interesting structural information about AChE.
5
 Initially three complexes were studied 
mAChE in the apo form, propidium-mAChE, and tacrine-TcAChE. The apo form was the 
enzyme without an inhibitor, the propidium-mAChE complex was the protein with a 
peripheral anionic site (PAS) binder, and the tacrine-eel AChE complex was an active 
site binder with eel AChE. These crystal structures were then used as comparative models 
for the X-ray structures generated from anti-TZ2PA6 and syn-TZ2PA6 with mAChE 
(Figure 7.1) 
Figure 7.1. anti-TZ2PA6 and syn-TZ2PA6 mAChE Complexes 
 
 In the anti-mAChE complex the triazole ring participates in van der Waals 
contacts with side chains of Tyr124, Phe297, Tyr337, and Phe338 in the gorge, while N2 
and N3 nitrogen atoms of the triazole ring are hydrogen bonded with Tyr337 and Tyr124 
π – π Stacking
Hydrogen Bonding
Anti-TZ2PA6 Syn-TZ2PA6
mAChE Crystal Structure with anti/syn-TZ2PA6
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which are on opposite sides of the gorge. The positioning of the triazole influences the 
positioning of the phenylphenanthridinium (PA) moiety with respect to the PAS. The PA 
moiety has near parallel π-π stacking with the indole of Trp286 and establishes edge-to-
face interactions with Tyr72. Furthermore, the exocyclic phenyl ring of the PA system 
adopts a T-shape and has numerous interactions with other aromatic residues as the gorge 
entrance (Figure 7.1).
5
 
 In syn-mAChE complex, the triazole is buried deeper into the gorge as compared 
to the anti-mAChE complex. This burial occludes Tyr337 from hydrogen bonding and 
instead establishes hydrogen bonding with Tyr341 closer to the gorge entrance. Due to 
the triazole being deeper in the gorge, the PA moiety is subsequently pulled down deeper 
into the gorge entrance. This forces Trp286 to dislodge from its previous position out into 
solution. The new position allows for a unique conformation not seen before in AChE 
whereby the PA is intercalated on one side by Trp286 π-π stacking interactions and the 
other side by Tyr72. This change in conformation almost doubles the gorge mouth in 
size.
5
 
 These studies reveal that the binding of the syn isomer induces large 
conformational changes at the PAS, which were previously never observed. These 
changes were not nearly as drastic for the anti isomer and could not have been predicted 
by the X-ray structures of mAChE in apo form, propidium-mAChE complex, or tacrine-
TcAChE complex alone. Finally, the triazole was shown to have major binding 
contributions as evidenced by Tyr337.
5
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 Comparison of active site and gorge geometries of various AChEs reveals a large 
similarity between fish and mammalian homology. However, insect AChE had 
significant differences.
5, 7
  
Figure 7.2. Homology Difference of AChE 
 
It was not surprising when in situ click chemistry was used to screen libraries of azide 
and alkyne fragments that identical hits were received for both mouse and eel AChE 
(Figure 1.18) considering their homological similarities. All of the in situ hits for the 
mammalian and fish AChE were syn-triazoles which resulted from the curvature of the 
long and narrow gorge. The anti isomers which were more elongated in shape had 2-3 
orders of magnitude lower potency as compared to the inhibitory capability of the syn 
isomers. In 2008 Radić and co-workers showed that this preference was not ubiquitous 
amongst all species through binding studies and molecular docking of mAChE, dmAChE 
and eel AChE with triazole based inhibitors.
7
 Binding studies revealed the potency of 
anti-TZ2PA6 and syn-TZ2PA6 as well as several other analogs (unpublished results) 
which are shown below (Figure 7.3).  
mAChE
51% residue
homology
dmAChE
eAChE
70% residue homology
48% residue 
homology
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Figure 7.3. Potency of anti-TZ2PA6 and syn-TZ2PA6 Amongst Various Enzymes 
syn-TZ2PA6 
KD (fM) 
Enzyme 
anti-TZ2PA6 
KD (fM) 
Enzyme 
99 eel AChE 14,000 eel AChE 
410 mAChE 8,900 mAChE 
3600 dmAChE 1,700 dmAChE 
720 mBuChE 460 mBuChE 
 
These results show that anti-TZ2PA6 is slightly more potent against dmAChE than 
mAChE. Furthermore, all anti isomers were more potent against dmAChE while all syn 
isomers were more potent against mAChE. Further insight was gained by overlaying 
several triazole inhibitors (syn and anti) crystallized with various AChEs (eel AChE, 
mAChE, and dmAChE). All of the inhibitors have strikingly similar overlap with regards 
to the active site (tacrine binding portion) located at the bottom of the gorge. However, 
two areas within the enzyme have the most divergence amongst species: (a) the 
intervening chain and triazole moiety interaction with Tyr 124 which has become known 
as the “choke point”, and (b) the PA moieties interactions with the PAS namely Trp286.7 
In fish and mammalian AChEs the choke point is located deep in the gorge however, it is 
shifted closer to the PAS in dmAChE. In dmAChE the gorge becomes wider and 
increases in  volume. A severe restriction at the entrance to the gorge accompanies this 
increase in gorge width (Figure 7.4). This observation also suggests that perhaps a 
molecule smaller than the PA moiety would be a more appropriate binder. 
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Figure 7.4. Comparison of mAChE and dmAChE
 
 These detailed examinations of the mAChE and dmAChE provide a solid 
foundation of structural knowledge to begin the process of developing a species specific 
inhibitor. It is evident that a dmAChE inhibitor would have anti geometry and that the 
triazole moiety would be located closer to the gorge entrance as opposed to the lower 
positioning in the original proof of concept studies done on mAChE and eel AChE.
1, 2
 
 As a proof of concept study the building blocks TZ2-6, TA1-3, PZ5-8, and PA2-
6 were screened against mAChE and dmAChE. Upon incubating with dmAChE at 37ºC 
at pH 7.5,  three hits were identified and confirmed,  anti-TA1PZ6, syn-TZ2PA6, and 
anti-TZ6PA2. The binding of these compounds (Figure 7.5) is shown here, however 
these species selectivities were not satisfactory. Therefore, the synthesis of azides that 
would accommodate the conformation of dmAChE as well as the identification of an 
alternative PAS binder were sought out to achieve higher levels of species selectivity 
amongst mouse and eel AChE.   
Tyr 124 “Choke Point”
Located Lower
Tyr 124 “Choke Point”
Located Higher
mAChE dmAChE
Syn-TZ2PA6
Kd 0.41 pM mAChE
anti-TZ6PA2
Kd 2.7 pM dmAChE
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Figure 7.5. Binding Studies of anti-TA1PZ6, syn-TZ2PA6, and anti-TZ6PA2 
 
7.3 Synthetic Chemistry 
 Based on in silico data, an active site analog was envisioned to occupy a sub-
pocket in dmAChE (Figure 7.6). This sub-pocket was observed to correspond to the side 
of the active center where the aryl ring of the tacrine moiety binds. The volume of the 
sub-pocket was estimated to be similar to that of an iso-butyl group (Figure 7.6). Thus, a 
small SAR was envisioned to accompany the desired iso-butyl tacrine analog bearing an 
alkyl azide (IBTZ6). These analogs would be decorated with  the azide and would 
represent the anchor molecules for the in situ click chemistry screen.  
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Figure 7.6. Proposed IBTZ6PA2 and In Silico Docking Revealing Sub-Pocket 
 
The alkynes to be screened would be those previously used in the proof of concept 
experiments as well as PA2 (Figure 1.17).
3
 In silico docking of the dmAChE was utilized 
to better predict the azide analogs to be prepared (Figure 7.6). 
 IBTZ6 was prepared in a linear fashion over 11 steps (Scheme 7.1). The initial 
synthesis involved chlorobenzene as the starting material. However, very low yields were 
obtained in the transformation of 7.5 to 7.6 due to the incumbent chloride. The synthesis 
was scaled up to 800g with bromobenzene as starting material. 
 
 
 
 
 
Sub-Pocket
dAChE
mAChE
dmAChE
Proposed 
IBTZ6PA2
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Scheme 7.1. Linear Synthesis of IBTZ6 
 
  With IBTZ6 in hand a small series of analogous azides was prepared and 
then these compounds were to be tested for binding with mAChE and dmAChE (Scheme 
7.2). The synthesis followed similar work to the THA series, however instead 
hydrolyzing the 9-chloro-1,2,3,4-tetrahydroacridines to a THA, the chloro intermediate 
could be alkylated as in Scheme 7.1. The analogs prepared contained 5 or 6 methylene 
units to probe the length of the linker during the in situ click chemistry screen. 
Additionally, various aliphatic ring sizes were prepared to probe the most suitable ring 
for the active site. 
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Scheme 7.2. Synthesis of Azide Analogs Containing Five and Six Methylene Units 
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7.4 AChE Binding Measurements and In Situ Screening 
 The compounds were screened for their Ki in both mAChE and dmAChE. The 
results of the screen are listed below (Table 7.1). 
Table 7.1. Ki and Species Selectivity of IBTZ6 and 7.12B-7.20B 
 
enzyme Azide  K i (nM) K i 
m / K i d 
mAChE iBTZ6 2700 50 
dAChE 54 
mAChE 7.12B 89 5.9 
dAChE 15 
mAChE 7.13B 680 4 
dAChE 170 
mAChE 7.14B 30 3 
dAChE 9.7 
mAChE 7.15B 21 1.8 
dAChE 12 
mAChE 7.16B 110 1.3 
dAChE 87 
mAChE 7.17B 19 1.2 
dAChE 16 
mAChE 7.18B 190 0.56 
dAChE 340 
mAChE 7.19B 33 0.33 
dAChE 100 
mAChE 7.20B 4.3 0.23 
dAChE 19 
N 
H N N 3 
N M e O 
H N N 3 
N F 3 C 
H N N 3 
N 
H N N 3 
N F 
H N N 3 
N F 3 C 
H N N 3 
N 
H N N 3 
N O 2 N 
H N N 3 
N 
H N N 3 
N O 2 N 
H N N 3 
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Our prediction of IBTZ6 was supported by the finding that it was 50 times more potent 
against dmAChE than mAChE. The isobutyl group was not tolerated in the mAChE, due 
to the absence of a sub-pocket. However, several other compounds such as the 6-methoxy 
and 6-trifluoromethyl analogs, were shown to exhibit species selectivity which displayed 
a 6-fold and 4-fold greater inhibition against dmAChE respectively. Further support of 
the choke-point being located higher in the dmAChE gorge was evidenced by the fact 
that the un-substituted analog still maintained a greater inhibition against dmAChE than 
mouse, albeit slightly (3-fold more potent). The reason for this selectivity could be the 
more favorable van der Walls interaction of the six methylene units on the lower portion 
below the choke point. Furthermore, several of the analogs were slightly more potent 
against mAChE than dmAChE suggesting that even though there is not a sub-pocket in 
mAChE,there may be very minor differences in the active site that could be taken 
advantage of.  
 Based on these findings a more narrowed set of analogs was prepared. These 
compounds would alleviate the need for large amounts of screening based on all the 
possible combinations (azide and alkyne) in the screen (Scheme 7.6) by taking already 
known species specific inhibitors and making minor variations within them. The variation 
in methylene chain length and aliphatic ring size would aim to probe the minor 
differences in the active site while also probing the exact length of the gorge. The in situ 
screen was envisioned as including IBTZ6, 7.12B-7.20B (Table 7.1) and 7.27-7.44 
(Figure 7.6) as the azide portion of the library. In addition, due to the inaccessibility of 
PA2 the alkyne library previously screened would be used for these studies (Figure 1.16). 
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Figure 7.7. Follow-up Azides for Ki and Species Selectivity Determination 
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7.5 Conclusions 
 Design of a species specific inhibitor via in situ click chemistry would broaden 
the scope of kinetic TGS. In order to accomplish this, the design of an inhibitor that 
inhibited dmAChE with more potency than closely related eel AChE and mACheE was 
desired. Based on X-ray crystal structures of dmAChE and mAChE, a location in the 
gorge known as the “choke point” was to be exploited in terms of molecular design. An 
eleven step linear synthesis was achieved to prepare IBTZ6. The PA fragments were 
initially sought due to structural overlap with the known PAS binders. However, due to 
synthetic hurdles this compound was abandoned and the use of a previously prepared 
alkyne library would be used to screen with IBTZ6 (Figure 1.17). Follow-up binding 
studies highlighted the potential of various other azides which could also be used in the 
screen with IBTZ6. 
 Currently, the prepared azides in Figure 7.7 are being characterized and tested for 
their binding with dmAChE and mAChE. The in situ screening using mAChE and 
dmAChE is also underway. Several hits for both species have been identified however 
these hits are currently being confirmed. This includes the synthesis of the in situ hits. 
Preliminary data suggests that a PAS smaller than the PA2 is indeed more suited for the 
dmAChE protein. 
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7.6 Experimental Section 
7.6.1 General Information 
 All reactions were carried out under an argon atmosphere. Anhydrous solvent 
stored in SureSeal bottles were used for all reactions. 
 All new compounds were characterized by 
1
H NMR and 
13
C NMR. Known 
compounds were characterized by 
1
H NMR, or 
13
C NMR. 
1
H NMR and 
13
C NMR spectra 
were obtained on a 400 MHz 
1
H NMR spectrometer. All 
1
H NMR experiments are 
reported in ≥ units, parts per million (ppm) downfield of TMS and were measured 
relative to the signals for chloroform (7.26 ppm) and dimethylsulfoxide (2.50 ppm). All 
13
C NMR spectra were reported in ppm relative to the signals for chloroform (77 ppm) 
and dimethylsulfoxide (39.5 ppm) with 
1
H decoupled observation. 
7.6.2 General Procedures 
General Procedure A: Preparation of 9-chloro-1,2,3,4-tetrahydroacridines via 
POCl3 cyclization of anthranillic acids. 
Anthranillic acid (0.25 g, 1.7 mmol) is added to a dried flask, followed by cycloalkanone 
(0.23 g, 1.87 mmol). This flask is cooled to 0
o
C and POCl3 (1.4 mL) is added. The 
reaction is allowed to reflux for 1-8h. Upon completion the reaction is poured onto ice 
and water. The solution is brought to pH 10 using saturated K2CO3 . Next ethyl acetate or 
chloroform is added and the organic layer is removed and washed with brine (50 mL) 
followed by water (50 mL). Next the organic layer is dried over Na2SO4 and concentrated 
in vacuo. The crude oil is purified further further via flash chromatography (Hexane / 
EtOAc). A few representative examples of these compounds were characterized by 
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NMR, however, the majority were considered as intermediates and were taken on to 
acetic acid hydrolysis upon identification using LC-MS.  
General Procedure B: Preparation of Tacrine azides from 9-chloro-1,2,3,4-
tetrahydroacridines 
To a flame dried 10-mL round bottom flask is added 9-chloro-1,2,3,4-tetrahydroacridine 
(0.32 g, 1.2 mmol) and 6-amino-hexanol (0.5 g, 4.2 mmol) and 1 mL of freshly distilled 
pentanol. The reaction is refluxed for 18-48h until completion by HPLC analysis. Up to 
10 equivalents of 6-amino-hexanol may be added during this time for sluggish reactions. 
Upon completion, the reaction is cooled to 0ºC and SOCl2 (3 mL) is added dropwise. The 
resulting black slurry is refluxed until completion via HPLC analysis (typically 3h). The 
resulting solution is concentrated in vacuo and the resulting tar is dissolved in MeOH (5 
mL) and H2O (5 mL) and NaN3 (1.25 g) is added. The reaction is heated to 90ºC with a 
blast shield. Next, the solution is concentrated in vacuo until all MeOH is gone. Then the 
reaction is diluted with CHCl3 (15 mL) and water (15 mL). the organic layer is separated 
and then washed with H2O (X3) followed by brine (X2). The organic layer is then dried 
over Na2SO4 and concentrated. The resulting black tar is dissolved in MeOH and purified 
further by preparative HPLC. 
7.6.3 Compound Characterization 
1-(4-Chloro-phenyl)-2-methyl-propan-1-one (7.2). To a partial suspension of 
aluminum trichloride (8.29 g, 0.062 mol) in chlorobenzene (31g, 0.28 mol) was added 
isobutyryl chloride (10 g, 0.093 mol) via a dropping funnel overnight. When the 
evolution of HCl (g) ceases the reaction is quenched by pouring onto 500 mL of ice and 
water. Upon melting the mixture is extracted with Et2O (3 x 250 mL).  The organic phase 
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is dried over Na2SO4 and concentrated. The mixture of para-, ortho-, and meta- isomers 
were purified using flash chromatography with 10% EtOAc in hexanes. The para-isomer 
was further purified using fractional distillation (b.p. 100-104
o
C) in 84% yield. 
1
H-NMR 
(400 MHz, CDCl3) δ 7.83 (d, J = 4.1 Hz, 2H), 7.41 (d, J= 4.0 Hz, 2H), 3.5 (m, 1H), 1.2 
(d, J= 2.5 Hz, 6H); 
13
C-NMR (400 MHz, CDCl3) δ 203.2, 139.8, 135.5, 129.5, 128.7, 
35.8, 19.3. GC/MS: R. Time: 10.420. Base Peak: 139.05. Molecular Ion: 182. 
1-(4-chloro-3-nitrophenyl)-2-methylpropan-1-one (7.3).  207 mL of fuming nitric acid 
is cooled to 0
o
L and stored. 10 mL portions are cooled to -5
o
C and added to 1-(4-chloro-
phenyl)-2-methyl-propan-1-one (40.5 g, 0.192 mol) in a two neck flask between -10
o
C 
and -5
o
C over 7.5 hours. The reaction mixture is cooled to -30
o
C and poured onto ice. 
The precipitate is filtered and recrystallized from MeOH (2 x 98 mL). The resulting solid 
was dried under reduced vacuum to give an 88% yield (38.4 g) of the titled compound. 
1
H NMR (400 MHz, CDCl3) δ 8.38 (s, 1H), 8.06 (d, J = 3.8 Hz, 1H), 7.66 (d, J = 3.8 Hz, 
1H), 3.48 (m, 1H), 1.2 (d, J = 2.5 Hz, 6H); 
13
C NMR (400 MHz, CDCl3) δ 201.5, 135.8, 
132.6, 132.4, 131.8, 125.5, 36.8, 19.2. M.p. 46.1
o
C
 
to 48.1
o
C.  
1-(4-chloro-3-nitrophenyl)-2-methylpropan-1-ol (7.4). 38.4 g (0.17 mol) of  1-(4-
chloro-3-nitro-phenyl)-propan-1-one is added to 170 mL of MeOH and cooled to 0
o
C 
followed by portion-wise addition of NaBH4 (4.47 g, 0.12 mol). After one hour the 
reaction mixture is poured onto 350 mL of 1M HCl and ice. This mixture is extracted 
with Et2O (3 x 125 ml). The organic combines are washed with 1M NaHCO3 (1 x 150 
mL). The resulting water layer is extracted with Et2O (1 x 125 ml) and added back to the 
organic combines. The organic phase is then dried over Na2SO4. The final compound is 
purified using 20% EtOAc in hexanes, resulting in 34.4 g of alcohol with a yield of 
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88.3%. 
1
H NMR (400 MHz, CDCl3) δ 7.83 (s, 1H), 7.506 – 7.465 (br s, 2H), 4.50 (d, J = 
6.0 Hz, 2H), 1.93 (m, 1H), 1.83 (broad s), 0.894 (dd, J = 22 Hz, 6.4 Hz, 6H); 
13
C NMR 
(400 MHz, CDCl3) δ 144.5, 132.5, 133.4, 125.2, 122.8, 78.2, 35.6, 19.1, 17.7.  
1-chloro-4-(2-methylprop-1-enyl)-2-nitrobenzene (7.5). A solution of 1-(4-chloro-3-
nitro-phenyl)-2-methyl-propan-1-ol (34.2 g, 0.149 mol) and p-TsOH
.
H2O (8.5 g, 0.045 
mol) in 397 mL of toluene was refluxed under a Dean-Stark trap for 23 hours. The 
reaction was cooled, and washed with 500 mL of saturated NaHCO3; Followed by H2O 
(2 x 250 ml) and brine (2 x 250 ml), then dried over Na2SO4. The final compound is 
purified using flash chromatography using 5% EtOAc in Hexanes with a yield of 88% 
(27.6 g). 
1
H NMR (400 MHz, CDCl3) δ 7.65 (s, 1H), 7.42 (d, J = 8.4 Hz, 1H), 7.30 (dd, J 
= 8.4 Hz, 2.2 Hz, 1H), 6.165 (s, 1H), 1.89 (s, 3H), 1.82 (s, 3H); 
13
C NMR (400 MHz, 
CDCl3) δ 147.8, 139.7, 139.1, 133.6, 131.5, 125.6, 124.0, 122.2, 27.1, 19.5. 
2-amino-4-(2-methylprop-1-enyl)benzonitrile (7.6). To a flame dried back-filled 
schlenk tube (X3), 2.61 ml of  anhydrous DMA and CuCN (3.4g, 37.9 mmol) is added 
and heated for a few minutes at ~105
o
C. Next, 1-chloro-4-(2-methyl-propenyl)-2-nitro-
benzene (1 g, 4.7 mmol) is added. After 67 hours the crude reaction mixture was cooled, 
followed by dilution with EtOAc (~15 mL) then washed with 2N NH4OH (2 x 5 mL). 
The water layer is washed with EtOAc (2 x 10 mL). The organic combines were washed 
with brine (1 x 20 mL) followed by H2O (1 x 10 mL), then dried over Na2SO4. The 
desired compound was purified using flash chromatography with 25 % EtOAc in 
Hexanes with a yield of 42 % (0.41 g). 
1
H NMR (400 MHz, CDCl3) δ 8.12 (s, 1H), 7.78 
(d, J = 4.2 Hz, 1H), 7.57 (d, J = 4.2 Hz, 1H), 6.292 (s, 1H), 1.96 (s, 3H), 1.91 (s, 3H); 
13
C 
NMR (400 MHz, CDCl3) δ 148.62, 145.08, 143.44, 135.40, 134.12, 125.32, 122.44, 
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115.60, 104.30, 27.52, 20.50. HRMS (ESI-TOF) calcd for C11N2O2H10 (M+NH4) found 
220.10827 +/- 0.00021 mDa. 
2-Amino-4-isobutylbenzonitrile (7.7). In a Parr hydrogenator reinforced flask 4-(2-
methylpropenyl)-2-nitrobenzonitrile (3.3 g, 16.28 mmol) is dissolved in 115 mL of 
ethanol, followed by the addition of 0.65 g of 10% Pd on Carbon. Hydrogenation was 
carried out under 62 psi for 25 hours. The crude reaction mixture was filtered on celite 
under vacuum. The filtrate was concentrated into a brown oil. The resultant residue was 
further purified with flash chromatography using 25 % EtOAc in hexanes with a yield of 
72%. 
1
H NMR (400 MHz, CDCl3) δ 7.21 (d, J = 8.0 Hz, 1H), 6.49 (s, 1H), 6.47 (d, J = 
11.2 Hz, 1H), 4.41 (broad s), 2.34 (d, J = 7.2 Hz, 2H), 1.79 (m, 1H), 0.84 (d, J = 6.4 Hz, 
6H); 
13
C NMR (400 MHz, CDCl3) δ 149.8, 149.1, 132.3, 118.8, 118.2, 115.9, 93.9, 45.7, 
30.2, 22.5. 
2-Amino-4-isobutylbenzoic acid (7.8). 4-(2-Methyl-propenyl)-2-nitrobenzonitrile (01. g, 
0.57 mmol) was dissolved in 1.06 mL of 48% HBr and brought to reflux for 10 hours. 
The reaction was diluted with 10 mL of EtOAc, and the organic phase was washed with 
H2O (1 x 15 mL). The water layer was extracted with EtOAc (5 x 10 mL). The organic 
phase was dried over Na2SO4 and concentrated. The crude oil was taken directly on to the 
ring closure in the next step without any further purification. 
1
H NMR (400 MHz, CDCl3) 
δ 7.80 (d, J = 8.4 Hz, 1H), 6.46 (d, J = 8.4 Hz, 1H), 6.439 (s, 1H), 2.37 (d, J = 7.2 Hz, 
2H), 1.86 (m, 1H), 0.89 (d, J = 6.8 Hz, 6H); 
13
C NMR (400 MHz, CDCl3) δ 173.5, 151.4, 
150.2, 118.2, 117.6, 107.9, 45.8, 30.0, 22.7. 
9-Chloro-6-isobutyl-1,2,3,4-tetrahydro-acridine (7.9). Following general procedure A, 
2-amino-4-isobutylbenzoic acid (0.12 g, 57 mmol) was added to a dried flask, followed 
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by the addition of 0.06 mL of cyclohexanone. The reaction mixture is cooled to 0
o
C 
followed by the dropwise addition of POCl3 (0.5 mL). The reaction is then set to reflux 
for 3 hours. After completion, the reaction is cooled to room temperature and diluted with 
EtOAc. Saturated  K2CO3 (5 mL) is used to neutralize the reaction mixture. The water 
layer is extracted with EtOAc (4 x 5 mL). The organic combines are washed with brine (1 
x 10mL), followed by drying over K2CO3 (s). The crude product is further purified with 
flash chromatography using 33 % EtOAc in hexanes giving a yield of 75%.  
1
H NMR 
(400 MHz, CDCl3) δ 8.00 (d, J = 8.4 Hz, 1H), 7.70 (s, 1H), 7.30 (dd, J = 8.8 Hz, 2.2 Hz, 
1H), 3.06 (t, J = 5.2 Hz, 2H), 2.937 (t, J = 5.6 Hz, 2H), 2.62 (d, J = 7.2 Hz, 2H), 1.95 (m, 
1H), 1.893 – 1.878 (broad m, 4H), 0.90 (d, J = 6.4 Hz, 6H). 13C NMR (400 MHz, CDCl3) 
δ 159.5, 147.0, 143.4, 141.5, 128.8, 128.1, 128.0, 124.1, 123.5, 45.8, 34.3, 30.2, 27.5, 
23.1, 22.8, 22.6. HRMS (ESI-TOF) calcd for C17N1Cl1H20 (M+H) found 274.13566 +/- 
0.00004 mDa. 
N-(6-azidohexyl)-6-isobutyl-1,2,3,4-tetrahydroacridin-9-amine (IBTZ6). Following 
general procedure B, the title compound was prepared over 3 steps in a 23% (0.126 g) 
yield. 
1
H NMR (400 MHz, CDCl3) δ 8.18 (s, 1H), 8.13 (d, J = 8.9 Hz, 1H), 7.22 (d, J = 
8.8 Hz, 1H), 6.27 (s, 1H), 3.93 (dd, J = 12.8, 6.6 Hz, 2H), 3.26 (t, J = 6.7 Hz, 4H), 2.62 
(t, J = 5.9 Hz, 2H), 2.58 (d, J = 7.3 Hz, 2H), 1.96 – 1.80 (m, 7H), 1.59 (dd, J = 13.4, 6.8 
Hz, 2H), 1.45 (dd, J = 7.3, 4.1 Hz, 4H), 0.86 (d, J = 6.6 Hz, 6H). 
13
C NMR (101 MHz, 
CDCl3) δ 155.59, 151.12, 147.59, 139.37, 127.20, 124.22, 120.09, 114.27, 110.52, 51.44, 
48.39, 45.20, 31.14, 30.05, 28.87, 28.55, 26.58, 26.49, 23.97, 22.45, 22.16, 20.92. 
9-chloro-6-methoxy-1,2,3,4-tetrahydroacridine (7.12A). Following general procedure 
A the title compound was prepared from 2-amino-5-methoxybenzoic acid in 69% yield 
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(2.25 g). 
1
H NMR (400 MHz, CDCl3) δ 7.98 (d, J = 9.2 Hz, 1H), 7.26 (d, J = 2.2 Hz, 1H), 
7.13 (dd, J = 9.2, 2.2 Hz, 1H), 3.90 (s, 3H), 3.05 (t, J = 5.8 Hz, 2H), 2.92 (t, J = 5.9 Hz, 
2H), 1.93 – 1.87 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 160.74, 159.89, 148.50, 141.62, 
126.66, 125.06, 120.67, 119.75, 106.74, 55.72, 34.34, 27.36, 22.91. 
N-(6-azidohexyl)-6-methoxy-1,2,3,4-tetrahydroacridin-9-amine (7.12B). Following 
general procedure B the title compound was prepared over 3 steps in 27% (0.210 g). 
1
H 
NMR (400 MHz, CDCl3) δ 7.99 (d, J = 9.5 Hz, 1H), 7.52 (s, 1H), 6.97 (d, J = 1.6 Hz, 
1H), 5.69 (s, 1H), 3.90 (s, 3H), 3.82 (t, J = 6.8 Hz, 2H), 3.27 (t, J = 6.6 Hz, 2H), 3.03 (t, J 
= 5.8 Hz, 2H), 2.48 (t, J = 5.7 Hz, 2H), 1.84 (dd, J = 24.3, 5.9 Hz, 6H), 1.66 – 1.56 (m, 
2H), 1.46 (d, J = 3.4 Hz, 4H). 
13
C NMR (101 MHz, CDCl3) δ 162.66, 155.09, 150.62, 
141.62, 125.65, 117.60, 109.64, 99.69, 56.08, 51.20, 48.38, 30.93, 28.62, 27.92, 26.32, 
26.23, 23.15, 21.86, 20.64. 
9-chloro-6-(trifluoromethyl)-1,2,3,4-tetrahydroacridine (7.13A). Following general 
procedure A the title compound was prepared from 2-amino-5-(trifluoromethyl)benzoic 
acid in 68% yield (1.3 g). 
1
H NMR (500 MHz, DMSO) δ 8.27 (d, J = 8.8 Hz, 1H), 8.23 
(s, 1H), 7.88 (d, J = 7.6 Hz, 1H), 3.19 (d, J = 6.9 Hz, 4H), 1.85 – 1.82 (m, 2H), 1.69 (dd, 
J = 11.2, 5.4 Hz, 4H). 
13
C NMR (126 MHz, DMSO) δ 174.10, 167.07, 145.26, 138.64, 
136.72, 130.39, 130.14, 129.88, 129.62, 127.58, 127.01, 126.70, 126.67, 126.63, 126.60, 
126.49, 125.41, 123.24, 122.91, 122.89, 122.86, 122.84, 121.07, 39.79, 31.38, 30.22, 
27.27, 26.69. 
N-(6-azidohexyl)-3-(trifluoromethyl)-7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolin-
11-amine (7.13B). Following general procedure B the title compound was prepared over 
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3 steps in 14% (0.105 g).  
13
C NMR (101 MHz, CDCl3) δ 160.58, 154.92, 136.93, 129.39, 
124.85, 121.63, 118.93, 118.41, 117.45, 51.17, 48.93, 33.96, 31.01, 30.83, 29.62, 28.59, 
27.01, 26.66, 26.26, 26.23, 25.53. 
9-chloro-1,2,3,4-tetrahydroacridine (7.14A). Following general procedure A the title 
compound was prepared from anthranillic acid in 82% yield (4.4 g).  
N-(6-azidohexyl)-1,2,3,4-tetrahydroacridin-9-amine (7.14B). Following general 
procedure B the title compound was prepared over 3 steps in 29% (0.211 g).  
9-chloro-6-fluoro-1,2,3,4-tetrahydroacridine (7.15A). Following general procedure A 
the title compound was prepared from 4-fluoroanthranillic acid in 63% yield (0.8 g). 
1
H 
NMR (400 MHz, CDCl3) δ 8.14 (dd, J = 9.2, 6.0 Hz, 1H), 7.60 (dd, J = 9.9, 2.1 Hz, 1H), 
7.34 – 7.26 (m, 1H), 3.09 (d, J = 5.6 Hz, 2H), 2.98 (s, 2H), 1.94 – 1.89 (m, 4H). 13C 
NMR (101 MHz, CDCl3) δ 164.43, 161.94, 161.07, 147.61, 147.48, 141.88, 128.49, 
126.28, 126.18, 122.65, 117.19, 116.93, 112.39, 112.18, 34.25, 27.52, 22.71, 22.68. 
N-(6-azidohexyl)-6-fluoro-1,2,3,4-tetrahydroacridin-9-amine (7.15B). Following 
general procedure B the title compound was prepared over 3 steps in 23% (0.176 g). 
1
H 
NMR (400 MHz, CDCl3) δ 8.19 (dd, J = 9.2, 5.2 Hz, 1H), 7.59 (d, J = 8.8 Hz, 1H), 7.08 
(dd, J = 12.1, 4.7 Hz, 1H), 6.56 (s, 1H), 3.84 (s, 2H), 3.25 (t, J = 6.4 Hz, 2H), 3.00 (d, J = 
5.4 Hz, 2H), 2.56 (d, J = 4.8 Hz, 2H), 1.82 (d, J = 6.4 Hz, 6H), 1.64 – 1.54 (m, 2H), 1.43 
(d, J = 2.9 Hz, 4H). 
9-chloro-6-(trifluoromethyl)-1,2,3,4-tetrahydroacridine (7.16A). Following general 
procedure A the title compound was prepared from 4-trifluoroanthranillic acid in 75% 
yield (0.95 g). 
1
H NMR (500 MHz, DMSO) δ 8.40 – 8.17 (m, 2H), 7.86 (d, J = 8.4 Hz, 
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1H), 3.04 (s, 2H), 2.94 (s, 2H), 1.88 (d, J = 3.1 Hz, 3H). 
13
C NMR (126 MHz, DMSO) δ 
161.98, 145.34, 140.39, 131.72, 130.16, 129.90, 126.75, 126.55, 126.51, 125.72, 125.41, 
123.25, 122.55, 34.03, 27.59, 22.20, 22.17. 
N-(6-azidohexyl)-6-(trifluoromethyl)-1,2,3,4-tetrahydroacridin-9-amine (7.16B). 
Following general procedure B the title compound was prepared over 3 steps in 29% 
(0.191 g). 
1
H NMR (400 MHz, CDCl3) δ 8.14 (s, 1H), 8.00 (d, J = 8.8 Hz, 1H), 7.43 (d, J 
= 8.8 Hz, 1H), 3.44 (t, J = 7.2 Hz, 2H), 3.20 (t, J = 6.8 Hz, 2H), 3.00 (s, 2H), 2.64 (s, 
2H), 1.88 (dd, J = 6.3, 3.1 Hz, 4H), 1.64 – 1.50 (m, 4H), 1.41 – 1.27 (m, 4H). 13C NMR 
(101 MHz, DMSO) δ 154.80, 145.32, 141.40, 124.59, 121.47, 121.43, 119.11, 113.72, 
113.69, 112.15, 46.08, 44.26, 28.85, 26.50, 23.53, 21.30, 19.52, 17.65, 17.39. 
9-chloro-6-methyl-1,2,3,4-tetrahydroacridine (7.17A). Following general procedure A 
the title compound was prepared from 4-methylanthranillic acid in 82% yield (3.95 g). 
1
H 
NMR (400 MHz, CDCl3) δ 7.92 (d, J = 8.5 Hz, 1H), 7.65 (s, 1H), 7.25 (d, J = 8.5 Hz, 
1H), 3.00 (d, J = 5.7 Hz, 2H), 2.89 (d, J = 5.8 Hz, 2H), 2.44 (s, 3H), 1.84 (s, 4H). 
13
C 
NMR (101 MHz, CDCl3) δ 159.45, 147.03, 141.37, 139.53, 128.78, 127.95, 127.77, 
123.54, 123.46, 34.30, 27.48, 22.82, 21.83. 
9-chloro-6-nitro-1,2,3,4-tetrahydroacridine (7.18A). Following general procedure A 
the title compound was prepared from 4-nitroanthranillic acid in 52% yield (2.7 g). 
1
H 
NMR (400 MHz, CDCl3) δ 8.85 (s, 1H), 8.27 (s, 2H), 3.15 (s, 2H), 3.04 (s, 2H), 1.96 (d, 
J = 2.4 Hz, 4H). 
13
C NMR (101 MHz, CDCl3) δ 162.75, 148.03, 145.62, 141.47, 132.72, 
128.68, 125.75, 125.11, 119.88, 34.42, 28.02, 22.49. 
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N-(6-azidohexyl)-6-nitro-1,2,3,4-tetrahydroacridin-9-amine (7.18B). Following 
general procedure B the title compound was prepared over 3 steps in 11% (0.101 g). 
1
H 
NMR (400 MHz, CDCl3) δ 8.59 (s, 1H), 8.43 (d, J = 9.3 Hz, 1H), 7.92 (d, J = 8.5 Hz, 
1H), 7.37 (d, J = 28.6 Hz, 1H), 3.94 (s, 2H), 3.32 (t, J = 6.7 Hz, 2H), 3.08 (s, 2H), 2.72 (s, 
2H), 1.91 (s, 6H), 1.70 – 1.50 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 155.04, 154.70, 
148.32, 137.42, 127.18, 119.18, 117.92, 115.44, 112.27, 51.47, 48.21, 31.18, 28.85, 
28.70, 26.52, 26.43, 25.23, 22.08, 20.46. 
11-chloro-3-methyl-7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolone (7.19A). 
Following general procedure A the title compound was prepared from 4-
methylanthranillic acid in 63% yield (2.4 g). 
1
H NMR (400 MHz, CDCl3) δ 7.97 (d, J = 
8.5 Hz, 1H), 7.72 (s, 1H), 7.31 (d, J = 8.4 Hz, 1H), 3.18 – 3.11 (m, 4H), 2.49 (s, 3H), 
1.83 – 1.67 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 164.89, 146.86, 139.73, 139.50, 
133.09, 128.96, 128.19, 124.37, 123.65, 40.44, 32.04, 30.41, 27.72, 27.08, 21.86. 
N-(6-azidohexyl)-3-methyl-7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolin-11-amine 
(7.19B). Following general procedure B the title compound was prepared over 3 steps in 
19% (0.11 g). 
1
H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 8.5 Hz, 1H), 7.68 (s, 1H), 7.16 
(d, J = 8.4 Hz, 1H), 3.23 (t, J = 7.2 Hz, 2H), 3.16 (t, J = 6.8 Hz, 2H), 3.10 – 3.05 (m, 2H), 
2.83 – 2.77 (m, 2H), 2.40 (s, 3H), 1.79 (d, J = 4.7 Hz, 2H), 1.71 – 1.31 (m, 12H). 13C 
NMR (101 MHz, CDCl3) δ 164.60, 150.53, 146.05, 138.99, 127.34, 127.11, 122.60, 
122.06, 119.68, 51.45, 50.47, 39.45, 32.08, 31.41, 28.89, 28.32, 27.66, 26.96, 26.70, 
26.66, 21.65. 
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11-chloro-3-nitro-7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolone (7.20A). Following 
general procedure A the title compound was prepared from 4-nitroanthranillic acid in 
47% yield (2.0 g). 
1
H NMR (400 MHz, CDCl3) δ 8.83 (s, 1H), 8.27 (d, J = 1.1 Hz, 2H), 
3.24 (t, J = 5.4 Hz, 4H), 1.90 – 1.75 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 167.82, 
148.02, 145.63, 139.66, 137.65, 129.06, 126.57, 125.29, 120.19, 40.46, 31.85, 30.85, 
27.41, 26.86. 
N-(6-azidohexyl)-3-nitro-7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolin-11-amine 
(7.20B). Following general procedure B the title compound was prepared over 3 steps in 
17% (0.105 g). 
1
H NMR (400 MHz, CDCl3) δ 8.66 (s, 1H), 8.42 (d, J = 9.3 Hz, 1H), 7.91 
(d, J = 9.2 Hz, 1H), 3.68 (t, J = 7.1 Hz, 2H), 3.28 – 3.11 (m, 4H), 2.83 (s, 2H), 1.86 (dd, J 
= 15.2, 6.7 Hz, 6H), 1.72 (s, 2H), 1.64 – 1.55 (m, 2H), 1.43 (s, 4H).13C NMR (101 MHz, 
CDCl3) δ 162.06, 155.05, 148.38, 136.53, 126.43, 120.77, 118.78, 117.08, 115.86, 51.44, 
48.84, 34.36, 31.23, 30.63, 28.81, 27.73, 26.99, 26.51, 26.46, 25.80. 
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Chapter 8: Research Synopsis 
8.1 Successful Application of Modern Drug Discovery Techniques for the 
Identification and Optimization of Antimalarials 
 The general process of advancing a molecule from a hit to a FDA approved drug 
is taxing.
1
 Following an outline of lead identification and optimization, we successfully 
obtained several candidates for preclinical development with superb antimalarial activity 
and adequate physicochemical properties. Multiple synthetic routes were developed to 
arrive at our target molecules including a divergent route that utilizes chloro-iodo-
quinolone precursors to chemoselectively generate diverse analogs in high yield and 
excellent purity.
2
  
Our initial optimization strategy began by analyzing in vitro activity data based on 
a screening conducted at the WRAIR.
3
 We initiated our research based on three core 
scaffolds found in this screen to be promising: (a) 3-substituted-4(1H)-quinolones, (b) 
THAs, and (c) PEQs. Previously known and well studied examples of antimalarial 
compounds existed within each of these scaffolds. These examples included endochin, 
floxacrine, and ICI56,780 all of which possessed either a lack of potent in vivo activity, 
poor aqueous solubility, lingering toxicity or all three.
4-6
 Several factors that attributed to 
the success within our research program including (a) the assessment of three historic 
antimalarials endochin, floxacrine, and ICI56,780 for their physicochemical and 
toxicological liabilities which could be used as a foundation for future development, (b) 
the systematic structure-activity relationship (SAR) studies of all three scaffolds which 
provided steady and comparative data from which to draw upon for compound design 
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directions, (c) the parallel screening of the physicochemical properties solubility, 
permeability, microsomal stability and logD7.4 amongst each scaffold, and (d) the 
thorough in vivo testing that included P. berghei infected mouse models such as the 
Thompson test and/or an in-house developed scouting protocol. 
 For the 3-substituted-4(1H)-quinolones series, the initial identification of poor 
solubility and microsomal stability of endochin provided key insights as to where to 
begin our SAR and SPR studies (Chapter 2). By simultaneously examining the benzenoid 
ring substituents as well as the 3-position for antimalarial activity, solubility, 
permeability, and logD7.4, we obtained several key findings. First, the substitution of the 
3-position was the most critical for biological activity and had a moderate impact on 
solubility and permeability. In contrast, the substituents on the benzenoid ring were less 
important for biological activity, however they were more important for solubility. A 
synergistic effect regarding biological activity emerged when it was observed that a 6-
chloro-7-methoxy substitution pattern was superior in comparison to either the mono 6-
chloro or 7-methoxy analogs.  Furthermore, the biological activity was superior when the 
4(1H)-quinolone nitrogen and oxygen were unsubstituted and the 5- and 8-position of the 
benzenoid ring were unsubstituted. From this study the compound 6-chloro-7-methoxy-3-
phenyl-4(1H)-quinolone (6.2) emerged as our initial hit. This compound was promising 
as the aryl motif provided opportunistic design directions.  
 Simultaneously, several synthetic routes were implemented for the design of 
1,2,3,4-tetrahydroacridones (Chapter 4). Several examples of this scaffold were identified 
to have low nanomolar activity in the initial WRAIR in vitro screen. Floxacrine was a 
well known THA derivative that had some significant advances towards becoming a pre-
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clinical antimalarial candidate.
6
 Unfortunately, this compound suffered from poor 
solubility and a lingering toxicity issue. Our aim therefore was to repeat the successes 
from our work in optimizing endochin. By assessing nine distinct series of THA analogs, 
we arrived at several analogs with good activity and superior physicochemical properties 
as compared to floxacrine. Through the use of several routes to access THAs starting 
from anilines or anthranillic acids, we individually examined each benzenoid ring 
position with various substituents. It was found that the same 6-chloro-7-methoxy 
substitution at the benzenoid ring provided EC50s in the low nanomolar range. 
Furthermore, the 5- and 8-substituents of the benzenoid ring were determined to 
significantly increase the solubility, while making these compounds inactive with EC50s 
in the µM range. Through Suzuki-Miyaura cross-coupling conditions developed in our 
laboratory (Chapter 3) we were able to generate a small library of 6- and 7-substituted 
THAs. Several analogs possessed in vivo activity.  
 Finally, a small set of PEQ analogs were prepared based on the known 
antimalarial ICI56,780. ICI56,780 was shown to possess in vivo activity in P. cynomologi 
infected rhesus monkeys (Chapter 5).
5
 When the synthesis of ICI56,780 began in our 
laboratory, we had not achieved in vivo activity yet. Therefore obtaining the molecule 
ICI56,780 and the intermediate necessary for constructing similar analogs seemed 
necessary. Using a modification of a previously described synthetic route, we obtained 
large amounts of an intermediate aniline, which was required for the preparation of 
ICI56,780, and subsequently studied related analogs using SAR and SPR.
7
 As with the 
4(1H)-quinolone or THA scaffolds, improvements to ICI56,780 were achieved within our 
subset of compounds.  
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 By assessing the advantages and disadvantages of each optimized scaffold, the 
decision to advance the 6-chloro-7-methoxy-4(1H)-quinolone series for detailed follow-
up studies became apparent (Chapter 6). These compounds not only showed great 
promise in antimalarial activity, but also a unique structural opportunity. The most 
important hurdles to overcome at this stage of the hit-to-lead optimization were to 
increase the aqueous solubility and the microsomal stability. Our initial hit 6-chloro-7-
methoxy-3-phenyl-4(1H)-quinolone (6.2) failed to reduce parasitemia levels in P. berghei 
infected mice using the Thompson test, and we suspected that this failure to achieve in 
vivo efficacy resulted from a lack of good oral bioavailability. Therefore, we were very 
encouraged after observing that 6-chloro-7-methoxy-2-methyl-3-o-tolylquinolin-4(1H)-
one (6.3), which possessed improved aqueous solubility (19 µM) and antimalarial activity 
with EC50s of 5.8 nM and 4.0 nM against W2 and TM90-C2B respectively, achieved 
modest levels of parasitemia suppression in mice. This compound had a 17% parasitemia 
reduction at a 10 mg/kg dose and a 41% parasitemia reduction at a 50 mg/kg dose. 
Although these results were a breakthrough in regards of in vivo activity, the compound 
lacked in the antimalarial potency we were aiming for. Importantly, it was discovered 
during microsomal degradation studies that several compounds amongst our library 
displayed minimal degradation in human and rat microsomes whereas 6-chloro-7-
methoxy-2-methyl-3-o-tolylquinolin-4(1H)-on (6.3) showed moderate microsomal 
stability. Several analogs with improved stabilities were examined for in vivo activity in 
Thompson test studies. These compounds with high levels of microsomal stability 
achieved significant improvement for in vivo activity with parasitemia reduction of up to 
97% at a 50 mg/kg dose. These results showed that not only was aqueous solubility 
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important for achieving in vivo activity but that the microsomal stability of the compound 
was equally impactful for obtaining high levels of in vivo efficacy. A final SAR and SPR 
optimization lead to the design of 6-chloro-7-methoxy-2-methyl-3-(2-methyl-4-(4-
(trifluoromethoxy)phenoxy)phenyl)-quinolin-4(1H)-one (6.71) which had great potencies 
against the multi-drug resistant strains and an excellent microsomal stability. Even 
though this compound had poor aqueous solubility, it was able to reproduce radical cures 
in the Thompson test at various dosages.  
 Purity of tested compounds as well as timely in vitro activity data was important 
to the success of the project. First, the vast majority of the compounds that were sent for 
testing, were extremely pure. The purity was measured to be ≥ 95% by HPLC and 99% 
by 
1
H NMR. This was achieved by a multi-step process in where the compounds were 
initially purified via flash chromatography. The solids were then precipitated from diethyl 
ether and filtered. Next, the compounds would be washed from both ice-cold methanol 
and ice-cold diethyl ether. Similarly, if flash chromatography was not necessary, a 
recrystallization from DMF was employed and the same washing process was employed. 
The compounds were re-subjected to this process if NMR revealed anything more than 
trace amounts of DMF or other impurities. This extensive purification protocol 
minimized the rate of false-positives in the in vitro activity testing.  
Secondly, a robust two-week make-test cycle was implemented in which 
synthesized compounds were delivered to the Kyle laboratory for in vitro testing every 
two weeks. During this time the compounds were analyzed for their antimalarial activity 
against both the W2 and TM90-C2B strains as well as potential cytotoxicity (J774 
macrophage assay). Typically, the biological activity data was available to the chemists 
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within approximately 10 days enabling the chemists to evaluate their latest structural 
modifications and to redesign their leads. This process was extremely helpful in making 
informed decisions as to which analogs to prepare next eliminating the need to synthesize 
unnecessary compounds. 
8.2 Medicines for Malaria Venture (MMV) and Collaborative Efforts 
 Historically, many of the traditional sciences were based upon individual 
findings.
8
 In the mid-1900s, a paradigm shift occurred where the emphasis became more 
about the team and less about the individual.
8
 A team can bring a greater understanding 
of the goal to a research effort as well as streamline the productivity.
9
 Recently, 
discussion has emerged on the essentials of working within a team as a response to the 
National Institute of Health’s (NIH) roadmap initiative.9 Several of the key topics within 
this discussion included (a) reasonably identifying the roles of principal investigators, 
department chairs, and even deans, (b) properly giving credit to those within a project, 
and (c) the process in which universities’ appoint, promote, and create tenure.9 All these 
factors may not be transparent for some of the workers in a research team and quite often 
these can erode the foundation of a solid research unit. Team members should feel 
equally important and common goals should not be overshadowed by individual gains. 
Fortunately, by forming solid multidisciplinary teams in an academic environment, 
modern medicinal research can be facilitated and lead to success. This enhances the 
opportunities for everyone involved in the project and bolsters the morale of the 
individuals.
10
 Thus, team efforts are important in academic settings (public sectors) when 
one considers that the public sector has traditionally performed the upstream and basic 
research efforts while the private sector has championed more downstream efforts such as 
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clinical development that bring drugs to market.
11
 In the past 40 years, only 153 new 
FDA-approved drugs, vaccines, or new indications for existing drugs were identified by 
the public sector.
11
 The field of drug discovery is tilted in favor of the private sector, 
nonetheless, with good collaborations and teamwork the public sector and academia are 
poised to utilize newer technologies in the future. 
 The identification and optimization of antimalarials within our research efforts 
hinged upon great teamwork. Detailed planning and open communication between 
several research groups lead to a successful approach from the onset of our project. The 
synthetic work based out of the Manetsch laboratory consisted of the efforts of myself as 
well as Andrii Monastyrskyi, Jordany Maignan, Dr. David L. Flanigan, and Dr. Niranjan 
Namelikonda. The Kyle laboratory conducted the in vitro antimalarial and toxicity 
screenings, as well as all of the in vivo testing including the Thompson test and the in-
house scouting protocol. Tina Mutka, Dr. Alexis LaCrue, and Dr. Fabian Saenz 
conducted the majority of these experiments. The pharmacokinetic studies of our 
advanced compounds as well as much of the microsomal stability studies were conducted 
at Monash University in Australia in the laboratory of Dr. Susan Charman. Karen White 
and co-workers carried out the majority of these experiments.  The Program Officer of 
the funding agency Medicines for Malaria Venture, Dr. Jeremy Burrows, was extremely 
helpful in guiding the team to make very informative decisions. Later on, the laboratories 
of Dr. Michael Riscoe from the Portland VA Medical Center and Dr. Akhil Vaidya from 
Drexel University joined the multi-laboratory team extending and complementing the 
existing disciplines in medicinal chemistry and development of antimalarial agents. Over 
the course of three years, the funding agency Medicines for Malaria Venture gave several 
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specific aims, which were met by the team throughout hard work, novel ideas, and mostly 
great teamwork.  
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Appendix A: Compound Contributions 
Chapter 2: Compounds 2.1-2.3, 2.5-2.6, 2.8, 2.18-2.22, 2.27-2.42, 2.49-2.56 provided by  
Andrii Monastyrskyi 
Chapter 3: Table 3.1 Entries 1-2, and 4-8 provided by Andrii Monastyrskyi 
Chapter 4:  Compounds 4.58- 4.93, 4.96-4.97, 4.98-4.113 provided by Jordany Maignan 
Chapter 5: Compound 5.28 provided by Andrii Monastyrskyi and Compounds 5.29-5.42  
Provided by Niranjan Namelikonda 
Chapter 6: Compounds 6.11-6.20 provided by Andrii Monastyrskyi 
